CELL CYCLE PROGRESSION PROTEINS

Abstract: Polynucleotides encoding a number of <i>Drosophila</i> gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Description: CELL CYCLE PROGRESSION PROTEINS The present invention relates to a number of genes implicated in the processes of cell cycle progression, including mitosis and meiosis. We have now identified a large number of genes in Drosophila, mutations in which disrupt cell cycle progression, for example the processes of mitosis and/or meiosis. We have determined the phenotypes of these mutations and recovered nucleotide sequences associated with the corresponding genes. Many of these nucleotide sequences correspond to protein open reading frames (ORFs) present in the Drosophila genome. Accordingly the present invention provides in one aspect a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 70 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 70, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 70 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). There is provided, according to another aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 14 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 14, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 14 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). We provide, according to yet a further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 15 to 19 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 15 to 19, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 15 to 19 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). As a further aspect of the present invention, there is provided a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 20 to 30 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 20 to 30, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 20 to 30 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). We provide, according to a yet further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 31 to 53 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 31 to 53, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 31 to 53 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). The present invention, in a further aspect, provides a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in 54 to 70 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in 54 to 70, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 54 to 70 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of the above aspects of the invention. The present invention also provides a polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 70 or in any of Examples 1 to 14, Examples 15 to 19, Examples 20 to 30, Examples 31 to 53 and Examples 54 to 70, or a homologue, variant, derivative or fragment thereof. Preferably the polypeptide is encoded by a cDNA sequence obtainable from a eukaryotic cDNA library, preferably a metazoan cDNA library (such as insect or mammalian) said DNA sequence comprising a DNA sequence being selectively detectable with a Drosophila nucleotide sequence as shown in any one of Examples 1 to 70. The term "selectively detectable" means that the cDNA used as a probe is used under conditions where a target cDNA of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other cDNAs present in the cDNA library. In this event background implies a level of signal generated by interaction between the probe and a non-specific cDNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target cDNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with P. Suitable conditions may be found by reference to the Examples, as well as in the detailed description below. A polynucleotide encoding a polypeptide of the invention is also provided. The present invention further provides a vector comprising a polynucleotide of the invention, for example an expression vector comprising a polynucleotide of the invention operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell. Also provided is an antibody capable of binding a polypeptide of the invention. In a further aspect the present invention provides a method for detecting the presence or absence of a polynucleotide of the invention in a biological sample which method comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe comprising a nucleotide of the invention under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample. In another aspect the invention provides a method for detecting a polypeptide of the invention present in a biological sample which comprises: (a) providing an antibody of the invention; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed. Knowledge of the genes involved in cell cycle progression allows the development of therapeutic agents for the treatment of medical conditions associated with aberrant cell cycle progression. Accordingly, the present invention provides a polynucleotide of the invention for use in therapy. The present invention also provides a polypeptide of the invention for use in therapy. The present invention further provides an antibody of the invention for use in therapy. In a specific embodiment, the present invention provides a method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polynucleotide, polypeptide and/or antibody of the invention. The present invention also provides the use of a polypeptide of the invention in a method of identifying a substance capable of affecting the function of the corresponding gene. For example, in one embodiment the present invention provides the use of a polypeptide of the invention in an assay for identifying a substance capable of inhibiting cell cycle progression. The substance may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (GO), GI progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions. For example, possible functions of genes of the invention for which it may be desired to identify substances which affect such functions include chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways. In a further aspect the present invention provides a method for identifying a substance capable of binding to a polypeptide of the invention, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide. In an additional aspect, the invention provides kits comprising polynucleotides, polypeptides or antibodies of the invention and methods of using such kits in diagnosing the presence of absence of polynucleotides and polypeptides of the invention including deleterious mutant forms. Also provided is a substance identified by the above methods of the invention. Such substances may be used in a method of therapy, such as in a method of affecting cell cycle progression, for example mitosis and/or meiosis. The invention also provides a process comprising the steps of: (a) performing one of the above methods; and (b) preparing a quantity of those one or more substances identified as being capable of binding to a polypeptide of the invention. Also provided is a process comprising the steps of: (a) performing one of the above methods; and (b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of binding to a polypeptide of the invention. We further provide a method for identifying a substance capable of modulating the function of a polypeptide of the invention or a polypeptide encoded by a polynucleotide of the invention, the method comprising the steps of: incubating the polypeptide with a candidate substance and detennining whether activity of the polypeptide is thereby modulated. A substance identified by a method or assay according to any of the above methods or processes is also provided, as is the use of such a substance in a method of inhibiting the function of a polypeptide. Use of such a substance in a method of regulating a cell division cycle function is also provided. DETAILED DESCRIPTION OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, In Situ Hybridization: Principles and Practice; Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, Irl Press; and, D. M. J. Lilley and J. E. Dahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference. Preferably, the polypeptides and polynucleotides of the invention are such that they give rise to or are associated with defined phenotypes when mutated. For example, mutations in the polypeptides and polynucleotides of the invention may be associated with a failure to complete cytokinesis; such polypeptides and polynucleotides are conveniently categorised as "Category 1". Phenotypes associated with Category 1 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Mitotic defects in brain: cytokinesis defect (polyploidy); Male semi-sterile, Meiotic defects in testis: cytokinesis defects, segregation defects.(Seg-01/62); Meiotic defects in testis: cytokinesis defects, abnormal spindles. (Ab-02/12); Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, high polyploidy); Meiotic defects in testis: cytokinesis defects. Dark bands in eyes, dominant; Meiotic defects in testis: cytokinesis defects; Meiotic defects in testis segregation defect, cytokinesis defect(Ck-09/32); Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, very high polyploidy); Mitotic defects in brain: cytokinesis defect(very high polyploidy); Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects (Mitotic higher level of condensation, polyploidy, Meiotic: Ck05/07); Mitotic defects in brain, Cytokinesis defect (no overcondensation of diploids, high polyploidy); Mitotic defects in brain: cytokinesis defect (very high polyploidy, chromosomes entangled?); Mitotic defects in brain: cytokinesis defect (very high polyploidy; Meiotic defects in testis: cytokinesis defects (Ck-04/06) Λ ; Female sterile (anaphase bridges, lagging chromosomes); Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects: (mitotic: high polyploidy, no diploids, higher mitotic index, meiotic: Ck-01/05); Meiotic defects in testis: cytokinesis defects; Meiotic defects in testis: cytokinesis defects(Ck-06/09); Meiotic defects in testis: segregation defects, cytokinesis defect(Ck-07/35); Meiotic defects in testis: cytokinesis defects. Alternatively, mutations in the polypeptides and polynucleotides of the invention may be associated with a failure to enter M-phase; such polypeptides and polynucleotides are conveniently categorised as "Category 2". Phenotypes associated with Category 2 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Meiotic defects in testis: no division(no meiosis); Mitotic defects in brain: no mitosis; Meiotic defects in testis: segregation defects, meiotic failure(Mf-07/75); Meiotic defects in testis: segregation defects, meiotic failure(Mf-05/31); Meiotic defects in testis: cytokinesis defects, meiotic failure(Mf-02/15). Mutations in the polypeptides and polynucleotides of the invention may be associated with a metaphase arrest phenotype ("Category 3"). Phenotypes associated with Category 3 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Mitotic defects in brain: prometaphase arrest (overcondensation, polyploidy, scattered chromosomes with bipolar spindle); Male sterile, Female sterile, Mitotic defects in brain: prometaphase arrest (Overcondensation, polyploidy, fewer anaphases, high mitotic index, scattered chromosomes with bipolar spindle); Mitotic defects in brain: (weak overcondensation, metaphase with bipolar spindle); Mitotic defects in brain: prometaphase arrest; Mitotic defects in brain: metaphase arrest; Mitotic defects in brain: metaphase arrest, (overcondensation, polyploidy, aneuploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle); Mitotic defects in brain: metaphase arrest, (overcondensation, polyploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle); Mitotic defects in brain: Metaphase arrest (overcondensation, polyploidy, aneuploidy, no anaphases, high mitotic index, metaphase with bipolar spindle); Mitotic defects in brain: metaphase arrest (overcondensation, metaphase with bipolar spindle; Meiotic defects in testis: segregation defects, multipolar spindles (Mul- 02/29); Meiotic defects in testis: cytokinesis defects,abnormal spindles. (Ab-01/03); Mitotic defects in brain: metaphase arrest; Mitotic defects in brain: metaphase arrest (overcondensation, polyploidy, metaphase with bipolar spindle); Mitotic defects in brain: metaphase arrest. Meiotic defects in testis: segregation defects. Abnormal spindles (mitotic: High mitotic index, meiotic: Ab-08/24); Mitotic defects in brain: metaphase arrest(overcondensation, few anaphases, some polyploids); Mitotic defects in brain: prometaphase arrest (overcondensation, fewer anaphases, metaphase with bipolar spindle); Mitotic defects in brain: metaphase arrest(condensation, no polyploidy, no anaphases, metaphase with bipolar spindle). Mutations in Category 4 polypeptides and polynucleotides of the invention may be associated with an anaphase defect phenotype; phenotypes associated with Category 4 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Mitotic defects in brain: anaphase defects (overcondensation, high polyploidy, some lagging chromosomes); Meiotic defects in testis: segregation defects; Male and female sterile, small wings, meiotic defects in testis: segregation defects, elongation defect; Mitotic defects in brain: anaphase defects(overcondensation, anaphase bridge, metaphase with swollen chromosomes and bipolar spindle); Mitotic defects in brain: Anaphase defects, (overcondensation, aneuploidy, some lagging chromosomes and breaks); Meiotic defects in testis: segregation defects; Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/17); Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/18); Meiotic defects in testis: cytokinesis defects, segregation defects (seg-01/01); Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defect. Multi-stage defects Polyploidy, no overcondensation Pl-01/10; Meiotic defects in testis: segregation defects, abnormal spindles. (Ab-03/30); Mitotic defects in brain: anaphase defects (weak, higher condensation, some polyploidy, fewer anaphases, polyploids with monopolar spindles); Mitotic defects in brain: anaphase defects (overcondensation, polyplody (with overcondensation), few anaphases, metaphase with bipolar spindle); Meiotic defects in testis: cytokinesis defects; Meiotic defects in testis: segregation defects,multipolar spindles(Mul-02/22); Meiotic defects in testis: segregation defects, abnormal spindles (Ab-04/26); Meiotic defects in testis: cytokinesis defects,abnormal spindles (Ab-16/13); Mitotic defects in brain: anaphase defects. Meiotic defects in testis: segregation defects, abnormal spindles (mitotic : Overcondensation, lagging chromosomes/less aligned metaphase with bipolar spindles, Meiotic: Ab-06/20 ); Meiotic defects in testis: segregation defects; Meiotic defects in testis: no division (no meiosis); Meiotic defects in testis: segregation defects, abnormal spindles (Ab-12/48); Meiotic defects in testis: segregation defects, multipolar spindles(mitotic: High polyploids, no diploids, higher mitotic index Meiotic: Mul-02/59); Meiotic defects in testis: segregation defect; Meiotic defects in testis: segregation defects,abnormal spindles (meiotic: Ab-08/42); Female sterile. Meiotic defects in testis: cytokinesis defects, segregation defects (Mitotic: Less condensed chromosomes, nuclear bridges, Meiotic: Seg-01/02; Mitotic defects in brain: anaphase defects; Meiotic defects in testis: cytokinesis defects,abnormal spindles(Ab-01/04); Meiotic defects in testis: segregation defects(overcondensation, fewer anaphases); Mitotic defects in brain:(some overcondensation, anaphase bridge, metaphase with swollen chromosome and bipolar spindle). A fifth category ("Category 5") of polypeptides and polynucleotides of the invention are associated with the presence of small imaginal discs (block to proliferation). Phenotypes associated with Category 5 polypeptides and polynucleotides include any one or more of the following, singly or in combination: 2nd chromosome, small imaginal discs. The polypeptides and polynucleotides of the invention may also be categorised according to their function, or their putative function. For example, the polypeptides described here preferably comprise, and the polynucleotides described here are ones which preferably encode polypeptides comprising, any one or more of the following: a CBP activator protein; a CCR4-associated regulator of polymerase II transcription; a CTP synthase (CTPS); a Cyclin specific ubiquitin conjugating enzyme; a DNA packaging protein; a DNA repair protein; a DNA- binding protein involved in cliromosomal organisation; a DNase IV; a EIF4G2 translation initiation factor; a eukaryotic translation initiation factor 6; a Ecdysone-induced protein 78C; a Egf2 translation factor; a G protein-coupled receptor kinase 7; a GTPase exchange factor; a phosphatidylinositol transfer protein beta isoform; a His-rich protein; a Lk6 kinase; a MAP kinase; a MAP kinase interacting kinase 1; aN-arginine dibasic convertase; a Phosphatidylinositol transfer protein; a RIP protein kinase; a RNA binding motif, single stranded interacting protein; a RNA binding protein; a RYKreceptor tyrosine kinase; a Ribosomal protein LI; a selenide, water dikinase 1; a selenium donor protein 1; a selenophosphate synthetase 1 ; a Sqv-7-like protein; a sugar modification protein; a protein involved in cytokinesis and signalling; a TEK tyrosine kinase; a Translation elongation factor; a UDP-galactose transporter; a v-erba related protein; a WD40 protein; a brahma protein; a calcium binding protein; a cell adhesion protein; a chaperone; a chromodomain helicase DNA binding protein; a chromodomain-helicase-DNA-binding protein; a coiled coil protein with ubiquitin like domain; a component of the 19S proteasome regulatory particle; a couch potato RNA binding protein; a cytidine 5-prime triphosphate synthetasea; a cytoskeletal structural protein; a death domain containing protein; a developmentally expressed in axons of the CNS; a diacylglycerol-activated/phosholipid dependent protein kinase C inhibitor; a diazepam binding inhibitor; a diphosphate kinase; a dodecasattelite DNA binding protein; a doughnut protein tyrosine kinase; an elongation factor 2; a endoplasmic reticulum ATPase; a eukaryotic translation initiation factor 4E binding protein 2; a factor involved in axon guidance; a fatty-acid-Coenzyme A ligase; a flap structure-specific endonuclease 1; a protein involved in the formation of the contractile ring and the initiation of cytokinesis; a glucose-6-phosphate transporter; a glycoprotein glucosyltransferase; a growth factor; a transmembrane receptor protein tyrosine kinase involved in cell growth and maintenance; a guanyl-nucleotide exchange factor involved in signal transduction; a heat shock protein; a helicase; a high density lipoprotein binding protein; a histone acetyl transferase transcriptional activator; a histone acetyltransferase; a histone acetyltransferase GCN5; a protein involved in development of the abdomen (embryos); a protein involved in the development of the imaginal discs (larvae or pupae); a kinesin like protein 67a; a ligand-dependent nuclear receptor; a ligand-dependent nuclear receptor; a lola-like specific RNA polymerase II transcription factor; a matrix associated protein; a membrane glycoprotein; a mitotic heterochromatin fragment clone CH(2)6; a motor protein; a motor protein involved in cytoskeleton organization; a mushroom body RNA binding protein; a myosin like proteins; a nemo-like kinase; a non- ATPase protein; a nuclear receptor NR1E1; a nucleic acid binding protein; a nucleoside diphosphate kinase (NBR-A); a oly(rC)-binding protein 2 (hnRNP-El); a peroxisome biogenesis factor 1; a phosopholipid transporter involved in lipid metabolism; a phosphatase or enhancer of Pi uptake protein; a protease; a proteasome regulatory particle; a protein involved in cytoskeleton organization and/or biogenesis; a protein kinase associated with microtubules; a protein kinase mitogen-activated 7; a protein serine/threonine kinase involved in cell cycle, possibly targeted to cytoskeleton; a protein serine/threonine kinase involved in eye morphogenesis; a protein which associates with cdc25 phosphatase; a protein which induces apoptosis; a ribonuclease P; a ribonuclease P protein subunit p29; a ser/thr phosphatase; a signal transduction protein; a signal transport protein; a sin3- associated polypeptide; a single stranded DNA/RNA binding protein; a sodium-dependent dicarboxylate transporters; a ssDNA/RNA binding proteins; a striatin, calmodulin-binding protein (STRN); a structural protein of ribosome involved in protein biosynthesis; a subtelomeric heterochromatin repeats; a sugar acetylase; a sugar modification protein; a suppresspr of ras; a tRNA processing enzyme Ribonuclease P protein subunit; a thyroid hormone responsive gene; a tie receptor protein tyrosine kinase; a transacylase; a transcription factor; a transcription factor involved in chromatin remodelling; a transcriptional regulation of c-myc expression; a transcriptional regulator; a transcriptional regulators/telomeric silencing; a translation initiation factor; a tumor metastasis inhibitor; a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; a ubiquitin carrier protein; a ubiquitin-conjugating enzyme; a ugtUDP-glucose-glycoprotein glucosyltransferase; a zinc finger protein; an RNA polymerase II transcription factor; an acetylcholinesterase (NT blood, group) precursor; an actin binding protein; an actin dependent regulator of chromatin; an acyl-CoA-binding protein; an alanine :glyoxylate aminotransferase; an alpha esterase; an ankyrin protein; an imitation-SWI protein; and an integrin beta 4 binding protein. POLYPEPTIDES It will be understood that polypeptides of the invention are not limited to polypeptides having the amino acid sequence set out in Examples 1 to 70 or fragments thereof but also include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof. Thus polypeptides of the invention also include those encoding homologues from other species including animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans. More specifically, homologues included within the scope of the invention include human homologues. Thus, the present invention covers variants, homologues or derivatives of the amino acid sequence set out in Examples 1 to 70, as well as variants, homologues or derivatives of the nucleotide sequence coding for the amino acid sequences of the present invention. In the context of the present invention, a homologous sequence is taken to include an amino acid sequence which is at least 15, 20, 25, 30, 40, 50, 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 50 or 100, preferably 200, 300, 400 or 500 amino acids with any one of the polypeptide sequences shown in the Examples. In particular, homology should typically be considered with respect to those regions of the sequence known to be essential for protein function rather than non-essential neighbouring sequences. This is especially important when considering homologous sequences from distantly related organisms. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These publicly and commercially available computer programs can calculate % homology between two or more sequences. % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids). Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology. However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al, 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al, 1999 ibid- Chapter 18), FASTA (Atschul et al, 1990, J. Mol. Biol, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program. Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62. Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. The terms "variant" or "derivative" in relation to the amino acid sequences of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains substantially the same activity as the unmodified sequence, preferably having at least the same activity as the polypeptides presented in the sequence listings in the Examples. Polypeptides having the amino acid sequence shown in the Examples, or fragments or homologues thereof may be modified for use in the present invention. Typically, modifications are made that maintain the biological activity of the sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the biological activity of the unmodified sequence. Alternatively, modifications may be made to deliberately inactivate one or more functional domains of the polypeptides of the invention. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide. Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: Polypeptides of the invention also include fragments of the full length sequences mentioned above. Preferably said fragments comprise at least one epitope. Methods of identifying epitopes are well known in the art. Fragments will typically comprise at least 6 amino acids, more preferably at least 10, 20, 30, 50 or 100 amino acids. Proteins of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Proteins of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the function of the protein of interest sequence. Proteins of the invention may also be obtained by purification of cell extracts from animal cells. Proteins of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A protein of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%), 98% or 99% of the protein in the preparation is a protein of the invention. A polypeptide of the invention may be labeled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. 125 I, enzymes, antibodies, polynucleotides and linkers such as biotin. Labeled polypeptides of the invention may be used in diagnostic procedures such as immunoassays to determine the amount of a polypeptide of the invention in a sample. Polypeptides or labeled polypeptides of the invention may also be used in serological or cell- mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols. A polypeptide or labeled polypeptide of the invention or fragment thereof may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labeled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to the polypeptides or their allelic or species variants by immunoassay. Immunoassay methods are well known in the art and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said polypeptide is formed. Polypeptides of the invention may be used in in vitro or in vivo cell culture systems to study the role of their corresponding genes and homologues thereof in cell function, including their function in disease. For example, truncated or modified polypeptides may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides of the invention may be introduced into the cell by in situ expression of the polypeptide from a recombinant expression vector (see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide. The use of appropriate host cells, such as insect cells or mammalian cells, is expected to provide for such post-translational modifications (e.g. myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Such cell culture systems in which polypeptides of the invention are expressed may be used in assay systems to identify candidate substances which interfere with or enhance the functions of the polypeptides of the invention in the cell. POLYNUCLEOTIDES Polynucleotides of the invention include polynucleotides that comprise any one or more of the nucleic acid sequences set out in Examples 1 to 70 and fragments thereof. Polynucleotides of the invention also include polynucleotides encoding the polypeptides of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed. Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention. The terms "variant", "homologue" or "derivative" in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence. Preferably said variant, homologues or derivatives code for a polypeptide having biological activity. As indicated above, with respect to sequence homology, preferably there is at least 50 or 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is the GCG Wisconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and -9 for each mismatch. The default gap creation penalty is -50 and the default gap extension penalty is -3 for each nucleotide. The present invention also encompasses nucleotide sequences that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length. The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction technologies. Polynucleotides of the invention capable of selectively hybridising to the nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides. The term "selectively hybridizable" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with 32 P. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Nol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below. Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe); high stringency at about 5°C to 10°C below Tm; intermediate stringency at about 10°C to 20°C below Tm; and low stringency at about 20°C to 25°C below Tm. As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences. In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions (e.g. 65°C and 0.1 SSC {lxSSC = 0.15 MΝaCl, 0.015 M Νa 3 Citrate pH 7.0). Where the polynucleotide of the invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention. Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the Examples. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any on of the sequences shown in the Examples under conditions of medium to high stringency. The nucleotide sequences of the human homologues described in the Examples, may preferably be used to identify other primate/mammalian homologues since nucleotide homology between human sequences and mammalian sequences is likely to be higher than is the case for the Drosophila sequences identified herein. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention. Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used. The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. It will be appreciated by the skilled person that overall nucleotide homology between sequences from distantly related organisms is likely to be very low and thus in these situations degenerate PCR may be the method of choice rather than screening libraries with labeled fragments the sequences disclosed in the Examples. In addition, homologous sequences may be identified by searching nucleotide and/or protein databases using search algorithms such as the BLAST suite of programs. This approach is described in the Examples. Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences, such as the sequences disclosed in the Examples. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides. For example, further changes may be desirable to represent particular coding changes found in the sequences disclosed in the Examples which give rise to mutant genes which have lost their regulatory function. Probes based on such changes can be used as diagnostic probes to detect such mutants. Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labeled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 8, 9, 10, or 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein. Polynucleotides such as a DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art. Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector Polynucleotides or primers of the invention may carry a revealing label. Suitable labels include radioisotopes such as 32 P or 35 S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers of the invention and may be detected using by techniques known per se. Polynucleotides or primers of the invention or fragments thereof labeled or unlabeled may be used by a person skilled in the art in nucleic acid-based tests for detecting or sequencing polynucleotides of the invention in the human or animal body. Such tests for detecting generally comprise bringing a biological sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridising conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilising the probe on a solid support, removing nucleic acid in the sample which is not hybridised to the probe, and then detecting nucleic acid which has hybridised to the probe. Alternatively, the sample nucleic acid may be immobilised on a solid support, and the amount of probe bound to such a support can be detected. Suitable assay methods of this and other formats can be found in for example WO89/03891 and WO90/13667. Tests for sequencing nucleotides of the invention include bringing a biological sample containing target DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridising conditions and determining the sequence by, for example the Sanger dideoxy chain termination method (see Sambrook et al.). Such a method generally comprises elongating, in the presence of suitable reagents, the primer by synthesis of a strand complementary to the target DNA or RNA and selectively terminating the elongation reaction at one or more of an A, C, G or T/U residue; allowing strand elongation and termination reaction to occur; separating out according to size the elongated products to determine the sequence of the nucleotides at which selective termination has occurred. Suitable reagents include a DNA polymerase enzyme, the deoxynucleotides dATP, dCTP, dGTP and dTTP, a buffer and ATP. Dideoxynucleotides are used for selective termination. Tests for detecting or sequencing nucleotides of the invention in a biological sample may be used to determine particular sequences within cells in individuals who have, or are suspected to have, an altered gene sequence, for example within cancer cells including leukaemia cells and solid tumours such as breast, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone tumours. Cells from patients suffering from a proliferative disease may also be tested in the same way. In addition, the identification of the genes described in the Examples will allow the role of these genes in hereditary diseases to be investigated. In general, this will involve establishing the status of the gene (e.g. using PCR sequence analysis), in cells derived from animals or humans with, for example, neurological disorders or neoplasms. The probes of the invention may conveniently be packaged in the form of a test kit in a suitable container. In such kits the probe may be bound to a solid support where the assay format for which the kit is designed requires such binding. The kit may also contain suitable reagents for treating the sample to be probed, hybridising the probe to nucleic acid in the sample, control reagents, instructions, and the like. NUCLEIC ACID VECTORS Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E. coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells. Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences. The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators. Vectors of the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Vectors will be chosen that are compatible with the host cell used. The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell. Control sequences operably linked to sequences encoding the polypeptide of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers. The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other eukaryotic cells, such as insect cells, may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α-actin, β-actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RS V) LTR promoter or the human cytomegalovirus (CMV) IE promoter. It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated. In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above. Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of RNAs transcribed from genes comprising any one of the polynucleotides of the invention. HOST CELLS Vectors and polynucleotides of the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides of the invention encoded by the polynucleotides of the invention. Although the polypeptides of the invention may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells. Vectors/polynucleotides of the invention may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation. PROTEIN EXPRESSION AND PURIFICATION Host cells comprising polynucleotides of the invention may be used to express polypeptides of the invention. Host cells may be cultured under suitable conditions which allow expression of the proteins of the invention. Expression of the polypeptides of the invention may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG. Polypeptides of the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption. Polypeptides of the invention may also be produced recombinantly in an in vitro cell- free system, such as the TnT™ (Promega) rabbit reticulocyte system. ANTIBODIES The invention also provides monoclonal or polyclonal antibodies to polypeptides of the invention or fragments thereof. Thus, the present invention further provides a process for the production of monoclonal or polyclonal antibodies to polypeptides of the invention. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing an epitope(s) from a polypeptide of the invention. Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an epitope from a polypeptide of the invention contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art. hi order that such antibodies may be made, the invention also provides polypeptides of the invention or fragments thereof haptenised to another polypeptide for use as immunogens in animals or humans. Monoclonal antibodies directed against epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody- producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. Panels of monoclonal antibodies produced against epitopes in the polypeptides of the invention can be screened for various properties; i.e., for isotype and epitope affinity. An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art. Antibodies, both monoclonal and polyclonal, which are directed against epitopes from polypeptides of the invention are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotype antibodies. Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the agent against which protection is desired. Techniques for raising anti-idiotype antibodies are known in the art. These anti- idiotype antibodies may also be useful in therapy. For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400. Antibodies may be used in method of detecting polypeptides of the invention present in biological samples by a method which comprises: (a) providing an antibody of the invention; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed. Suitable samples include extracts tissues such as brain, breast, ovary, lung, colon, pancreas, testes, liver, muscle and bone tissues or from neoplastic growths derived from such tissues. Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. ASSAYS The present invention provides assays that are suitable for identifying substances which bind to polypeptides of the invention and which affect, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (GO), GI progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, cytokinesis functions, chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways. In addition, assays suitable for identifying substances that interfere with binding of polypeptides of the invention, where appropriate, to components of cell division cycle machinery. This includes not only components such as microtubules but also signalling components and regulatory components as indicated above. Such assays are typically in vitro. Assays are also provided that test the effects of candidate substances identified in preliminary in vitro assays on intact cells in whole cell assays. The assays described below, or any suitable assay as known in the art, may be used to identify these substances. According to one aspect of the invention, therefore, we provide one or more substances identified by any of the assays described below, viz, mitosis assays, meiotic assays, polypeptide binding assays, microtubule binding/polymerisation assays, microtubule purification and binding assays, microtubule organising centre (MTOC) nucleation activity assays, motor protein assay, assay for spindle assembly and function, assays for dna replication, chromosome condensation assays, kinase assays, kinase inhibitor assays, and whole cell assays, each as described in further detail below. CANDIDATE SUBSTANCES A substance that inhibits cell cycle progression as a result of an interaction with a polypeptide of the invention may do so in several ways. For example, ifthe substance inhibits cell division, mitosis and/or meiosis, it may directly disrupt the binding of a polypeptide of the invention to a component of the spindle apparatus by, for example, binding to the polypeptide and masking or altering the site of interaction with the other component. A substance which inhibits DNA replication may do so by inhibiting the phosphorylation or de-phosphorylation of proteins involved in replication. For example, it is known that the kinase inhibitor 6-DMAP (6-dimethylaminopurine) prevents the initiation of replication (Blow, JJ, 1993, J Cell Bioll22,993-1002). Candidate substances of this type may conveniently be preliminarily screened by in vitro binding assays as, for example, described below and then tested, for example in a whole cell assay as described below. Examples of candidate substances include antibodies which recognise a polypeptide of the invention. A substance which can bind directly to a polypeptide of the invention may also inhibit its function in cell cycle progression by altering its subcellular localisation and hence its ability to interact with its normal substrate. The substance may alter the subcellular localisation of the polypeptide by directly binding to it, or by indirectly disrupting the interaction of the polypeptide with another component. For example, it is known that interaction between the p68 and pi 80 subunits of DNA polymerase alpha- primase enzyme is necessary in order for pi 80 to translocate into the nucleus (Mizuno et al (1998) Mol Cell Bioll 8,3552-62), and accordingly, a substance which disrupts the interaction between p68 and pi 80 will affect nuclear translocation and hence activity of the primase. A substance which affects mitosis may do so by preventing the polypeptide and components of the mitotic apparatus from coming into contact within the cell. These substances may be tested using, for example the whole cells assays described below. Non-functional homologues of a polypeptide of the invention may also be tested for inhibition of cell cycle progression since they may compete with the wild type protein for binding to components of the cell division cycle machinery whilst being incapable of the normal functions of the protein or block the function of the protein bound to the cell division cycle machinery. Such non-functional homologues may include naturally occurring mutants and modified sequences or fragments thereof. Alternatively, instead of preventing the association of the components directly, the substance may suppress the biologically available amount of a polypeptide of the invention. This may be by inhibiting expression of the component, for example at the level of transcription, transcript stability, translation or post-translational stability. An example of such a substance would be antisense RNA or double-stranded interfering RNA sequences which suppresses the amount of mRNA biosynthesis. Suitable candidate substances include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size, based on the sequence of the polypeptides described in the Examples, or variants of such peptides in which one or more residues have been substituted. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used. Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for a polypeptide of the invention. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of binding of a polypeptide of the invention to the cell division cycle machinery, for example mitotic/meiotic apparatus (such as microtubules). The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. Candidate substances which show activity in in vitro screens such as those described below can then be tested in whole cell systems, such as mammalian cells which will be exposed to the inhibitor and tested for inhibition of any of the stages of the cell cycle. Polypeptide Binding Assays One type of assay for identifying substances that bind to a polypeptide of the invention involves contacting a polypeptide of the invention, which is immobilised on a solid support, with a non-immobilised candidate substance determining whether and/or to what extent the polypeptide of the invention and candidate substance bind to each other. Alternatively, the candidate substance may be immobilised and the polypeptide of the invention non-immobilised. In a preferred assay method, the polypeptide of the invention is immobilised on beads such as agarose beads. Typically this is achieved by expressing the component as a GST-fusion protein in bacteria, yeast or higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts using glutathione-agarose beads (Smith and Johnson, 1988). As a control, binding of the candidate substance, which is not a GST- fusion protein, to the immobilised polypeptide of the invention is determined in the absence of the polypeptide of the invention. The binding of the candidate substance to the immobilised polypeptide of the invention is then detennined. This type of assay is known in the art as a GST pulldown assay. Again, the candidate substance may be immobilised and the polypeptide of the invention non-immobilised. It is also possible to perform this type of assay using different affinity purification systems for immobilising one of the components, for example Ni-NTA agarose and histidine-tagged components. Binding of the polypeptide of the invention to the candidate substance may be determined by a variety of methods well-known in the art. For example, the non- immobilised component may be labeled (with for example, a radioactive label, an epitope tag or an enzyme-antibody conjugate). Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used. Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 μg/ml, more preferably from 200 to 300 μg/ml. Microtubule Binding/Polymerisation Assays In the case of polypeptides of the invention that bind to microtubules, another type of in vitro assay involves determining whether a candidate substance modulates binding of a polypeptide of the invention to microtubules . Such an assay typically comprises contacting a polypeptide of the invention with microtubules in the presence or absence of the candidate substance and determining ifthe candidate substance has an affect on the binding of the polypeptide of the invention to the microtubules. This assay can also be used in the absence of candidate substances to confirm that a polypeptide of the invention does indeed bind to microtubules. Microtubules may be prepared and assays conducted as follows: Microtubule Purification and Binding Assays Microtubules are purified from 0-3h-old Drosophila embryos essentially as described previously (Saunders, et al., 1997). About 3 ml of embryos are homogenized with a Dounce homogenizer in 2 volumes of ice-cold lysis buffer (0.1 M Pipes/NaOH, pH6.6, 5 mM EGTA, 1 mM MgSO4, 0.9 M glycerol, 1 mM DTT, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The microtubules are depolymerized by incubation on ice for 15 min, and the extract is then centrifuged at 16,000 g for 30 min at 4°C. The supernatant is recentrifuged at 135,000 g for 90 min at 4°C. Microtubules in this later supernatant are polymerized by addition of GTP to 1 mM and taxol to 20 μM and incubation at room temperature for 30 min. A 3 ml aliquot of the extract is layered on top of 3 ml 15% sucrose cushion prepared in lysis buffer. After centrifuging at 54,000g for 30 min at 20 °C using a swing out rotor, the microtubule pellet is resuspended in lysis buffer. Microtubule overlay assays are performed as previously described (Saunders et al, 1997). 500 ng per lane of recombinant Asp, recombinant polypeptide, and bovine serum albumin (BSA, Sigma) are fractionated by 10% SDS-PAGE and blotted onto PVDF membranes (Millipore). The membranes are preincubated in TBST (50mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 5% low fat powdered milk (LFPM) for 1 h and then washed 3 times for 15 min in lysis buffer. The filters are then incubated for 30 minutes in lysis buffer containing either 1 mM GDP, 1 mM GTP, or 1 mM GTP-γ-S. MAP -free bovine brain tubulin (Molecular Probes) is polymerised at a concentration of 2 μg/ml in lysis buffer by addition of GTP to a final concentration of 1 mM and incubated at 37°C for 30 min. The nucleotide solutions are removed and the buffer containing polymerised microtubules added to the membanes for incubation for lh at 37°C with addition of taxol at a final concentration of 10 μM for the final 30 min. The blots are then washed 3 times with TBST and the bound tubulin detected using standard Western blot procedures using anti-β -tubulin antibodies (Boehringer Manheim) at 2.5 μg/ml and the Super Signal detection system (Pierce). It may be desirable in one embodiment of this type of assay to deplete the polypeptide of the invention from cell extracts used to produce polymerise microtubules. This may, for example, be achieved by the use of suitable antibodies. A simple extension to this type of assay would be to test the effects of purified polypeptide of the invention upon the ability of tubulin to polymerise in vitro (for example, as used by Andersen and Karsenti, 1997) in the presence or absence of a candidate substance (typically added at the concentrations described above). Xenopus cell- free extracts may conveniently be used, for example as a source of tubulin. Microtubule Organising Centre (MTOC) Nucleation Activity Assays Candidate substances, for example those identified using the binding assays described above, may be screening using a microtubule organising centre nucleation activity assay to determine if they are capable of disrupting MTOCs as measured by, for example, aster formation. This assay in its simplest form comprises adding the candidate substance to a cellular extract which in the absence of the candidate substance has microtubule organising centre nucleation activity resulting in formation of asters. In a preferred embodiment, the assay system comprises (i) a polypeptide of the invention and (ii) components required for microtubule organising centre nucleation activity except for functional polypeptide of the invention, which is typically removed by immunodepletion (or by the use of extracts from mutant cells). The components themselves are typically in two parts such that microtubule nucleation does not occur until the two parts are mixed. The polypeptide of the invention may be present in one of the two parts initially or added subsequently prior to mixing of the two parts. Subsequently, the polypeptide of the invention and candidate substance are added to the component mix and microtubule nucleation from centrosomes measured, for example by immunostaining for the polypeptide of the invention and visualising aster formation by immuno-fluorescence microscopy. The polypeptide of the invention may be preincubated with the candidate substance before addition to the component mix. Alternatively, both the polypeptide of the invention and the candidate substance may be added directly to the component mix, simultaneously or sequentially in either order. The components required for microtubule organising centre formation typically include salt-stripped centrosomes prepared as described in Moritz et ah, 1998. Stripping centrosome preparations with 2 M KI removes the centrosome proteins CP60, CP190, CNN and γ-tubulin. Of these, neither CP60 nor CP190 appear to be required for microtubule nucleation. The other minimal components are typically provided as a depleted cellular extract, or conveniently, as a cellular extract from cells with a nonfunctional variant of a polypeptide of the invention. Typically, labeled tubulin (usually β- tubulin) is also added to assist in visualising aster formation. Alternatively, partially purified centrosomes that have not been salt-stripped may be used as part of the components. In this case, only tubulin, preferably labeled tubulin is required to complete the component mix. Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 μg/ml, more preferably from 200 to 300 μg/ml. The degree of inhibition of aster formation by the candidate substance may be determined by measuring the number of normal asters per unit area for control untreated cell preparation and measuring the number of normal asters per unit area for cells treated with the candidate substance and comparing the result. Typically, a candidate substance is considered to be capable of disrupting MTOC integrity ifthe treated cell preparations have less than 50%, preferably less than 40, 30, 20 or 10% of the number of asters found in untreated cells preparations. It may also be desirable to stain cells for γ-tubulin to determine the maximum number of possible MTOCs present to allow normalisation between samples. Motor Protein Assay Polypeptides of the invention may interact with motor proteins such as the Eg5-like motor protein in vitro. The effects of candidate substances on such a process may be detennined using assays wherein the motor protein is immobilised on coverslips. Rhodamine labeled microtubules are then added and their translocation can be followed by fluorescent microscopy. The effect of candidate substances may thus be determined by comparing the extent and/or rate of translocation in the presence and absence of the candidate substance. Generally, candidate substances known to bind to a polypeptide of the invention, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of motor proteins and the resulting identified substances tested for affects on a polypeptide of the invention as described above. Typically this assay uses microtubules stabilised by taxol (e.g. Howard and Hyman 1993; Chandra and Endow, 1993 - both chapters in "Motility Assays for Motor Proteins" Ed Jon Scholey, pub Academic Press). If however, a polypeptide of the invention were to promote stable polymerisation of microtubules (see above) then these microtubules could be used directly in motility assays. Simple protein-protein binding assays as described above, using a motor protein and a polypeptide of the invention may also be used to confirm that the polypeptide of the invention binds to the motor protein, typically prior to testing the effect of candidate substances on that interaction. Assay for Spindle Assembly and Function A further assay to investigate the function of polypeptide of the invention and the effect of candidate substances on those functions is an assay which measures spindle assembly and function. Typically, such assays are performed using Xenopus cell free systems, where two types of spindle assembly are possible. In the "half spindle" assembly pathway, a cytoplasmic extract of CSF arrested oocytes is mixed with sperm chromatin. The half spindles that form subsequently fuse together. A more physiological method is to induce CSF arrested extracts to enter interphase by addition of calcium, whereupon the DNA replicates and kinetochores form. Addition of fresh CSF arrested extract then induces mitosis with centrosome duplication and spindle formation (for discussion of these systems see Tournebize and Heald, 1996). Again, generally, candidate substances known to bind to a polypeptide of the invention, or non-functional polypeptide variants of the invention, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of spindle formation and function and the resulting identified substances tested for affects binding of the polypeptide of the invention as described above. Assays for DNA Replication Another assay to investigate the function of polypeptide of the invention and the effect of candidate substances on those functions is as assay for replication of DNA. A number of cell free systems have been developed to assay DNA replication. These can be used to assay the ability of a substance to prevent or inhibit DNA replication, by conducting the assay in the presence of the substance. Suitable cell-free assay systems include, for example the SV-40 assay (Li and Kelly, 1984, Proc. Natl. Acad. Sci USA 81, 6973-6977; Waga and Stillman, 1994, Nature 369, 207-212.). A Drosophila cell free replication system, for example as described by Crevel and Cotteril (1991), EMBO J 10, 4361-4369, may also be used. A preferred assay is a cell free assay derived horn. Xenopus egg low speed supernatant extracts described in Blow and Laskey (1986, Cell 47,577-587) and Sheehan et al. (1988, J Cell Biol. 106, 1-12), which measures the incorporation of nucleotides into a substrate consisting of Xenopus sperm DNA or HeLa nuclei. The nucleotides may be radiolabelled and incorporation assayed by scintillation counting. Alternatively and preferably, bromo-deoxy-uridine (BrdU) is used as a nucleotide substitute and replication activity measured by density substitution. The latter assay is able to distinguish genuine replication initiation events from incorporation as a result of DNA repair. The human cell-free replication assay reported by Krude, et al (1997), Cell 88, 109- 19 may also be used to assay the effects of substances on the polypeptides of the invention. Other In Vitro Assays Other assays for identifying substances that bind to a polypeptide of the invention are also provided. For example, substances which affect chromosome condensation may be assayed using the in vitro cell free system derived from Xenopus eggs, as known in the art. Substances which affect kinase activity or proteolysis activity are of interest. It is known, for example, that temporal control of ubiquitin-proteasome mediated protein degradation is critical for normal GI and S phase progression (reviewed in Krek 1998, Curr Opin Genet Dev 8, 36-42). A number of E3 ubiquitin protein ligases, designated SCFs (Skpl-cullin-F-box protein ligase complexes), confer substrate specificity on ubiquitination reactions, while protein kinases phosphorylate substrates destined for destruction and convert them into preferred targets for ubiquitin modification catalyzed by SCFs. Furthermore, ubiquitin-mediated proteolysis due to the anaphase-promoting complex/cyclosome (APC/C) is essential for separation of sister chromatids during mitosis, and exit from mitosis (Listovsky et al., 2000, Exp Cell Res 255, 184-191). Substances which inhibit or affect kinase activity may be identified by means of a kinase assay as known in the art, for example, by measuring incorporation of P into a suitable peptide or other substrate in the presence of the candidate substance. Similarly, substances which inhibit or affect proteolytic activity may be assayed by detecting increased or decreased cleavage of suitable polypeptide substrates. Assays for these and other protein or polypeptide activities are known to those skilled in the art, and may suitably be used to identify substances which bind to a polypeptide of the invention and affect its activity. Whole Cell Assays Candidate substances may also be tested on whole cells for their effect on cell cycle progression, including mitosis and/or meiosis. Preferably the candidate substances have been identified by the above-described in vitro methods. Alternatively, rapid throughput screens for substances capable of inhibiting cell division, typically mitosis, may be used as a preliminary screen and then used in the in vitro assay described above to confirm that the affect is on a particular polypeptide of the invention. The candidate substance, i.e. the test compound, may be administered to the cell in several ways. For example, it may be added directly to the cell culture medium or injected into the cell. Alternatively, in the case of polypeptide candidate substances, the cell may be transfected with a nucleic acid construct which directs expression of the polypeptide in the cell. Preferably, the expression of the polypeptide is under the control of a regulatable promoter. Typically, an assay to determine the effect of a candidate substance identified by the method of the invention on a particular stage of the cell division cycle comprises administering the candidate substance to a cell and determining whether the substance inhibits that stage of the cell division cycle. Techniques for measuring progress through the cell cycle in a cell population are well known in the art. The extent of progress through the cell cycle in treated cells is compared with the extent of progress through the cell cycle in an untreated control cell population to determine the degree of inhibition, if any. For example, an inhibitor of mitosis or meiosis may be assayed by measuring the proportion of cells in a population which are unable to undergo mitosis/meiosis and comparing this to the proportion of cells in an untreated population. The concentration of candidate substances used will typically be such that the final concentration in the cells is similar to that described above for the in vitro assays. A candidate substance is typically considered to be an inhibitor of a particular stage in the cell division cycle (for example, mitosis) ifthe proportion of cells undergoing that particular stage (i.e., mitosis) is reduced to below 50%, preferably below 40, 30, 20 or 10% of that observed in untreated control cell populations. THERAPEUTIC USES Many tumours are associated with defects in cell cycle progression, for example loss of normal cell cycle control. Tumour cells may therefore exhibit rapid and often aberrant mitosis. One therapeutic approach to treating cancer may therefore be to inhibit mitosis in rapidly dividing cells. Such an approach may also be used for therapy of any proliferative disease in general. Thus, since the polypeptides of the invention appear to be required for normal cell cycle progression, they represent targets for inhibition of their functions, particularly in tumour cells and other proliferative cells. The term proliferative disorder is used herein in a broad sense to include any disorder that requires control of the cell cycle, for example, cardiovascular disorders such as restenosis and cardiomyopathy, auto-immune disorders such as glomerulonephritis and rheumatoid arthritis, dermatological disorders such as psoriasis, anti-inflammatory, anti- fungal, antiparasitic disorders such as malaria, emphysema and alopecia. One possible approach is to express anti-sense constructs directed against polynucleotides of the invention, preferably selectively in tumour cells, to inhibit gene function and prevent the tumour cell from progressing through the cell cycle. Anti-sense constructs may also be used to inhibit gene function to prevent cell cycle progression in a proliferative cell. Another approach is to use non-functional variants of polypeptides of the invention that compete with the endogenous gene product for cellular components of cell cycle machinery, resulting in inhibition of function. Alternatively, compounds identified by the assays described above as binding to a polypeptide of the invention may be administered to tumour or proliferative cells to prevent the function of that polypeptide. This may be performed, for example, by means of gene therapy or by direct administration of the compounds. Suitable antibodies of the invention may also be used as therapeutic agents. Alternatively, double-stranded (ds) RNA is a powerful way of interfering with gene expression in a range of organisms that has recently been shown to be successful in mammals (Wianny and Zernicka-Goetz, 2000, Nat Cell Biol 2000, 2, 70-75). Double stranded RNA conesponding to the sequence of a polynucleotide according to the invention can be introduced into or expressed in oocytes and cells of a candidate organism to interfere with cell division cycle progression. In addition, a number of the mutations described herein exhibit aberrant meiotic phenotypes. Aberrant meiosis is an important factor in infertility since mutations that affect only meiosis and not mitosis will lead to a viable organism but one that is unable to produce viable gametes and hence reproduce. Consequently, the elucidation of genes involved in meiosis is an important step in diagnosing and preventing/treating fertility problems. Thus the polypeptides of the invention identified in mutant Drosophila having meiotic defects (as is clearly indicated in the Examples) may be used in methods of identifying substances that affect meiosis. In addition, these polypeptides, and conesponding polynucleotides, may be used to study meiosis and identify possible mutations that are indicative of infertility. This will be of use in diagnosing infertility problems. ADMINISTRATION Substances identified or identifiable by the assay methods of the invention may preferably be combined with various components to produce compositions of the invention. Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable earners and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition of the invention may be administered by direct injection. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight. Polynucleotides/vectors encoding polypeptide components (or antisense constructs) for use in inhibiting cell cycle progression, for example, inhibiting mitosis or meiosis, may be administered directly as a naked nucleic acid construct. They may further comprise flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic acid administered may typically be in the range of from 1 μg to 10 mg, preferably from 100 μg to 1 mg. It is particularly prefened to use polynucleotides/ vectors that target specifically tumour or proliferative cells, for example by virtue of suitable regulatory constructs or by the use of targeted viral vectors. Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam™ and transfectam™). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition. Preferably the polynucleotide, polypeptide, compound or vector described here may be conjugated, joined, linked, fused, or otherwise associated with a membrane translocation sequence. Preferably, the polynucleotide, polypeptide, compound or vector, etc described here may be delivered into cells by being conjugated with, joined to, linked to, fused to, or otherwise associated with a protein capable of crossing the plasma membrane and/or the nuclear membrane (i.e., a membrane translocation sequence). Preferably, the substance of interest is fused or conjugated to a domain or sequence from such a protein responsible for the translocational activity. Translocation domains and sequences for example include domains and sequences from the HIV- 1 -trans-activating protein (Tat), Drosophila Antennapedia homeodomain protein and the herpes simplex- 1 virus VP22 protein. In a highly preferred embodiment, the substance of interest is conjugated with penetratin protein or a fragment of this. Penetratin comprises the sequence RQIKIWFQNRRMKWKK and is described in Derossi, et al., (l 994), J Biol. Chem. 269, 10444-50; use of penefratin-drug conjugates for intracellular delivery is described in WO/00/01417. Truncated and modified forms of penetratin may also be used, as described in WO/00/29427. Preferably the polynucleotide, polypeptide, compound or vector according to the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition. The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention. EXAMPLES Generation and Identification of Lethal, Semi-Lethal and Sterile Third Chromosome Mutants Having Defects in Mitosis and/Or Meiosis, and Second Chromosome Mutants Having Defects in Imaginal Disc Development By P-Element Insertion Mutagenesis P-element mutagenesis Transposable elements are widely used for mutagenesis in Drosophila melanogaster as they couple the advantages of providing effective genetic lesions with ease of detecting disrupted genes for the purpose of molecular cloning. To achieve near saturation of the genome with mutations resulting from mobilisation of the P-lacW transposon (a P-element marked with a mini- white gene, bearing the E.coli lacZ gene as an enhancer trap, and an E.coli replicon and ampicillin resistance gene to facilitate 'plasmid rescue' of sequences at the site of the P-insertion), Drosophila females that are homozygous for P-lacW (inserted on the X chromosome) are crossed with males carrying the transposase source P(Δ2-3) (Deak et al., 1997). Random transpositions of the mutator element are then 'captured' in lines lacking transposase activity. Stable, or balanced, stocks bearing single lethal P-lacW insertions are made. More than 41,000 lines are derived, of which approximately one-half are on the third chromosome. Originally some 3100 lethal or strong semi-lethal lines (in homozygous conditions) are identified. During preliminary characterisation unstable lines and clusters of the same mutation event are eliminated leaving 2460 lines to be characterised. Screening for Mitotic and Meiotic Defects About half of the mutants in the collection are embryonic lethals. We have carried out cytological screens of the 1155 lines that comprise late larval lethals, pupal lethals, pharate and adult semi-lethals for defective mitosis in the developing larval CNS. This has identified 69 mutations falling into 43 complementation groups that affect all stages of the mitotic cycle. The cytological screens involve examining orcein-stained squashed preparations of the larval CNS to detect abnormal mitotic cells. In lines where defects are identified, the larval CNS is subjected to immunostaining to identify centromeres, spindle microtubules and DNA for further examination. This leads to clarification of the mitotic defect. As a set of common functions are essential to both mitosis and meiosis, we then identify mutations resulting in sterility and failed progression through male meiosis. This involves examining squashed preparations larval, pupal or adult testes by phase contrast microscopy. We examine "onion stage" spermatids in the 519 pupal and pharate lethal lines and 463 adult "semi-lethal" and viable lines for variations in size and number of nuclei which provides an indication of whether there have been defects in either chromosome segregation or cytokinesis, respectively. A total of 54 lines of the 519 pupal and pharate lethal lines and 22 of the adult lines show such defects. However, another 67 lines show male sterility without having onion-stage defects. 12 lines showing onion stage defects have been scored as having mitotic defects in the independent cytological screen of squashed preparations of the larval CNS. Twelve further lines with onion stage defects show female sterility and of these, 10 show maternal effect mitotic defects in syncytial embryos. Thus greater than one half of the meiotic mutants scored appear to represent cell division functions specific to male meiosis or have targeted male germ-line specific enhancer elements, thus revealing their meiotic function but in this test not their mitotic function. Further characterisation of testis preparations of each line by phase-contrast microscopy with and without staining with Hoechst to reveal DNA defined 6 broad categories of meiotic mutants: 8 mutants from the collection show defects in meiotic entry or at early stages in the first meiotic division (MF1-8). 18 mutants (15 complementation groups) show abnormal meiotic spindles (AB1- 16). Mutants in this group almost invariably show an associated weak defect in cytokinesis, and 7 show a strong defect in spermatid differentiation. 3 of these mutants also show mitotic defects in larval brains or in embryos derived from homozygous mutant mothers. 18 mutants (16 complementation groups) also show abnormal meiotic spindles that ' are strongly multipolar (MULl-15). Three of these also show maternal effect mitotic abnormalities of multipolar spindles in syncytial embryos. 4 mutants (3 complementation groups) show strong defects at all stages of spermatogenesis from the pre-meiotic stages to spermatid elongation stages (PL1-3). In this respect they resemble the polo 1 mutation. 4 mutants show segregation defects as indicated by spermatid nuclei of heterogeneous sizes (SEGl-4). The spindles appear normal but all have what are either chromosome bridges or lagging chromosomes. One of these also shows a maternal effect. 9 mutants (7 complementation groups) show predominant cytokinesis defects. Two complementation groups also have cytokinesis defects in mitotic cells in the larval brain. In the Examples below, the designations MF, AB, MUL, PL, SEG or CK are included in the category description where available. Further phenotype information for each mutant described in the results section is provided in the "Phenotype" field. There is considerable overlap between these categories, and it will be of much interest to distinguish between mutants in which the primary defect results in secondary consequences, and mutants that affect more than one aspect of spermatogenesis, as for example appears to be the case with_pø/o mutants (Sunkel and Glover, 1988; Carmena et al, 1998). In the Examples, lines exhibiting mitotic and meiotic phenotypes are categorised generally into four categories: Category 1 : Failure to complete cytokinesis Category 2 : Failure to enter M-phase Category 3 : Metaphase arrest Category 4: Anaphase defect Category 5: Small Imaginal Discs (Block to Proliferation; see below) Category 1 phenotypes are exhibited by mutations in Examples 1 to 14; while Category 2 phenotypes are exhibited by mutations in Examples 15 to 19. Category 3 phenotypes are exhibited by mutations in Examples 20 to 30, Category 4 phenotypes are exhibited by mutations in Examples 31 to 53. Mutations in Examples 54 to 74 exhibit a Category 5 phenotype. Generation and identification of second chromosome mutants having small or no imaginal discs. In the case of the second chromosome the flies used were from a second chromosome P-element collection established in Szeged, Hungary (Torok et al, 1993). The process of P-element insertion mutagenesis is essentially as described above. 15475 insertions were recovered, of which 2711 were lethal or semi-lethal. After elimination of clusters of identical mutants, 2399 lines representing 1748 independent lethal insertions were recovered. Lines were chosen from the second chromosome collection on the basis of having small or no imaginal discs, to indicate a disruption in cell cycle progression that leads to underdevelopment of the discs. All the second chromosome mutants referred to in the results section are noted under the "Phenotype" field as "second chromosome, small imaginal discs" and comprise Category 5. Cytological Mapping of the P-Element Insertion Sites The site of insertion of the P-element in each mutant line was determined by in situ hybridisation of P-element DNA to salivary gland polytene chromosomes as described in Saunders et al., 1989. Wandering third stage larvae were dissected and fixed as described and incubated with biotin-labeled DNA made from the P-lacW plasmid. After signal detection chromosomes were stained with Giemsa and examined by microscopy and signals indicating the presence of P elements were assigned to polytene chromosome bands refening to the Bridges map (Lefevre, 1976). In the majority of cases a single P element was detected, only 10% of lines having multiple (two or three) insertions. The site of insertion is given as the "Map Position" field in the results section (for example 77B) Plasmid Rescue of P-Elements from Mutant Drosophila Lines Genomic DNA was isolated from adult flies by the method of Jowett et al., 1986, and plasmid rescue from the genomic DNA was performed according to Pinotta et al., 1986. This allows the recovery of genomic DNA adjacent to the P-element which facilitates the identification of the site of P-element insertion and of genes which may be disrupted by the insertion. Essentially, genomic DNA derived from about 200 flies was digested with a restriction enzyme known to have a site within the P-element (EcoRl or SacII for cloning sequences to the left of the element, or Xbal, Bglll, Pstl or BamHI for sequences to the right of the element). The digested DNA was ligated overnight, and plasmids recovered by electroporation of the ligated DNA into E. coli XL 1 -blue competent cells. Appropriate primers from within the P-lacW sequence were used to determine the sequence of the genomic DNA flanking the element (on average, 400 bp of sequence were obtained). The rescue sequences are provided in the results section under the heading "Rescue sequence". Where more than one sequence was recovered, the orientation of each sequence is also given. Sequence Analysis of P Element Insertion Lines Sequences flanking the insertion site of the P-element were derived by P element rescue as described above. In some cases sequence was obtained from only one side of the insertion, while in other cases sequences were obtained from both sides of the insertion. As a first step, each P element rescue sequence was used to search a total database of Drosophila melanogaster sequences (database of the Berkley Drosophila Genome project) using the BLASTN program (which compares a nucleic acid sequence with a nucleic acid database, (Altschul and Lipman 1990)) with default parameters. The search may identify a number of different types of match including Drosophila ESTs, known Drosophila genes and cloned genomic regions. The ability to identify genes already known to be essential for cell cycle progression using this approach was confirmed, in this example, by the rescue sequence obtained from line 1324/8 which mapped to the 77B locus which was used to search the database. A BLASTN search identified a number of matching Drosophila ESTs, a match with the known cell cycle regulatory gene polo and a cloned genomic region designated CSC: AC018188. These matches are recorded in the results sections under the field headings "Drosophila ESTs", "Drosophila gene hit" and "Genomic hit, Accession No.", respectively. Any entries under "Drosophila gene hit" are further annotated with "(BLASTN with Rescue sequence)" to show that the match was obtained using the rescue sequence rather than a Drosophila EST or genomic clone ORF (see below). Accession numbers of ESTs, genes and genomic clones are provided where known. Genomic clones designations often include the Genbank designation as part of a longer designation. However the Genbank designation is always the code beginning with "AC" and followed by six digits. Where an EST was identified, this was subsequently used to search using the BLASTX program (default parameters) against databases of sequences from Drosophila and Homo sapiens (databases of the National centre for Biotechnology Information (NCBI), National Library of Medicine, National Institue of Health, USA). In the case of line 1104/16, the search identified a known human gene, phosphatidylinositol transfer protein (accession no. P48739) implying a novel function for this protein in cytokinesis. Human Homologues identified as a result of a BLASTX search using a Drosophila EST are shown in the results section under the heading "Human homologues" and annotated with "(BLASTX with EST)". Drosophila genes identified as a result of a BLASTX search using a Drosophila EST are shown in the results section under the heading "Drosophila gene hit" and annotated with "(BLASTX with EST)". Where no Drosophila gene was identified using the initial BLASTN search but a matching genomic clone was found (a Bac or PI clone often in excess of 100 kilobases), a 20 kilobase segment of this genomic sequence (10 kilobases either side flanking the site of the P-element insertion) was subjected to a number of analyses. Ifthe rescue sequence matched sequences that lie within a known gene present within the genomic clone then these are presented under the heading "Drosophila gene hit (BLASTN with Rescue sequence". The known gene sequence was then used in a BLASTX search of a human database (NCBI - see above) to identify any human homologues. These are shown in the "Human homologue" field and annotated with "(BLASTX with Drosophila gene)". Ifthe rescue sequence does not match any sequences that lie with a known gene within the genomic clone then the occunence of ORFs within the 20 kilobase genomic segment was predicted using the Genscan programme (Burge and Karlin, 1997). Where the P-element was observed to be inserted into the coding region or within the 5' untranslated region (which we defined as within 2 kilobases of the predicted start of the coding region) we assume the P element to be capable of disrupting the expression of the predicted gene. Each predicted open reading frame (or predicted coding sequence) was then used to search Drosophila and human databases using the TBLASTN program (compares a protein query sequence against a nucleotide sequence database dynamically translated in all reading frames) and/or the TBLASTX program (compares a nucleotide query sequence dynamically translated in all reading frames against a nucleotide sequence database dynamically translated in all reading frames) to determine whether the predicted open reading frame conesponded to a known gene. Typically, TBLASTX is only used when no matches are found using TBLASTN. Where the TBLASTN search found a known Drosophila gene, then this is indicated in the results in the "Drosophila gene hit" field, annotated with "(TBLASTN with predicted ORF)". The Drosophila gene sequence was then typically used to search a human database (NCBI - see above) to identify any human homologues using BLASTX. These are shown in the "Human homologue" field and annotated with "(BLASTX with Drosophila gene)". Where the TBLASTN and/or TBLASTX search found a known human gene, then this is indicated in the results in the "Human homologue" field, annotated with "(TBLASTN (or TBLASTX) with predicted ORF)". Ifthe TBLASTN and/or TBLASTX search found no Drosophila or human genes, then it was assumed that the original ORF conesponds to a novel gene. Ifthe TBLASTN search found no Drosophila genes but identified a human homologue, then it was assumed that the original ORF corresponds to a novel Drosophila homologue of a known human gene. Additional Sequence Analysis using the Annotated D. melanogaster Sequence (GadFly). Rescue sequences were also used to search the fully annotated version of the Drosophila genome (GadFly; Adams, et al., 2000, Science 287, 2185-2195), using GlyBLAST at the Berkeley Drosophila Genome Projects web site to identify the genome segment (usually approximately 200-250 kb) containing the P-element insertion site. The graphic representation of the genomic fragment available at GadFly allows the identification of all real and theoretical genes which flank the site of insertion. Candidate genes where the P-element is either inserted within the gene or close to the 5' end of the gene were identified. In GadFly, the Drosophila genes are given the designation CG (Complete gene) and usually details of human homologues are also given. In most cases, this data confirms the data derived from the sequence analysis procedure described above, and in some cases new data is obtained. Where available both sets of data are included in the individual Examples described below. To identify further candidate human homologues, BLASTP (amino acid query sequence against amino acid database) searches with Drosophila sequences are used against the human genome project database and also the Ensembl dataset. The Ensembl dataset comprises Gene Wise gene predictions using a protein template where possible or Genscan followed by BLAST confirmation via protein, cDNA or EST hits. These are matched using WUBLASTP with default parameters (Altschul et al., 1990, JMol Biol 215, 403-10). The results are filtered to contain only potential homologues. Only matches with the identity of more than 50% and length of more than 50 amino acids are included. Confirmation of Cell Cycle Involvement of Candidate Genes Using Double Stranded RNA Interference (RNAi) P-elements usually insert into the region 5' to a Drosophila gene. This means that there is sometimes more than one candidate gene affected, as the P-element can insert into the 5' regions of two diverging genes (one on each DNA strand). In order to confirm which of the candidate genes is responsible for the cell cycle phenotype observed in the fly line, we use the technique of double stranded RN interference to specifically knock out gene expression in Drosophila cells in tissue culture (Clemens, et al., 2000, Proc. Natl. Acad. Sci. USA, 6499-6503). The overall strategy is to prepare double stranded RNA (dsRNA) specific to each gene of interest and to transfect this into Schneider's Drosophila line 2 to inhibit the expression of the particular gene. The dsRNA is prepared from a double stranded, gene specific PCR product with a T7 RNA polymerase binding site at each end. The PCR primers consist of 25-30 bases of gene specific sequence fused to a T7 polymerase binding site (TAATACGACTCACTATAGGGACA), and are designed to amplify a DNA fragment of around 500bp. Although this is the optimal size, the sequences in fact range from 450 bp to 650 bp. Where possible, PCR amplification is performed using genomic DNA purified from Schneider's Drosophila line 2 as a template. This is only feasible where the gene has an exon of 450 bp or more. In instances where the gene possesses only short exons of less than 450 bp, primers are designed in different exons and PCR amplification is performed using cDNA derived from Schneider's Drosophila line 2 as a template. A sample of PCR product is analysed by horizontal gel electrophoresis and the DNA purified using a Qiagen QiaQuick PCR purification kit. lμg of DNA is used as the template in the preparation of gene specific single stranded RNA using the Ambion T7 Megascript kit. Single stranded RNA is produced from both strands of the template and is purified and immediately annealed by heating to 90 degrees C for 15 mins followed by gradual cooling to room temperature overnight. A sample of the dsRNA is analysed by horizontal gel electrophoresis. 3μg of dsRNA is transfected into Schneider's Drosophila line 2 using the transfection agent, Transfect (Gibco) and the cells incubated for 72 hours prior to fixation. The DNA content of the cells is analysed by staining with propidium iodide and standard FACS analysis for DNA content. The cells in GI and G2/S phases of the cell cycle are visualised as two separate population peaks in normal cycling S2 cells. In each experiment, Red Fluorescent Protein dsRNA is used as a negative control. In some cases the phenotype is confirmed by fixing cells on poly-lysine covered slides which are then stained for DNA using DAPI and for tubulin using an anti-tubulin antibody YL1/2 and appropriate fluorescent secondary antibody to visualise abenant mitoses. It should be noted that RNAi could not confirm phenotype in all cases. This is to be expected as the method relies on the ability of dsRNA to prevent new protein expression. Consequently, it is necessary that S2 cells express the specific cDNA of the gene in question, and also that the protein is turned over rapidly. It would therefore probably be difficult to sufficiently reduce levels of very stable proteins using this approach. The layout of a typical entry in the results section is shown below. Not all fields present in the actual results section contain information for each individual Drosophila line described. TYPICAL RESULTS LAYOUT Line ID - Drosophila line designation Category - Description of phenotype Reversion - R = revertant, NR = non revertant, ? = not determined Map Position - according to the Bridges map (Lefevre, 1976). Rescue ID Rescue Sequence [nucleotide sequence] Genomic hit, Accession No. Associated ORF GENSCAN_predictedjpeptide [results of Genscan - amino acid sequence] GENSCAN_predicted_CDS [results of Genscan nucleotide sequence] Drosophila Gene Hit (BLASTN with rescue sequence) (TBLASTN (or TBLASTX) with predicted ORF) (BLASTX with EST) Human Homologue (BLASTX with Drosophila gene) (TBLASTN (or TBLASTX) with predicted ORF) (BLASTX with EST) Drosophila EST Annotated Drosophila genome genomic segment Annotated Drosophila genome Complete gene candidate Human homologue of Complete gene candidate Putative function Derived from homologies or Drosophila experimental data Confirmation by RNAi Description of Facs analysis DNA content profile A specific example is as follows: Line ID 1324/8 Category Mitotic defects in brain: metaphase arrest (overcondensation, some circular chromosomes, no anaphases, very high mitotic index, metaphase (or less aligned) with bipolar spindle, no CP 190 staining) Reversion R Map Position 77B Rescue ID B1E Rescue Sequence GTTTTGCCCATCGATTGCACGAAAACCAAGCACAAAGCGGAGAACGCGCCGA AACCGTTCGATTTTTTAAATGCCAAAATGAATTGGACGTGAAGCGTCAGCTGA ATTGGTGTGCCCGTTTCGGTGGCTATCGCACACTTTCTGGTATTTATCGCGGTA TTTTGTTGAGTGTTGAACAACAAATTCTATGGCCGTTACCCTTTTGAATTTACT TACTGGCGTTTACTCTGTTCGAATTGAGCGCAATATTTTTTCCTATTGCTCTGC GCAACACTGTGTTTTAACCGCTATTTATTTGAAAATCTACAAAAACTAACCGTT TACATTTTTGAAATTTCCAAAAGGGTTTTCCATAAATTGAGTTTTACTAAAACC AGTCCAACGGTCCAACTTTATATTGTTAGAAGCCCCTTTTCCTAATTTGAATTG GCTTGCAAACGTTTTCCTGAATTTAAAAATACTGCCACCCTTGTTAATTGCAGG TTTTCCGAATCCCTGATTTGTTGTTTTAAAAAGAAAATTTATTAGAAACAGCTA TCTCAACC Genomic hit, Accession No. CSC:AC018188 Drosophila Gene Hit Polo (X63361) Human Homologue BLASTX PLK-1 (P53350) Drosophila EST several including LD11851 (AA392613) which match polo Annotated Drosophila genome genomic segment AE003514 Annotated Drosophila genome Complete gene candidate CG12306 Human homolog of Complete gene candidate le-169 1709658 P53350 PLK1 TUMAN SERJNE/THREONΓNE- PROTEIN KINASE PLK (PLK-1) Putative function Serine/threonine kinase known to be required for mitosis Confirmation by RNAi Reduced GI and G2/M peaks indicating fewer cycling cells, microscopy analysis of DNA and tubulin staining identified monopolar spindles characteristic of polo mutation in Drosophila. CATEGORY 1: FAILURE TO COMPLETE CYTOKINESIS Example 1 (Category 1) Line ID 1031/14 Category Mitotic defects in brain: cytokinesis defect (polyploidy) Reversion R Map Position 74B Rescue ID 2A3B Rescue Sequence 1 CCCCGGAACATATGTTCAGTGTGGCCGCAGCAGAGTTGTCAAAACACGCTCCC CAATGAAATAACCTAAATGTGCCATCACTGTTACTTAACAGTTTCTGTTACTTT TCTAGCGGCATGTCAAAAAAACAAAAATATAGAAAATGCTAAATATATATTG GACTAATGTGTTTAAATGTAACTTACACTAGTAACAGATCCCCATTAATAAAA GCCAAACTCTAAAATTCTGCCACAAGTACTATTTCTCACGTAACACCTTACTA ACGGATTTCACATGATATCTACGACAAGAAACTGTTTGCTGATATAAAATTGC TATCACCGCTTTCCGTAAACACTTTTACACTGATGGATTACAAGTTCAATTAAT ACATCAACTTACCTTAACAATTTTAAGACAACTAACACTCCCACAATTTAATT CAACCTACACCGCTTGATAATCAGCTGTTCTGTACAAAAAACAATAACACTGT TAACAACAGCGCACAGTGGATAATACAGTCCTAAAGGCAATATACCCATTTG GCATTTTT Rescue ID 2A3S Rescue Sequence 2 TTCCGGGGAGAATGGCTGCGATTTCGCGTCGGTAAAAATAGCAAATACTCGTTA ATGTGCTGTGGGAACGCTTCCTCCCCGGCCCCAAAGTGGCCCCGAAGAAAGTGA GCAAATGTGCGCGCCGCAAGATAGTCGCCGCCGAACAAACGATAGTGACGAAA GTGATTTAATTCAACTACCAGCACTCCCGCAAATACGATGAGTATGTCGCGCGG CGGCAACACAACTCTGGACTTGCAGCCGCTCCTGGCGGAGAGCGATGTCGGAA ACAGGGAGCTGGAGGAGAAGATGGGCGGATCGGCGGATCGGTCATCGCTGCTC GATGGATCCGGTTCGAAGGAGCTGAGTCACCGGGAACGCGAGGACTCGGCGTT GTTCGTCAAGAAGATCGGGAGCGCCTTGTTCTATGGCTTGTCCTCCTTCATGATT ACGGTGGTAAACAAGACGGTGCTTACCTCCTACCACTTCCCCTCGTTCCTGTTCC TCAGCCTCGGGCAACTTACTGCTAGCATTGTGGTCCTGGGCATGGGCAAAGCGC CTGAAAATGGTGAACTTTTCCCCTTTTGCAGAGGAATACCTTCGCCAAGATCTTT CCGCTGCCACTGATATTTCTGGGAAACATGATGTTTGGACTGGGTGGCACAAAA ACCTTGAGTCTGCCCATGTTCGCAGCCCTACGAC Genomic hit, Accession No. AC019515 Associated ORF Genscan ORF1 predicted sequences:>15:31:57|GENSCANjpredicted_peptide_4|373_aa MSMSRGGNTTLDLQPLLAESDNGNRELEEKMGGSADRSSLLDGSGSKELSHRER EDSALFVKKIGSALFYGLSSFMITVVNKTVLTSYHFPSFLFLSLGQLTASIVVLGMG KRLKLVNFPPLQRNTFAKIFPLPLIFLGNMMFGLGGTKTLSLPMFAALRRFSILMT MLLELKILGLRPSNAVQVSVYAMIGGALLAASDDLSFNMRGYIYVMITNALTASN GVYVKKKLDTSEIGKYGLMYYNSLFMFLPALALNYVTGNLDQALNFEQWNDSV FVVQFLLSCVMGFILSYSTILCTQFNSALTTTINGCLKNICNTYLGMFIGGDYNFSW LΝCIGIΝISVLASLLYTYVTFRRKRAPDKQDHLPSTRGEΝV >15 :31 :57|GEΝSCAΝ_predicted_CDS_4| 1122_bp atgagtatgtcgcgcggcggcaacacaactctggacttgcagccgctcctggcggagagcgatgtcggaaacagggagctgga ggagaagatgggcggatcggcggatcggtcatcgctgctcgatggatccggttcgaaggagctgagtcaccgggaacgcgag gactcggcgttgttcgtcaagaagatcgggagcgccttgttctatggcttgtcctccttcatgattacggtggtaaacaagacggtgc ttacctcctaccacttcccctcgttcctgttcctcagcctcgggcaacttactgctagcattgtggtcctgggcatgggcaagcgcct gaaattggtgaactttccccctctgcagaggaataccttcgccaagatctttccgctgccactgatatttctgggaaacatgatgtttg gactgggtggcacaaaaaccttgagtctgcccatgttcgcagccctacgacgcttctctatcctgatgaccatgctgctggagctca agatcctgggactgcgaccttcgaatgcggttcaggtcagcgtatacgcaatgatcggtggagcgctgctggccgcctctgatga tctgtccttcaacatgaggggctacatctatgtgatgatcactaacgccttgaccgcctcgaatggcgtatatgtgaagaaaaaactc gacacctcggagatcggaaagtacggcctaatgtactacaactcgctgtttatgtttctgcctgccctggccctcaactatgttacag ggaatctagatcaggcgctgaactttgaacaatggaatgactcagtgtttgtggtgcagttcctgctcagttgcgttatgggtttcatc ctatcgtacagcaccatcctgtgcacgcaattcaactcggcgctgaccaccaccattgtgggatgcctgaaaaacatctgcgtaac atatctgggcatgttcattggaggcgactacgtcttctcgtggctcaactgtattgggatcaacatcagcgtgctggctagtctgctct acacgtacgtcacttttcggcggaagcgggctcccgataagcaggaccacttgcccagcacccgcggcgagaatgtctag Human Homologue (TBLASTN with ORF1): KIAA0260 gene (D87449) and putative Sqv-7-like protein (AJ005866) Drosophila EST CK00510 ( AA140776) Annotated Drosophila genome genomic segment AE003524 Annotated Drosophila genome Complete gene candidate CG3874 - novel glucose-6- phosphate transporter Human homologue of Complete gene candidate EMBL:D87449 protein KIAA0260_id:BAAl 3390 gi: 166578 Similar to a C.elegans protein encoded in cosmid C52E12 (U50135) and Ensembl predicted gene ENSG00000024527 Clone: AL133320 Contig:AL133320.00001 8.10E-95 Putative function Sugar modification protein similar to proteins involved in Drosophila cytokinesis and signalling Confirmation by RNAi Marked increased GI and S peak indicating mainly arrest in GI Example 2 (Category 1) Line ID 1066/5 Category Male semi-sterile, Meiotic defects in testis: cytokinesis defects, segregation defects. (Seg-01/62) Reversion ? Map Position 89B Rescue ID F9E Rescue Sequence GTATACCATTAGAGAATATGATGAAGAAGGACTGTAAGAAGATCCTTCAGTG AATTTGACTGCTGACGTCGATCGGAACTTGCTGCGCTGACGTACAAAATCGCG AAGTGAATAAATAATATGGATGAGACCCTGTTTCGCCGACATATACAATAGTG CTCAAGACCTAATGGAATTATACGTTAATAACCAGCCACATTTCTTAGATATTT CTAATATGAGCCATCTGCTGCAGGTTCTTTCCAATATCTAATTCTAGATCTTCT TCGAATACGACCTTTTTGGCCATGAAACGATGATTTGCCACTTCATTCACAAG CATTAATTTGTCATGATTCTCTTAAGCGTGCACTTTATCTGAAAGTCTGAACAG CTGGCTGCGAAATGGATCCCCGGGATTGGAGATGGCAAGTAAATCTGTCCTCG CTACAAACAAGTGGGCACCACTGGGCATTCGGGGAATAGGGATATGGGTTGG GAATGGGGATATATTGTGGCATTGGCGAAAGGTCGCTATGC Genomic hit, Accession No. CSC:AC019750 Associated ORF >16:04:57|GENSCAN_predicted_peptide_4|418_aa MKPIPNESKGTLAAVGDATVVHDVCTLFAVELDPYLRSSMGMRTRRAQSGALLL QLLANADGGFAAHICACKCRLRLPHVTCCCNRNPFKATAKAKGQAVSSTKPNQL CFHGCCGWIITTKGETFTENSPSIMSGFAWERHSLGECVVVAGTEQILLIGRTLIGR MSHTQTDSTSPFVVDCHSQLCGSKCKCICVSVGFCVRPSCQRFDMKIVWANLAM QKRFLLGAAIADMCCRNSVIWCKLQLDPVKPIDERADGSGLALVTKVCDNNNIV HYVVVAGVTGSQSRSRLQPLRSGQNESTEQWPRTKGGEGGFNNNSRNNKHSAPT QEQQELWQKQLLQDQRDDCHASGSFQSASFAETRSFTFDDTTAHSEFCFRTRAEK RRILVLLETSIKLKPDKYATSGHTRRCAIGLLHSII >16:04:57|GENSCAN_predicted_CDS_4|1257_bp atgaaacccattcccaacgaatccaagggaacccttgcggcagttggagatgctactgttgttcatgacgtgtgtactttgtttgccg tagagcttgatccctatctcaggagcagcatgggaatgaggacgcgtagagctcaaagcggcgctctgttattacagctccttgcg gttgccgatggaggttttgctgctcatatilgtgcctgcaagtgtcggcttcgtttgccacatgtcacatgttgctgcaaccggaatcct ttcaaggcaactgcaaaagcaaaaggtcaggcggtcagctccactaaaccaaaccagctttgctttcacggctgctgtggctggat aattactaccaaaggtgaaacgttcaccgaaaactcgcccagcatcatgagcggttttgcgtgggagcggcatagccttggtgagt gcgtggttgtggctggaacggaacaaatcctgctgattggcaggacattgattggccgcatgagccatactcaaactgattcgacc agcccctttgttgtcgactgtcactcgcaactgtgcggctccaagtgcaaatgtatctgtgtatctgtaggtttctgtgtgcgcccgtct tgtcagcgctttgacatgaaaatagtttgggccaacttggctatgcaaaagcgatttctattaggagccgccatcgccgacatgtgct gccgaaattcggtgatttggtgcaaactgcagctagatccagtcaagccaattgacgaaagagccgacggcagcggtcttgcact ggttaccaaagtatgcgataacaataacatcgtccactatgtggtcgttgctggggttacgggcagtcagtcacggtcacggctgc aacccctccgctccggccaaaacgagtccacagaacaatggccaaggacgaaggggggggaggggggattcaataacaaca gcaggaacaacaaacattctgctcccacgcaagagcagcaggaactgtggcaaaaacagctgctgcaggatcaacgagacgat tgtcatgccagtggaagcttccagtctgcgtcattcgcggagacgcgtagtttcacgttcgacgacacaaccgctcacagcgaattt tgttttcggactagagctgagaaacggcgaattttggtgcttctggaaacatcgattaaactaaaacccgataagtatgcgacaagc ggtcacactcggcgatgtgcgataggattgctgcattcgattatatag Drosophila Gene Hit rescue sequence: mitotic heterochromatin fragment clone CH(2)6 (L36595) and subtelomeric heterochromatin repeats (L03284). TBLASTN with ORF1: nebula (nla) (AF147700) Human Homologue BLASTX with nebula: Down Syndrome candidate region 1-like protein 2 (AF 176117) Drosophila EST rescue sequence: CK01138 (AA141069) Annotated Drosophila genome genomic segment AE003712 Annotated Drosophila genome Complete gene candidate CG6072 - nebula CG6046 - sapl8 Human homologue of Complete gene candidate CG6072- 8e-36 'ZAKI4 a thyroid hormone responsive gene in human skin fibroblasts' also known as DOWN SYNDROME CANDIDATE REGION 1-LIKE 1; DSCR1L1 EMBL:D83407 protein_id:BAAl 1911 gi: 143504 CG6046- 3e-45 2108210 (U96915) sin3 associated polypeptide pi 8 [Homo sapiens] and gi5032067 C7E479FFE9CA5774 |ref]NP_005861.1| sin3-associated polypeptide, 18kD [Homo sapiens] (1.90E-43) Putative function Nebula unknown function, Sapl 8 transcription factor Confirmation by RNAi Both show reduction in GI and G2/S peaks indicating fewer cycling cells Line ID 234/50 Category Meiotic defects in testis: cytokinesis defects, abnormal spindles (Ab-02/12) Reversion R Map Position 89B Rescue ID 2C5E Rescue Sequence GTTTGACTGCTGACGTCGATCGGAACTTGCTGCGCTGACGTACAAAATCGCGA AGTGAATAAATAATATGGATGAGACTCCTGTTTCGCCGAC ATATAC AATAGTG CTCAAGACCCTAATGGAATTATACGTTAATAACCAGCCACATTTCTTAGATAT TTCTAATATGAGCCATCTGCTGCAGGTTCTTTCCAATATCTAATTCTAGATCTT CTTCGAATACGACCTTTTTGGCCATGAAACGATGATTTGCCACTTCATTCACAA GCATTAATTTGTCATGATTCTCTTAAGCGTGCACTTTATCTGAAAGTCTGAACA GCTGGCTGCGAAATGGATTCCCCGGATTGGAGATGGC AAGTAAATCTGTCCTC GCTACAAACAAGTGGGCACCACTGGGCATTCGGGGAATAGGGATATGGGTTG GAAA Drosophila EST rescue sequence: CK01138 (AA141069) All other entries as for 1066/5. Example 3 (Category 1) Line ID 1104/16 Category Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, high polyploidy) Reversion R Map Position 92A Rescue ID B5P Rescue Sequence 1 CTCCGGACACGCAGTAGCTAAATAACAAACTCATTACTAGTATATTACTGCCG CCGATTTGCAAGCGCGTACCGATCCCGATACCAGGCCAATCGCACTCCCCAGT TGTACGTCATCACTTAAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATT GATATTCCGCCCGCTGTGTGTGCGTGTGTATTTGCAAGAGAGTGTGTGTGTGT GTGTGCATATGACTCGTGCGTTTAGCCGAC AATTGGAGAAAAAGC ATTACC AA TCCCAATTGGCTAACTAAACTAAAGTTGGCTTGGCCAAACATAAACAAAAAGT GCGGGCGCAGCGATTTGGCAGCGAAACATATACACCAAAGCGCTATTGGCAG ATATATATGTAGATTAAATATAGAAAGTGCGTGCGAAGGTTAAGAGTCGAGT GCAAGTGCATTTATATTTGGAAATAATAAATGCTACAAT Rescue ID B5E Rescue Sequence 2 GTCCGGAGCGGAGCTAAAGTTCGATGTTCGTGCAAAACACTTCGATTCCGATA GGCGGATGCTATCGATTTCGGCGATGCCCGTTGGTCACACTTGGTGGTGGGCG CTGCCCGTCGCCGACTATCGATAGCACAAGCGGGTTATTTAGGTGTGCGCAGC TTGTAAGGGTGACTCATGCTGTTAAAATTATTATAAAAAGTTAATGAATATAA TATAGTTATAATAAAATTATATATAAATCTATAAGATCAAAGATCATCAGTTA TCATTTATCATTTGATTATATGAAAAACAAGAACAGAAACAAGATTTAATAGG TTTTTGAAATGTGAAAATGTGGGTTACCCCCAATTCTTATTCGAAATTAAATAA CCTAAAGAACAGTTATACACAGATAGGTAATTTGCACATAAGCCAAATTTTGT CTAGAATTCCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCCGTGATACGCC TATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTA Genomic hit, Accession No. AC006589 Associated ORF Genscan: ORF1 predicted sequences >/tmp/aaaaainga| GENS C AN jpredicted_peptide_2| 850_aa MATRGANVIWFRHGLRLHDNPALLAALADKDQGIALIPVFIFDGESAGTKNVGY NRMRFLLDSLQDIDDQLQAATDGRGRLLVFEGEPAYIFRRLHEQVRLHRICIEQDC EPIWNERDESIRSLCRELNIDFVEKVSHTLWDPQLVIETNGGIPPLTYQMFLIRCTH HNGDVNGDEDTGEGEGTGGRIDWAKEGACWRAGNSDEQECQACQSVSSVIMM VLQYSNNPAHHCQLLECLMTLKHNVVKDILCVVAYGTAVSRTSAAKLLFYYWP AFNANLFDRKVLLSKLTNDLVPFTCQREHCPNSGNAEAAKVCYDHSISIAYAPDC PPPLYLCIECANEIHREHGSLEFGDILHPMQQVSMVCENKNCRSNEKSAFSICFSTE CASFNGNHPIRYCSQCHSNRHNSRRGGDHVVHRSLQPAWQMDPEMQMHMVESV VSLLREAKPLNFEPGKESSSSESKKNGSGITADNISLEERQRLGRYGIWLLVGRCTP TADTPVEVLGRILSMLFHWFHNTAYSYDGFISCLVPHPPEYARVGGHWETLASRT SHLKEGLQRLICLNPYENITSEIWDYNMPHWMEAITΝDNAEKELΝELKINLSKILD PEMSPLGFDAKTMYΝFNAIRFEKTTAKNQQQALHWLQILTKLEILIPLNQLFAMF GDGNRIMKYGIQHELMREKDAQSQSLAKAPKTPCKESKETKADMAΝPPRPPVVE DDSGΝTSAISDDEAPTΝRHTEFSTDAEHΝLTCCILMLDILLKQMELQDVEQHMGI HTSVCEΝVSRLIKCMVTAARVGLSSHVCALKVPIEDIIEEEKSSRKSPPESDKEKTR DRDVSLSMAPLPIPLGPLGGFADP >/tmp/aaaaainga|GEΝSCAΝ_predicted_CDS_2|2553_bp atggccacgcgaggggcgaatgtgatttggtttcgccatggattgcgcctccatgataat cccgctctattggccgccctcgccgataaggatcagggtatagccctaattcccgttttcatattcgatggagagagtgcaggtacc aagaatgtgggttacaatcggatgcgtttcctcctggactcgttgcaggacatcgatgatcagctacaggcggcaactgatggacg tggacgcctcctggtcttcgagggcgaaccggcttatatcttccgccggctacatgagcaagtgcgtctgcacaggatttgcatag agcaggactgcgagccaatttggaatgagcgcgatgaaagcatccgttctctatgtcgggagctgaatatcgactttgtcgagaag gtatcacacacgctttgggatccgcaattggtgattgagaccaatggtggcattccaccgctgacctaccaaatgttcctgatacgct gcacgcaccacaatggagatgtgaatggggatgaggatacgggagaaggagaaggaaccggcggaaggatcgactgggcta aggaaggggcctgttggagggcgggaaactccgacgaacaggaatgtcaggcctgccaatcagtgtcctcggtcatcatgatg gtgctccagtactccaacaatccagcgcatcattgccagctcctggagtgcctgatgactcttaagcacaatgtcgtcaaggacatc ctctgcgttgtggcatacggaaccgctgtttcccgcacctcggctgccaagctgctcttctactactggccagcctttaacgccaatc tgttcgatcgcaaagtcctactctccaaactaaccaatgacctagtgcccttcacctgccaacgggagcactgtccgaactccggg aatgcggaggcagcaaaggtgtgctacgaccacagcattagcatcgcatacgcgcccgattgtccaccgcccctttacctgtgca tcgagtgcgccaacgagattcatcgggagcacggaagcctggagttcggcgacattctgcatcccatgcagcaggtatcgatgg tgtgcgaaaacaagaactgtcgctccaacgagaagtccgccttctccatctgcttctccacggagtgtgccagcttcaatggcaac catccgatccgctactgcagccagtgccacagtaataggcacaattcccggcgaggtggcgatcacgtggtccatcgcagtctgc agcccgcctggcagatggatccagagatgcagatgcacatggtggagtcggtggtaagccttctgcgagaggcgaagccacta aactttgagcccggcaaggagtcctcgtcgtccgagtccaaaaagaacggctccggcatcacagctgacaatatttctctggagg aacgccagagactgggacgctatggtatctggctactggtgggtcgctgtacacccactgcagatactcccgtagaagttctggg caggattctgagcatgctcttccactggtttcatgtaaccgcttactcatacgatggttttatatcctgcctggtgccacatcccccgga gtatgcccgtgttggaggccactgggagaccttggcgtcgcgaacaagccacttgaaagagggtcttcagcggcttatatgcctg gtgccatatgaggttatcacttccgaaatttgggactatgtgatgccgcactggatggaggccatcaccaacgacgtggccgaga aggaactgaacgagctgaagattgtgctcagcaagatcctcgatccggaaatgtcgcctctgggctttgatgccaaaaccatgtac aactttgtggccattcgatttgagaagacaacggcaaaggtgcagcagcaggcactccactggctgcagatcctcaccaagctgg agattctcattccactggtccagttgttcgccatgttcggcgatggtgttcgcataatgaaatacggcatccagcacgagctgatgcg cgagaaggatgcccaatctcagtccctggccaaggctcccaagaccccgtgtaaagagagcaaggagaccaaagcggatatg gccaatccgcccaggcctcctgttgtcgaggatgactctggtaatacgtctgccatttcggatgacgaggcgcccacgaatcgtca cacggaattctccacggatgctgagcacaatctcacctgttgcatcctcatgctggacatacttctgaagcaaatggaactacagga cgtggagcagcacatgggcatccatacgagtgtctgcgagaacgtctccaggctgatcaagtgcatggtcactgcagctcgagt gggtctcagtagtcatgtctgcgccttaaaggttcccatcgaggacatcattgaggaagaaaagtcctcgcgcaaatctccacccg aatccgacaaggaaaagacccgtgatcgagatgtttccctctcgatggctccactacccattccgctgggacctttaggaggatttg cagacccttaa Human Homologue BLASTX with EST: Phosphatidylinositol transfer protein (P48739) Drosophila EST SD01527 (AI530804), GH18602 (AI387906) Annotated Drosophila genome genomic segment AE003725 Annotated Drosophila genome Complete gene candidate CG5269 - vib PIP transfer protein Human homologue of Complete gene candidate le-90 1346772 P48739 PPI2_HUMAN PHOSPHATIDYLINOSITOL TRANSFER PROTEIN BETA ISOFORM Putative function phosopholipid transporter involved in lipid metabolism Confirmation by RNAi Slight reduction of GI and increase in G2/M peaks indicating anest in G2/M Line ID 418/32 Category Meiotic defects in testis: cytokinesis defects. Dark bands in eyes, dominant. Reversion ? Map Position 69C Rescue ID G2E Rescue Sequence AGCTAAATAACAAACTCATTACTAGTATATTACTGCCGCCGATTTGCAAGCGC GTACCGATCCCGATACC AGGCCAATCGC ACTCCCCAGTTGTACGTC ATC ACTT AAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATTGATATTCCGCCCGCT GTGTGTGCGTGTGTATTTGCAAAAGAGTGTGTGTGTGTATGTGCATATGACTC GTGCGTTTAGCCGACAATTGGAGAAAAAGCATTAGAATCCCAATTGGCTAACT AAACTAAAGTTGGCTTGGCCAAACATAAACAAAAAGTGCGGGCGCAGCGATT TGGCAGCGAAACAAAAACACCAAAGTGTTATTGGCAGATATATATGTTAATTA AATATNAAAAAGTGCGTGCGAA Genomic hit, Accession No. AC006589 Drosophila EST SD01527 (AI530804), GH18602 (AI387906) Rest of results same as line 1104/16 Example 4 (Category 1) Line ID 1285/1 Category Meiotic defects in testis: cytokinesis defects Reversion ? Map Position 85D1-5 Rescue ID D8E Rescue Sequence GTTCGCAAAAAATATATCTCACCGTGAGTGCGAAAGAGAAAAAGAGAAGCGG AGAGGTGGAGAGCAAGTGGACATGAATCGTCGAGAGTCAGAGAGAGAGAGG TGGAGAGGGTGAGCAGCTGTTGTCTGACAATAACATAATCAGCAACAATTTAT GCTGTTTAAAAAGAGCAAGAGAAACGCTAATGAAGGGGAACACGGGCAGGGT CAGGGGTTGGTGGATCCCCTACATATCTCTCTCTTTCACCGCCCCCGCTCTGGC ACCCTCTCTGTCGCTCTCCCATTAGCCGCACACGTGCAAGCTTAGCATTCTATC TGTCTGTCTCTGTTTGTGTTTGTTTGCTAAGCCGAATTCT Genomic hit, Accession No. CSC:AC014256 Associated ORF Genscan ORF1 predicted sequences >/tmp/aaaaakfaa|GENSCAN_predicted_peptide_l|702_aa MIQRCVVLLWIVCFCDLFLGLLFLKRKRNAHTPPPPPQFTTYRHLLCYCFRNGEIM ANICLSRLSVLEEIVLLLRVPCAFYFVDYYYVPCLLSVLSESFLYHDQLKVFNRTK QQHQQQQQQQQQQLYQQHQQQQQQHYGPPPPYFQQLHQQHQQQQQQQQQQQ HQQHMKFLGGNDDRNGRGGVGVGTDAIVGSRGGVSQDAADAAGAAAAAAVG YVFQQRPSPGGVGVGVGGVGGGVPGVGAVGSTLHEAAAAEYAAHFAQKQQQT RWACGDDGHGIDNPDKWKYNPPMNPANAAPGGPPGNGSNGGPGAIGTIGMGSG LGGGGGGGAGGGNNGGSGTNGGLHHQSMAAAAANMAAMQQAAALAKHNHMI SQAAAAVAAQQQHQHPHQQHPQQQQQQQQAQNQGHPHHLMGGGNGLGNGNG LGIQHPGQQQQQQQQQQQQQHPGQYNANLLNHAAALGHMSSYAQSGGSMYDH HGGAMHPGMNGGMPKQQPLGPPGAGGPQDYVYMGGQTTVPMGAAMMPPQNQ YMNSSAVAAANRNAAITTSTAKKLWEKSDGKGVSSSTPGGPLHPLQIPGIGDPSS VWKDHTWSTQGENILVPPPSRAYAHGGASDTSNSGNAGILSPRDSTCAKVVEYVF SGSPTNKDSSLSGLEPHLRNLKFDDNDKSRDDKEKANSPFDTNGLKKDDQNTNSN GNVNGIDDDKGFK >/tmp/aaaaakfaa|GENSCAN_predicted_CDS_l]2109_bp atgattcagcgctgcgttgttcttctatggatagtctgcttctgcgacttgttcttggggctcctgttcctcaaacgtaaacgcaacgca cacactccccccccccccccgcaattcaccacttatcggcatctactttgttattgttttcgtaatggggaaatcatggctaatatttgc cttagtcgtctttcagttttagaagaaattgttttgcttttacgcgtgccttgtgcgttttatr^ ctgtgttatcggaatctrttctttaccatgaccagctcaaagtttttaatcgcacaaaacagcaacaccaacagcagcagcagcagca gcagcagcaactctatcagcaacatcaacagcagcagcagcaacattacggtccaccaccgccctactttcaacagctacacca gcaacaccaacagcagcagcaacaacagcagcagcagcaacaccagcaacacatgaagtttttgggtggtaacgatgatcgca atggccgcggaggcgtcggcgttggcacggatgccattgtaggatctcgaggtggcgtctctcaggatgccgccgatgcagctg gtgccgccgcagccgccgccgtcggctatgtcttccagcagcgtccatcgcctggtggggttggcgtcggcgtgggcggagtg ggtggcggtgtgccaggggtcggagccgtaggctcgaccttgcacgaggccgccgccgccgagtacgccgcccactttgccc agaagcaacagcagacccgatgggcgtgcggcgacgacggccatgggatcgataacccggacaaatggaagtacaatccgc cgatgaatccggccaatgccgctcctggcggtccaccgggaaatggcagtaatggtgggcccggcgccattggaaccattggc atgggcagcggattgggtggtggtggcggcggcggagctggcggcggaaataatggcggctctggtacgaatggcggtctgc atcatcaatcgatggccgctgcagctgcgaatatggcagccatgcaacaggcggcggcgttggccaagcacaatcacatgatat cacaggcagcagccgcagttgcagctcagcaacaacatcagcatccacaccagcagcatccccagcagcagcagcaacagca gcaggcgcagaaccaggggcatccacatcaccttatgggcggtggcaatggactgggcaacggcaatggattgggcatacaa catcccggccagcaacagcagcagcagcagcaacaacagcagcagcaacatcccggccagtacaacgcgaatctgcttaacc atgcggctgccttgggtcacatgtcatcttatgcccaatcgggtggcagcatgtacgaccatcatggtggagccatgcacccggg aatgaacggcggcatgcccaagcaacagccattgggtccacccggagccggaggaccccaggactatgtctacatgggtggc cagaccactgtgcccatgggagccgcaatgatgccgccacagaatcaatatatgaacagctctgctgttgcagctgccaatcgga atgcagcgattaccacatccactgccaagaaattgtgggagaaatccgatggcaagggcgtatcctcgagcactcccggtggac cgttgcatcccctgcagatccccggcatcggggatccctcctccgtgtggaaggatcacacctggtccacacagggcgagaatat attggtgccgcccccctcgcgagcctacgcccatggaggcgcctccgatacttcaaacagcggcaatgcgggcatactgagtcc ccgcgattcgacttgcgccaaagtggttgaatatgttttcagtggctcgcccaccaacaaagatagctcgctttccggattggaacc gcatttgcggaatctaaagtttgacgacaacgataagtcacgcgacgataaggagaaagcaaactctccgtttgacacaaacggtt tgaagaaagacgatcaggtcacaaactcaaatggtgttgtcaacggcattgacgatgacaagggcttcaagtga Drosophila Gene Hit TBLASTN of ORF1 : pumilio protein (L07943) Human Homologue TBLASTX with pumilio: Soares fetal heart NbHH19W Homo sapiens cDNA clone (W77820) Annotated Drosophila genome genomic segment AE003681 Annotated Drosophila genome Complete gene candidate CG9755 - pumilio RNA Human homologue of Complete gene candidate 1 e- 154 1944416 dbj|BAA19665| (D87078) similar to D. melanogaster pumilio protein (S22026) Putative function Putative RNA binding protein which is localised to the cytoplasm. Wild-type allele of pum involved in development of the abdomen (embryos) and of the imaginal discs (larvae or pupae), perhaps having a function in signal transport. Confirmation by RNAi Only wild type profiles observed Example 5 (Category 1) Line ID 1389/1 Category- Meiotic defects in testis segregation defect, cytokinesis defect (Ck-09/32) Reversion NR Map Position 93B4-8 Rescue ID 2C9P Rescue Sequence 1 GTTCGGGGTGTGTGCGTGCTTGCGAGTGTGCCTGTGTGTGTGTAGGAAAGGAG CAAGAAGCAGCAGCAGCGGCAGCAGTAGAAATAGCAAAAGGAGGCAGCAAC AACAATAAGCTAGAGAAACCGCCAGCAGCAGCCCCCTAATAAAGAGCAGAGA AAAAAATGAGTTCAAGTTGTGAAAGGTGTGTGCCGTTACACTACAAACTACAA CACCACCATCAGCGGCAGCAAAGAAATACAACAACAAATACGGCAATCTCCA GACAACGCGAATGTCGAAATTGTGTATACAATTTATTAAGAAAGCAAGAGCA GCAACAACAATGACCAGCTGCAGTTCATCAGCGGTGTCCTCCTGAATGCCGCT GTCGTCGTTGGTGTCTGCCACCGGCGGTTCCTCAATAATAAGGGCAGGAGGAG CTGCTTAGGTGCACACAATGTAGTTTGGCTTGGTGAATGCTTCTCTTTTTGTTG CTGCTGGCGCATACGTTCCTCTTCTCCCCTCATGATCTCAGTTGTCTGCATCGA TGAGCCGCCACCAACGGTGGCTTCTTCTGCTCCTCTTTGGCAACGGACTGCTG CAGTCTTGCCAGAATTTTTCCTAAAATACTGAGCTTCAACTTGGTCTGCTTGGT AATGGTATACCATAAGCCATGGACTTGATGCCCCTACAAAGCTCTGTGATTTG AAATGGGATGCA Rescue ID 2C9E Rescue Sequence 2 CCCCGAACGCACTTTATATATATAAATATATATATTATTTTCTTTCACTTATTTT CGTTTCGGCCGCGACAGCGAATATGCAATTTTCCTCTCAATTGATTTTTTTACA CACTCGCACTCCTTTTCACATGCGTGCAGTTTATGTTGCTATTGCTGCTACTGC TGCTGTTGTTGTTATTGTTGTTCTGGCTGCCGCTGCAGTGCAACTTGTAACACT TTCACATTTATGACATAATGCACTGGCCATATTTTTGCTTGGCTCTCCGTTTGT GCAACTGCATGTTCCCAGTGCTTTTTTAATATTTATGCTGCAGTGCGTGCAAAT TCGAACGCGAGACGATCCGCTTTTCGCTGCATCTATGCGCTGAAGATGTGCTG CAGTCGATGGGCTCGTCGATAGTGGGAAGGCTCGGTGCCGGCACTATCGATTC CCAACACCATACGATAATATCGGCTAAAGTTATCAATATCGAAGTTTACTATA TTTCGGGTTTTTACGTTTTAAATCTACCTTATCAACATTTTTGNAAGAAGTAAA AAGTAGTTCTCTTATGGATGCATC Drosophila EST several including LD 10379 (AA816796) Annotated Drosophila genome genomic segment AE003733 Annotated Drosophila genome Complete gene candidate CG3421 - novel protein with weak homology to myosin Human homologue of Complete gene candidate Ensembl predicted Gene:ENSG00000071333 Clone:AC022505 Contig:AC022505.00011 5.60E-37 (predicted protein with Core domain in kinesin and myosin motors ENSG00000087179) Putative function Possible novel motor protein involved in cytoskeleton organization Confirmation by RNAi Marked reduction of GI and G2/M peaks indicating fewer cycling cells Example 6 (Category 1) Line ID 293/9 Category Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, very high polyploidy) Reversion NR Map Position 66B Rescue ID 2G5E Rescue Sequence GTACAAACGAATTATTTGTCTCCTTGTGCGTTCGTTTTATTGTGTTTCGAGTTCT GTTGGTGTGTGTTTTTGTGTATGTTCCACGAGTTGTTCGCATTAAAAAATTAAC TGCAGAAGATCCATGGAAATGGAGACCATTGAAGAGCAATCGAAGTGCGGTG AGTACTGAAAGAGGGCGCGGGGCGTGGCAGCTCCAAATGGCCGGCGAATTTA TCATTTTTCAATGTCGTCCAAAGGGGTTGGGTACGGGGTAAAACCACATTCGG GGCCAAAAGATCCTCATAAAAAATGTCGCTGCCAGCAAATGCAAAAAATAAA ATAAAATAAGAACGACTATAAGTACATCTTTGTGTGTATTTGTGTGACTAAAA AAGCAACGGCATCGTGTCGCANATATTTTAATCTTTNTTTCTGAATTTATTTCG GTGTACAAAATATTTATCGCATAAATGCGAAATGCCTCCCTCTCTTCATCATCG T Genomic hit, Accession No. AC008303 Associated ORF Genscan ORFl predicted sequences >20:53:38|GENSCAN_predicted_peptide_3|261_aa MMDNDDALLNNGGPQSGAETNYGTEDNNMVMSEKCRIFPATQRTGFVGATFSG VLLLDLGALQHCDVIRIDVNIATLEQIKRERQEELAARERIRAQIAADRAEQAQRF NTPDISSTTNSVAATAASNVITTDASVSSVDETRLQIRLPGGIQRTKSFPAGEVLAT VRVYVRNEMLAASDVRDFTLATSYPRREFQTEDEVKTLNELNLVPNAVVLVLTK EQ VNP ADDQTAKRS ASTKRTKTHRHKRQLMADEPQSDHYKN >20:53:38|GENSCAN_predicted_CDS_3|786_bp atgatggacaacgatgatgcactgctcaacaatggaggaccacagtccggagctgaaactgtctacggtaccgaggacaacaac atggtcatgtcggagaagtgccgcatattcccggcgactcagcgtactggatttgtgggcgcgacgttttcgggagtgctgcttctt gatcttggtgccctccagcattgtgatgtgatccggattgatgttaacattgcaacgctggaacagattaagcgtgagcgtcaggag gagctggcggccagggagcgcattcgtgcccaaattgcagccgatcgggcagagcaggcacaacgttttaatacgccggacat tagcagcacgaccaattcggtggcggccaccgctgcctccaacgtgatcacaacagacgcctcggtgagttcggtggacgaga cgaggctgcagatccgactacccggtggcattcagcgcaccaaatcctttccagccggcgaggtgctggctaccgttcgtgtcta cgtgcgaaacgagatgctggcggcgagcgatgtacgcgactttaccctggctaccagttacccacgaagggagttccaaacgg aggacgaggtcaagaccctgaacgagctaaatctagtgcccaatgcggtggttctggtgctgaccaaggagcaagtgaatccag ctgatgaccagacagcaaaacgatcagcaagcaccaaacgcacaaaaacacacagacacaagcggcaattgatggcagacga gccacaatctgaccattataaaaactga Drosophila Gene Hit rescue sequence: pebble (rhol GTPase exchange factor) (AF136492) Human Homologue BLASTX with pebble: KIAA0337 (AB002335) Drosophila EST SD09146 (AI542703), SD01796 (AI530981) Annotated Drosophila genome genomic segment AE003557 Annotated Drosophila genome Complete gene candidate CG8114 - pbl pebble rhol GTPase exchange factor Human homologue of Complete gene candidate 2224615 dbj|BAA20795| (AB002335) KIAA0337 [Homo sapiens (3e-21 ) also mouse homologue 3e-95 42359 transforming protein (ect2) - mouse >gi|293332 (L11316) ect2 [Mus musculus] Putative function A guanyl-nucleotide exchange factor involved in signal transduction which is localised to the mitotic anaphase. pbl is required for the formation of the confractile ring and the initiation of cytokinesis in Drosophila Confirmation by RNAi Slightly reduced GI and G2/M peaks indicating fewer cycling cells Line ID 542/3 Category Mitotic defects in brain: cytokinesis defect (very high polyploidy) Reversion NR Map Position 66A Rescue ID 2A1E Rescue Sequence GTCCAGTTAATGAAAGTAAACGAATCGAGTACAAACGAATTATTTGTCTCCTT GTGCGTTCGTTTTATTGTGTTTCGAGTTCTGTTGGTGTGTGTTTTTGTGTATGTT CC ACGAGTTGTTCGC ATTAAAAAATTAACTGC AGAAGATCCATGGAAATGGA GACCATTGAAGAGCAATCGAAGTGCGGTGAGTACTGAAAGAGGGCGCGGGGC GTGGCAGCTCCAAATGGCCGGCGAATTTATCATTTTTCAATGTCGCCCAAAGG GGTTGGGTACGGGGTAAAACCACATTCGGGGCCAAAAGATCCTCATAAAAAA TGTCGCTGCCAGCAAATGCAAAAAATAAAATGAAATAAGAACGACTATAAGT ACATCTTAGTGTGTATTTGTGTGACTAAAAAAGCAACGGCATCGTGTCGCANA TATTTTAATCTTTTTTTCTGAATTTATTTCGGNGTANAAAATATTTATCGCATA AATGCGAAATGCCTCCCTCTCTTCATCATCGNTTCCCCTNACTCTCCCTCTCTT CGCCCGACACTGTACCGACGCAAGAAGAAC Genomic hit, Accession No. CSC: AC018042 Drosophila EST SD09146 ( AI542703), SD01796 (AI530981) rest of results same as line 293/9 Example 7 (Category 1) Line ID 229/30 Category Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects (Mitotic higher level of condensation, polyploidy, Meiotic: Ck05/07) Reversion ? Map Position 91F Rescue ID A7E Rescue Sequence TCTTGGCCAAACAACGCGAGCAGCTGATGTCGCATGGTGGGAAAATGAGGGT GGCGCGAGTGGAAGTTGCCATATCGCTGCGATCACAAGCAGCAAATATGGAA GATTAAGCGGAAAACGAAAGACAAAATAATTACAATCAAACAACCGAATTAT AAAAAGAAAATGGTTTGTCCTCCGAGTTCGTTTAAATATGCTTATCTACGTATC AATTAAAAAAACCGTAGAAAGAAATTCACGATTCACCCTAATCTAGCTAAGA CACCAACCAAAAATTTCCGATTTACTTTCAGTTGAAGTTGTTGTTACACACTTT TCTTGTCGATGTTTTGAAGCGCCCATTGAAATTGATCATTTGAATGTTTTTCCA AATTACCCACATCCATTACAATAAATTTAAATTGCTTATTATTTGATTTTTACT TGGGAAAATCCCGTTGCCAAATTGGAATTACAATTCCAGCTTGGAATCCGTCA AACTTTACAACATAAACTTATTGTTCTTTTCCGGACAATGCTTCCA Annotated Drosophila genome genomic segment AE003686 Annotated Drosophila genome Complete gene candidate CG6284 - novel protein possible sir2 family of transcriptional regulators/telomeric silencing Human homologue of Complete gene candidate gi7706710 0268A424791DE5BF |ref|NP_057623.1| sir2-related protein type 6 [Homo sapiens] (1.10E-74) Putative function Putative transcriptional regulator Confirmation by RNAi Complete loss of GI and G2/M peaks indicating fewer cycling cells Line ID 1104/16 Category Mitotic defects in brain, Cytokinesis defect (no overcondensation of diploids, high polyploidy) Reversion R Map Position 92A Rescue ID B5E Rescue Sequence GTCCGGAGCGGAGCTAAAGTTCGATGTTCGTGCAAAACACTTCGATTCCGATA GGCGGATGCTATCGATTTCGGCGATGCCCGTTGGTCAC ACTTGGTGGTGGGCG CTGCCCGTCGCCGACTATCGATAGCACAAGCGGGTTATTTAGGTGTGCGCAGC TTGTAAGGGTGACTCATGCTGTTAAAATTATTATAAAAAGTTAATGAATATAA TATAGTTATAATAAAATTATATATAAATCTATAAGATCAAAGATCATCAGTTA TCATTTATCATTTGATTATATGAAAAACAAGAACAGAAACAAGATTTAATAGG TTTTTGAAATGTGAAAATGTGGGTTACCCCCAATTCTTATTCGAAATTAAATAA CCTAAAGAACAGTTATACACAGATAGGTAATTTGCACATAAGCCAAATTTTGT CTAGAATTCCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCCGTGATACGCC TATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTA Rescue ID B5P Rescue Sequence CTCCGGACACGCAGTAGCTAAATAACAAACTCATTACTAGTATATTACTGCCG CCGATTTGCAAGCGCGTACCGATCCCGATACCAGGCCAATCGCACTCCCCAGT TGTACGTCATCACTTAAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATT GATATTCCGCCCGCTGTGTGTGCGTGTGTATTTGCAAGAGAGTGTGTGTGTGT GTGTGCATATGACTCGTGCGTTTAGCCGACAATTGGAGAAAAAGCATTACCAA TCCCAATTGGCTAACTAAACTAAAGTTGGCTTGGCCAAACATAAACAAAAAGT GCGGGCGCAGCGATTTGGCAGCGAAACATATACACCAAAGCGCTATTGGCAG ATATATATGTAGATTAAATATAGAAAGTGCGTGCGAAGGTTAAGAGTCGAGT GCAAGTGCATTTATATTTGGAAATAATAAATGCTACAAT other results same as 229/30 Example 8 (Category 1) Line ID 343/5 Category Mitotic defects in brain: cytokinesis defect (very high polyploidy, chromosomes entangled?) Reversion NR Map Position 75B Rescue ID C6E Rescue Sequence GGTTTCGAGTTCGTTCGGTTTCGGCCTCTCCGTTCGGCTCTCTCTCGCCATCCC GCTGCCGCACACATTGGCCTCTCTCTCGCAGCTCCACATTCGAAGGTGGCTGA CCGAAATGTGGGTCACGACAATGGCGGGGTTCGTTGAACTGAACCACCGCCG CAGTCGCTGCCGTGCTCGCTGCTCTGCCTCTGCTGACGTCGTTAACGTTTTGGG GCTTTCGGTTACGTAGCTCGTGTGCGAGCGAGAGGGGCTACTAGAGGGACTGC GACACACAAGTTGTGTGCATTTTTTGGCCCCAAAAAATCACAATGGGCACAAA ATATTATTTAATACATCACATAATTGTTTAATCATCTGGCTGGAAAGTGTCGAG TTCATCGAACTGCCAGCGATTGACAAATTGCGATTTTCAATGCGGCAAAAATA TTTACTCAAGCAAATTGTTTGCACTTCGTTAATTAGGCGGGGAGTGCCGCCAA ATTGGGTCATATTGCAGAAGTATCCAAGAAGTTGGAGAAACAAGCTGCTTAA ACATTAATTAACACACACCTAAATGGATACATTTGCTACAAACAATTATAAAT GTTACCCTTATATTAATTTTCAAATTTCTAAATAATCAA Genomic hit, Accession No. CSC:AC015427 Associated ORF Genscan ORFl predicted sequences MVCAMQENAAVQHQQQQQQLQLPQQQQQQQQTTQQQHATTINLLTGNGGGNL HIVATPQQHQPMHQLHHQHQHQHQHQQQAKSQQLKQQHSALVKLLESAPIKQQ QQTPKQIVYLQQQQQQPQRKRLKNEAAINQQQQQTPATLVKTTTTSNSNSNNTQT TNSISQQQQQHQIVLQHQQPAAAATPKPCADLSAKNDSESGIDEDSPNSDEDCPN ANPAGTSLEDSSYEQYQCPWKKIRYARELKQRELEQQQTTGGSNAQQQNEAKPA AIPTSΝIKQLHCDSPFSAQTHKEIAΝLLRQQSQQQQNNATQQQQQQQQQHQHQQ QRRDSSDSΝCSLMSΝSSΝSSAGΝCCTCΝAGDDQQLEEMDEAHDSGCDDELCEQH HQRLDSSQLΝNLCQKFDEKLDTALSΝSSAΝTGRΝTPANTAΝEDADGFFRRSIQQK IQYRPCTKΝQQCSILRIΝRΝRCQYCRLKKCIANGMSRDNLRLEQPKAGAKΝKSCE PSKΝSTVΝQLΝSKLELGΝSΝEMK >21:55:09|GEΝSCAΝ_predicted_CDS_l|1533_bp atggtttgtgcaatgcaagaggttgctgccgtgcagcatcagcagcagcaacagcaactccagttgccccagcagcaacagcag cagcagcagacaacacagcagcaacatgcaacaactatagtgctgctgacgggcaatggcggcggtaatctgcacattgtcgcc acaccgcaacagcatcagccgatgcatcagctccaccatcagcatcagcatcagcatcagcaccagcagcaggccaagagcc aacagctgaagcaacaacactcggcgctggtcaagttgctggagtcggcgcccatcaagcagcaacagcagacgcccaagca aattgtttacctgcagcagcagcagcagcaaccgcaacgcaaaagactgaaaaacgaagcagcaatcgtacaacagcaacaac aaacacctgcaacactagtaaagacaacaaccaccagcaacagcaacagcaacaacacccagacaacaaatagtattagtcag cagcaacagcagcatcagattgtgttgcagcaccagcagccagccgcggcagcaacaccaaagccatgtgccgatctgagcg ccaaaaatgacagcgagtcgggcatcgacgaggactcccccaacagcgatgaggattgccccaatgccaacccggcgggcac atcgctcgaggacagcagctacgagcagtatcagtgcccctggaagaagatacgctatgcgcgtgagctcaagcagcgcgagt tggagcagcagcagaccaccggaggcagcaacgcgcagcagcaagtcgaggcgaagccagctgcaatacccaccagcaac atcaagcagctgcactgtgatagtcccttttcggcgcagacccacaaggaaatcgccaatctcctgcgccaacagtcccagcaac aacaggttgtggccacgcagcagcagcagcaacagcagcagcagcaccagcaccagcaacaacgaagggatagctccgaca gcaactgctcgctgatgagcaactcgagcaactccagtgcgggcaattgttgcacctgcaacgctggcgacgaccagcagctgg aggagatggacgaggcccacgattcgggctgcgacgatgaactttgcgagcagcatcaccagcgactggactcctcccaactg aattacctgtgccagaagttcgatgagaaactggacacggcgctgagcaacagcagcgccaacacggggaggaacacgccag ctgtaacagctaacgaagatgccgatggattcttccgccgctccatccagcaaaagatccagtatcgcccgtgcaccaagaatca gcagtgcagcattctgcgcatcaatcgcaatcgttgtcaatattgccgcctgaaaaagtgcattgccgtgggcatgagtcgcgatgt tctgcgcctagagcaacctaaagctggtgccaaaaataagtcatgtgaaccgagcaaaaattcgaccgtcaaccaaataaacagc aaactcgaactcggcaacagcaatgaaatgaaatga Drosophila Gene Hit TBLASTN with ORFl : ecdysone-inducible gene E75B (X51549) and nuclear receptor superfamily protein (U01087) BLASTN with genomic sequence matches ecdysone inducible gene Annotated Drosophila genome genomic segment AE003522 Annotated Drosophila genome Complete gene candidate CG8127 Eip75B ecdysone- inducible gene E75B nuclear receptor NR1D3 Human homologue of Complete gene candidate ORPHAN NUCLEAR RECEPTOR NR1D1 (V- ERBA RELATED PROTEIN EAR-1) (REV-ERBA- ALPHA) Q15304 ( 9.40E-74) Putative function Ligand-dependent nuclear receptor, putative transcription factor Confirmation by RNAi Slightly reduced GI and G2/M indicating fewer cycling cells Line ID 448/23 Category Mitotic defects in brain: cytokinesis defect (very high polyploidy Reversion NR Map Position 75B Rescue ID 2G4E Rescue Sequence GCTGGTGGACGCTGCTTTCATTCGCAAATTGCTCGTCGTTGGCAGCGGTTGTGC AGAGC AAGAAAAGCGCGCGAAAAACCAAGC AAAAAATTAATACAGCTGGAT CAAGCGAAAGAGATAGAGAGCAGAGTCAACAGCAACAAATGTTCAATAGCA AATGATATCGCATATTTTTGTTGGTGCCAGTGAAGTGAGATCAAAGTGAAGTG TGCAATGTTCCTTATTAGCAAATCGTAGAGCAACCAACAATCGAGAGTTCAAG TGTCATTTCGAAGCCAAAAAGCAAAATCTCTAATTCAAATATGGTTTGTGCAA TGCAAGAGGTTGCTGCTGTGCAGCATCAGCAGCAGCAACAGCAACTCCAGTT GCCCCAGCAGCAACAGCAGCAGCAGCAGACAACACAGCAGCAACATGCAAC AACGATAGTGCTGCTGACGGGCAATGGCGGCGGTAATCTGCACATTGTCGCCA CACCGCAACAGCATCAGCCGATGCATCAGCTCCACCATCAGCATCAGCATCAG CATCAGCACCAGCAGCAGGCCAAGAGCCAACAGCTGAAGCAACAACACTCGG CGCTGGTCAAGTTGCTGGAGTCGGCGCCCATCAAGCAGCAACAGCAGACGCC CAAGCAAATTGGTTACCTGCAGCAGCAGCAGCAGCAACCGCAACGCAAAAGA CTGAAAAACGAAGCACAATCGTACAACAGCAACAACAAACACCTGCAACAC Genomic hit, Accession No. CSC:AC015427 Drosophila EST GM03519 (A801874) Other results same as line 343/5 Example 9 (Category 1) Line ID 36/1 Category Meiotic defects in testis: cytokinesis defects (Ck-04/06) ' Reversion R Map Position 79C Rescue ID A8B Rescue Sequence GAGTAAAGTAAACTACAGAGAAAAAACGCTTTACGGCGAGAGAACGCTTTAA TTATACTTAATTTGTTGTTAATCAAACGCACAGAGCACACAACACAGAAACAC AAAACACCGCTTGGGAAAAATCTGTAGGTAGANGAAAGGAGCTCACGTTTTT CTGGTGCAGATCGAAATCGGTATCGGGTTTATTCGCTTTGCCGGATTGTTACTT CACGTTTGTTAATTGCGTTTCTTTGTTTCTTATTCTCCTGCGCACACTTTGATTT GCGTTTGCAACTCGCAATTCGCAATTGGCATTTGCTATGCGACAACTGCCGTT ATTTCCGGTCCGTTTACTTTTCCAATGGCTTGCCTACACACCGCCAAACTTTGG CTTGAACTTGGGATATTGGTTGCCCGAATTTCCTGANAAATTTTTCCTT Genomic hit, Accession No. CSC:AC013886 Associated ORF Genscan partial ORFl: >18:33:59|GENSCAN_predicted_peptide_ l|99_aa CICFALLGLLIRRKLMVNFGSTSRKAQSLESRRAKNTSQKIGNQYPKFSQNCGKPS KSΝDRΝΝGSCRIAΝAΝCELRNAΝAΝQSNRRRIRΝKETQLTΝVK >18 :33 :59)GEΝSCAΝ_predicted_CDS_l )300_bp tgtatctgcttcgccctgcttgggctactcattcggcgaaaattaatggtggtgttcggttctacgtcgcgcaaggcacagtctctaga gtctcgcagagctaagaatacatctcagaaaatcggcaaccaatatcccaagttcagccaagtttgcggcaagccatcgaaaagt aacgaccgaaataacggcagttgtcgcatagcaaatgccaattgcgaattgcgagttgcaaacgcaaatcaaagtgtgcgcagg agaataagaaacaaagaaacgcaattaacaaacgtgaagtaa Drosophila Gene Hit rescue sequence and TBLASTN with ORFl : nucleic acid binding protein (mub) (X99340) Human Homologue BLASTX with nucleic acid binding protein: poly(rC)-binding protein 2 (hnRNP-El) (S42471) Drosophila EST several including LD32520 (AA951799 BLASTN matches nucleic acid binding protein (X99340) Annotated Drosophila genome genomic segment AE003596 Annotated Drosophila genome Complete gene candidate CG7437 - mub mushroom bodies RNA binding protein Human homologue of Complete gene candidate 4826886 ref]NP_005007.1|pPCBP2| poly(rC)-binding protein 2 >gi|542853|pir||S42471 (4e- 75) Putative function A putative RNA-binding protein specifically expressed in the CNS of Drosophila melanogaster Confirmation by RNAi Only wild type profiles observed Line ID 472/22 Category Female sterile (anaphase bridges, lagging chromosomes) Reversion ? Map Position nd Rescue ID sau 5'spl Rescue Sequence GC ACGATCNCTAAAGTCTNGCAN AGCTAAAAATAC ATCTNAGAAAATCGGC A ACCAATATCCCAAGTTCAGCCAAGTTTGCGGTGTGTAGGCAAGCCATCGAAAA GTAACGACCGAAATAACGGCAGTTGTCGCATAGCAAATGCCAATTGCGAATT GCGAGTTGCAAACGCAAATCAAAGTGTGCGCAGGAGAATAAGAAACAAAGA AACGCAATTAACAAACGTGAAGTAACAATCCGGCAAAGCGAATAAACCCGAT ACCGATTTCGATCGGTGCGGGCCTCTTCGNTATTACGCCAGNTGGCGAAAGGG GGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACG ACGTTGTAAAACGACGGCC ANTGCCAAGCTCTGCTGCTCTAAACGACGCATTTCGTACTCCAAAGTACGAAT TTTTTCCCTCAAGCTCTTATTTTCATTAAACAATGAACAGGACCTAACGCCNGT AAC Rescue ID Sau 5'splac Rescue sequence GTTGTGATCNTCTTGGTNAATCNNNTTGGAAATTCCCCTAANGCTTCCGACAA TGACCCNGNCNTACNNAGCAAANAATNGNAGNACNNGCNGNTGGNCGTANT ANCAANAACAGGCCCGCACCGATCGAAATNGGNATCGGNTTTATTCGCTTTGC CGGATTGTTACTTCACGTTNGTTAATTGCGTTTCTTTGTTTCTTATTCTCCTGCG CACACTTTGATTGCGTTTGCAACTCGCAATTCGCAATTGGCATTTGCTATGCGA CAACTGCCGTTATTTCGGTCGTTACTTTTCGATGGCTTGCCTACACACCGCAAA CTTGGCTGAACTTGGGATATTGGTTGCCGATTTTCTGAGATGTATTCTTAGCTC TGCGAGACTCTAGAGACTGTGC Other results same as line 36/1 Example 10 (Category 1) Line ID 459/2 Category Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects: (mitotic: high polyploidy, no diploids, higher mitotic index, meiotic: Ck-01/05) Reversion NR Map Position 66B1-6 Rescue ID 2D5P Rescue Sequence GCTCCGTTCGAAAGTTGAGAGAGACTTGAAACATATGTTCGGCGTTGCTAGAG CTGGTCGGCTACCGATAGAAACATCGATAGGTCCGATGTTTTTTACTCGTATAT TGATTCANAGTTTGGCTATCGATGTTTTTAGAGTGCCCGCACATTATCTATTTT CATCTCTATTTCGTTGGTATTTTTTGTATTTTATGACATTTCGACTGCAAAAGC AGGATGGCAACGCCAGATTGCCGCGAAAGTACGTTATTTTTAAATTGGCGCAT TGAATATGAAAAATTGCAGGCACATACAGTTTCTAATAAATAATAGCAATAAT TATTATTTAGCTTGTATCATACGAAGTGCACATTACAGCTACGCATCTGAAAT AATAATTTTAATATATCGTCTTTTCTCCCATCGATAGAGTTCCGCGCCTATCGA TATATCGTTGATCACCAAATAAATAAAACTAAATAACGCCGCAATGGAACAC GCGACGAGTGAATTGAGGGAATTTATCTCAGATCTTGTAATTCCGCACCACGT TGCAATGGTAACATCAATCCGGATCACATCACAATGCTGGAAGGCACCCAGA TCCAGAACAG Annotated Drosophila genome genomic segment AE003557 Annotated Drosophila genome Complete gene candidate CG8038 - novel gene ribonuclease P homology CG7892 nmo - protein serine/threonine kinase involved in eye morphogenesis Human homologue of Complete gene candidate CG8038- 5e-24 4309676 gb|AAD00893| (AF001176) ribonuclease P protein subunit p29 [Homo sapiensj CG7892- protein kinase mitogen-activated 7 (MAP kinase)' gi:4506093 and gi7706445 D919050533B3C33A ]ref|NP_057315.11 nemo-like kinase [Homo sapiens] (3.30E-174) Putative function CG8038: tRNA processing enzyme Ribonuclease P protein subunit CG7892: a protein serine/threonine kinase involved in cell cycle, possibly targeted to cytoskeleton Confirmation by RNAi Both showed a marked increase in GI peak indicating anest in GI Example 11 (Category 1) Line ID 623/8 Category Meiotic defects in testis: cytokinesis defects Reversion ? Map Position 37E1-3 Rescue ID 2E2E Rescue Sequence CTACGGGCATTCGCATGTTCGAACATCTGGTGTAAACAAGTTCTGAGCAGTGT TGCCAACTCTTCAGTTAAACAGTTAAAAATAGCTAAAAAATGTTGACGGTAGC TAAATTATAAAGCTAGAAAAGAAATGATATATGATAAAATAAGTATTTCGACT CACAGCATTTATTATTTAAGACGGTCAGATGAAGTTACAAAAATCCTAAATTG GCCCGCTGTATCTAAGAATTAATACCAAGAAGTTGTCATCAAAGGTCGAACTC GACGGAAATTCTACTTTGAGTTTTTAAATTTAATAAATATGTATTTAAAATTAT GTAAATTTGTTTGTAAAACAAAAATAGTATATAGTATAGTAATAGTAGTTAAG TAGTTTTAAAAATGGCCAGATCAAAGACTTTTGAGATATGATACTAATCAAAA GTCGAATTCGCGGAATTAATTCTTGAAGACGAAAGGCCTCGTGATCGCCTATT TTTATAGGTAATGTCATGATAATAATGGTTTCTTAGACGCAGGTGGACTTTTCG GGGAAATGTGCGCGGAACCCCTATTTGTTATTTTCTAAATACATTCAAATATGT ATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG AAGAGTATGAGTATTCAACATTTCCGGGCGCCTTATTCCTTTTTTGGGCGGCAT TTGCCTTCCTGTTTTTGTTACCCAGAACGCTGGTGAAAGAAAAGATCTGAAGA CAGT Annotated Drosophila genome genomic segment AE003662 Annotated Drosophila genome Complete gene candidate CG17559 dnt - doughnut protein tyrosine kinase Human homologue of Complete gene candidate Homo sapiens RYKreceptor tyrosine kinase GDB:21773 Putative function growth factor transmembrane receptor protein tyrosine kinase involved in cell growth and maintenance Confirmation by RNAi Only wild type profiles observed Example 12 (Category 1) Line ID 629/14 Category Meiotic defects in testis: cytokinesis defects (Ck-06/09) Reversion NR Map Position 64D Rescue ID 2A9X Rescue Sequence 1 GACGGGAGGAAGTAAGTGGGAGGAGAGAGTAGTGCCTCTTTTTTACTGGAGA AATGGACAAACTCTGGGAACTGCGAACTGCGAACTAACCGAGGCAAAAATTG AGAAGCGAGCTGAAAGCGGAATTCAAACAACGCAGCGCTGACGGCGACGCCG GCAGAAGCAGCGCCGCACAAGGCATGCGCACAGAGAGTAAGAAAGAGCGCG GCTAATGAATGAATGAACGAGGCGGAATGCGGGAAGAGCGCAGAGAGGCGC AATGACAAAATAGTTGTAGAAAAGCGCCGGCAAGCGGAACTCCACACTCTTT CTCACTCTCTCTTTCCACCCACACCCCTAGTTCACCGGAAAAAGAAAATTCGTT TGCGGCGGGGGTGTATTTTTCACCAAAAAGAGAGTGTGTGCAAAACGCTAGA GAGAGAGAGAGAGAGAGAAAGAACTGACGTCAGTTCTGCCTCCGTCGACGCC GCTGCCGGCGTCCCAAAGCGCCACCACCCAAAAAAACGCGAGAAGAAGCAGA ACAAACACACACAAAAATTCGCACAGTGGAGCAGAAATCAAGC Rescue ID 2A9E Rescue Sequence 2 CTCCCGTCGTTTTGAGATCAGCTGCTCTCGCAACAACAACAACTATAACTGTA GTTACCGTCTCTTTTGCATCGTTCGTTTTTCGTTTGTGTCGCCAAGTGATTGTGT GTGTGCGTAAGCTTAAAGCTGACTAACAAAACGAAACAAGAAAAAATATAAA TTATAGGAAAATTGTTAAATTATAACCAGAAAGAGAGCGGCACTTACGTGTGT TATTGTGTGCGTGTGCTTTAAAAAGATATAAAAATAGCAATAGAAAGTTATTA AAGCGTTGGCAAAAAAGTCCAACGAACAGCGAGAGGAAGCGGAGAACGAAA TAGTTAAAGCCAAAGTCGCTGCCGACGTCGCACTTGAAAACGTCGCAAAAGTT TGTAAACACACCAGTGTGTGTTCGTGTGTGTTTTTGCCGGCGTGCCAGTGTGCG TGCGCCTAGAAAAGAGTAAAGAAGCAGAAGAAAAGGAAGAAGCCGAAGAAG CAGCAAAAGAAGCCGACAGCAAAAAGTAAATAAAATCAAATGCCCCCTGGCA GAATAATATTAAATTAAGACACATACTCAAATTAATAAC Genomic hit, Accession No. CSC:AC015076 Drosophila EST LP08767 (AI295205) Annotated Drosophila genome genomic segment AE003567 Annotated Drosophila genome Complete gene candidate CGI 0668 - novel with homology to ssDNA/RNA binding proteins Human homologue of Complete gene candidate CGI 0668 - 3e-12 4506449 ref|NP_002889.1 |pRBMS2| RNA binding motif, single stranded interacting protein 2 >gi|1082 Putative function Possible single stranded DNA/RNA binding protein Confirmation by RNAi Slightly increased GI and reduced G2/M indicating GI arrest Example 13 (Category 1) Line ID 653/12 Category Meiotic defects in testis: segregation defects, cytokinesis defect (Ck-07/35) Reversion NR Map Position 75B Rescue ID I5E Rescue Sequence GTAAAAGCTTAGCCCATGGCGTCGACGTCGACTGCGACAGCGACGCTAGCCG AGGCAGTGACTGCGACGTTGGCCACTTTTCGCCTTCGTTTCGCTGTCGTTTTCA GTTGTCTCTCGTTGCTCAAAGCGCGCGGCACGCGAACGCTCTGAAATCCCAAG TTACAACAGCAACATCAAGCAGCAGCAACAACAGTGATTCGCTGGCAAACAA ACAAACAAACCAACATATTTTTGTGTATCAATTGTCGGCCTAAAACTTCACAT AAAAGTGCGTTCAATACGAAACAAATATATTTGTATATATAGAGAGCGAAGC AATCGGTTGCATAAATTGAATTCCGTTCATATACTTCAATATAAATATTATTAA GTACTACAATTTGAAAACATCTTTAAATATACAACATATTTTGAATTAAGTTTA TTTTTTTTTTTAGCCACATAGAGACATCTTTGTGGCATGCTAAATTCTGTAGTA AAACTTTCTTGGGGAAAGTGAAAGCCACGTATCAGACCAAAATCCACCCAAC CCTGCACACACGCATCCCCATAAAGAACGACCTTGAGCT Genomic hit, Accession No. CSC:AC014071 Associated ORF Genscan ORFl predicted sequences >16:36:33|GENSCAN_predicted_peptide_2|477_aa MLILMRPSIKLAANQNAIKAPNGPKNFLDKVLVVRCWLSVCLLENGHIAVTASGS NNNNNSNNINLNLKANYQMSATSIRDSFATILLDAQNRNQNATNAAKNFMLPLR LRSDTSGDTSNNNENNSRRARQAYNCGVNWLTTHRPKRRRQVHPPLGSTPSCNN NSSKISRNSSSSSNNIASATATRIFLGTSAILAIDFDNTRNPGYYQPTGEWIWNSKS MIKQLFANAATADDVAAAAASRGΝALTFLPGKEKGPRKKAEGCGMEWSGVEWS GGDVMCVLSSVATVDDDDHHGGGHFDGLLGTPSALIRLΝCLIΝPKKMRMDFEVE VAWQIARAADLRLISMHLΝVPYEMKTMKTMESVIDGGSLYQPTALFGSLFCLVY SSAADNLLLLAΝCKSLAHGNDNDCDSDASRGSDCDNGHFSPSFRCRFQLSLVAQS ARHAΝALKSQVTTATSSSSΝΝSDSLAΝKQTΝQHIFVNQLSA >16:36:33|GEΝSCAΝ_predicted_CDS_2|1434_bp atgttgatcctaatgcggccgtcaatcaaattggccgcaaatcaaaatgcaattaaagcgccaaacgggccgaagaactttttgga caaagttctggttgtccgctgttggctgtctgtctgtctgcttgagaatgggcacattgctgtcactgccagcggcagcaacaacaa caacaacagcaacaacatcaacctcaatttgaaagccaactatcaaatgtcagctacaagcatccgagattcgttcgccacgattct tctagacgcccaaaatcgagtgcaaaacgcaactgttgctgccaaaaacttcatgttgccgctgcgcctgcgcagtgacaccagc ggtgacaccagcaacaacaacgaaaacaacagccggagagcaaggcaggcttataattgtggcgttaactggttgacaacgcat cgcccgaagcggcggcggcaagtgcacccgcctttgggttcaacgcccagctgcaacaacaacagcagtaaaatcagcagaa acagcagcagcagcagcaacaacatcgcatcagcaacagcaacacgcatttttcttggcacttccgcgattctggccatcgacttc gacaatacacgagtaccggggtattatcagccaactggggagtggatttgggtatccaagtccatgattaagcagctgtttgctgtt gctgccactgcggatgatgttgctgctgctgcagcttcacgcggcaatgcgttgacctttttgccgggaaaggaaaaggggccaa ggaaaaaggcggaagggtgtggaatggagtggagtggagtggagtggagtggtggcgatgtgatgtgtgtgctctcgagtgtg gccacagttgacgatgatgatcatcatggtggcggccactttgacggcttgttgggaacaccttcagcgctcatccgacttaactgc ttaatcaacccgaagaagatgaggatggactttgaggttgaggttgcatggcaaattgctcgagctgctgatctgcggctgatctca atgcaccttaatgtgccttatgaaatgaaaacgatgaagacgatggagagcgtgatcgatggtggctccctgtaccaaccgactgc tctcttcggttctttgttttgcttggtgtattcttcagctgctgatgtgttgttgctgctggcgaactgtaaaagcttagcccatggcgtcg acgtcgactgcgacagcgacgctagccgaggcagtgactgcgacgttggccacttttcgccttcgtttcgctgtcgttttcagttgtc tctcgttgctcaaagcgcgcggcacgcgaacgctctgaaatcccaagttacaacagcaacatcaagcagcagcaacaacagtga ttcgctggcaaacaaacaaacaaaccaacatatttttgtgtatcaattgtcggcctaa Drosophila Gene Hit rescue sequence, ORFl and genomic sequence: Canton S E78B nuclear receptor superfamily protein (U01088) Drosophila EST LP11082 (AI296953 similar by BLASTN to U01088) Annotated Drosophila genome genomic segment AE003593 Annotated Drosophila genome Complete gene candidate CGI 8023 - Eip78C Ecdysone-induced protein 78C nuclear receptor NR1E1 Human homologue of Complete gene candidate CG18023- 4e-32 119100 P20393 EAR1 IUMAN V- ERBA RELATED PROTEIN EAR-1 >gi|1082832|pir||A32608 Putative function ligand-dependent nuclear receptor , putative transcription factor Confirmation by RNAi Not done due to failure of PCR procedure Example 14 (Category 1) Line ID 876/2 Category Meiotic defects in testis: cytokinesis defects Reversion ? Map Position 73A Rescue ID 2H1E Rescue Sequence GATCAAACAGAAAATCCAAAAACGAACAGCGCGCGGCGAACGAGAGCCGTT GAAGCCGGCAGAGAAGTGCGCTGCTCGCGTCGCTGCCGGTATGTGCGTGTCTG TGCACTGAGAGAAAATGCTCGATTAAACAGAGAAATTAATAGTAATATAAAA AAAAAAAAAATTTGTTTATTATTCTCAATTCAATAAAATGTAATTATTTATTAT ATTGGTTGTATAAGAATTTTTATAAAGTAGTATAAATTTTCAATCAAATAAAT ATGTACATCTAACAAAAAATGTTATTATCTTATAACAAAGAGGTAAAATCATA AGTAGTACGAAATCTTTAAAAGAGAAAGTGTGTTACGCAAAAAGTATTCAAA GCAGTCTTTTATTTAATTTAATTAATTTATTTGTGCTTTATCCCTTATATATATA TGTACATTTCATTAAAGCTAATGGTATAATTAGGTATTTACAGTGTTTAGCTAA GGCTTTCATCTGAAATATTTATTAATTATGTCTAGTTGACCTGTTTTTAGTTTTT TTGNATAACAATATTTATTATTTATTAAGGAAAACAAGGGGAGAAGAAAAAC CTTAATTGAAGCAAAGCAGTCTTTTGAACCCACTGGTG Genomic hit, Accession No. AC005633 Drosophila Gene Hit rescue sequence: argos (M91381 Annotated Drosophila genome genomic segment AE003527 Annotated Drosophila genome Complete gene candidate CGI 0162 - Egf2 translation facto Human homologue of Complete gene candidate CG10162 - 4e-l 1 181969 (Ml 9997) elongation factor 2 [Homo sapiens] Putative function Translation elongation factor Confirmation by RNAi Not done due to failure of PCR procedure CATEGORY 2: FAILURE TO ENTER M-PHASE Example 15 (Category 2) Line ID 1216/12 Category Meiotic defects in testis: no division (no meiosis) Reversion NR Map Position 82F1-2 Rescue ID 2I5X-1 Rescue Sequence 1 AAACCAAGCAACAGAAATATCTCCAGTAGAGAGCGCCACTGGAAGATCGGAA TTTTTAGTGCTCTGCTCTGACTAACAGGTTTTAGTAGTAGTGCTTACTTTTCTAC TACGATTTTTGTCGCGGCTAACAATTCTGTTTTCCCACTCCCTCTCTCAGTTTTT GCATGGTAACTTTTCGGTCATTGTACTGTTGTTGTTGTCTTGCAC ACCGCAAGA GAACAACAACAATCGGAGAAACACTGATAGCGCGGTACAGTGGGGCAGGCCA AACTAGAACCTATACATTTAAGATGTCTCCAATTTGTGATTTTGCCTTTCAAGC ATACTAGTTCATAGTTGATTGTTTTGTTATGTTTTGTCTTGAATGCGATGTTTCA AGAAATCTTATTTTCGAATTACGATATTATTCTTATTCCTTTGACTTATTAAAA TAAATGAAAACGGCGAGTAGAGCAAAAGAGCGACCACTGTGGCTCCACAAGC TCGTTTCTCTGTTTCTCATTCGCGCCAGCTCCAATTTCGCCTTATTCACACACA CACCTCACTGCTTGCGACTGCAAATTTGTGCAGCTGAACTTTG Rescue ID 2I5E-1 Rescue Sequence 2 CTTGGTTTATCACCCTCTCTCTCTCTCTATCGCGCGCGCGCGCTCTTTGTGGAA ACAGGTATAACTGTTTGGCGTGAGGGAGCACGAAACTCCAGTGGAGACTTCTC CGCATCGCCAGCGAAACAAACGATCAAAATGAATACTCTGATAACGTGTGAA GGTGAGCAACAAAATAAAGTATAAGAAAATACCGCCACGAAAACAACAACA ATAGAAATGTCGACGCACCCTTTTCTTTTTCTCGCAAAGAACGAGGAAATGGA GAAGCGCAAAACCACATCCCGCTTAAAGAGTCCCTTTCCCCCGCTGGAAGTGG AAGGAAAGGCAGCTTAAAGAGGAGCGGGTGGCTTCCAGTATGTGGAAAACAA AGCAGACGCCATTGGAATGCCGTCGTTTTTTGTTGTTGCTAAGCCGGACATGG CAATTGTTGCTTTTGTTTTCGAGAGGGGGTGGTGAAACTCATAAATATCAGCT ATGGCGAGGGGGTGGGGGC AGTCTTTGTCTGACGTACCGTACTTTTAATTTCTT GTCGCCCGGTTTAATCCAATTTATCCAGCTTTGAATTTCGCGG Genomic hit, Accession No. AC007532 Annotated Drosophila genome genomic segment AE003603 Annotated Drosophila genome Complete gene candidate CGI 116 - novel Human homologue of Complete gene candidate 2495728 HYPOTHETICAL PROTEIN KIAA0258(aa) Putative function No homologies which indicate function Confirmation by RNAi Slight loss of GI peak Example 16 (Category 2) Line ID 1344/15 Category Mitotic defects in brain: no mitosis Reversion NR Map Position 83C Rescue ID 2F6E Rescue Sequence AGCGGGAGTGAGCCGAAAGAGAGTAATTTTGGCCGTCACCAAAAAAGTGGCT GCATAGTGCCAAACCAATGTATGGCCGTTACGCATCTTGTTATTCTAGTGTCTT TGGCTGTAATCAGTTTGCAGTGACAGAGGAGTTCAGTTTCAGTTGACTCGGCT TGGTTCAGGGTTTCTGATTGCCGTCCTCTTCTCCCTCTTCGCCTACAAGTCCGC TGTTCGGCACCGTGACGTCACCTAGACTTACACCCCTAATCAAAGATCCACTA GTTTAGATTTCCTGCATCAACGCCATATTAACTTTATAAGCAGTCGTTATATCT CAAGTAGGCAAAAAAGTGTAATAGATATGTATCTAAATTGTCGTACATTCTAT TTATTAAAATTCGTTTTTACATCCAACAGGTGTTATTTTTGAAGTCTTAGATAA CAAACAATATTCGAATTATGTGGTAGAATACTTAGCAATATACGCACATACAT ATACATATGAACATTATATCCAATGCTTTAAAACCGGAATATCAAGACAACAT AATGCAACATCTGGTCCGAGCTATCCAGGCAATCACATTTTTGAAGTTCCCCC GGTTATCACACATATATCGATCATACCCCGAAATGTGTAACACAGATACAGCT CACCATCCCTCTGATAAGATCTTATCAAGTTCGGGCTTGCTCGCTATCGTGAAT TGGGTTGAAGGGTCCGCGATAATTGCATTGGGCATGCCATTGGTAATCACAAT TGGCTGATAATGCTGCTGCTGCAATTCCACGGGTATGAA TTCATCAATTGGTTA Annotated Drosophila genome genomic segment AE003602 Annotated Drosophila genome Complete gene candidate CGI 347 - novel protein with myosin homology Human homologue of Complete gene candidate 1503990 |dbj|BAA13194| (D86958) KIAA0203 similar to mouse CCl.(aa) Putative function similar to coiled coil protein with ubiquitin like domain Confirmation by RNAi Marked reduction of GI and G2/M indicating fewer cycling cells Example 17 (Category 2) Line ID 703/16 Category Meiotic defects in testis: segregation defects, meiotic failure (Mf-07/75) Reversion R Map Position 83B Rescue ID 2E7E Rescue Sequence AAGCAGCCCAACAGCTACGCAAAAAGTTACTTATATTCGCAGCAAAACAGAT TTTTTTGTTTTAATCGTAAGTATAGGAGTGAAAAATAGCGCTAGAGTAGACCT AAGTACACAGAAAGACAAATAGGGCGAGTAAAATCGCGGTCCTGGTCATTTC TCTGGCCTTGACCAATCCTTTGTCTGCGCTTTCGTTGGAAAAGGGGTTATGTAC GAACTGCGTGCGTACCTAAGGCCAGATTAGTCATCGGGCAGTCATATATTCAT GCAAAAAATCATTTGGTGGCCGTCGGCCTTTGTTCGACTGTACCTTGCTCATTA TTTAATAAGCGCGACAGCAATATACACACTTTGAACCCCCATCCCACATTTTTT CTCACCGTTTCCCCCTAATTTTCGTTTTCCCTGTGCCCATCATTCCGCTTTCGCC ATGTCAGTGTATCGCTTCAAAATGGCGCCGAACCACATGTCTTCGTTCTCGGC TCGTCCGCTTCGTTCGTGCGCTCGTGTGTCGTCTCATTCGCTCTCCGAATTTCG TTTAACAAAGTGGTGCGAGCAGAGGGGCCGCTGGATTCGAGGCAAACAACAC ATATACCTA Genomic hit, Accession No. CSC:AC013960 Drosophila EST several including LD15903 (AA440858), GH20091 (AI389018). Annotated Drosophila genome genomic segment AE003602 Annotated Drosophila genome Complete gene candidate CG2922 - novel Human homologue of Complete gene candidate 286001 dbj|BAA02795| (D13630) KIAA0005 [Homo sapiens] also NP_054757.1| HSPC028 protein [Homo sapiens] e-179 Putative function Weakly similar to a region of human and murine EIF4G2 translation initiation factors; may act as a translation initiation factor Confirmation by RNAi Only wild type profiles observed Example 18 (Category 2) Line ID 741/3 Category Meiotic defects in testis: segregation defects, meiotic failure (Mf-05/31) Reversion NR Map Position 88D Rescue ID H6E Rescue Sequence GCCTGGAGCCACCTCTAGAGCCACGGCCAAAAAATTGTGTGCCAAAAAATCG TATGGCGTTACGCATCTTGTTATTCTAGTGTCTTTGGTTCTACAAATCTGGCCA ATGGGATGGACGGATTTTGGGGCTTTTGCGCCCCACATATGTNTCTTACAACC CACTCGGCCCGGCAAGTGGGTGTCAATTACGGACATCGGCAATCCGAAGACC GGAGACCCAGAGACCCTCAGACCCCAGGGCCCCATTCGATTCGATTTCGAGTT GCGTGGGCCGATCTCACATTAGTCACATCGAAGGAATGAAATAAAAAGAAAA AACATGACGGCCGAAAAGAACTTATCCATCTTCAAAGCTCTCAGAAAATACA AAAAACTAAAAAACTTTTGACTCTTCGTCTTTCACATTTCGAAATCACAAAAT GTCTGCCATAAATTCCAAAGTGAACAATTGAAATAAATTTTTGCGCCATGAAC ACGCCGACTG Annotated Drosophila genome genomic segment AE003705 Annotated Drosophila genome Complete gene candidate CGI 2600 - novel protein Human homologue of Complete gene candidate CGI 2600- 5e-27 4240227 dbj|BAA74892.1| (AB020676) KIAA0869 protein [Homo sapiens] Putative function putative cytoskeletal structural protein Confirmation by RNAi Reduction of GI and G2/M peaks indicating fewer cycling cells Example 19 (Category 2) Line ID 773/1 Category Meiotic defects in testis: cytokinesis defects, meiotic fai (Mf-02/15) Reversion R? Map Position 83F Rescue ID 2D9P Rescue Sequence CCACCGCCCATGCCGCCATTTATTGAAAGGCCTGTACGCAGTTTGTTTTTGTTT TTCTCTTTTTTGCTAGCTCAAACACAAAATTACTTTTTGTGGCTTGACTGGTGA GGTCTCTCTATCTCGCTTTTTCGTCTTTACCTCGCTCTCATTCCCTCTCTATCTG CCCTGCTTCCTCTCACTATCTATCTACAACTGAGGTCAACAAAATAAGTGCGT AGTCAAAAATGTAATTGAATTGATTGACAAACACAGCGAACGTAAATTTCCGT AATGTTTAACCTTGAATTCAAATGAACAACTGTATAAATATAATACACGGGTT AAACTCCATTTCAAAGCAAGCTAAAACATTTTAAATACATTTTAGGGAAACGG CCAATTAAAAGAATAATATTGTGGGGATCAATCTGGGGAAAAATGCAGTATC AGTAATGCTGAATATTTATTTTACTAAATTACAATGAAATGTCTCAAACAAAT GGGTTAATCATTTTCTTGCTCCATCTGCTTTTCCCAACTGTATCCAAGTACAAC TACAGCATTATCCTCAACTG Annotated Drosophila genome genomic segment AE003675 Annotated Drosophila genome Complete gene candidate CGI 0272 - novel protein Human homologue of Complete gene candidate CGI 0272 - 2995577 AC004490 (AC004490) R29381_l(aa) protein includes HMG-I and HMG-N DΝA- binding domain (A+T-hook) found in HMG non-histone components in chromatin Putative function Chromosomal protein Confirmation by RΝAi Loss of GI peak indicating arrest in G2/M CATEGORY 3: METAPHASE ARREST Example 20 (Category 3) Line ID 1067/13 Category Mitotic defects in brain: prometaphase anest (overcondensation, polyploidy, scattered chromosomes with bipolar spindle) Reversion NR Map Position 69C4-10 Rescue ID 2F8E Rescue Sequence GTTTGGGCACAGGGTTGTATTTCATTTATTTTTGGGGGGAGTCGATACGCTCTC TTGGCGTGGTCGAACGGTCACACTGGCCGAGAGATAACGGAAAATGTTTCAA AGGTAAGTAAAGATTATAAACGTATTAAGCTTAATACTATAATTAGCTTACTA TTCCAAGTATGTATAATTATTACACGTTTAAAAGGCATAACGTTAAGTGTAAC CAAATTATATCAATGGATTTTGAATACCAATATTATTTATTTTATATTTTGAGC TTAATATATTAAATCACATATATTTAAGCCTCTTTATATATGTAAATATTTTAA TTTTATTAAAATAAATTATATATTGTTTTGTAATATGATCGAGGGCTGCCACCT TGTGATAAATGCTTACCAACACTTTTAGGTACGCCGTTTAGTGTACGTAAGTTG CGTACCTAGATATCCAGCGAAATCAAAACATTGAGTAAATCGTGGAAAATGG ATGAAAATAGCTTAATCTACGGACTCGAACTGCAGGCGCGGGCTTTAACACCT CAGTACGGAGAGAGCAACGATGTGTGCTTCTTCATAGCCACCAACTCCTTGAA GCCCACCAATCAGGTTCACTTAATCCAGTACGAAGA Genomic hit, Accession No. CSC:AC020333 Associated ORF Genscan: ORFl predicted sequences: >16:51:l l|GENSCAN_predicted_peptide_2|178_aa MAQNISPEQSGGAGGGGSKHSDDSMPVKDNHAVSKRLHKELMNLMMANERGIS AFPDGENIFKWVGTIAGPRNTVYSGQTYRLSLDFPNSYPYAAPNNKFLTSCFHPNV DLQGAICLDILKDKWSALYDVRTILLSIQSLLGEPNNESPLNAQAAMMWNDQKEY KKYLDAFYEKHKDT >16:51 : 11 |GENSCAN_predicted_CDS_2|537_bp atggcgcagaatatcagccccgagcaaagtggtggagcaggcggcggcggcagcaagcacagcgatgactccatgcccgtg aaagacaatcacgccgtgagcaaaagactgcacaaggaactgatgaacctgatgatggccaacgagaggggcatctcagcgtt tccggacggcgagaacatcttcaagtgggtgggcaccatagcgggtccacggaacacggtgtattcggggcaaacgtatcgttt gtcactggattttcccaattcctatccgtatgcagcacccgtggtgaagttcctgacgtcctgcttccatcccaatgttgatctgcagg gcgccatctgtttggacatactgaaggacaaatggtcggccctgtacgatgtgcgcaccattctgctgtccatacaatccctgctgg gcgaaccgaacaacgagagtccactgaatgcgcaggccgcgatgatgtggaatgac Drosophila Gene Hit TBLASTX with ORFl : poor homology to several sequences including homolog of RAD6 (DHR6) (M63792), bendless (L20126 ) and Ubc Dl mRNA for ubiquitin-conjugating enzyme ( X62575). Human Homologue TBLASTX with ORFl : ubiquitin carrier protein E2-C (UBCHl 0) (NM_007019.1) and ubiquitin-conjugating enzyme E2B (RAD6 homolog) (NM_003337.1 ). Annotated Drosophila genome genomic segment AE003541 Annotated Drosophila genome Complete gene candidate CGI 0682 - vihar ubiquitin- conjugating enzyme Human homologue of Complete gene candidate gi5902146 0B6F58A1F0665D9A |ref|NP_008950.11 ubiquitin carrier protein E2-C [Homo sapiens] (2.50E-50) Putative function Cyclin specific ubiquitin conjugating enzyme Confirmation by RNAi Complete loss of GI and G2/M peaks indicating fewer cycling cells. Immunostaining shows metaphase arrest with condensed chromosomes Line ID 1105/1 Category Male sterile, Female sterile, Mitotic defects in brain: prometaphase arrest (Overcondensation, polyploidy, fewer anaphases, high mitotic index, scattered chromosomes with bipolar spindle) Reversion R Map Position 69C Rescue ID A5B Rescue Sequence GTACATATAATCACAATTGAGAATCGAAAACCCGACCGCCACGAAGCGCGCT AAATTACACGCACATACTGAAAGCCAAACAGCGGATAGCACTAGCATCCTAC ATATATAGACGTAGATATATAGTCATGGCGCAGAATATCAGCCCCGAGCAAA GTGGTGGAGCAGGCGGCGGCGGCAGCAAGCACAGCGATGACTCCATGCCCGT GAAAGACAATCACGCCGTGGAGCAAAAGGTGAGTATCACATGGTGCAGCCTA AGATAATCCGCCAATATACACACACACTCACACTCACCCACAGACTGCACAA GGGAACTGATGAACCTGAATGAATGGGCCCACCGAAAAAAGGGG Rescue ID A5E Rescue Sequence 2 ATATGTACTGTATAGTGGAAATTTAGTTTGATCGGTCGGAATACGCGTCTGTT GCTTTTTCAGATATTTTTTTTTTCACTTTTGTGTGAAAACAAAATGGAAGGAGA ACGAGAAGAAACTGTGTTTGGGCACAGGGTTGTATTTCATTTATTTTTGGGGG GAGTCGATACGCTCTCTTGGCGTGGTCGAACGGTCACACTGGCCGAGAGATAA CGGAAAATGTTTCAAAGGTAAGTAAAGATTATAAACGTATTAAGCTTAATACT ATAATTAGCTTACTATTCCAAGTATGTTATAATTATTACACGTTTTAAAAGGCA TAACCGTTAAGTTGTTAACCCAAATTATATCAATGGATTTTGAATACCAATATT ATTTATTTTATATTTTGAGCTTAATATATTAAATCCACATATATTTAACCCCCCT TTATATATGTTAAATATTTTAATTTTATTAAAATAAATTATATATTGTTTGGTTA AAA Genomic hit, Accession No. AC007328 69B-69C Associated ORF Genscan: ORFl predicted sequences >/tmp/aaaaanjda|GENSCANjpredicted_peptide_l|357_aa MGKKAKHKKKGKGPEKTAMKADKKQAARQKKMLEKLGEANIADIIQLLEAKEG KIEAISESNCPPPTPRSNFTLVCHPEKEELIMFGGELYTGTKTTNYNDLFFYNTKTV EWRQLKSPSGPTPRSGHQMVAVASNGGELWFPNFACISRNQSWFVFHNCRLKAA SREKVLLNFNGTVLHPANNIIVHVKLFKKANGFKPWLLDVKLDACRFVRTNFHPF VRIIFDLFKDFSTΓNHTCPYVVLRSMRYIVRRSPRLVHPIVDVPAIGHTRPRRKAAV RGIGCAHRCPLIRMATPCRTNVVMMTLMRGSVRSRVMAICCYRRPAIAIARRRHP TAIAHSQEVAERLGGLLYPDIQRTNP >/tmp/aaaaanjda|GENSCAN_predicted_CDS_l 11074_bp atgggcaaaaaggccaaacacaagaagaagggcaaagggcccgagaaaacggccatgaaagcggacaaaaagcaggcgg cgcggcaaaagaaaatgctggaaaaactgggagaagcaaatatagctgatatcatccaattgctggaggccaaggagggcaag attgaagccatcagtgaatccgtttgcccgccaccaactccacgatccaatttcaccttagtttgccatccggaaaaggaggagctc atcatgtttggcggcgaactgtacactggcacaaaaaccacagtgtataacgatttgttcttttacaacaccaaaaccgtcgagtgg aggcagctgaaatcgccatcgggacccacgcccagaagtggacaccaaatggtggctgtggccagcaatggaggagaactct ggtttccgaacttcgcctgtataagtcgcaatcaatcctggtttgtgttccacaattgtcgtctgaaggcggccagtcgtgagaaggt cttactcaactttaatggaacggttctacatccggccaataacataatagttcacgtcaagctgtttaaaaaggccaacggttttaagc cttggttattagacgtaaaactcgatgcttgtcgctttgtgcggaccaacttccatccgtttgtacgcattatattcgatctcttcaaagat ttctccaccataaaccacacgtgcccatatgtggtcctccgatcgatgcggtatattgtccgccgatccccacgacttgtgcacccc atcgtagatgttccggctattgggcacactcgccctcgacggaaggccgccgttcgtggcatagggtgtgctcatcgctgccctct gattcggatggcgactccgtgtcgtaccaacgtggtgatgatgacgctgatgaggggctcggtgagatcgagggtgatggcgatt tgctgctaccgccgacccgccattgccatagcccgtcggcgccaccccactgccattgcccactcccaagaagttgctgaacgc ctcggtggtcttctttacccggacattcagagaaccaatccgtag Drosophila EST several ESTs including LD04777 (AA201675) All other entries as for 1067/13. Example 21 (Category 3) Line ID 1407/13 Category Mitotic defects in brain: (weak overcondensation, metaphase with bipolar spindle) Reversion NR Map Position 92B1-3 Rescue ID 2D3P Rescue Sequence 1 ATCACGAATTTGACATTGCTACCACATTCGGTGCGTGGACTCTGAAAGCTCTG AGTGTTTTGTTTATGCAAAGCTTTTTTGGACTATCGCGTGGTAAGTAGCCGAAA GAGAAAGCTCTCTTATACGGAAGATGAAGAGTGTGATTCATGAAAATGTATA AGAACGCGGGTCCAAAAAGTCAAGGGAGTTCTAGTGAAATGAAAAGTTCCAA AGGTTTTGAAATCGTTTTATTTTCTCGTTCGTATAATTATTGGGTGTCGATCTTT GTTGGGCAGTGTAAAGCACAAACTTTGAGCTTCATCATACATATCATATGTAA AGCCGGGACGAAAGCTTATGATTCTGTTAAGTGTCCGCCCAAGATAACATTTC TCCAGCCCTTCAAATCTTCAAATAAATACGGCTTAAGGCGAGCAAATTTGTAA ATCAAATGATTTGTTAAATAAACATTATATGTATTTTATCATGCCAGGTTAGAA CACATTGTGCTGATGCAAATAAAATTCCAATTAAACGCCCCTGAATGGGAAGA TGACGCATCTTTAATGGGAATATTATGGTAAATTTAATA Rescue ID 2D3E Rescue Sequence 2 TNCGTGATTATCAGCGTTAATTGTACAATATTATGATTTATTCGAGCTGTAAAT CTTCACAGCAAGCACAAACTGTAATTATACCACTTAGAATTCCGCGGAATTAA TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCAT GATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG GAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGA GACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT GTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTG GGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG Drosophila EST LD05707 (AA246767) Annotated Drosophila genome genomic segment AE003727 Annotated Drosophila genome Complete gene candidate CG7444 - very short ORF with EF hand homology Human homologue of Complete gene candidate none Putative function Possible calcium binding protein Confirmation by RNAi Slight loss of GI peak Example 22 (Category 3) Line ID 1439/7 Category Mitotic defects in brain: prometaphase arrest, (overcondensation, polyploid, no anaphases, scattered chromosomes with bipolar spindles) Reversion ? Map Position 96F10-14 Rescue ID G3X Rescue Sequence GTCGGATGTAGAAGACGTGCCCGAAACCCAGTTAGAAATCGATGTCAGCGAT GGCGCCGGACTGGAGGATGAGGATGATGACGATATGGAACAGATTACAGCTC AGAAGGTAAGGTAAATCGTAACAGAGCTTTTTAATACGCAAGTAATCACATTC TGATATCCCTAGGTTCTGGAAATCATAGAAACCGCGTGGATAAATGAAATGTG TGCGCCGGAGATCCTGCCCAGCCAGACGGACATGCTGGAGCTGATGGTCTCCC AGGTGGCCCATATGGAGGAGCAGATGCGCGATCTGGACAAGAACGATTTCCG AGCGGTGGTGCACTCCATGGAACTGGAGAGGGTGCGCTACATAATGGCCAGT TATCTGCGTTGCCGCCTGCAGAAGATCGAAACCTTCACGCAGCACATCCTCAA CCAGGAGGAGAGCCGTGAGCCGGATGACAAACGTCTGTCTCCCGAGGAGACT AAGTTCGCCCAGGAGTTTGCCAGTAAT Genomic hit, Accession No. AC007825 Annotated Drosophila genome genomic segment AE003754 Annotated Drosophila genome Complete gene candidate CGI 4549 — novel Human homologue of Complete gene candidate none Putative function no homologies which indicate function Confirmation by RNAi Only wild type profile observed Example 23 (Category 3) Line ID 1466/4 Category Mitotic defects in brain: metaphase arrest. (overcondensation, no polyploidy, fewer anaphases, metaphase with bipolar spindle) Reversion NR Map Position 72F Rescue ID E5E Rescue Sequence 1 GGCTGGATGCGATTCGCTTTCGGATTCGGATGGATTCAGCCGCTGTCTCGACA CCGCCGCAACCGCTCTCGGGAGTTTGAAAATTTGAAATGAGCGGATTCGCGTT GCGAAGGCGAGCTAGCGTTGCAGGCAGTGTGGCCAGATGCCGCGTGCGAACG TATTCTCGAATGCAATCGGCCGAGTGCAGATGCACTAAAAATAACCCACTTCC AGTGACTGGAAATTAAGATC AAGGNAATAGATTTTATAAAAACTTATATGAGT AAAAATTTTAAAATTGTGGAGTCAACCTAAATTATAAGCAACTAATTTATAAC ACAAGTAAAGAATGATATTAAGTAACTTTTTAAATAATATTCCATTATGCTTA CGCTCAATTTATGAACAAATGTTTTCTCGATCCTTAGGTAAAGTTTCGAGTTTC GCGACTANATTTATTAAAATTAAGAACATCTCCATTTATGTACACATTTAAAG ATTTATGAGCGGTAATATTAGCTGGTTGAC Rescue ID E5P Rescue Sequence 2 ATCCAGCCAAGATATCCTATCGTGCAGCTGAAACCCGAAACCCGAATCCGAGT TCGAAACGAAACGAATCGCAGTGGTGGTTTCTCTCTCGCTCTCTAGCTCTCCCT CTCTCTCGCGTGTGTGTATGTGTGCGAGTGGCAGGAAAAGTGCGAAGCCGAAA TCTTTTTAGCTGAAAGAAAGCGCAACTTCAATTAGCGAAAAGCAAGAGTAGCT AACAAAAAGAAAAGCGGATCGAAAAGTAAAGAAAAACAAAAAAAAAAAACA AAAGCAACAAATCGAAATGGCAAGCGAAGTGGCCCAAATACCCGCCGAGGG AAACGCCCGCAGTGGCGGCGGCGGAAAAATCAGAGGAGCCGGAAAAGTCAG CGGCCCCGCCAGCGGACTCAGCGGCCGCTCCAGCTGCCGCCCCCGCAGTGGA GAAGGCTGAGGATGCCGATGGCGAAAAAAAGGACGGCGAGGCCGGAAAGCA GGACAAGCAGCAGGATGGC Genomic hit, Accession No. CSC:AC020154 Associated ORF Genscan ORF: ORF2 predicted sequences >21:06:03|GENSCAN_predicted_peptide_5|415_aa MASEVAQIPAEETPAVAAAEKSEEPEKSAAPPADSAAAPAAAPAVEKAEDADGE KKDGEAGKQDKQQDGEEPKKDEAVAAPVATKSEAPPAQKFNVHKTNFEKDIIYL YQFSRTPLLPSLSPYCLKNETWLRLNGLKYENNDHKMRFRSKKGQLPFIELNGEEI ADSAIIIKELSSKYEKYLDSGLTAEQRNVSYATIAMLENHLIWIIFYWRAKYPDNV LKGYKVNLQHALGLRLPNSILNFFFKITFGRKGTKKLKAHGIGVHSAEEIEEFGKD DLKVLSEMLDCKPFFFGDEPTTLDVVAFAVLSQLHYLSKDIAYPLRDYMTEKCPN LIGHVSRMKDKCFPDWDEICTKLDLNAHIPKPEPETKEGKEGGEQEKSNEQEGTE GDKIEKELEKDKSNEKESTEENKEKEETK >21:06:03|GENSCAN_predicted_CDS_5|1248_bp atggcaagcgaagtggcccaaatacccgccgaggaaacgcccgcagtggcggcggcggaaaaatcagaggagccggaaaa gtcagcggccccgccagcggactcagcggccgctccagctgccgcccccgcagtggagaaggctgaggatgccgatggcga gaagaaggacggcgaggccggaaagcaggacaagcagcaggatggcgaggagcccaaaaaggacgaggcggtggcagc acccgtggcgaccaaatcggaagccccgcccgcccagaaattcaatgtgcacaagaccaacttcgagaaggacatcatctatct gtaccagttctcgcgcaccccactgctgccctccctgtcgccctactgcctgaaggtggagacctggctgcgtcttgtgggcctga aatacgagaatgtcgatcataagatgcgtttccgctccaagaagggtcagctgccgttcatcgagctgaatggggaggaaatcgc cgattcggccatcatcatcaaggaactgtcgtccaaatacgagaagtacctggactcgggactcaccgccgagcaaaggaatgt ctcgtacgccacgattgccatgctggagaaccatctcatctggatcatcttctactggcgcgccaagtatccggacaatgtgctcaa gggctacaaggtcaacttgcagcacgccctcggcctgcggctgcccaactcgattctgaacttcttctttaagatcacctttggtcgc aagggcacgaagaagctgaaggcgcacggcatcggtgtccacagcgccgaggagatcgaggagttcggcaaggacgacctg aaggtgctcagcgagatgctcgactgcaagcctttcttcttcggcgacgagcccaccaccctggatgtggtggccttcgctgtcct ctcgcagctccactatctgtccaaggacattgcgtatccgctgcgcgactacatgaccgagaagtgccccaacttgattggccacg tatctcgcatgaaggacaagtgcttccccgactgggacgagatctgcacgaagctggacctcaatgcgcacattcccaagccag agcccgagaccaaggagggcaaggagggtggcgagcaggagaaatcaaacgaacaggagggcactgagggcgacaagat cgagaaggagttggagaaggacaagtcaaacgagaaggagtcgaccgaggagaacaaagagaaggaggaaacaaagtaa Drosophila Gene Hit rescue sequence and TBLASTN with ORF2: failed axon connections (U21685) Human Homologue BLASTX with fax: Metaxin 1 and 2 (Q13505 and AF053551) Drosophila EST several including LD31362 (AA951078 similar by BLASTN to U21685 failed axon connections) Annotated Drosophila genome genomic segment AE003527 Annotated Drosophila genome Complete gene candidate CG4609 - fax failed axon connectionsconnections Human homologue of Complete gene candidate 4505281 ref|NP_002446.1|pMTX| metaxin>gi|3024205|sp|Q135 05|MTXN_HUMAN METAXIN (4e-06) Putative function Drosophila fax is a dominant genetic enhancer of the Abl mutant, developmentally expressed in axons of the CNS Confirmation by RNAi Weak reduction of GI and G2/M peaks indicating fewer cycling cells Line ID 262/20 Category Mitotic defects in brain: metaphase arrest. (overcondensation, polyploidy, aneuploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle) Reversion NR Map Position 72F Rescue ID G6E Rescue Sequence AGCTGCACGATAGGATATCTTGGCTGGATGCGATTCGCTTTCGGATTCGGATG GATTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA ATTTGAAATGAGCGGATTCGCGTTGCGAAGGCGAGCTAGCGTTGCAGGCAGT GTGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCA GATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAAT AGATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCT AAATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTT TTTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCG ATCCTTAGGTAAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACA TCTCCATTTATGTTCCC Drosophila EST several including LD28084 (AA949260) All other results as for line 1466/4 Line ID 262/22 Category Mitotic defects in brain: metaphase arrest. (overcondensation, polyploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle) Reversion NR Map Position 72F Rescue ID FIE Rescue Sequence 1 AGCTGCACGATAGGATATCTTGGCTGGATGCGATTCGCTTTCGGATTCGGATG GATTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA ATTTGAAATGAGCGGATTCGCGTTGCGAAGGCNAGCTAGCGTTGCAGGCAGT GTGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCA GATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAAT AGATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCT AAATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTT TTTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCG ATCCTTAGGTAAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACA TCTCCATTTATG Rescue ID F1P Rescue Sequence 2 GTGCAGCTGAAACCCGAAACCCGAATCCGAGTTCGAAACGAAACGAATCGCA GTGGTGGTTTCTCTCTCGCTCTCTAGCTCTCCCTCTCTCTCGCGTGTGTGTATGT GTGCGAGTGGCAGGAAAAGTGCGAAGCCGAAATCTTTTTAGCTGAAAGAAAG CGCAACTTCAATTAGCGAAAAGCAAGAGTAGCTAACAAAAAGAAAAGCGGAT CGAAAAGTAGAGAAAAACGAAAAAAAAAAACCAAAGCAACAAATCGAAATG GCAAGCGAAGTGGCCCAAATACCCGCCGATGAAACGCCCGCAGTGGCGGCGG CGGGAAAAATCAGAAGAGCCGGAAAATCAGCGGGCCCGCCAGCGGGACTCTG CGGGCGCTCCAGCTGCCGCCCCCGCAGTGGAGAAGGCTGAGGATGCCGATGG CGAA Drosophila EST several including LD28084 (AA949260), LD38479 (AI518768) Other results as for line 1466/4 Line ID 262/3 Category Mitotic defects in brain: Metaphase anest (overcondensation, polyploidy, aneuploidy, no anaphases, high mitotic index, metaphase with bipolar spindle) Reversion NR Map Position 72F Rescue ID H3E Rescue Sequence AGCTGCACGATAGGATATCTTGGCTGGATGCGATTCGCTTTCGGATTCGGATG GATTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA ATTTGAAATGAGCGGATTCGCGTTGCGAAGGCGAGCTATCGTTGCAGGCAGTG TGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCAG ATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAATA GATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCTA AATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTTT TTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCGA TCCTTAGGTTAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACATC TCCCTTTATGTTC Other results as for line 1466/4 Example 24 (Category 3) Line ID 238/20 Category Mitotic defects in brain: metaphase arrest (overcondensation, metaphase with bipolar spindle Reversion NR Map Position 75E1-3 Rescue ID D7E Rescue Sequence TTCAGTCGCGCATTTCACCGTTTCCGAATCGGACGAACCGGGCGTGATTGCTC TCCTGCTGCTTTCGAGATCGGAGTCCCGATAAGGATATAACTACAACCTAAAG AGGAATCCAAGCCTCCTCCTGCCGCTAGTTTCGAAAAGTAAATAGAGTACTTG TTATCAACTGGGGAAGCGGAGATACATAGCTCCGATATTCCTGTGAAAGCCAG ACAAACGGATACCAACGAACAATCGCCATGTGCGTCGTCGTCCCTTCTCGTTT CACACATCGTGCGATAAAAATACCGCTTTGCTTTTTGTGTTTATTTAAAAATTT TGGTTAGGAAGTGAACTCGAACTCGTGACGTTTGCATTTTCACAACAACAAAA AGAGCAAAACATAGCAGAAGAACCCCAGAAGAAACAGGAACAGAAACCGTT GACCGAGTGCCAGTGTGAAGGTCTAGGCACAAAGAACGCTACCAAGAACTCT TGGGAGTTAGGGAGGCTCTTTACAATGACAACATTGCACCAAAGATGGACTCT CTCTCTAAAATGCATTTCATACCAATATTTACTTT Drosophila EST several including LP04802 (AI260815) Annotated Drosophila genome genomic segment AE003519 Annotated Drosophila genome Complete gene candidate CG3979 - novel gene with homology to sodium- dependent dicarboxylate transporters Human homologue of Complete gene candidate 3e-87 4506979 ref|NP_003975.1|pSLC13A2| UNKNOWN >gi|2499523|sp|Q13183|NDCl _HUMAN RENAL SODIUM/DICARBOXY Putative function sodium/dicarboxylate transporter Confirmation by RNAi Only WT profiles observed Line ID 490/9 Category Meiotic defects in testis: segregation defects, multipolar spindles (Mul-02/29) Reversion NR Map Position 95C1-8 Rescue ID I4E Rescue Sequence GCTCTGCCGCTTCAACCGCCCGCGTTCTGTGTGTTGGTGTGCCGCGACGTAGG TGTAGGGTCCGCTGCACACGTGTGTGTGGGAGCGCGCGAGAGCGGGAGAAGA GCAGAACGTTTTTGGGCGGCTAGTGGTGGCACCGTGAGCATGCCGGTCGTCGT AAGATAGGCTTAGGAACACTCAGAGAAAATTTGTTTAGCTCAGCATTTTCCTA TTATTGAAATCATTTATTTGATGGTCTATGGGGGTTTCTTTCGTAGTTATTCAT AGATCGGCGATTTAAGCTACGCTTAAAGGGTAATTTGTCTGAGATATCTTTGT CATTTAAAGTTAAGTCTCAGCTTATCC AAAAGTC AGTTATTGGAAAAAAGGAG CCAGCTTTTCAGCAGAGTTCGGCTTAAGCGCTTATTATCATATTAACCAGCTTA ATTAATGTATCTTTTAAATTGTTATATGCATTAAATCACTAATTAAGGTGATTA CCATTTGTACGTTTTAAATTAAAGTATTTTGATTTTCACTAATACAGGCTCTAA GCTGATCCAAATCTACAAGCTTAGTTTTTGAATAGTCTTCACATGTTGACTTTT ATTCTCT Genomic hit, Accession No. CSC:AC015160 Other results same as 238/20 Line ID 660/3 Category Meiotic defects in testis: cytokinesis defects,abnormal spindles (Ab-01/03) Reversion R? Map Position 75E Rescue ID H8E Rescue Sequence GCTCTGCCGCTTCAACCGCCCGCGTTCTGTGTGTTGGTGTGCCGCGACGTAGG TGTAGGGTCCGCTGC AC ACGTGTGTGTGGGAGCGCGCGAGAGCGGGAGAAGA GCAGAACGTTTTTGGGCGGCTAGTGGTGGCACCGTGAGCATGCCGGTCGTCGT AAGATAGGCTTAGGAACACTCAGAGAAAATTTGTTTAGCTCAGCATTTTCCTA TTATTGAAATCATTTATTTGATGGTCTATGGGGGTTTCTTTCGTAGTTATTCAT AGATCGGCGATTTAAGCTACGCTTAAAGGGTAATTTGTCTGAAATATCTTTGT CATTTAAAGTTAAGTCTCAGCTTATCCAAAAGTCAGTTATTGGAAAAAAGGAG CCAGCTTTTCAGCAGAGTTCGGCTTAAGCGCTTATTATCATATTAACCAGCTTA ATTAATGTATCTTTTAAATTGTTATATGCATTAAATCACTAATTAAGGTGATTA CCATTTGTTCGTTTTAAATTAAAGTATTTGAATTTC Genomic hit, Accession No. CSC:AC015160 Other results same as 238/20 Example 25 (Category 3) Line ID 273/18 Category Mitotic defects in brain: metaphase arrest (overcondensation, very high mitotic index, few polyploids, metaphase with bipolar spindle ) Reversion NR Map Position 75E Rescue ID DIE Rescue Sequence AACTGGGCTAAAACCAGCTGAAAACTGGTGAAAAGTAAAATATTTGGAGAAG GAAAGCCTTAAGTTCCTCTCTACGCTTCGTACACGTAATGTGCGTGGTTTAATC TACGTTAAAACAAGTGGAAACCATGTTACGTGCCGTGGCTTTGTGTGTGTCAG TGGTGCTCATAGCACTATATACGCCAACTTCTGGGGAATCCAGTCAGAGCTAT CCCATTACCACGCTAATCAACGCGAAATGGACGCAGACGCCCCTATATCTGGA AATCGCCGAGTATCTGGCCGATGAGCAGGCGGGCCTCTTCTGGGATTACGTTT CGGGGGTGACAAAGTTGGACACGGTTCTCAACGAATATGGTTTGTGTTTATAA GTCATGGAGAACCCGCATTAAAGAGCTTTTTATATTCTCCTCAATGTGAATCC GAATCCATATAAAATC Genomic hit, Accession No. AGO 15160 Associated ORF Genscan: >ORF2 predicted sequences >16:57:34|GENSCAN_predicted_peptide_5| 1548_aa MLRANALCNSNNLIALYTPTSGESSQSYPITTLLNAKWTQTPLYLEIAEYLADEQA GLFWDYNSGNTKLDTVLNEYDTESQQYNAALELVKSHVSSPQLPLLRLVVSMHS LTPRIQTHFQLAEELRSSGSCQSFTFAQNGSELACSFNELQKKLEVPLAKDSLDAS VVTYSFDHIFPGSENNTRTVVLYGDLGSSQFRTYHKLLEKEANAGRIRYILRHQLA KKDKRPVRLSGYGVELHLKSTEYKSQDDAPKPEAGSTSDEDLANESDVQGFDFK VLKQKHPTLKRALDQLRQRLLQGNDEIAQLKAWEFQDLGLQAAAAIAEIQGDET LQILQYTAHNFPMLARTLLAHKVTDGLRAEVKHNTEAFGRSLNVAPPDGALFING LFFDADTMDLYSLIETLRSEMRVLESLHSNNNRGSLASSLLALDLTASSKKEFAIDI RDTANQWVΝDIEΝDVQNRRWPSSNMDLLRPTFPGMLRΝIRKΝNFΝLNLNVDAL QPTARSVIKLSESFVIHQAPIRLGLVFDARDAΝEDΝLAD YNAITCANΝYNSQKKD ARAALSFLTDIYAANGETKNNTKKDINKQLTKEFTSLSFAKAEEFLEEDSTNDNGR ELAAEFIQRLGFGDKGQPQALLΝGNPMPSΝVVTADSDFEEAIFTEIMTHTSΝLQKA VNKGELTDΝDNAIDNLMΝQPHNMPRLΝQRILSQEDNKYLDIΝGNAYKΝLGΝNG NLΝRLSΝRDMTATLMDΝLKYFGGKKSTELIGRASLQFLTIWNFADLETDQGRDLL THALDYVQSGESVRVAFIPΝTESSSASSRRΝLΝRLVWAAMQSLPPTQATEQVLK WLKKPKEKIEIPTQLEDILGSTELHLKMLRNYSQRNLGLΝKSQRLNIGΝGRLYGPL SSDESFDSADFALLARFSSLQYSDKNRQNLKESAQDNΝEEFΝSDTLLKLYASLLPR QTKTRFKLPTDLKTDHSNNKLPPKQEΝLPHFDNAANLDPASRAAQKLTPILILLRQ NLΝCQLΝLYLIPNPQHSDMPNKΝFYRYVVEPEVQFEAΝGGRSDGPLAKFSGLPAΝ PLLTQQLQVPEΝWLVEAVRAVYDLDΝIKLTDIGGPVHSEFDLEYLLLEGHCFDAA SGAPPRGLQLVLGTQSQPTLVDTIVMAΝLGYFQLKAΝPGAWSLRLREGKSADIYA ISHIEGTNTHHSAGSSEVQVLITSLRSHVVKLRVSKKPGMQQAELLSDDNEQAAQS GMWNSIASSFGGGSANQAATDEDTETINIFSVASGHLYERLLRIMMVSLLKHTKSP VKFWFLKNYLSPQFTDFLPHMASEYNFQYELVQYKWPRWLHQQTEKQRTIWGY KILFLDVLFPLNVRKIIFVDADAIVRTDIKELYDMDLGGAPYAYTPFCDSRKEMEG FRFWKQGYWRSHLMGRJRYHISALYVVDLKRFRKIAAGDRLRGQYQALSQDPNS LSNLDQDLPNNMIHQVAIKSLPDDWLWCQTWCSDSNFKTAKVIDLCNNPQTKEA KLTAAQRIVPEWKDYDAELKTLMSRIEDHENSHSRDSAVDDSVDDSVEVTTVTPS HEPKHGEL >16:57:34|GENSCAN_predicted_CDS_5|4647_bpatgttacgtgccgtggctttgtgtgtgtctgtggtgctca tagcactatatacgccaacttctggggaatccagtcagagctatcccatcaccacgctaatcaacgcgaaatggacgcagacgcc cctatatctggaaatcgccgagtatctggccgatgagcaggcgggcctcttctgggattacgtttcgggggtgaccaagttggaca cggttctcaacgaatatgataccgagtcgcaacagtacaatgccgccttggagctggtcaagagccatgtgagttctccccaattg cccctgcttaggctggtggtatccatgcatagcttgacgccccggatccagacccacttccagttggccgaggaactgaggagca gtggctcttgtcagagctttacttttgcccaggtgggttccgaactggcctgcagctttaacgagctgcagaagaagctggaagtgc cgctcgccaaggatagcttggatgcttctgttgtcacctacagctttgatcacattttccctggcagtgagaacaatacccgcactgt ggtactatacggcgatttgggaagctctcaattccgcacctatcacaaactattggaaaaggaagccaatgctggccggattcgtta catcttgcgtcatcaattggccaagaaggacaagcgaccggtacgactttcgggctatggagtggaactccatctgaagtcaacg gaatacaagagtcaggatgatgctccaaagcccgaagctggttccacttctgatgaggatttggctaatgaatcggacgtccagg gctttgatttcaaggtgctgaagcagaagcatcctacacttaagagagcgctggatcaactgcgtcagaggcttcttcagggaaac gatgagatcgcccaattgaaagcatgggagttccaggatttgggtctccaggcggccgctgctattgcagaaatacagggtgatg aaaccctacaaattcttcaatatactgcccataatttccccatgttggccagaaccctgctggcccacaaggttacggatggcttaag ggcggaggtaaagcataatacggaagcatttggaagaagcttgaatgtagcgcctccagatggtgcccttttcatcaatggactctt cttcgatgctgacacaatggatctgtattccctgattgagacgctgcgctcggagatgcgtgttctcgagagtctgcacagtaataat gtgaggggaagccttgccagctccttgctcgccttggatctgacggcctccagcaaaaaagaattcgccatcgacatccgtgaca ctgcagtacagtgggtcaacgatattgaaaacgatgtgcagtaccgcaggtggccctcatcggtgatggatcttttgcgtccaacct ttcctggcatgttaaggaatatccgaaagaatgtgttcaatttggtcctagtggtagacgcgctgcagcccacagctagaagtgttat taaactgtcagagtcglfrgtcatccatcaagctcccattcgcttgggtttggttttcgatgcgagggacgccaacgaggataatcttg cagattacgtagccatcacgtgcgcctataactatgtgagtcagaaaaaggatgcccgagctgctttaagtttcctcaccgacatct acgcagcagttggtgagaccaaagtggtcacgaaaaaagacatagtcaagcaactaacgaaggaatttacatcattaagctttgc caaagcggaggagttcctggaggaagattccacgtacgactatggcagggagctcgcagcagagttcattcagcggctgggatt cggagacaagggacaacctcaggccttgttgaatggtgttccaatgcccagcaacgttgtgaccgccgatagcgacttcgagga ggctattttcaccgagattatgacccacaccagcaatctccaaaaggctgtgtacaaaggtgaactgacagacaacgatgtagcca ttgattatctgatgaatcaacctcacgtgatgcccagattgaatcagcgaatcctaagccaggaggatgtgaaatatcttgatattaac ggcgtggcctacaaaaatcttggcaatgttggagttttaaatcgtctgtctaaccgggatatgaccgctacgctaatggataatcttaa atactttggtggcaagaagtctacggagcttattggccgagcatccctacagttcctaacgatttgggtgtttgctgatttggaaactg accagggtcgagatctgctcacccatgccctggactatgtccaaagtggagagagtgtgcgagtcgcattcattccaaacactga aagctcttccgcctcaagccggaggaatcttaatcgattggtttgggctgccatgcagagtcttccaccaactcaagccacggagc aggttctcaagtggctaaagaaaccaaaggagaaaattgagatacccactcagctcgaggatatcctgggatctacagagctgca cctgaagatgttgagagtttattcccagcgagtgttgggtctaaataaatcccagcgtttggtcatcggtaatgggcggctttatggg cccctttcgtcggatgaaagctttgatagcgccgatttcgctttgctagccaggttcagttctctacagtatagcgataaggtgcgtca ggtcctgaaggaatctgctcaagatgtcaatgaggaattcaacagcgatacattgcttaagttgtatgccagcctgcttcccaggca aaccaaaactcgctttaagctaccaacggacttaaaaaccgatcactcggttgtaaaactaccgcccaaacaggagaatcttcccc attttgatgttgccgccgttttggatcccgcctcccgagcagctcaaaaactaacgccaatacttattttgcttcgtcaagtgctgaact gccaattgaacttatacctgattcccgtcccccagcacagcgatatgcccgtgaagaacttctacagatacgttgtggaaccggag gtccaattcgaggcgaatggaggccgatctgatggtcctttggccaaattcagtggattgccagccaatcctctgctgacccagca gctgcaggttcccgagaactggttggtcgaagctgtgagagcagtttacgatctggacaacattaagttgaccgatattggtggac ctgtgcacagcgaattcgatctggagtatctgctgttggagggtcactgctttgatgctgctagcggcgctccgcccagaggacttc agttggtgttgggtacccagagtcaacctaccttggtagatactattgtgatggcgaatttgggttatttccaacttaaagccaatcca ggagcttggtccctacgcttgcgtgaaggcaaatcggcggatatttatgcaatcagccacattgaaggaacaaatacccatcattc ggctggctcttctgaagttcaggttcttataacctccttgcgatcccatgttgtcaaattaagggtgtctaagaagccaggcatgcag caggcggaactcctgtcagatgacaacgaacaggcagcgcaatcaggcatgtggaacagcatcgccagcagttttggcggcgg cagtgccaaccaagcagccactgatgaggatacggaaaccatcaacattttctctgtggcatcgggacacttgtacgaacgtcttct aaggatcatgatggtttcgctgctaaagcacacaaaatcacctgtgaagttctggttcttgaagaactatctttcgccgcaatttacgg atttccttcctcacatggccagtgagtacaacttccagtacgaattggtccagtacaaatggccccgctggctgcatcagcaaacgg aaaaacagaggaccatttggggctacaagatccti cctggacgtgctcttcccgctgaatgtgaggaaaatcattttcgtggatgc cgatgccatcgtaagaacggatataaaggagttgtatgacatggacctcggaggagcaccctatgcctacacgccattctgcgatt cccgcaaagagatggagggcttccgattctggaagcagggatactggcgaagccatctgatgggcaggcgttaccacatttccg ccttgtacgtggtggacttgaagagattccgcaagattgcggcaggagataggctaagaggccaataccaggcacttagccagg atccgaacagcttatccaatttggatcaggacttgcccaacaacatgatccaccaggtcgccatcaaatccctgcccgacgactgg ctatggtgccaaacgtggtgcagcgacagcaacttcaagactgctaaagtgattgatttgtgcaacaacccgcagaccaaggagg ccaaactcacggccgcccagaggattgtgcccgaatggaaggactacgatgccgagctgaagaccctgatgtctcgcatcgag gatcatgagaattcgcatagcagggactcggcagttgatgattcggttgacgattcggtggaggtcaccactgtgacgccttctcat gagcccaagcacggcgagctgtga Drosophila Gene Hit rescue sequence and BLASTX with EST and TBLASTN with ORF2: UDP-glucose:glycoprotein glucosyltransferase (U20554) Human Homologue BLASTX with UDP-GGT: hypothetical protein (AL133051) Drosophila EST several including GH16576 (AI293351) Annotated Drosophila genome genomic segment AE003519 Annotated Drosophila genome Complete gene candidate ugtUDP-glucose-glycoprotein glucosyltransferase Human homologue of Complete gene candidate CG6850- IGI_Ml_ctgl4521_41 D65BCE6EEC187AE3 TRANS:SEPT20T.ctgl4521.2 2 FPC_ctg:ctgl4521 FPC_start: 1284609 FPC_end: 1284696 FPC_strand:+ ( 1.20E-215) Putative function ugtUDP-glucose-glycoprotein glucosyltransferase Confirmation by RNAi Only wild type profiles observed Example 26 (Category 3) Line ID 430/5 Category Mitotic defects in brain: metaphase arrest (overcondensation, polyploidy, metaphase with bipolar spindle) Reversion NR Map Position 98B5-8 Rescue ID 2C2E Rescue Sequence GTGCGGCCCATGGATGTGCGAACGTGTACGAAGACCAAGATCGGCATCGCCA TCGGCGGCAGCACGACGGACGATAACGAAAAAGCTACAGCCGCCGCCACAGA TACAGATGCAGATGCCATGCCGCTGTTATCAGCGCGAGCGGGAGAATGATAA GGGATGGGATCGCTCAGCGCGGCAGGCAAGACGACCAAAAAGAGAGCCAAC TAAATGATGTGCCTAAGACTAAGAGTTTAATGAGCATTACTGTCGCGCACTCT ATGTATTATGAATAAAATTCATACAACTTTTGTGGTTTATTATAATATAAAAGT GTGTCAGCTCTACTCGGGGGAAAGTAAGTTTACTTCTTGGCCGCTGGCTTCTTG GCGGCGACCTTCTTCTTGCGGGCGGCCAGCAACTTGGCGCGATTGGCGCAGCC TTGGTGGCCACATTGGCGAAGTGCGACTTGGCCAGCTCGACGTTCTGCTTCTT GGCTTGGCCAGCACCTTGGCCACGGTGCGCTTCTCGGCGGCGAGGGCGGCAC GACGCTTGAGTACCTCGGCATAAGGGTTCAACTTGATCAACTTGCGCACGGTT GGTAAGGGGGTT Drosophila EST several including LD45359 (AI513164) Annotated Drosophila genome genomic segment AE003763 Annotated Drosophila genome Complete gene candidate CG5502 RpLl - Ribosomal protein LI Human homologue of Complete gene candidate le-126 432359 dbj|BAA04887| (D23660) ribosomal protein [Homo sapiens] Putative function structural protein of ribosome involved in protein biosynthesis Confirmation by RNAi Marked decrease in GI and G2/M indicating fewer cycling cells Example 27 (Category 3) Line ID 472/12 Category Mitotic defects in brain: metaphase arrest. Meiotic defects in testis: segregation defects. Abnormal spindles (mitotic: High mitotic index, meiotic: Ab-08/24) Reversion R? Map Position 96C7-9 Rescue ID 2B6E Rescue Sequence 1 GTCTGACGTTCTCTGAGGGCAAAAGTTTCGAGTTAGTTGAAGGTGAGGGTGCT CGATCACCGATTTGCGGTGAGACGAAAGAAAAGTATGCATTGTTGCGTTGTAA AGAGAGCCGGCGCTCGTCTTGTTCACATTGTCGCTGAGAACGTATGTTGTGCT TCATCATTTCCTTGTTGATTTCCCTTTGACGTGGCAACTTGACCATGTATGACA ACTCTTTGGTGGTGCCATCTGGAAGGCAGAAATTTGATGTCAACGGTGCTCCC AGCCAGTCCACTCCCCAACTCACCCTGCAGCTCCACTTCGATATTAACTCGCA ACATATTAGTGGCGTAGTTGTCACCTGCCGCGGATCCCATTTCCGCTTTGAAAT TTCGCACTTTCGAATATCCGTCCACATTCGATTTGAGAACATCTTCGAAACGTT CAGCGGTGACCCAATCGGGTATTTTGCCAGCCGCCATTGTAGATAATCGGGAT AAGTATTTTGAAATCGAGCAGAAAACACATATACGTCCAGTGTGACGGTCTTG CGTAGACTGATGAAAGCCGAGTATTAGACTCTACACATCTGTGGAGCTTTTTA ATTTCGTAGTGCGCGGCCGATTTCTCTCGATCTTCTCTCAAAAGCTCCGCTAAT Annotated Drosophila genome genomic segment AE003751 Annotated Drosophila genome Complete gene candidate CGI 0618 - novel Human homologue of Complete gene candidate none Putative function no homologies which indicate function Confirmation by RNAi Only wild type profiles observed Example 28 (Category 3) Line ID 571/15 Category Mitotic defects in brain: metaphase arrest (overcondensation, few anaphases, some polyploids) Reversion NR Map Position 93D Rescue ID 2A8E Rescue Sequence GGCGGCGCTACATTTGTTGTTGTCGCTGCTGCTCACAGCTCCACCACCATTTGC ACAGTTATATTACCTCGCTCAAGTCGCCCCTCTCCCTCTCGCCCACTCGCTGTG TCAATCGAATTAAAACGAATGCTCTTCGGCGAATAATTGGGTTTAGATACTTT TCCAGCAGACAAAGTTGTATTTTTTGCACTTCTTATTGATATTAGGCAAAACGC ATCGGCCGAATC ACACGC AC AC AAAGCAC ACACGCGAGCAGCGGTTTTTC AA TCTGCAGTACACCAAACAACACACACTATTTCCTAATGCCTGTTCTTATCCCTC TGATATTCCCAATGAATCGCTGGGCAATTGGCGATTCGAACCGATTTTCACTT GGCTCTTTGTTTTATTTAATTTTCACCGAAACGCTCTCACACGCAGAGACGCTT TTGCTCGTTCGCTGATGCTTCTGCTGCAATACACACCACCTACGAAACGAGCC AAGGGAAATTGTATCTATGGGCTGTGTATCTGTTTCTACGCGGCACGCGCTGC ACGTCCGCTCGCTTCGGGTTTTCGAGAGAGAATATAACTTTTTCGATACGGTA CGGTAAACGAATTCCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATA CGCCTATTTTATAGGGTAATGCATGATAATAATGGGTTCTTAGACGTCA Drosophila EST LP07504 (AI294185), LP06548 (AI293427) Annotated Drosophila genome genomic segment AE003734 Annotated Drosophila genome Complete gene candidate CGI 5802 - novel homology to Doom, a product of the Drosophila mod(mdg4) gene, induces apoptosis and binds to baculovirus inhibitor-of- apoptosis proteins Human homologue of Complete gene candidate none Putative function inducer of apoptosis Confirmation by RNAi Only wild type profiles observed Example 29 (Category 3) Line ID 736/15 Category Mitotic defects in brain: prometaphase arrest (overcondensation, fewer anaphases, metaphase with bipolar spindle) Reversion NR Map Position 73 C Rescue ID H5E Rescue Sequence CTAATGAGTAAGGAAAACCAATCAGCCTTGCTAATCGCTTGGCAGTATTGGCT TCTATGCAGGGGGGCGTGTCCCGCGCCCCTTGAAGCTCAAATTTTTGCAAGGG CACAGGTCGTCCCCTCCTCCTCCGCGTGGGTGGCGTTCGGCCGAACGAACCGG CGCCTACTTTGCGTCCGGCTAGCGAGGATCTCTGGGTGCCACCCCACGGCTGG GTGTTGCGATCTGCCCGATTGATAATCCATGCGTGAGAAAGCTTTAGAGAATC TGCCAGATTATTATTACTCCCCGCATACTCAGAAAAATGTATCCTTCAGATATG TTTATGTTTATGAAGTGAAAAAAGTCCTTTGAAATACTACAAAAAGTGAGGAT CTGACCAATGATTTGATTTCTATAGAAATATACTATAAACTATAAACTAC Genomic hit, Accession No. CSC:AC014181 Annotated Drosophila genome genomic segment AE003526 Annotated Drosophila genome Complete gene candidate CG3971 baldspot - with homology to membrane glycoprotein Human homologue of Complete gene candidate CG3791 -9e-08 4680391emb|CAB41293.1| (AL034374) dJ483K16.1 (novel protein) [Homo sapiens] Putative function membrane protein, function unknown Confirmation by RNAi Slight reduction of GI and G2/M peaks indicating fewer cycling cells Example 30 (Category 3) Line ID 82/24 Category Mitotic defects in brain: metaphase arrest (condensation, no polyploidy, no anaphases, metaphase with bipolar spindle) Reversion NR Map Position 100D Rescue ID 2E3E Rescue Sequence GGTCAAGCCCGATGGCGTCCAGCGCGGGCTCGTCGGCAAGATCATCGAGCGC TTCGAGCAGAAGGGCTTCAAGCTGGTCGCCCTGAAGTTCACCTGGGTAAGCGG ATAATTGAATTAGGAAGAAATCAATAGATATACATACGTGGAAACGGGTTGC CCCACGCGGGGTTGCTATCGGACCTAACCTCAAAGGCTGGGTGCAGGCGTCAT CGCGGAATGACATGTGTTTAGAGGTCAGAACTGCAATTAACTGATAACGAACC GTTTTGTAACCAGGCCTCCAAGGAGCTGCTGGAGAAGCACTACGCTGATCTGT CCGCCCGCCCCTTCTTCCCCGGACTCGTGAACTACATGAACTCCGGCCCCGTG GTGCCCATGGTGTGGGAGGGTCTGAATGTGGTCAAGACCGGTCGCCAGATGCT CGGCGCCACCAACCCCGCCGACTCGCTGCCCGGCACCATCCGCGGTGACTTCT GCATTCAGGTCGGACGCAACATCATCCACGGCTCCGATGCCGTCGAGTCTGCC GAGAAGGAGATCGCCTGTGGTTCAACGAAAAGGAGCTGGTCACCTGGACCCC GG Genomic hit, Accession No. CSC:AC012727 Associated ORF Genscan ORFl predicted sequences >16:43:49|GENSCAN_predicted_peptide_7|172_aa MKLLMLGTILAFFSNISATMAANKERTFIMVKPDGNQRGLNGKIIERFEQKGFKLV ALKFTWASKELLEKHYADLS ARPFFPGLVΝYMΝSGPNNPMNWEGLΝNNKTGRQ MLGATΝPADSLPGTIRGDFCIQNGRΝIIHGSDANESAEKEIALWFΝEKELNTWTPA AKDWINE >16:43:49|GEΝSCAΝ_predicted_CDS_7|519_bp atgaagctcctgatgctcggcacaattttggcattcttttctgtaatctcggcgacaatggcggctaacaaggagaggactttcatcat ggtcaagcccgatggcgtccagcgcgggctcgtcggcaagatcatcgagcgcttcgagcagaagggcttcaagctggtcgccc tgaagttcacctgggcctccaaggagctgctggagaagcactacgctgatctgtccgcccgccccttcttccccggactcgtgaa ctacatgaactccggccccgtggtgcccatggtgtgggagggtctgaatgtggtcaagaccggtcgccagatgctcggcgccac caaccccgccgactcgctgcccggcaccatccgcggtgacttctgcattcaggtcggacgcaacatcatccacggctccgatgc cgtcgagtctgccgagaaggagatcgccctgtggttcaacgaaaaggagctggtcacctggaccccggccgccaaggactgg atctacgaatag Drosophila Gene Hit rescue sequence and TBLA: abnormal wing disc (awd) (XI 3107) Human Homologue BLASTX with awd and TBLASTN with ORFl : tumor metastasis inhibitor nm23-H2 (A49798) non-metastatic cells 2, protein (NM23B) (P22392) and nucleoside diphosphate kinase B. Drosophila EST several including LP05977 ( AI257573 similar by TBLASTX to X92956 B.taurus mRNA for nucleoside diphosphate kinase (NBR- A) Annotated Drosophila genome genomic segment AE003779 Annotated Drosophila genome Complete gene candidate CG2210 - awd abnormal wing discs nucleoside diphosphate kinase Human homologue of Complete gene candidate gi4505409 1A5C3F84D7AD272C |ref|NP_002503.11 non- metastatic cells 2, protein (NM23B) expressed in [Homo sapiens] (1.90E-61) Putative function human nucleoside diphosphate kinase, transcriptional regulation of c-myc expression.a candidate suppressor of tumor metastasis Confirmation by RNAi Only wild type profiles observed CATEGORY 4: ANAPHASE DEFECT Example 31 (Category 4) Line ID 1132/8 Category Mitotic defects in brain: anaphase defects (overcondensation, high polyploidy, some lagging chromosomes) Reversion ? Map Position 86F3-6 Rescue ID 2C3E Rescue Sequence GGCCGGAGGTACCATTTTGGTAGGACCGTTTTTCGGGCCAACGAAAATACCAC AAGACGGCAGCGATAATAGTGTTTTTTGCTTCAAATGTAGTATGGCTACGCAA CTCACATATGGTTAAGAACTTCGCTGTTTATTTGGTGGTTAAACTAGCTAAATA CAATAAGAGTGGCAACGCCGTCACGTTTTCTACATGTATTTTACTTGGCGTAGT GCGCCAAGCTTATAAACCACAGTTGGGCGGTTCTTTTGAATTGTTTAATTTACA CCCCACTATGAAACTTATTAGCCTTCTTTATTTATTTTATATTTTATTTTTAGGA AGAATACGTTTACTCAAGGTTCGCAGCTTGTCAATCAGTATTCGCAAATATCA ATAATAAAAGGCATCAATTTTCCAATCAGCAGTTGAAAAGAACTCCCCTCGAC ATTTGAACAAAATGCATTTTTGGGTGATTATAATTTATTAGAATTTTTATTGAC TTAAGGTAAATATAAATAAAATATTATTCAAGTACAAAGGTATATATACTCAT TAATANTATTTGGATTCAAGGAAAATATATTTCAAAATGGCGGGGGTTTAATA AAACAATTTTTCAAATTAAGG Genomic hit, Accession No. AC007805 Drosophila EST several ESTs including LP09688 (AI295922) Annotated Drosophila genome genomic segment AE003693 Annotated Drosophila genome Complete gene candidate CG6929 - Lk6 kinase Human homologue of Complete gene candidate gi4505191 DB39E49EC0BED990 |ref]NP_003675.1| MAP kinase interacting kinase 1 [Homo sapiens] (6.20E-113) and gi9994197 551A82FA3D09FD58 |ref|NP_060042.1| G protein- coupled receptor kinase 7 [Homo sapiens] (1.70E-106) Putative function Protein kinase associated with microtubules Confirmation by RNAi Complete loss of GI and G2/M indicating fewer cycling cells Line ID 483/19 Category Meiotic defects in testis: segregation defects Reversion ? Map Position 86F Rescue ID H2S Rescue Sequence 1 CTCCGGCCACACGGATGAATTCGTCGTCATTCGTCGGAATCATTCGAACTTTG AAAATGGATCGGTAGCTGGGAAGGAAACTTAAAGCGAAATACGCAAAGAAA ACGGCTTTTGTCCGCTATTC AGCGATTTTTTTTGTGTTGTAATC AGC AGAGGAA ATTTTAACGACCAACTCCACCGCCACACCAGCCATCTCCAGCAGCCCCGGAAA ATAAAATAGAACTAAATTAACGCCACCATCACTACAACAACCATCTCACCAAC AACTACAAGAGCAACAACCACAGCAACAGCACTACTGCACCAAGCCCACAAA GAAGAGGTGAAACGCAATAATCGA=CAATACCCGAAGAAAAAAACAAAAAA ATATCGCAGATAACCGAAAAAAGCGGTGCAATAGATAAACCCCATTTTTTGCT TGAGCTTTTTTCGCCTGTGTGATGAGAGAAATCAGCAGCAGCCATCGATTACA ACAACAACAGCAGCCACACCAACGACGACTCACCACCAAACGAAGAATAATA ACCAGCGGANAGCGATAGATA Genomic hit, Accession No. CSC.AC018284 Drosophila EST several including GH28825 (AI517767), LP04213 Other results same as 1132/8 Example 32 (Category 4) Line ID 1422/14 Category Male and female sterile, small wings, meiotic defects in testis segregation defects, elongation defect Reversion NR Map Position 90B4-8 Rescue ID 2F1E Rescue Sequence GGCCAGCTGCTCAAACATTCTGCAGCTATTTGGCCGCCAGCGAGTAGAACGAT ATTGCCAAATATTTTATAATAGTAACCAATACGTTACCAGTATGACCGCGCCG ATAACGATAGAAAATACCACACGGTCTAAAAGTAAATACCATTTGGGGTATTC CCTAATCTTTTGAATTATTTACCGTTAGGTTTCGGTCGTTTTTTTTTGTCAGCTG TTCTTTGTATGAAACGGATTAGTAATTTTATTTGTTGTTTTTGTGCATTTTTGCA TATTAAAAGCCTTGAAACATGCCTTAAATCGTTAAAATAGATTATAAGAGGGA TGGACTGTTTGTTAAAACCAATTGGAAAATTTGTAATCGCTGGTAATAACTAT CGAGATAAGCTTAATTATCGCTGTTTTCTTTGTATCTAGTTATAAATAATAATA ATAAAACTGGTAATTAACAAAAGTAAAAAGTTACTTAACTTATACAAAAATAT TTAGTTATTGNATTCAATAATAAGATGGTAATAATAGATGGTAAGATAGTAAT ATTTTAATAATTGAATTTCATCACACATGCTGGTGCACGTTCCACAACTTACAA TCAAACGAAA Annotated Drosophila genome genomic segment AE003718 Annotated Drosophila genome Complete gene candidate CG7623 - novel with homology to UDP-galactose transporter. Human homologue of Complete gene candidate 2136348 UDP-galactose transporter related isozyme 3 - human >gi|1669564|dbj|BAAl 3527| (le-36) Putative function sugar modification protein Confirmation by RNAi Slightly reduced G2/M Example 33 (Category 4) Line ID 1479/10 Category Mitotic defects in brain: anaphase defects (overcondensation, anaphase bridge, metaphase with swollen chromosomes and bipolar spindle) Reversion NR Map Position 69F3-7 Rescue ID 2D6E Rescue Sequence 1 CCACGGGCAAATGTGGTCCGGAGGTCCACGACAACGTGCCGCTGACCATATC CCAGATTGAGCGCGCAACTCAGGATCCGGAGAACGAGAATGTGTTCATCACA GACGACGTGCATCCGATTCACTTCTGCACCTGCATCATCTACGCCTTTGTAACT GGCAATGGAACGCACAACGAGTCGTTCATGAAGTTCATGATCGATGATGGCA CCGGCTCCCTGGAGGCCAGCATCACCAAAAAACCCTTCAATGGACGCGTGATC AGCAGCCTGTACAGTGAAGCCAGTTCGCTGGCCTCGTCCGAGGCCTACAAGA GCATTGCCGTGAGCATGATGCGGCTGCTGCAGGTCTCCATGGAGTACATTGAT CCCACGCGCATCTCGAGGGGCCACAGCCTATTCCTGCGCGGTCGTCCGAATAG GTTCCGCGGCAAGATGGGTCTGGACGCTTTTCAGTTCTTCATAGACAGCGGCC GATCGCGGAATATGGAAATTGGCTTCGTGGACTACCTAACCGACTGGCAACG AAGGCATAAAACAATGCAAAATAC Rescue ID 2D6P Rescue Sequence 2 GCCCGTGGACTTTTCACTCTGTTGATTCTTGCGTATCACGAAGTTATCCAGCTG GCTTTCTATGTCCTCGAAACTCTGATTAAAATCCATTCTATTTGCTTAGTCTGC GATTTCAAAGGGGATTTCTTTATTGCAGTGCATTTTGCATTAGCGCCAAAAAA AAAAAAGTTGTGAGCATGGGCGTAGACTTCGTATTTTCTTACAAATAATATTA ATTAAAATTAATTTTGTGAGCAATTTTCACACAATTGTATTATAAGTTAAAACC AGGGTCACATTAATTTGC AGAACCGCGC AATATTTTCTTTTTAACCCCCTTACA AATTTTCAGTTGTTTTGACTACGCCCCTGCTAATTTTTACTTATTAAATTCAAA GTCTAAAAACATTGTCACCAGATAATACGAGTATACACTATATGGACAAACGT AAAATCGTTAATAGAATATATATATTCAACCATTATTTCACCACCGAGAGAAA TTCATTTGCACAAAACGCCAGGTTGGCAGCACCATCATTGCGCACAGCAAGTG GGCAAACTCGTTGTATCGCTTG Genomic hit, Accession No. AC007328 Associated ORF Genscan ORFl predicted sequences >17:42:01|GENSCAN_predicted_peptide_2]1507_aa MKLAPTVKLNNGYEMPILGLGTYNLKKSRCEAANCHALEMGYRHIDTAYLYRNE GIIGKVLAKLIGDQKLKREQNFLNTKLWDIYHEPKMNKNACDMQLKLLGNDYID LYLMHSPVGVDYISDEDLMPHEΝGQLRTΝDVDYVDTYRSMEQLVHLGLVRSLG LSΝFΝAΝQLKRLLEΝCQIKPAΝLQIECHPELVQVPLIELCKFHΝITVVAYSPLGRSQ TCΝPLPDNYTDSKLLALAAKYGKTPAQIILRYLSKDΝEGEAANKHAIDVGYRHID TAYFYQΝEAEVGKAIRDKIAEGVVKREDIFLVTKLWΝIFHDPERVEGICRKQLSΝF GLDYIDLYLMHMPVGYKYVDDΝTLLPKΝEDDVLQLSDVDYLDTYKAMEKLVKL GLRIEQLAGLSHLSTHSDGMQFRIRMFLTFQRGGPSHNNMQQQQQRGGGSGTDF YNQQRDRRDSGRQMDNNYSNNYNNNNNNQRNRGGGNGMQQQQRGGNGGSGG GGGNGGGNNPAWNMHRGNQNSNNMMNMRNRGMGSRGPMRPNQVHLLVTHT AIDGLLNPGFHILQGYRPQSANNQNKPRNKIKFEGDFDFEQANNKFEELRSQLAKL KVAEDGAPKPATNATAATATATNEQVGEKVEGVHTLNGETDKKDDSGNETGAG EHEPEEDDVAVCYDKTKSFFDNISCEAAQDRSKNKKNDWRQERKLNTETFGVSS TRRGSVAHQLNVFQAVTADATNTTTIMATAALTRDMEERQATTGTIIAWVGGGG NFRNRSNNRNNGGGRGGNGMPNITNGNTAAALKAANNAAGHGSNATDSSAPNA TTATTKSTSLLPEQTQQVAAVSLPVLLPSIGWLFIVMDGPPDIPRSADIAILFVSFEQ S VLFLKFHKRYNEFAHLLCAMMSFEDIESQLDNFVIRKNQQSEKSTGKCGPEVHD NVPLTISQIERATQDPENENVFITDDVHPIHFCTCIIYAFVTGNGTHNESFMKFMID DGTGSLEASITKKPFNGRVISSLYSEASSLASSEAYKSIAVSMMRLLQVSMEYIDPT RISRGHSLFLRGRPNRFRGKMGVCTNATAPSVSSΓNRILRNRAAERAAAEFARAAS YGYAIHPTHPHPYTSFPTWPAHHPLWGAVPLATPPGGGPAGAGGALQPGGSGSSY GSDGNMSSNPNSSNSNTTHSNGHNTNSGSGCGDSSAGSGRLSLPALSPDSGSRDS RSPDADANRMIDIEGEDSESQDSDQPKFRRNRTTFSPEQLDELEKEFDKSHYPCVN TREKLAARTALSEARVQVWFSNRRAKWRRHQRVNLIKQRDSPSTSSSPTPLVNPV VSPVSPIPVPVPVAVPESGQQKQPYPYSTSNMCNTSSSSSNSQPCNTΓNPGSKMSSK TSSVSSNQHMEEPAAAVATASPTASAPLSMGGENSAFRALPMTLPMPMTLPTASA AAFALSFARQYIAKTLLGSPPRSQPPTTNQHKPEPNREFLNEACSSAASVQNSTTP ATTADTPTAKSAMCVHCEKKGGAMEWM >17:42:01|GENSCANjpredicted_CDS_2|4524_bp atgaagctcgctccgactgttaagctaaacaatggctacgagatgccaattctgggcctaggaacctacaatttaaagaagtctcgc tgtgaggctgccgtgtgccacgccctcgaaatgggctatcggcatatagacaccgcatatctgtacaggaatgaaggcattatag gcaaggttttagctaaacttattggcgaccagaaactgaaacgcgaacaggtgtttctggtcacaaagctgtgggacatataccac gaacccaagatggtgaaatacgcctgtgatatgcaattaaagctactgggcgtggactatatagatctatatctgatgcattcgccg gtgggcgtggactacatctctgatgaagatctgatgccccacgagaatggccagctgaggaccaacgatgtggactatgtggac acctacagaagtatggagcaactggtgcatctggggctggtgcgcagcttgggattgtccaactttaatgccaatcagctgaagag attactggaaaactgccaaatcaagccggcaaacctacaaatagaatgtcatccggaattggtgcaagtcccattaattgagctctg taaatttcacaatatcaccgtggttgcctattcgccactggggcgttcccaaacctgcaatccgctgccggattactacactgattcc aaactactggcgttggcagcgaaatacggcaagacaccagctcaaatcatcctaagatacttgtcgaaggacaacgaaggcgaa gccgctgtgaaacatgcgattgatgtgggctatcgtcatatagatacggcctatttctaccaaaacgaggccgaagtgggcaagg cgattcgggacaagatcgcagaaggtgtggtcaagcgagaggatatatttttggtcactaagctttggaacattttccacgatccag agcgcgttgagggcatttgccgcaagcagttaagcaattttggcttggactatatcgatctgtatctgatgcatatgccagtgggcta caaatatgtagatgacaacaccctgctgcccaaaaatgaggacgatgtgctccaactgagcgatgtcgactatctggatacgtaca aagccatggaaaagctggtaaaactgggcctgcgtatcgaacaacttgctggcctgagtcatctttcaactcattcagatggcatgc agtttcggatacggatgtttctaacattccaacgtggcggacccagccacaacaatatgcagcagcagcagcaacgaggcggcg gcagtggaacggacttctataaccagcagcgggatcgtcgggactccggacgtcaaatggacaacaactatagcaacaactaca acaacaataataataatcagcgcaatcgcggcggcggcaacggaatgcaacagcagcagcgaggaggaaacggcggcagc ggcggcggcggtggaaacggaggtggaaacaacccggcctggaacatgcatcgcggcaaccagaactcgaacaacatgatg aacatgcgcaaccgcggcatgggatcccgcggccccatgcgacccaatcaggtacacctgctggtgactcacactgctatagat gglfrattaaaccctggctttcacattttgcagggctatcgtccgcagtcggccaataatcagaacaagccgcggaacaagatcaa gttcgagggcgacttcgatttcgagcaggcaaacaacaagttcgaggaactgcgctcccaactggccaagctcaaggtggccga ggatggtgcacccaagccagccaccaatgcaacggccgccactgcaactgcaaccaatgagcaggtgggtgagaaggttgaa ggcgttcacacactgaatggcgagaccgacaagaaggatgattctggcaacgagaccggcgctggagagcacgagcctgagg aggatgatgttgctgtgtgctacgacaagaccaaatcgttcttcgacaacatctcgtgcgaggctgcccaggatcgcagcaagaa caagaagaacgattggcgccaggagcgcaagttgaacacggagaccttcggagtgtcctccacacgacgtggcagtgtggctc atcaactgaatgtattccaagcagttaccgcggacgcaaccaatactacaacaataatggcaacggcggcattaactcgggatatg gaggagcgccaggctacaacaggaacaattatcgcatgggtgggcggcggcggaaacttccgaaacaggagcaacaatcgc aacaacggcggcggtcgtggcggaaacggaatgccaaacatcaccaatggcaacacggctgctgcgctgaaggcggccaac aatgctgctggccacggatccaatgccacggactccagtgcaccaaatgccacaaccgcgacgacaaagtcgacgtccctcttg ccagagcagacgcaacaggtggcggcagtttcgttgcccgtgttgttaccatcgattggttggctttttatcgttatggatggaccac cagacattccaagatcggcagatattgcgattctcttcgttagttttgaacaaagtgtactlttccttaaatttcacaagcgatacaacg agtttgcccacttgctgtgcgcaatgatgagtttcgaggacatagaaagccagctggataacttcgtgatacgcaagaatcaacag agtgaaaagtccacgggcaaatgtggtccggaggtccacgacaacgtgccgctgaccatatcccagattgagcgcgcaactca ggatccggagaacgagaatgtgttcatcacagacgacgtgcatccgattcacttctgcacctgcatcatctacgcctttgtaactgg caatggaacgcacaacgagtcgttcatgaagttcatgatcgatgatggcaccggctccctggaggccagcatcaccaaaaaacc cttcaatggacgcgtgatcagcagcctgtacagtgaagccagttcgctggcctcgtccgaggcctacaagagcattgccgtgagc atgatgcggctgctgcaggtctccatggagtacattgatcccacgcgcatctcgaggggccacagcctattcctgcgcggtcgtc cgaataggttccgcggcaagatgggtgtctgcaccaatgccactgctccttcggtgagcagcatcaatcgcatattgcgtaatcga gcggcggaaagggcagctgcggaatttgctcgggcggcgagttacggctatgccatccatcccacacatccgcatccgtacacc agtttccccacttggccggcgcatcatccgctgtggggagccgtgcccctggccacgccacctggtggcggccctgctggagcc ggtggtgcactgcagccgggcggcagtggcagcagctatggcagtgatggcaacatgagctcaaatcccaatagcagcaaca gcaacaccacccacagcaatggccacaataccaacagcggcagtggatgcggggatagtagtgccggaagtggacgcctctc cctgccggcactttcgccggattccggaagtagggacagccgctccccagacgcagatgccaatcggatgatagatatcgaagg cgaggacagcgagtcgcaggacagtgaccagccgaagttccggcgcaatcgcaccaccttcagtccggagcagctggatgag ctggagaaggagttcgacaagtcgcactatccctgcgtgaatacccgcgagaaactggccgcccggacggcactgagcgagg ccagggtgcaggtttggttttccaacagacgagcgaaatggcggcgccaccagcgggtcaacttgatcaagcagcgcgactcg ccctcgacatcgagctcacccacgccgttggtcaatccggtggtcagtccggtcagtccaatcccagttccagttccagttgcagtt ccagaatctggccaacagaagcagccatatccgtacagcaccagcaacatgtgcaacaccagcagcagcagcagcaacagtc aaccgtgcaacaccatcaatcccggcagcaaaatgagcagcaaaaccagcagcgtcagcagcaaccagcacatggaagagc cagcagcggcggtggccactgcctcacccacagcatcagctccattatcaatgggcggtgagaacagtgcatttcgcgctctgcc catgaccttgccgatgcccatgaccttgcccacggcatcggcggcggccttcgcgctcagcttcgcccgccagtacatagccaa gacgcttctcggttctccagatcccagatcccagccaccaaccaccaaccagcataagcccgagccaaatcgcgagttcctcaat gaagcctgcagctccgcagcatctgtccagaattcgacaacgccggcaacaaccgcagatactcctacagccaaatcagcaatg tgcgtgcactgcgagaaaaagggaggggccatggagtggatgtga Drosophila Gene Hit BLASTN with rescue sequence 2: Histone acetyltransferase GCN5 (AF029776) very small match at end, TBLASTN with ORFl : middle domain histone acetyltransferase GCN5 (AF029776). Genomic matches histone acetyltransferase Annotated Drosophila genome genomic segment AE003541 Annotated Drosophila genome Complete gene candidate CG4107 -Pcaf /GCN5 histone acetyl transferase transcriptional activator protein Human homologue of Complete gene candidate gi6382076 72F516F8BD10CD0C |ref|NP_003875.2| p300/CBP- associated factor [Homo sapiens] (1.20E-197) Putative function Transcriptional activator Confirmation in RNAi Only wild type profiles observed Example 34 (Category 4) Line ID 184/5 Category Mitotic defects in brain: Anaphase defects. (overcondensation, aneuploidy, some lagging chromosomes and breaks) Reversion R Map Position 71B Rescue ID C4E Rescue Sequence CTCGAGCAGATGTGGGACGAGCTGAGCGGAGCGCACAAACTGCCAAGTAAGT GGAGCATGTGGATGAAAGGAGTTCCCAGAACAGTGTTGCCAACCAAAAAAAA AAAAAAGTTAAAAAGTTAATTTTAATAGTGTAAATAAATATGAATTAAATTAA ATTTTTATGTAAAC AGTATTAGCTTTACATGAGATTACC AAATTGTGAGTGTCT GTGTTTGTTTGTCTTTTAAAAACTTTAAAAGCACATAAAGAAATATATTTTAAA TTTAATTAAAAAGTTCGTAAAAAGTAAAAGGTAGCTAAATTAAAAAGTTTCCT ATTCAAATCAGATTTGGCGAACAAAGAGCCAAGTTGGCAACACTGACAATGA CTCCAAGCGCGAACAAAGCGATTTCTATCGTTATCCCACTCTCTCTCCCAGAG ATCGTTCTCAAGGCCAAATGGAAGGGACTTCGAGACAATTTCCGTGTGGAGTC AAAAGGATCCGGCGGCCGAATAACGG Genomic hit, Accession No. CSC: AGO 19852 Associated ORF Genscan ORFl predicted sequences >22:43:26|GENSCAN_predicted_peptide_2|1003_aa MAPKKSTINLNNEQFIHDIEERPAIWNRNFHCNKAFLEQMWDELSGAHKLPKINL KAKWKGLRDΝFRNENKRIPRADΝGDFMVDPATFESKWLHNNALLFLTDHMRHR LPKΝEQDQSFYFSQQSEDCEKTNVEPDLTΝGLIRRLQDSDEDYDEEEMEADGEAS EATMEETMPTPPAAHQMΝQVSTTPLATGALRAQEEAHQHALIKAGLLRAQLMEL EKEAEDLSRKPPPPQQMTSPVAPSLQVLVEPPAAHCSPPPMVTTTSAQVQQPGSA AVLAPATTTSASSVSSΝGAPMGGKRSVSPPPLYΝKAHHPLATLAAAHLAAKDRΝ EDFGPTSAVGGΝGDHLSFTQHSYAΝGLIPALKLKRPRLSEDSΝFΝGSSTMDTPLVP EDDDNHNLLSLHPYMKQLTAAQKLRIRTKIQKLIFKELYKEDLEESΝLDRENNVL DDGAEVDLDLGΝNERFLDNTLHRDΝΝITTGKIYKLNIEKERTGENLGKTNQNNPH ITDAIQEWNERNAQTPNQGSSKPQNCINELGGTIGDIEGMPFVEAFRQFQFRVKRE ΝFCLAHVSLVPLPKATGEPKTKPTQSSVRELRGCGLSPDLIVCRSEKPIGLEVKEKI SΝFCHVGPDQVICIHDLΝSIYHVPLLMEQΝGVIEYLΝERLQLΝIDMSKRTKCLQQ WRDLARRTETVRREVCIAVVGKYTKFTDSYASVVKALQHAALAVΝRKLELVFIE SCLLEEETLHSEPSKYHKEWQKLCDSHGILVPGGFGSRGMEGKIRACQWAREΝQ KPLLGICLGLQAAVIEFARΝKLGLKDAΝTTEIDPΝTAΝALVIDMPEHHTGQLGGT MRLGKRITVFSDGPSVIRQLYGΝPKSVQERHRHRYEVΝPKYVHLLEEQGMRFVG TDVDKTRMEIIELSGHPYFVATQYHPEYLSRPLKPSPPFLGLILASVDRLΝQYIQRG CRLSPRQLSDASSDEEDSVVGLAGATKSLSSLKIPITPTΝGISKSCΝGSISTSDSEGA CGGVDPTΝGHK >22:43:26|GENSCAN_predicted_CDS_2|3012_bp atggcgccaaaaaagtccaccattgtgctcaatgtggagcagtttattcacgacatcgaggagcgcccggccatctggaaccgca atttccactgcaacaaggccttcctcgagcagatgtgggacgagctgagcggagcgcacaaactgccaaagatcgtgctcaagg ccaaatggaagggacttcgagacaatttccgtgtggagtacaaaaggataccgcgggcggataacggtgattttatggtggatcc ggccacctttgagtccaagtggctgcactactatgcattgttgtttttaactgatcacatgcgtcatcgtttgccaaagaacgaacagg atcagtcattttacttcagccagcaaagcgaggactgtgaaaagacagtggtggagccggatttaacaaacggtctaatacgtcgt ctgcaggacagcgacgaggattacgacgaggaggaaatggaggcggacggagaggctagcgaagccaccatggaggaaac gatgcccacgccaccggctgcgcatcaaatgaatcaagttagcaccacaccactggccaccggagctttgcgagcccaagaag aggcacatcagcacgctttaattaaggcaggattactccgcgctcagttgatggagctggaaaaggaggcggaggacttgagca gaaagccacctccgccacagcaaatgacatctccagtggcaccctcactacaagtgctagtggaaccaccagccgcacactgtt ctccaccgccaatggtgaccaccacatccgcacaagtacaacaaccgggctcagcagctgttctggcgccggcaacgaccaca tccgcgtcatctgtatcctcgaatggagcgccaatgggcggcaagagatctgtgtcgccaccgcctctatacaacaaagcacacc atccgctggccactctggcagcagcacatcttgcggccaaagaccgaaatgaggatttcggacccacctctgctgtaggaggaa acggagatcacctgagcttcactcaacactcctacgccaatggactgatacccgcccttaagctgaagcgcccgcgtctctccga ggatagcaattttaatggttcctcgacaatggacactccgctcgtaccagaggacgatgactaccactacttgctcagcctacatcc gtacatgaagcagctgaccgcagcccagaagctgcgcatacgcaccaagatacaaaagctcatcttcaaggaactctacaaaga agatcttgaggagtccaacctagatcgcgaggtttacgttttggacgatggcgccgaggtggatctggatctgggaaactatgaac ggtttttggatgttaccctgcatcgggacaacaacataaccaccggaaaaatttacaagttggtcattgagaaggagcgcactggc gagtacttgggcaaaacggttcaagttgtcccacacatcactgatgccattcaggaatgggtggagcgcgtggcccagacaccc gttcagggatcttcaaagccacaggtgtgcatcgtggaattgggaggaacgattggtgacatcgaaggcatgcctttcgtagagg ccttccgtcagtttcagttccgcgtaaagagagagaacttctgtttggcccatgtgtcgctggttccgttgccaaaggctaccggag aacccaagaccaagcccacacaaagttcggtcagagaactgagaggatgtggcctgagtcccgatttgattgtctgccgatcgga gaaacccattggactggaggtcaaggagaagatcagcaacttttgtcatgtggggccggatcaggtgatatgcatccacgatttga actccatttatcatgttccgctgctgatggagcagaatggtgttattgaatacctaaatgagcgcctacagcttaatatcgacatgagc aagaggaccaaatgcttgcagcaatggcgagatttggcgcgtcgaacggagaccgttcgccgtgaagtttgcatcgccgtcgtg ggaaagtacaccaagttcacggattcgtacgcctccgtagttaaagccctgcaacatgccgccctggcagtgaatcgcaaactgg aactggtctttatcgagtcgtgcctgctggaggaggaaactttgcattctgagccgagcaagtaccacaaggagtggcagaagct atgcgatagccatggcatcctagtccccggtggattcggttcccgtggaatggagggcaagattcgtgcatgccaatgggcgcga gagaatcaaaagccattgcttggcatctgcttgggtctgcaagcggcggtcattgaattcgcacgaaataaacttggtctcaaggat gcaaacaccacagaaatcgatccgaacacagctaatgccttggtcatcgatatgccagagcatcacacgggtcaattgggcggc actatgcgcttgggcaagcgaataactgttttctctgatggtcctagtgtcattcgccagttgtatggcaatccgaaaagcgtgcagg agcgtcatcggcatcgttacgaggttaatcccaaatacgtgcatctgctggaagagcaaggcatgcgatttgtgggcaccgacgt cgacaaaactaggatggaaatcattgagctcagcggtcatccctactttgttgccacccaatatcatccagagtacttgtcgcggcc tctgaagccgtcgcctcctttcctcggcctgatcctggcctcagtggatcgattgaaccaatatattcagcgcggttgccgcctgtcg ccccgccagctatccgacgcatcctcggatgaggaggacagtgttgtgggcttggccggagcaacaaaatcgctgagctccttg aaaattcccattacacccacaaatggaatatcaaaaagttgcaatggtagcataagcacttccgacagcgaaggtgcctgcggag gcgttgatcctaccaatggccataagtaa Human Homologue TBLASTN with ORFl : CTP synthase (CTPS) (NM_001905.1) Drosophila EST LD27370 (AA941993) Annotated Drosophila genome genomic segment AE003532 Annotated Drosophila genome Complete gene candidate CG6854 - novel protein, possible CTP synthase? Human homologue of Complete gene candidate gi4503133 C33BD849A0044697 |refjNP_001896.1| CTP synthase; cytidine 5-prime triphosphate synthetase [Homo sapiens] (8.40E-217) Putative function Enzyme important in the biosynthesis of phospholipids and nucleic acids, and plays a key role in cell growth, development, and tumorigenesis. The region of the human gene is the location of breakpoints involved in several tumor types Confirmation by RNAi Loss of GI and G2/M peaks indicating fewer cycling cells Example 35 (Category 4) Line ID 225/27 Category Meiotic defects in testis: segregation defects Reversion NR Map Position 90D Rescue ID 2D2P Rescue Sequence 1 Rescue ID 2D2E Rescue Sequence 2 GCCTGAACTTAAAACGCTGCCTTCGGCTCTCGCTCGGCACTCGCTCGGCTGCG ACGTCGACTGCGACGCTGGCAGCGACAACAACGATTGGCCTCTCTCATTCACT TACCTCCTCTCTCTCTCTCGCACTCTCTCTTAGCGGTGAGAGAGTGTTTTCCTC ACATTTGTTTTGCTTTTGCGGTTCGCCAATGGCCCCCCAAAACGAAAAGAGCG CGCAAGAGCTAGCTCCACAGTGGATCCTAAGAGAACGGTCCCTGTGGACTCC ATCTAGCTAAGAGAAACGCACTTAGTTAGTTTCTATTTTTGGTTGTTTAAGTAC TGCTAGCTGCCTGCCAGTTGAGTGTCCGTCCAAAAACGGTGGTGGAAATGGGG GTGACCACTTCAAACATGAAAGCGAAATGTCCTGAGACCCTACAAAAACTAG AAATACGCGGGTGCACTGAGAGAAATTTTTTATTTCAAGTAAATTGGCAGAGG CTACATTTTGAATGTTCACAATGAAAATTGCTGGGGAAGCTAGTGAACAACCA TTTCGCCATAATTTACACTATCTAAGCTTTTATTTTTAGCCACATGATATATGC ATGCA Genomic hit, Accession No. AC008361 Associated ORF Genscan ORFl predicted sequences >20:36:39|GENSCAN_predicted_peptide_2)515_aa MSSTIRLQTSSCQCCKLYKYERHPNKPNLQPTPIPNYPCEILHIDIFALEKRLYLSCI DKFSKFAKLFHLQSKASNHLRETLNEALHYFTAPKNLNSDNERGLLCPTVLNNLR SLDIDLYYAPTQKSEVΝGQVERFHSTFLEINRCLKDELPTFKPNELVHIAVDRYΝT SNHSNTΝRKPADNFFDRSSRVΝYQGLTDFRRQTLEDIKGLIEYKQIRGΝMARΝKΝ RDEPKSYGPGDEVFVAΝKQIKTKEKARFRCEKVQEDΝKKΝRΝGKAAGGKGKTR RVARGAQIYQΝWAICRΝLFLFLSLACCRVCKVCDIVVEFRKGTΝAVVΝVQIREAI SHVFHKEDIVIDVQESKEWCIWTDDQVQSPLPELEΝLWHELWIGPSHAYLIDQIVD QRSAIGGDPQQKDSAVQQVQARSSDAFCQIPHRSPRFPGRSQLIPKPΝREILRΝASA TKΝLLFRIRSQ >20:36:39|GEΝSCAΝ_predicted_CDS_2|1548_bp atgtccagtacgatccgtctgcaaacttcctcatgtcagtgttgcaaactctacaagtacgagagacaccctaacaaaccaaaccta caacctacgccaattcctaactacccatgtgaaatacttcacatcgacatttttgcgctcgaaaaaaggttatacctaagttgtattgac aaatttagcaagtttgccaaacttttccatctgcagtcaaaagcatctgtgcatttgcgagaaactttggtggaggccctacattacttc accgcccctaaggtcttggtttcggataacgagcgagggttgttatgccccacagtgctcaactatcttcggtctctagatatcgatct gtattatgctccaacccagaagagcgaagtaaatggtcaagtcgagagattccactctacgttcctagaaatttatcgttgccttaaa gatgagctccctaccttcaaacccgttgagctggtacacatagcagtggaccgctacaacacttccgttcactcggtaacgaatcg aaaaccagcagacgtttttttcgaccgctcgtcaagggtaaactatcagggtctgacagatttccggcggcagactttagaggacat caagggcttaattgagtataagcaaattagaggtaatatggctcggaataaaaatagggacgagccaaagtcttatgggccggga gatgaagtttttgttgcaaataagcaaataaaaacaaaggaaaaagcgaggttcagatgcgaaaaggtacaggaagacaacaag aaaaatcgcaacggaaaagcggcgggtggaaaggggaaaactcgcagagtagcccgtggagctcagatttatcaaaactggg caatctgccggaatctgtttctgtttctgtctcttgcctgctgccgagtgtgtaaagtgtgtgatatagtcgtagaattcagaaaaggaa ccaacgccgtcgtgaacgtgcagatccgtgaagctatcagccatgtgttccataaagaagacatagtcatcgatgtccaggagtcc aaggaatggtgtatttggaccgatgatcaggtgcagtcgcctctgccagaacttgagaatctgtggcatgaactgtggataggccc tagccatgcgtacctgatcgatcagattgtcgatctcttcgaaaatctgctcgaaaaatataatgtgcaggttgtcgatgtagttcggtt caatttcctccatcgcgctctcgtagtcgtgatcatttcgggtatcatcatcatcattatcatcatgatcatcggcgttagcggcggcca aagaacaaatgccttttcacaccaccgatctcagcgatcagcgatcggcggcgaccctcaacaaaaagattcagcggtgcaaca ggtgcaggcacgatcttcggatgccttttgccagataccccaccgatctcccaggttcccagggcgcagccaacttattccgaagc caaatcgagaaattcttcgaaacgcgagtgccaccaaaaatttattgtttcgaattcgcagccagtga Drosophila Gene Hit BLASTN with rescue sequence: couch potato (Z14974). Human Homologue BLASTX with couch potato: RBP-MS/type 2 (RNA binding motif family)(D84108) Annotated Drosophila genome genomic segment AE003720 Annotated Drosophila genome Complete gene candidate CGI 8434 -couch potato RNA binding protein Human homologue of Complete gene candidate 2224621 dbj|BAA20798| (AB002338) KIAA0340 [Homo sapiens] (2e-19) and Ensembl predicted peptide Gene:ENSG00000070877 Clone: AC009710 Contig:AC009710.00004 (predicted unknown protein) Putative function Possible RNA binding protein Example 36 (Category 4) Line ID 238/37 Category Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/17) Reversion ? Map Position 70D Rescue ID I7E Rescue Sequence GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGAGCAACTTTGTTC TGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGG TCTTCGCTCCATTCAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTCT GATTAGGACACGGGCTGCCTGAGCTTGCAGTACAATGGTCGGACGCACTACG CCTCCTGGGCGCCACAAAAGGGCGGCGGCGGCATTAAAGACACCGAGATTGG GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATCTGCCCCG TACCTCGTACGCTAGCAGCACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGA GAATGATCTGGTCAAGTGTGCGCTCATCGCTGACGTTCTCAACCTGCGCAGCG TCCACGTTACCCCCGTCTCGTCCAAGGACTGGGAGATCATAGTGAGTGACGGT TTCGCCTGCTTGGCGGCGTGG Genomic hit, Accession No. CSC:AC017664 Associated ORF Genscan ORFl predicted sequences >15:26:30|GENSCAN_predicted_peptide_l|1819_aa EMVQAKDPPSHYLSKLRTYLDPKASRSHRLYLFYFLCQKRKMNGESTSTQNLRD LEISLRTΝHIEWVKEFLDDTΝQGLDALVDNLSFRLQMMRHEQRLQGVLCASEERL ΝLTΝGGDGGEINMGΝSSSNSPGGGGGLLSHGΝSTGHGLAΝGTLDSRQQHTMSNG FLRPTIADALDSPSLKRRSRHIAKLΝMGAATDDIHNSIMCLRAIMΝΝKNGFΝMNIQ HREArΝCIALSLIHKSLRTKALNLELLAAICLNKGGHEIILGSFDΝFKDNCQEKRRF QTLMEYFMΝFEAFΝIDFMNACMQFMΝINNHSNEDMΝYRNHLQYEFTALGLDKY LERIRLTESEELKNQISAYLDΝNFDNAALMEDSETKTSALERNQELEDQLEREIDR ΝSEFLYKYAELESESLTLKTEREQLAMIRQKLEEELTVMQRMLQHΝEQELKKRDT LLHTKΝMELQTLSRSLPRSASSGDGSLAΝGGLMAGSTSGAASLTLPPPPPPMPASP TASSAAPPPPPPPAPPAPPPPPGFSPLGSPSGSLASTAPSPPHAPPMLSSFQPPPPPVA GFMPAPDGAMTIKRKVPTKYKLPTLΝWIALKPΝQVRGTIFΝELDDEKIFKQIDFΝE FEERFKIGIGGALRΝGSΝGTEVDGSLQSSKRFKRPDΝVSLLEHTRLRΝIAISRRKLG MPIDDVIAAIHSLDLKKLSLEΝVELLQKMVPTDAEVKSYKEYIIERKDQQLLTEED KFMLQLSRVERISSKLAIMΝYMGΝFVDSVHLISPQVQSIAGASTSLKQSRKFKAVL EIVLAFGΝYLΝSΝKRGPAYGFKLQSLDTLIDTKSTDKRSSLLHYIVATIRAKFPELL ΝFESELYGTDKAASVALEΝVVADVQELEKGMDLVRKEAELRVKGAQTHILRDFL ΝΝSEDKLKKIKSDLRHAQEAFKECVEYFGDSSRΝADAAAFFALIVRFTRAFKQHD QEΝEQRLRLEKAAALAASKKEΝDQVLMRΝKVΝQKKQQEAVIΝELKSKAHSVRE KKLLQQDEVYΝGALEDILLGLKSEPYRRADAVRRSQRRRIDΝΝRLSRTLEEMDCL HEΝDLVKCALIADVLΝLRSVHVTPVSSKDWEIIELSTEKISGSVLEQTRIVΝSTQILI VWINKSMQVALTVDRLKPHMNYGRIDHNTELVVAPNLYKGLTNGTSNGVIEENT KLSRSKTTAQVKDELTEKLTPLTHSSTVSNVKNTIQRNKRQDHMERLKKDLRRES SRSFEFRVIRGLWREQAQESDVFVNGKHLPEFFDLDLFYCMHTAADKDYYVRVR TVEDDIEDDLPETIHPSIELNANLMKLLGIKELERVVLRPKTTVVNFVEKIELFANK KTHYKIMENAFKRFVIERTQHKPMLFNQEEVVRLEDDLLVTVGILPEHFRYCVVD AQFLKESKIYAADLVRPVGEIIKEETPPTSPLSVQDLIQLPEYDKIVDQVVQELRMN LCLSADNSVMRQCNVLLAGASGTGKTVLVERILDQLSRKPDYCHFEFFHGSRSKG RKTESIQKDLRNIFTSCLQFIAPAIVVLENLDVLAHAAGEQSSQDGEYYNRMADTV YQLIVQYTTNNAIAVIATVNELQTLNKRLSSPRGRHVFQTVARLPNLERADREIILR ELCSHINVAKDLDLVKFSNLTEGYRKCDLVQFVERAIFYAYRISKTQPLLTNDQLI ESLEHTNSYCLQGIQSNQRTGNDADANEMRVEELPGLESVVGVLEEVLMWPSRY PTIFNASPLRNQAGVLLYGPPGTGKTYLVSQLATSWNLRIISVKGPELLAKYIGQSE ENVRNLFNRARSARPCVLFFDEFDSLAPKRGHDSTGVTDRV >15:26:30|GENSCAN_predicted_CDS_l|5457_bp > gaaatggtgcaggcaaaggatccgccctcacattacttgagtaaactgcgcacatatctggacccaaaggcatcaaggagtcatc ggctttatctcttctactttctttgtcagaaacggaaaatggtcggcgagtccacgtccacccaggtgctccgcgatctggagatctc gctgcgcacgaaccacatcgagtgggtgaaggagttcctggatgacacgaaccagggtctggacgccctggtcgactatctcag cttccgactgcagatgatgcgacacgagcagcgccttcagggtgtcttgtgtgcctcggaggagcgtctgaatctcacaaacggc ggcgatggcggtgagatagtgatgggaaacagtagttctgttagtcctggtggaggtggtggtttactatcacatggaaacagtac gggacatggtctggccaatggcacacttgactcgaggcagcagcacacaatgtcctatggattcctacgacctaccattgccgat gctctggatagtcctagtttgaagcgaaggtcacgacatattgccaaattaaacatgggtgccgccacggacgacatccatgtgtc cattatgtgcctgcgagctatcatgaacaataagtatgggttcaacatggttatccagcatcgcgaggccatcaactgcattgccttg agtcttatccacaaatcgctgaggacgaaagccctggtcctggagctgctggcagccatctgtctggtaaagggaggacacgaa atcattttgggttcgttcgataattttaaggatgtgtgccaggagaagcgacgcttccaaacgctcatggagtactttatgaacttcga ggcctttaacatagattttatggttgcctgcatgcagttcatgaacatcgttgtccactcggtggaggacatgaactacagggtgcac ttacagtacgagtttacagccctgggcttggataagtatctggagcgaattcgattgacagaatcggaggaactgaaggtgcagat atcagcctatttggacaacgtctttgatgttgctgccttgatggaggattccgagacaaaaacttcagccctggaacgagtccaaga gcttgaggatcaacttgagcgagaaatagatcgtaactcagagttcctctataagtatgcggaattagagtccgagagtctaacgct gaaaacggaacgcgagcagctggctatgattcggcagaagctggaggaggaacttacagtgatgcagcgaatgttgcagcaca acgagcaggagctgaagaaacgggacacactgctgcacacaaagaacatggagctgcagacgctttcgcgttccctgccacga tccgcctccagcggcgatggttctctggcgaatggtggcctcatggctggttccacatcgggggpagcctctctaacattgccacc acctccgccgccaatgcccgcctcgcctactgcaagttcagctgctcctccaccacctccgccgccagcaccaccggctccacc accaccgccgggcttcagtccgctgggcagtccgagcggcagcctagcctcgacagcgccatcgccgccacatgccccgccc atgctaagctccttccaaccgccaccgcctccagtggccggctttatgcccgctcccgatggcgccatgaccatcaaacgcaagg tgcccactaaatacaagttgcccaccttgaactggatagcactaaagcctaatcaggtacgtggtacaatattcaacgagctggatg acgaaaagatcttcaagcaaatcgacttcaatgagtttgaggagcgcttcaagatcgggattggcggtgctttgcgcaatggtagc aatggaaccgaggtcgatgggtcgctgcagtccagcaaacgcttcaagaggcccgacaatgtctcgctgctggagcacacgag gttaagaaacattgcaatctcccgtcgcaagctgggtatgcccattgatgatgtcatcgccgccattcatagtctggacctgaagaa actttccctggagaacgtcgagctgctgcaaaaaatggtgcccacggatgccgaggtcaaatcctacaaggaatatatcatcgag cgcaaggaccaacagctactcaccgaagaagacaagtttatgctgcagttgtcgcgtgtggagcgtatctcgtccaagctagcca ttatgaactatatgggcaattttgtcgacagcgttcatctcattagtccgcaagtgcaatcgatagcaggagcgtcgacttccttaaaa caatctcgaaaattcaaggcggttttggaaattgtcctggctttcggcaactatctcaacagcaacaaacggggaccagcctatgg ctttaagctgcaatcgctggacacgctgatcgatacaaaatccacagacaagcgatcgtcactgcttcactatattgtggccaccat acgggccaaatttccggagctgctgaacttcgagagcgagctgtatggaacagacaaggctgcatcggtggcactagagaatgt ggtggccgatgttcaggagcttgaaaagggcatggatctggtgcgcaaggaggccgagctgcgagtgaagggtgcccagacg catatcctgcgtgacttcctgaacaacagcgaggacaagctgaagaagatcaagagcgatctgcggcatgcacaggaagcgttc aaggagtgcgttgagtactttggcgactcctcgcggaatgcagatgcggctgctttctttgcgttgatcgtacgcttcacgagagcg tttaagcaacacgatcaggagaacgagcagcgtcttcgcctggaaaaggccgctgcgctggccgcttccaagaaagagaacga tcaggtgcttatgcgcaacaaggttaaccagaagaagcaacaggaagctgtcataaacgagctgaagagcaaggcgcactcgg tgcgcgagaaaaagctgctgcagcaggacgaggtgtacaacggagccctggaggacatcctgctcggcctgaagagcgagcc gtacaggcgggcggatgctgtgcggcggtcgcagcgccggaggatcgacaataatcgtttatcgcgcaccctggaggaaatgg attgtctgcacgagaatgatctggtcaagtgtgcgctcatcgctgacgttctcaacctgcgcagcgtccacgttacccccgtctcgt ccaaggactgggagatcatagaacttagcactgaaaagatatcgggcagtgtgctggaacaaactcgcatagtgaattcaacgca gatccttattgtttggattaataagtcgatgcaagttgcgctgacagtggatcgtctgaagccgcacatgaactacgggagaataga tcacaatacggaactcgtggtggcgcccaatctgtacaagggtctgaccaatggaacttcaaatggtgttatagaggaaaacacaa aactctccagaagtaaaaccactgcccaggtcaaggatgagctgactgaaaagttaacaccgttgacccattcctccacggtgtcc aatgtgaaaaatactattcagcgtaacaagcgtcaggatcacatggagcgtcttaaaaaggacttgcgccgcgaaagctcgcgta gcttcgaatttcgtgtcattcgaggtctatggcgggagcaggcccaggagtcggatgtgtttgtgaacggaaagcatctgcctgag ttctttgatctagatctattctattgcatgcacaccgcagccgacaaggattactatgtgagagtgcgcacagtagaagacgatattg aggacgatctaccagaaaccattcatccatcgatcgaactaaatgccaatcttatgaagttgctgggtattaaggaattggaacgag tggttctaagacctaaaactaccgtagttaactttgtagaaaaaattgagctatttgccaacaagaagacgcactacaaaatcatgga gaacgcatttaagcgatttgtgatagagagaactcagcacaagccgatgctcttcaaccaggaggaggtggtacggctggagga cgatttactggttactgttggaattttaccagaacactttcgttattgcgtggtggacgcgcagtttctgaaggagtccaagatctacg cagcagatctggtgcgtccggttggcgagattattaaggaggagacgcctccgacatcgccactaagtgttcaggatctcatcca gttaccggagtacgataagattgtggatcaggtagttcaggaattgcgaatgaatctatgcctcagtgctgacaattccgtcatgcgt cagtgcaatgtcctactcgctggtgcctcgggaacgggtaaaacagttcttgtggagcgcattttggaccagctgtcacgcaagcc ggattattgtcacttcgagttcttccacggatcgcgaagcaaaggccgcaagacggagtccatccaaaaagatcttcgcaacatttt taccagctgcctgcagcatgcccccgccattgttgtgctagaaaacttggatgtactggcccacgctgctggagagcagtccagtc aggatggagagtactacaatcgcatggcggatactgtgtatcagttgattgttcagtataccaccaacaacgctattgcagtaatcg ccaccgtcaacgagttgcagaccctcaataagcgattgagctcaccaaggggaagacatgtcttccagactgttgctcgtctgccc aatttggaacgagcagatcgagagataattcttcgagagctgtgcagccatatcaatgtggccaaggacctggatcttgttaagttct ccaacctcacggagggctaccggaaatgtgatcttgttcagttcgtggagcgtgcaatattttatgcttatcgcataagcaagaccc agcctcttctgaccaatgatcagcttattgagtccctggagcacacaaactcgtactgcctgcagggcattcagagcaatcaaaga actggcaatgatgccgatgccaatgaaatgcgcgtcgaggagttgcctggcctggagtcagttgtgggagttctggaggaggtcc ttatgtggccatcaaggtatccaaccatttttaacgcctctccactgcgcaaccaggccggagtacttctatatgggccaccaggaa caggtaaaacctatctggtctctcagttggccacatcgtggaacctgcgcatcatttccgtcaagggtcctgagttgctcgccaaata tattggtcaaagcgaggaaaatgttcgaaacctgttcaatcgagctcgcagtgcccgaccatgtgtgcttttcttcgacgagtttgac agcttggcgccgaaacgtggtcacgattccacgggggtcaccgatcgagtg Drosophila Gene Hit recue sequence and TBLastn with ORFl : mRNA for l(3)70Da (AJ243811) Human Homologue BLASTX with l(3)70Da: peroxisome biogenesis factor 1 (AF026086) Drosophila EST LD43687 ( AI512050) Annotated Drosophila genome genomic segment AE003536 Annotated Drosophila genome Complete gene candidate CG6760 mRNA for l(3)70Da - novel protein with homology to endoplasmic reticulum ATPases Human homologue of Complete gene candidate 4505725 ref|NP_000457.1|pPEXl| peroxisome biogenesis factor 1 >gi|2655141 (AF026086) (8e-80) Putative function Putative member of the AAA protein family (ATPases associated with diverse cellular activities) including homologies to transitional endoplasmic reticulum atpases, and an E.coli membrane-bound AAA-type metalloprotease which degrades degrades sigma32, an alternative sigma factor for heat shock promoters Confirmation by RNAi Slight loss of GI , increase in G2/M indicating arrest in G2/M Line ID 238/44 Category Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/18) Reversion R Map Position 70D Rescue ID F8E Rescue Sequence GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGAGCAACTTTGTTC TGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGG TCTTCGCTCCATTCAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTCT GATTAGGACACGGGCTGCCTGAGCTTGCAGTACAATGGTCGGACGCACTACG CCTCCTGGGCGCCACAAAAGGGCGGCGGCGGCATTAAAGACACCGAGATTGG GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATTTGCCCCG TACCTCGTACGCTAGCAGCACCCACTTACCCTTTCTTGCCGTATGTCTGCACGA GAATGATCTGGTCAAAGTGTGCGCT Other results same as for line 238/37 Line ID 428/5 Category Meiotic defects in testis: cytokinesis defects, segregation defects (seg-01/01) Reversion ? Map Position 70A Rescue ID G4E Rescue Sequence GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGGAGCAACTTTGTT CTGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAG GTCTTCGCTCCATTCAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTC TGATTAGGACACGGGCTGCCTGAGCTTGCAGTACAATGGTCGGACGCACTACG CCTCCTGGGCGCCACAAAAGGGCGGCGGCGGCATTAAAGACACCGAGATTGG GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATCTGCCCCG TACCTCGTACCTAGCAGCACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGAA AATGATCTGGTCAAGTGTGCGCTCATCGCTGACATTCTCAACCTGCGCA Other results same as for line 238/37 Line ID 848/7 Category Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defect. Multi-stage defects Polyploidy, no overcondensation Pl-01/10 Reversion R Map Position 70D1-2 Rescue ID G1E Rescue Sequence 1 GGCCACCTTAAAAGTGCGTTTGAACATTCTCGTCGTGGGCGTGTGCGAATTTA GTACGCTCCTTCCTGGTTTAAATCATTTTCGCACTAAACTTCTGCTCTCAGCGG AATTTACTTTTGCTTTATTAGAGATGGGAGCTCGCGCATCAGCTGAGCCGATA CTTGCGCAACAGGTGATACAGCTGATTAGAGATGGCCCTTTTCAACTGTTCCC AGCAGTGACCGCTGCCATAACCGTTTTTCAAATTTACGTGAGAACAGACATAA AATAAATATTACAGCTCGTAGTAAATGTTATTCTATATTTAAAAGGAAATTGT AATAGTTAAAACTTGCAATGAATCAGTTACGTTCAAAAAAGGAAACACACTTT AGTTTTTGGCTAGTTTATTGGGTTAATAATATTTTATTTAAAATAGTTCGAGTG TTCAATATAGTCATGTAAATGTGTACAGAAAGATCCGGCATTTGATATTTAAT ATATCGATTTCCCTTCACTTTCGCTCCTCGTATACCATGCTGGGGTCTTATCAA ATTTATT Rescue ID G1P Rescue Sequence 2 AAGGTGGCCTATCGGCCCATCAGGAAGCAACTTTGTTCTGCTGCCGGATCAGT ACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGGTCTTCGCTCCATTCAA ATTAGATACGCCAAAGATTAATCCGGTCAACCATTCTGATTAGGACACGGGCT GCCTGAGCTTGCAGTACAATGGTCGGACGCACTACGCCTCCTGGGCGCCACAA AAGGGCGGCGGCGGCATTAAAGACACCGAGATTGGGATCAATGCCACAGCGG CCAAGGAGATCGGTAAGCCATTACTTAACGGCCGGATGTGCATCGGTTGCCAA TGTGCCGTAATATTGGACTCCGGCCATCTGCCCCGTACCTCGTACGCTAGCAG CACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGAAAAATGATCTGGTCAAG TGTGCGCCTCATCGCTGACGTTCTCAACCTGCACAGCGTCCACGTTACCCCCGT CTCGTCCAA Other results same as for line 238/37 Example 37 (Category 4) Line ID 252/40 Category Meiotic defects in testis: segregation defects, abnormal spindles. (Ab-03/30) VCV l &1U11 R Map Position 84E Rescue ID A4B Rescue Sequence 1 TACATGACTCTGCGATTTGACAAAAACAAAATTGAGTTTTGTCAAGAAAATCA ACTATTTTTCTGTGTTTAAAAAACCGAAGCCAACAAATCCGACCAAAATGCCT GCCGAAAACTTGGAGGAGCAGGGTCTGGAGAAGAACCCGAACCTGGAGCTGG CCCAGACGAAGTTCCTGCTTACCCTGGCGGAATACAAGCAGGATGCGGCATTG AAGGCGAAGCTTCTGGAGGCGATTCGCACGGAGAATATGGCCCCGTGGGTAC GAGCACATCCTGCTCCGGAACTCGGCTTGGACCCGTTAGACAAGGATCTTGCC TGGCGCCGAATTGAAGGAAAAACAATCGCGTTTAAGTTGGGAGCCA Rescue ID A4E Rescue Sequence 2 GTCATGTACTACCAGTGTGACCCCAAAGTTATCGATAAATTATACCGCATATT TTAACATTGCCAAAAATACCAGAGCGATGTCCATCAAGATAGCGACGAAATT AGAACAGTGCAATTGCCAATTGGGAATTTGTATTTTAATTTATTTTTAAATTCT GAAAGTAATTTTAATTTAAAAAAAACTTGAGAGCTGTCTAGAAAAGAACTTAT GTTTCATGATAACTTTGTCGAAGAATTAAGAAATATTTAGTTGTAAAATAATT GTNTGAATCTATTTTTTTCCAATAACACGACTTATATTTTTTTTTTAAAATATTC CGAGCTAAATCCCAAGAAAGTTAAACTCCAATCTTGGGATTTTGAAGTGCCCC AGAAACTCCAAATTAAACACTTCCTTTTTAAATAATTGTTAAGACCCGTATCA CTTATGGTTATATACTGACCTCGAAAGGGCCACACTAAGGGGGGAGTTTGAAA ATTGATTTTCCTGATAAAAATTTTCGCTTGGAAGCTACAGCATCGTCCACTGTC CATGTTTATATATCCTTATATTTGCCTATAAATATAT Genomic hit, Accession No. AC006494 Associated ORF Genscan: ORFl predicted sequences >23:00:28|GENSCAN_predicted_j)eptide_2|389_aa MPAENLEEQGLEKNPNLELAQTKFLLTLAEYKQDAALKAKLLEAIRTENMAPWY EHICSELGWTNDKDLLARMKENNRNEVEQLDAAIEDAEKNLGEMEVREANLKKS EYLCRIGDKAAAETAFRKTYEKTVSLGHRLDIVFHLIRLGLFYLDHDLITRNIDKA KYLIEEGGDWDRRNRLKVYQGVYSVAVRDFKAAATFFLDTVSTFTSYELMDYPT FVRYTVYVAMIALPRNELRDKVIKGSEIQEVLHGLPDVKQFLFSLYNCQYENFYV HLAGVEKQLRLDYLIHPHYRYYVREMRILGYTQLLESYRSLTLQYMAESFGVTVE YIDQELARFIAAGRLHAKVDRVGGIVETNRPDNKNWQYQATIKQGDLLLNRIQKL SRVINI >23:00:28|GENSCAN_predicted_CDS_2|1170_bp atgcctgccgaaaacttggaggagcagggtctggagaagaacccgaacctggagctggcccagacgaagttcctgcttaccct ggcggaatacaagcaggatgcggcattgaaggcgaagcttctggaggcgattcgcacggagaatatggccccgtggtacgag cacatctgctcggaactcggctggaccgtagacaaggatctgctggcgcgaatgaaggagaacaaccgcgtagaggtggagc agctagatgcggcaatcgaggatgcggagaagaatctgggcgagatggaagtgcgcgaggcgaatcttaagaagtcagagta cttgtgccgcatcggcgacaaggctgccgcagagactgccttccgcaagacctacgagaagaccgtttccctgggtcaccgcct ggacatcgtgttccatctgatccgcttgggactgttttaccttgaccacgatctcatcactcgcaacatcgacaaggccaagtatctg atcgaggaaggcggcgattgggaccgacgcaaccggttgaaggtctaccagggtgtttactcggtggcggtgcgtgacttcaag gcggcggccacgttcttcctggacaccgtaagcaccttcacctcatacgaactgatggactaccccaccttcgtgcgttacaccgtt tacgtggccatgattgccctgccgcgcaatgagctgcgcgacaaagtgatcaagggctccgaaatccaggaggtgctccatggc ctgcccgacgtgaaacagttcctgttttccttgtacaactgccaatatgagaacttctacgtacacctggccggcgtagagaagcaa ttgcgcttggactacctcattcatccccactaccgctactacgtgcgcgagatgcgcattctgggctacacccagttgctggagtcg tatcgctccctcaccctgcagtatatggccgagtcgttcggcgtaacagtggaatacattgaccaggagctggcacgcttcatcgc cgccggacggctgcatgccaaggtggatcgcgttggcggcattgtggagaccaatcggcctgacaacaagaactggcagtacc aggcgaccatcaagcagggcgatctgctgctcaaccgcatccagaagttgagccgcgtgataaacatctaa Drosophila Gene Hit BLASTN with rescue sequence 1 and TBLASTN with ORFl : 26S proteasome regulatory complex subunit p42A (AF145308). Human Homologue BLASTX with ESTand TBLASTN with ORFl : Hypothetical protein KIAAO 107 (D14663). Drosophila EST several including GH17651 (AD 87197) Annotated Drosophila genome genomic segment AE003739 Annotated Drosophila genome Complete gene candidate CG5378 - Rpn7 19S proteasome regulatory particle, non- ATPase protein, subunit SlOaHuman Homologue Human homologue of Complete gene candidate gi7661914 8843E6684AE91ACD |ref|NP_055629.1| KIAA0107 gene product [Homo sapiens] (3.40E-149) Putative function component of the 19S proteasome regulatory particle Confirmation by RNAi Marked decrease in GI and G2/M indicating fewer cycling cells Example 38 (Category 4) Line ID 277/7 Category Mitotic defects in brain: anaphase defects (weak, higher condensation, some polyploidy, fewer anaphases, polyploids with monopolar spindles) Reversion ? Map Position 71B Rescue ID B8E Rescue Sequence AGTCGGCGCATGCGGAGAGAGAATCGAAAGAGAAAGAGAAGCAAAGAGAGC GACATACAGCAAAAACAATTCAAAAAGAACTGGTGAAGAATACGAAAATAAG ATAATTTTTTAAGGAAGTCGCGCTTTGATCCGTATCCGTTTTAGCGTCCAAGAT TTATATCTTAAATCGGACCTATATTTTGAGGTACAGTGAAGCTTTGATGCGCCA GTCTTATATGAGTTAAAGTTTTAACGATTGAAAGACACCCCTGAGCTGCTCAT TATATTTCAATATTTATAAACAATCTTATATCAGAGCTTGAGAGACTTGCATGC GCCACAAAATTCCAATTCCAATTCCAATTCCGGAATAATTTCACAATAATCTC AATTAACATACGTATTTTATGTTCGTAATTTTTTAAAATTCCCAGATTCCCCAC AATTGCCATAATAATCTCGATTATGTTATTATACTCTGAGAAGTAGGAGTGTG TGCAAAGACCACAAACAAATCATTAGGGGCGT Annotated Drosophila genome genomic segment AE003584 Annotated Drosophila genome Complete gene candidate CGI 5383 - novel Human homologue of Complete gene candidate none Putative function No homologies to indicate function Confirmation by RNAi Slightly increased GI decreased G2/M indicating arrst in GI Example 39 (Category 4) Line ID 284/4 Category Mitotic defects in brain: anaphase defects (overcondensation, polyplody (with overcondensation), few anaphases, metaphase with bipolar spindle) Meiotic Reversion NR Map Position 89B Rescue ID 2C6E Rescue Sequence GTCTACCACTAGCTCTTTGTCTTCGCCTTCTAGTCTCTCTCATCTTGGCAGCCC GTTCTAGTGCGCGTATTTTTAGTCGCAACACATTGCCCAATTCGCCAGCCGCTA TTTGTGTCGTCCATTTGTTCATTCATCGGGCTCTTTTTCCGATTTCAGTGGGTGG CATTTAACAATAATCCCTGCGTTCGCTGTCCACGTCCACATTACGATACGTTTA GTGCACGGAAAGAAATAAGCGTGTGGTTTCATAATATTAGCTATTGAAAAAA GTTCTTAAATTTAAGCCTCACTCGATTCTGATGCATGAAATATTATTGGATTGT AAATGAGCGTCATGTTTTGGTATACAAATCTCAAAGTAATTTAAAAATTCTCA TCTTACCGTACCTTGAACCACTACCAATCATCTCAGTACAGCATTTCAGCGAA TTTCTCACTGTGCACTACAATGCCAGGCGGTACAAGCACCTGTATTTATTTATG GTCCGCTGCCGTAATCGACTGCAGTCGCCGCTTCCCTCTCTCTTTTGCTACCAA CAACTTGGGGTAGGGCACCTGAACTAGTTTCAAACGGCGGCGGTCGGCCTTTT CAGCTTTTTCGCATTTGCCATTTTCCCGCGG Annotated Drosophila genome genomic segment AE003711 Annotated Drosophila genome Complete gene candidate CG4275 - mor transcription factor involved in chromatin remodelling Human homologue of Complete gene candidate CG4275- 4507081 |refjNP_003066.1 |pSMARCC 2| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2(aa) Putative function Transcription factor, regulator of chromatin Confirmation by RNAi Decrease in GI and G2/M and increase in polyploidy Example 40 (Category 4) Line ID 407/8 Category Meiotic defects in testis: cytokinesis defects Reversion ? Map Position 64B1-2 Rescue ID A9E Rescue Sequence GACTCACCCTTTCACGCATTTCATTGGAACGTTTGTTTTCGTTTATGCACACGC GTGTTGACACTTTTCATGAAACGCAGTGCGTGAAAAGTGCATCGCATAAACGC AATAAATGTTTGATGGATGCGTTCTGATGGCTTGAAGTCGCCTATTTGGCCGA TTTTCGCACGTCCACTCCCGACGGCAACAGAGTCCTGACTGAATCCCGGAGCG GAAGGAGTGTGGATAGCCAGGACTGCCAAAGGACACTGCGCACTTTTACTTTT TCGAAAGCGAAAGCGAAAGTGGTGGGGCCCAGGCCAAAACAANCCCTTGAGT TGAAATTGGAAAAAAACCGGGACAGGGATGGGAGCCCAGCTCCAACAAACG GTTCCGGATTCCTTGGGAAAGCCACGCCCTGCGCCTGGAAAAGGAATGCCCTC CACCTCATTTGTCCTCCGTTTTGCGCTATCTCTCCCCCAAATTTCCGTTAAATG AAAAACAACTTTGGGTTTTTGGTTTTAACAATTTCTCCCCATTTGGTTTTNGGG TTTCCCTTTCCATTTTTGGAATTGGTTTTAATTAAAT Genomic hit, Accession No. AC005814 64A6-64B6 Associated ORF Genscan ORFl predicted sequences >22:57:22|GENSCAN_predictedjpeptide_2|524_aa MGRRKDKPRNIPEQDARICRAICLCQLTMNLSCVSIVYLSNAIYSPSLKAFKSGFEL DPNMCQTVDRQMPΝΝCPWASCGEWCLTKTSGFCPQIHSIVRRΝGTDIQLΝΝCTR VTΝTSCAMIDLSRLΝKFΝCΝΝGTACΝΝIRGVFΝCSΝGHCKΝMSEFFLCHHKADG LTVΝSQKDΝTKLΝGFFECHGVHCTKIKKPFSCDRYCSKITTTΝVΝTLIMHEDΝLIA ADCENAVAFNQ ARGSEHGVRIEPFEFWKEDDGNLLTNC ATVTRESDNRITATDCI NGTLLEHDTLPAPFMNFTQFWAIYENSTRSVDPEQRYLPNQANLTIYSWKKLFINL EGCVNTLRGECKDFVARYGNDGDNNTAQSRYQCYYNKDSNVEFVVARYDLDK VYRELLVSLIVPIVLFVISSISLCIITKSVKVGDDAKMRCVCAGDDSDNDGPFGPGL ANKQQDQMYDTDDDNVDLEHQANDGQELSDHGLPLDNQELIGSTKSLIPISPNGE SGTSDQIFDQDQEKATTCDVPEKPLVIL >22:57:22|GEΝSCAΝ_predicted_CDS_2| 1575_bp atggggcggcgcaaggacaaaccgcgggtgattcccgaacaggatgcgcgcatctgtcgcgccatctgcctgtgccagctgac catggtgctgtcctgcgtgtccatcgtctacctaagcgtggccatctactcgccctccctaaaggccttcaagtccggcttcgagct ggatcccgtcatgtgccagacggtggatcgccagatgcccaacaactgcccctgggcatcctgcggcgagtggtgcctgacca agaccagtggcttttgcccccagatccactcaatagtgcgtcgcaacggcaccgatatccagctgaacaactgcaccagagtcac caacacatcgtgcgccatgattgacctgagtcggctgaacaagttcaattgcaacaacggcaccgcctgcaacaatatcagaggc gtcttcaactgctccaatggacactgcaagaatatgtcggagttcttcttgtgtcaccacaaagccgatggacttacggtcaattcgc agaaggataacaccaagctgaatggattcttcgagtgtcacggggtgcactgcaccaagatcaagaagcccttcagctgcgatcg ctactgttccaagataacaactaccaatgtgaacacccttattatgcacgaggataatcttattgccgccgattgtgagaacgcagtg gctttcaaccaagcccgaggatccgagcacggtgtgcgtatcgaaccctttgagttttggaaagaggatgatggcaacctgctga ccaactgcgccacagtcacaagagagtcggacaatcgcatcactgccacggactgcataaatggaaccctcctggaacatgaca ccttgcccgctcccttcatgaacttcacccagttttgggccatctatgagaacagcaccaggtcggtggatcccgagcagaggtac ctgcccaaccaggccaacctgaccatctacagctggaagaaactgttcatcaacctggagggctgcgtgaacacactgcgtggg gagtgcaaggactttgtggctcgctatggcaacgatggcgataacaacaccgcccagtcacgctaccagtgctactataacaagg actcgaatgtggagtttgtggttgcacgctacgatttggacaaggtttacagggagcttctagtctcgctgattgtgcccattgtgctc tttgtgatctcatctatatcgttatgtatcatcaccaaatccgtcaaggtgggtgacgatgccaagatgcgctgtgtttgtgccggcga tgattcagataatgatggcccctttggcccaggactagcaaacaagcagcaggatcagatgtacgatacagacgacgatgtagtt gacctggagcaccaagcggtggatggtcaagaactatcggaccacggacttccgctggacaaccaagagctaatcggtagcac caagtcgttgataccaatcagtcccgtcggagaatccggaactagtgatcaaatctttgaccaggatcaggagaaagcaactacgt gcgatgttcccgagaaaccactagtcatactataa (conesponds to CGI 5003) Annotated Drosophila genome genomic segment AE003480 Annotated Drosophila genome Complete gene candidate CGI 5003- novel unknown Human homologue of Complete gene candidate none Putative function No homologies to suggest function Confirmation by RNAi Only wild type profiles observed Example 41 (Category 4) Line ID 422/28 Category Meiotic defects in testis: segregation defects, multipolar spindles (Mul-02/22) Reversion NR Map Position 68E Rescue ID 2I4E Rescue Sequence TCGTGGACCCTCAAAGNAACGGATTTCTCCAGTTTCTTCAAAGGGTTAATAAA CTTTTCGCACGTTTCGCATTTTTATGCTCAATCCGGTTACAAAATGCTGATAAA ACCACTTGAACTACACGTTTCCGTACTGATAAGGGCTTTTCTTCTTATCTGACC TCTGGAATTCCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCC TATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCA CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATT CAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATAT TGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTT TTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTA AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCT CAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA Genomic hit, Accession No. CSC:AC014962 Annotated Drosophila genome genomic segment AE003543 Annotated Drosophila genome Complete gene candidate CG5684 (putative transcription factor, human homolog Human homologue of Complete gene candidate le-100 4758946 ref|NP_004770.1|pPOP2| POP2 (yeast homolog) >gi|4106061|gb|AAD02685| (AF053318) CCR4-associated regulator of polymerase II transcription Putative function Transcription factor Example 42 (Category 4) Line ID 422/5 Category Meiotic defects in testis: segregation defects, abnormal spindles (Ab-04/26) Reversion ? Map Position 82D Rescue ID B9E Rescue Sequence 1 ATTGGCTCTTGATGGACTACAACGCTACCAAAATGGGGCTTGAGTTGAATTAC CTGTTGGAAGACACAATGCCACCCACGATCAACAATTCGGCGGTAAACAGTG CCGCCGAAAAGCGACCCAGCGGCAAACGGGAGCGCAAGTAAGTGAACAGAT CCCTAAACAGACCCAGATACTCAGACTGATGTGTACCTTGCAGATCCGAGATC ATTTGCCGCGTGAAGTATGGAAACAACCTGCCGGATATACCATTTGATCTGAA GTTTCTGCAGTACCCCTTCGACAGCCACCGCTTCGTGCAGTACAACCCAACGT CGCTAGAGCGTAACTTCAAGTATGACGTGCTGACGGAACACGATTTGGGTGTC ACGGTGGGACCTGATTAACCGGGAGCTCTATCAGGCCGACTCCATGACGCTGC TGGACCCGCCGATGAAAAACTGCTGGAGGAGGAGACTCTGACGCCCACAGAC TCTGTGCGTTCGCGCCAGCATTCGAGGACGGTGTCATGGTTGCGCAAATCCGA GT Rescue ID B9B Rescue Sequence 2 GGCCAAATCTAGAAATCCTCAAATCTGCGCTTGGCAGTGTGACCGTACTTGAC CGGTACGATAATACCTCCGGTAAAAAAAATACTATATTTCCGGGGGACTCAAA TGCAACATCCTCATCGTATATAACACAACATCTATTTGAATTTCATTTCCACAA CTAATATTATGGATAATGCTTTATTATCATTTTCCAAGTTAGCGATAAATCACC CCACAAGCTGAAAAATCAACGTTTAAAAACGATTGATATTTTTTTTAATACTTT TTGGTTTTACTATTTGAATTTTTGTATACTTTTAGATTTTACTATTTTAATTTTTC GTTTCTTCTAGCTGACTAACGGGTTAAAAAAGGATCCGTCGACCTGCAGATCT CTAGAAGCTTGCGTTGCTGGCGTTTTTTCCATAGGCTCCGCCCCCCTGACGAGC ATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATA AAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCCGTGCGCTCTCCTGTTCCG ACCTGCCGCTTACCGGATACCTGTCCGCCTTCT Genomic hit, Accession No. AC008189 Associated ORF Genscan ORFl predicted sequences >15:53:24|GENSCAN_predicted_peptide_3|211_aa MRNANESSGKPKSKFVSNEFHALFSTICSIADSPAVSREKLKIDLAARKIPSASAPK GDSPLERFSRDLFTYLRSVCRWGRFSAALFTAELLIVGGIVSSNRTSESSETGNPLA NEPDPLYMKLVDPMVAGESPKRMIKDQKDVGLKSTSSSEELRKLPKTRGRQKRFI RNPNYVKANEFYDKMLSSEYVSKRYKDLPPPHPGFGADQPPA >15:53:24|GENSCAN_predicted_CDS_3|636_bp atgcgcaacgcaaatgaatcgagcggtaaaccaaaatcgaaatttgtaagcaacgaattccacgcattgttttcaacaatttgttcaa ttgccgattccccggctgtctctcgagaaaaattgaaaatcgatttagctgctcggaaaataccttcggcatcagcccccaaaggg gattctccactcgagcgcttttcgcgggatctgttcacttacttgcgctccglttgccgctggggtcgcttttcggcggcactgtttacc gccgaattgttgatcgtgggtggcattgtgtcttccaacagaacgtcagagtcttctgaaactggaaacccacttgcaaacgagccc gatccattatatatgaaactggtggatcccatggtagcaggagaatcacctaaaaggatgattaaggatcagaaagatgtaggcctt aaatcaactagcagtagcgaagagctccgaaaattgccaaaaacgcgaggtcgacagaagagattcattcggaatccaaactat gtgaaagctaacgaattctatgataagatgttaagcagtgaatacgtaagtaagcggtataaggatcttccgccgcctcatccggga tttggagcggatcaaccgccagcatga Corresponds to CG2503 Annotated Drosophila genome genomic segment AE003605 Annotated Drosophila genome Complete gene candidate CG2503 - novel possibly RNA binding Human homologue of Complete gene candidate 3287674 AC005239 (AC005239) F23149_l(aa) Putative function Possible RNA binding protein Confirmation by RNAi Almost no GI and broadened G2/M indicating arrest in G2/M Example 43 (Category 4) Line ID 423/14 Category Meiotic defects in testis: cytokinesis defects,abnormal spindles (Ab-16/13) Reversion R Map Position 67B1-10 Rescue ID E9E Rescue Sequence GTTTGGCGTAAAAGCTTCGGCTGTGTTTGGTGCCCAAAATTTTCCACTGCTTCT CTTTTTGTGTATCTCTTATATCTTGTGCTTTTTTGTTGTGTATGTTTTCTCGTTTC TTTTTGCACACGCGCTTCGCGTTGCGGGCCAGCTGTTTTTGTTTGATAAGTGGT TACGGTTTGTGTGTGCCAGCGGGTTTTCCTTAGTCGAACTGCTCGCGATGACTG ATTTTTCACAAGTGACTCAAAAACAGTCGATCGCCCTTTTAAGAAAACCCGCT CAACGCACACAAAAGCGGTTTCTCTCTTTTTGTCGTTCTCTCTTTTCACACTGA CCACACGGAACGAAAAAATGATTACCGACCACACGGAAAGAAAAATTTATGT CCAGACGAAACTATTTTTGTCCAACTAGCTGATTTGCATAACAATTTAAGCCA CAAGAAACTAGATTAAAATTTTACATTTAAATACATTATCAAATCCGAAATAT CAATAATTGTAATTTATCCTTACAAAATGTTA Genomic hit, Accession No. CSC:AC020214 Drosophila EST several including LP12306 (AI297868) Annotated Drosophila genome genomic segment AE003552 Annotated Drosophila genome Complete gene candidate CG3967 - novel Human homologue of Complete gene candidate none Putative function No homologies to indicate function Confirmation by RNAi Only wild type profiles observed Example 44 (Category 4) Line ID 427/5 Category Mitotic defects in brain: anaphase defects. Meiotic defects in testis: segregation defects, abnormal spindles (mitotic : Overcondensation, lagging chromosomes/less aligned metaphase with bipolar spindles, Meiotic: Ab-06/20 ) Reversion ? Map Position 67B1-5 Rescue ID H4E Rescue Sequence GTACAGCCTGAAGTGATCGTTGTTGTTTGAATCGGTGCTATCGGCGGTTGCGC TTTGTGGGCATCTTTATCCAATTTGCTATGCGCGCTTGTCCTTAAATTTTGAAC TGTATTCCAAGGGTTGCTTTGGCGGCTATCGATAGTATCGGCATGGTTACATTT TAGTTTTATA AC AAGAATTTTAC AGGTATTTTGATTATCTGAGCTTAGTTTTAA GCAANAATATTATTGTTAAAAATTTAAAAAGTAAACAAGCTATTTTAACAAGC ATTTAAACAAATAGTATTAATAATATAAAAATATATCGATATGTGTTGCAAAT GTTCGTTCCCTTAGTATTCTCTCATATTTATTTCAAATAAACTGTATAAAATAT CTGAAAAAGCGAACATATTTATTTAATTTCATCGCAGATATCGATATCACAGC GCTGCTATCGATGGTGTGTCTGTCGCAGTGCCTATCGCTTACCCTGCCATCGCT AACAAAAA Genomic hit, Accession No. CSC:AC020120 Associated ORF Genscan: ORF2 predicted sequences >22:06:07|GENSCAN_predicted_peptide_7|464_aa MPSEQHTNIKNANRNRPYNVRELEQKQRSIIKVMDRSALLFDPDEEDDEFFFQGA KQPYRDITKRMNKKLTMEFDRVFDIDNSNQDLFEECTAPLVDAVLNGYNCSVFV YGATGAGKTFTMLGSEAHPGLTYLTMQDLFDKIQAQSDVRKFDVGVSYLEVYNE HVMNLLTKSGPLKLREDNNGVVVSGLCLTPIYSAEELLRMLMLGNSHRTQHPTD ANAESSRSHAIFQVHIRITERKTDTKRTVKLSMIDLAGSERAASTKGIGVRFKEGAS ΓNKSLLALGNCΓNKLADGLKHIPYRDSNLTRILKDSLGGNCRTLMVANVSMSSLTY EDTYNTLKYASRAKKIRTTLKQNVLKSKMPTEFYVKKIDEVVAENERLKERNKA LEAKATQLERAGNSGFDPLELKTWYSKIDAVYAAARQLQEHVLGMRSKIKNΓNY RQTLKKELEEFRKLMCVDQRVCQESF >22:06:07|GENSCAN_predicted_CDS_7|1395_bp atgccttcggaacagcatacgaatataaaagtggcggttcgcgtacggccgtataatgtccgtgaattggagcaaaaacagcgga gtattatcaaggtcatggatcgttcggcactgctgttcgatcccgacgaggaggacgatgagttcttctttcagggcgccaagcaac cgtaccgcgacatcaccaagcggatgaacaaaaagttgaccatggaattcgacagggtattcgatatagacaattccaaccagga tctgttcgaggagtgcacggcgccgctggtcgacgcggtgttaaatggatacaactgctcggtatttgtatatggagccactggcg ccggaaaaacattcacaatgctgggcagcgaggctcatccgggtctgacctatcttaccatgcaagatctcttcgataagatccaa gcgcagagcgacgtgcgcaagttcgatgtgggggtatcctatctagaggtgtacaacgaacatgtgatgaatctgctaactaaatc gggccctttaaaacttcgcgaggacaacaatggcgtggtggtcagtggtctttgtctcacgcccatctacagtgccgaggagctgc taagaatgctgatgctgggcaactctcatcgcactcagcaccccacagatgccaatgcagagagttccaggtcacatgccatcttc caggtgcacattaggatcacggagcgcaagaccgacaccaaaagaacggtcaaactatccatgatcgatctggcgggcagtga gagggcggccagtacgaaaggcattggagtgcgattcaaggaaggcgccagcatcaacaaaagtctcttagctttgggaaattg cataaacaagctagccgacggcttaaagcacatcccgtaccgcgactcgaacctgacacgcatcctgaaggactcgttgggcgg aaattgtcgcacattgatggtggccaatgtctcgatgagctcactgacctatgaagatacctacaacacccttaagtacgctagccg agctaagaagatacgcacgactctgaaacagaatgtcctcaagtccaagatgccaaccgagttctatgtgaagaagatcgacgag gtggtagccgagaacgagcgactcaaagagcgcaacaaggcgctggaggccaaggccactcagttggagcgcgccggcaat agtggattcgatccgctggagcttaagacgtggtacagcaagatagacgctgtatatgcggccgcccggcagcttcaggagcac gtccttggtatgcgtagcaagatcaagaacatcaactaccggcagacactgaaaaaagaactggaggagttcaggaagctgatgt gtgtcgaccagcgagtgtgccaggagagtttttaa Drosophila Gene Hit TBLASTN with ORF2: kinesin like protein 67a (U89264) Human Homologue TBLASTN with ORF2: kinesin family member protein KIF3 A (AF041853) Drosophila EST GH22018 (AI402731 ) Annotated Drosophila genome genomic segment AE003552 Annotated Drosophila genome Complete gene candidate CGI 0923 Klp67a - motor protein Human homologue of Complete gene candidate 2e-58 4758646 kinesin family protein 3B >gi|3913958|sp|O15066|KF3B ΪUMAN KINESIN-LIKE PROTEIN KIF3B and also predicted peptide ENSP00000166696 Gene:ENSG00000073652 Clone:AC015936 Contig:AC015936.00023 6.70E-91 (predicted kinesin?: ENST00000166696) Putative function motor protein involved in cytoskeleton organization and biogenesis Confirmation by RNAi Almost no GI and broadened G2/M indicating arrest in G2/M Example 45 (Category 4) Line ID 442/3 Category Meiotic defects in testis: segregation defects. Reversion ? Map Position 70D4-7 Rescue ID H7E Rescue Sequence CGC AAGACTGTCTTCGATAGC AGAAGCGTTATTTCGGAAC ATATCGTTTATCG AAACTACAGTTGCTCAATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTCAA ACCATTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAATT AAAATATAAACTACGAGGATCAAATATACATACATATTCCCAATATGTTAGCG AAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTCTA TGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTTCA ATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAAAT GTAACTGTTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTCATC GCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATTA Genomic hit, Accession No. CSC:AC017664 Drosophila EST CK02287 (AA141680) Annotated Drosophila genome genomic segment AE003536 Annotated Drosophila genome Complete gene candidate CG6650 - novel transacylase like Human homologue of Complete gene candidate none Putative function Transacylase Confirmation by RNAi Marked increase in GI indicating arrest in GI Line ID 473/22 Category Meiotic defects in testis: no division (no meiosis) Reversion R Map Position 70A1-5 Rescue ID 2B7E Rescue Sequence 1 CGCAAGACTGTCTTCGATAGCAGAAGGCGTTATTTCGGAACATATCGTTTTAT CGAAACTAC AGTTGCTC AATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTC AAACCATTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAA TTAAAATATAAACTACGAGGATCAAATATACATACATATTCCCAATATGTTAG CGAAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTC TATGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTT CAATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAA ATGTAACTGTTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTCA TCGCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATAAGAA AGTTGGCGTAGCCGGAAGGCGGATTGTCACATACAAAATAGTTTGGAAAGCC CAAACTGAG Genomic hit, Accession No. CSC:AC017664 Drosophila EST LD47104 (AI515336), SD03663 (AI532240) For other results see line 442/3 Line ID 670/6 Category Meiotic defects in testis: segregation defects, abnormal spindles (Ab-12/48) Reversion ? Map Position 70C Rescue ID H7E Rescue Sequence CGCAAGACTGTCTTCGATAGCAGAAGCGTTATTTCGGAACATATCGTTTATCG AAACTACAGTTGCTCAATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTCAA ACCATTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAATT AAAATATAAACTACGAGGATCAAATATACATACATATTCCCAATATGTTAGCG AAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTCTA TGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTTCA ATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAAAT GTAACTGTTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTCATC GCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATTA Genomic hit, Accession No. CSC: AC017664 Drosophila EST CK02287 (AA141680) For other results see line 442/3 Example 46 (Category 4) Line ID 460/20 Category Meiotic defects in testis: segregation defects, multipolar spindles (mitotic: High polyploids, no diploids, higher mitotic index Meiotic: Mul-02/59) Reversion NR Map Position 78A1-4 Rescue ID 2B8E Rescue Sequence AGCTGGTCCAATTGGAAACGTTAGCTGCTCCAATGGGAGCAGCTGGCGCTCTC TCTTCGATCGCGCTCGCTCTCATCCTCTCTCTTTAGCTTGTGCCACAGTAGCTG CCGAAGGCAATTTTCATGTGCTCGTGTGTCGACCCCCACTCAGCCCACTTCTG ATCGGAATCGGGGATTCGGAATCGTGTAAGGCAGCCTTTGAAGGTCCCTTTTC CAGGTGGCGGCCGTATCCTTAAAGTAAACATAGTTCAACTGACTTGGCAGCGC TCCAAATGCGGTGACTTCTTGGCTATGTCATATATACCCCCACTCCCCTCCTGA CTACCCTGCCACGCCCCACCGCCCACCGTCGGCGACGACAATTCCATTAAAAG TTGTACGTTGTCACTTTGCGTTAACTTATCTGTGGAGCATGTTGTGCGATCGCA TTTTTATTGTCGCCATTGTCTCTCGCTCTCTCCATCGCTCTTTCGCCTGGCTTCC CTACCCTGCCCACACAGGGAAGCCTACACACTCTTAAATCATGCACTTGGAAC AAAAAGTGCAAGCATTAAACTTTATTTAAACATTCAAGAGCCGCTTCTCTATT TACCATTGAAAATTTAATTTAAAATAGAAGAGGCCTTTTCAGAATAATATAAT ACCTTTAAG Genomic hit, Accession No. CSC:AC020460 Annotated Drosophila genome genomic segment AE003592 Annotated Drosophila genome Complete gene candidate CGI 0588 - novel gene with homology to proteases Human homologue of Complete gene candidate 2e-74 4505453 ref|NP_002516.1|pNRDl| nardilysin (N-arginine dibasic convertase) >gi|2462488|emb|CAA6369 Putative function Novel protease Confirmation by RNAi Marked increase in GI indicating arrest in GI Example 47 (Category 4) Line ID 477/16 Category Meiotic defects in testis: segregation defect. Reversion NR? Map Position 90C5-10 Rescue ID C3E Rescue Sequence 1 CTGTGGACGGTCGTCAATGCGTGAATATTCTTCTATGTGTAAGTGGTGTGCGT GTATGTAGATTTCTGGTTAAGAAAAGCCCCAAAAACCAAAGCGCCCCGCAAA ATATATATTGAGTCTTCTTGGCCCAACAACAAATCTGCCGCCGGACTTTCGCC GGAGGGCGAGTGAAAAATTCAGTTTCTCTCCTCTCGACGATGCACTTTGGAGG CTGTGTGAGTGTGTGTGCGAGTGAGTGCGTGTGTGTATACATATGCAAATGAT TGGATGTCGAATCCTTGCATCATCATCATCTTCATAAACACTTGGCGAAAAAC CGCAGGAAAACGCAAGCAGCCGAACAAAAAAAGAGAGCCTCTCAAGACAAC GGCAGCGGCCAAAAGTGAACGCGCAACAAACGCGGCCAAGCAGGCGCGGCA ATTATTTATAAATCTTAAGCCGTTAGCCCCCCTCTCTCTCCCACTCACGAAAAG AAAATAAGTTAAACCAATTGGTGAAGATGATGCCCC Rescue ID C3P Rescue Sequence 2 GTCCACAGACTGGCTATATATACTAAAAACGAACTCGCGTGAGAAGACAGGG ACAGGGCAGCAAACTCGGTATACGAACGGAACGAAATGAAACGATTCAAGTA GTAGTGTATGCAAGTCTTGTCTGTCTGCGCCTGGCGTTCTTTTCTCTTCTTTTTT TCGATGGTTTTTCGCCAGGCTGGGCGCTGCCAAAACGCTGATACGGCGGCCAC AATCACACGCGGCTAATCGCCAGTTGGGCCCTGCACAGGCTGCACATACTTTT CACTATTAATGCGCTGTATTTCACTTATTTTTCGAACAAATTCGCAGCATGACG AAGAAGCGAGCCTGTACAAGATTAGAGCGGGTAGCACGCACGATAGTATCGA TACGTACGAGTATTTGGCACTGCGATACATTATCGGTGCTCGTTTCGATAGCCC CCGATAGCTCTAGCACGAAATTTTATCGCTTTATCCATATTTTATACTATTTTT ATTTATTGGACTTCAATGAATATTTAATTTACGTCTGGGTCGCTTTTTAAATAT ATATGGTAATCAATAGCTGGCGAATTAGCGATATTTGAGTGTGACGCAAAAAT GAGTTGCATCGATATCGATTTCTCGCTACTCTGGGACGCCATCTTTATTGCGG Genomic hit, Accession No. AC007810 Associated ORF Genscan ORFl predicted sequences >17:48:58|GENSCAN_predicted_peptide_2|349_aa MSRILFILLLLINTQLSELQAAAFSVRQNRFDENPDLQTPAPLATSTESSKKPEKAT SGLLKKCLPCSDGIRCNPQIQCPAHNRMESHEKPQICDLPAGKFGNCCETGQΝHT APKPETSPKERRSGFPTILSPAVLDEARRΝFEHLMHGVAQIPVRRGFPDFAHGLVF HSTAKDDLHΝFAISΝSAIEQVMTTQLFGKKEQVPVEDFITΝΝVPIKFTETPLAHHC QPPPVCGΝIRSVYRSMDGTCΝΝPEPQRSLWGAAGQPMERMLPPAYEDNPSASPA AICSYIYGIASRLAPNSNVΝCCTFAWQLDWTTGMASGECVCVECMPAEWRLGQC PLLHEASSEMSRLLAKS >17:48:58]GENSCAN_predicted_CDS_2|1050_bp atgagtcgcatlttatttattttgttgctacttattgtgacgcaactgagcgagttgcaggcggcagcattttctgtgcgccaaa ttgatgaagttcctgatttgcagactcctgcacctctggccacttccactgaatcttctaagaaacccgaaaaagctaccagtggtct gctgaaaaaatgccttccctgcagcgatggtataagatgcgtgccccaaatccagtgtcccgcccacgttcgcatggaaagccat gaaaagccccaaatttgcgatctcccggctggaaaattcggctactgctgcgagactggacagaatcacactgctcccaagccg gagacctctcccaaggagcgtcgatccggatttcccaccattctgtcacccgcagttttggatgaggcgcgtcgcaatttcgagca cttgatgcatggagttgcgcagattccggtgcgccgtggctttccagattttgcccatggcctggttttccactcgacggccaaggat gaccttcacaacttcgccatatcgaacagtgccattgaacaagtgatgaccacccagttgtttgggaagaaggagcaggtgcccg tagaagatttcatcaccaacaatgtgcccatcaagttcactgagactccgctggcacaccattgccaaccgcccccagtttgcggc aatattcggtctgtttatcgcagcatggacggcacttgcaataatccagaaccacagagatctctgtggggtgctgctggtcaaccg atggagcgcatgctgccccccgcctatgaagatgttccgtcagcttctcctgctgctatatgtagttatatctatggcatcgcatctcg tctggcgcctgtttctgttgtcaattgttgcacatttgcatggcaattggattggaccactggaatggcgagcggggagtgtgtgtgt gtggaatgtatgccggcggagtggcgtttgggccaatgcccgttgcttcatgaggcgtcgagtgaaatgagccgcctcttggcta aaagctag Drosophila Gene Hit rescue sequence: eyelid/osa (AF053091) Human Homologue BLASTX with eyelid: KIAA1235 protein (AB033061) Brain protein 120 (AB001895) Drosophila EST several including LD04852 (AA201670), LD24466 Annotated Drosophila genome genomic segment AE003718 Annotated Drosophila genome Complete gene candidate CG7467 - osa DNA binding putatively involved in DNA packaging Human homologue of Complete gene candidate CG7467 - 7e-25 2588991 dbj|BAA23269| (AB001895) B120 [Homo sapiens] and 014497 SWI/SNF- RELATED, MATRIX- ASSOCIATED, ACTIN- DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY F MEMBER 1 3e-67 Putative function transcriptional regulator Confirmation by RNAi Only wild type profiles observed Example 48 (Category 4) Line ID 496/4 Category Meiotic defects in testis: segregation defects,abnormal spindles (meiotic: Ab-08/42) Reversion NR Map Position 65E4-7 Rescue ID 2C1E Rescue Sequence GCACGATCGCTCTCTCTTGGCTCTCTCTATCACTCTCTGGACTCTCTCTCAGCA CCTTTGCTACCGTTTCGCAGAACAGGTGTATCGGTTTTCAAGGCAACTGTGATT TTTTAACTCAACATTCTATATCGAAAACTTGTAGAGGTCGGAATTTTTCTTGAG CGCCTAAAAGTGTGCAGTGAAATCATTTAATCCACTTCCGGTTGCAAAACAGG AATC AC AC ATATGAAGTGATT AAAAATC ATAGAAGGTTTGAC ACCTTC AAATA ATAAGAAAACAAAAATTTGTAAACTGTGATAATTTATTTAATTGAAATCTTAA TTTAATGGCCTACAAATCTGTTGAATATCCGTTGAATACACTTTTCCAGGGTGT GTCCTAGTCGGCTCCTCTTTGTTACCCCAGTTTGCTGGTCTTCTTAGCCGCACA CCAGTTTATCGCTGTTTTGCCTTTGCGCTTTTCATTCATAAACAAAAAACAATG TTATTGTTATTGCGGTGGCTGTAGATGTAAATGTAAATGTAGATGTAGAGGCT GCTTCTTGGG Genomic hit, Accession No. CSC.ACO 18039 Associated ORF Genscan ORFl predicted sequences >19:35:36|GENSCANjpredictedjpeptide_6|190_aa MVSEQFNAAAEKVKSLTKRPSDDEFLQLYALFKQASVGDNDTAKPGLLDLKGKA KWEAWNKQKGKSSEAAQQEYITFVEGLVAKYDNGMHKQEPNTCQARNATRFR KSSECSLDQNTYTSSVTVIPAFHEGPKNSTASWPRIYRCYQRNQQAANCKWANTN SVCGKPHGKQSRRIIFAEFLAGHTVQILG >19:35:36|GENSCAN_predicted_CDS_6|573_bp atggtttccgagcaattcaacgccgccgccgagaaggtgaagagcctgaccaagcgtcccagtgatgacgagttcctgcagctg tacgccctgttcaagcaggccagcgttggtgacaacgacaccgccaagccgggtctcctggacctgaagggcaaggccaagtg ggaggcctggaacaagcagaagggcaagagcagcgaggccgcccagcaggagtacatcacctttgtggagggcctggtggc caagtatgacaatggaatgcacaaacaagaaccaaacacttgccaagcacgcaatgcgactcggtttcggaaaagctcggaatg ctcgctggatcagaatacgtatacgtccagtgtgacggttatacctgcattccacgaaggtccaaagaactcgacggcaagttggc caagaatttaccggtgctatcagcggaaccaacaagcggccaactgcaagtgggcaaacacaaatagcgtttgcgggaaaccc cacggaaaacagagccgccgaatcattttcgcagaatttctggccggccatacggtgcagattcttgggtaa Drosophila Gene Hit rescue sequence: melt (SI 44114) P element insertion site (AF174669), TBLASTN with ORFl : diazepam binding inhibitor (DBI) (U04823 ) and melted (AF205831) Annotated Drosophila genome genomic segment AE003560 Annotated Drosophila genome Complete gene candidate CG8624 melt - putative signal transduction protein CG8631 msl-3 - acyl-CoA- binding protein/diazapam binding inhibitor Human homologue of Complete gene candidate CG8624- predicted gene ENSP00000065899 Gene:ENSG00000055889 Clone: AGO 15904 Contig:AC015904.00014 1.70E- 15 (unknown predicted gene l: ENST00000065899 and AK022666 Homo sapiens cDNA FLJ12604 fis 2e-29 CG8631- gi5803104 0C85AE40FDF874CD |ref|NP_006791.11 male- specific lethal-3 (Drosophila)- like 1 [Homo sapiens] (1.70E- 36) and Ensembl predicted peptide ENSP00000006617 Gene:ENSG00000005302 Clone:AC004554 Contig:AC004554.00001 8.70E-19 (unknown predicted gene 1: ENST00000006617 Putative function CG8624: putative signal transduction protein CG8631 :acyl-CoA-binding protein/diazapam binding inhibitor Confirmation by RNAi CG8624: reduced GI and G2/M Indicating fewer cycling cells, CG8631: Increased GI to G2/M ratio indicating arrest in Gl Example 49 (Category 4) Line ID 523/19 Category Female sterile. Meiotic defects in testis: cytokinesis defects, segregation defects (Mitotic: Less condensed chromosomes, nuclear bridges, Meiotic: Seg-01/02 Reversion R Map Position 75C1-4 Rescue ID 2B4E Rescue Sequence ACTGAGAGCATATTTGTGCACCAGAGGGCTGCATAACAACATTCTCTTTGTCC ATTCGTTATACTTCGTATTCAGAATACATGTCATTCAGTTGGTCCCGTTCTTTTT GCGTTCACTTCGTATATATTCGGCGATCGAAATGAACTAACTGAATGTGTTCA AAGAATGAATGAAGCC AATGAATTTTC AATAGTAATTC AGAGTGCTTAAAATT CTTCATGTTGTCATTGAGTAAAATGAGTTCGGACAGCGCGAAGGTAAGTCGAA GTTTGTGTTTTATTATGTTTATTTGTATTATTATGTACACTAGTCGGCATACTTT TGCGTGCGTCTTATACGTGTGCGTCTTATTTAACAATATTGTAAAATAAAATAT ATAAATTATTTGTTATATGCGTAGGGGCCTTTATTTTGTGTATTGATAGTCTTTT GTCATAGATATCATTATTCTGACAAGATTTGAACTTTTCAAGTTATTGCCTCTC GTTATTCAATTCCTAGCTGGTCTTACGTTACGCGATATTTCCTAAAATATCCTA AAATCGCACAAAACAGTCACGCCCACACTTTTGAAAAACGTGGTAATATTTTT CATACTTGCATTAAGTCTGG Genomic hit, Accession No. AC007691 Annotated Drosophila genome genomic segment AE003520 Annotated Drosophila genome Complete gene candidate CG4306 - novel Human homologue of Complete gene candidate 4e-25 3242764 (AC005154) similar to protein U28928 (PID:g861306) [Homo sapiens] Putative function No homologies to indicate function Confirmation by RNAi Only wild type profile observed Example 50 (Category 4) Line ID 666/19 Category Mitotic defects in brain: anaphase defects (weak, overcondensation, aneuploidy, lagging chromosomes, metaphase with bipolar spindle) Reversion NR Map Position 64E1-5 Rescue ID I9E Rescue Sequence CCCTCGTCTACGTCGAAATTCTGGATGCTTCTCGGATTTAGGGTTGTATCTCGA AAACGTTTGACTGCGAATGTCAATATCGATATGCTAACCGATAGCTGTCGATG TTTTAAACACAGTGCACTGTTTTTAAATCGCTCCCCATTTATATATATTTGTGC NTGCTTTTGGCGGTNNTTTTCTTTATATGCTTCTTATGCTTTTACGATTATTATT AGCGCTTATTTGATTGCAAATGCCAAGGAAAGCGTGACTGTGATGGCGAAATG CGGAAAGTACTCCTTAAATCTCATATATCGCATAAAACTATCGGTTCTGGAAT GTTTCGTGTAAGTCTGCGAAGATAGAGATCGATCTATTTTGAGGATACATTTG TTAATATTATAAGGGATTCTTCTACAGGGGTCAGATTGCTTAAAAACACACAG AANAATAAACAAAATATTTCTTTGAAATATTGAAATATTTGAAATANAAAAAA CGTATTGACGAGGTAAGCATATTGAAAAAGATAGGAAGGTGATGGAGAAAGT GCACTTATATTGGTCACCAAAGAGCTTATAATCAAAAGATCAATAGATATAAA TATCTTTATATGATATAAAATATAATACATATAATATAATATCATATACAATG GATAAATTGCAAGTGGCAAAATGAATTCCGCGGAATTAATTCTGAANCGAAA GGGCCT Genomic hit, Accession No. CSC:AC014815 Associated ORF Genscan ORFl predicted sequences >17:46:43|GENSCAN_predicted_peptide_l|334_aa MGKDFNKILGLERKASDDEIKKAYRKLALKYHPDKNKSPQAEERFKEIAEAYENL SDKKKRDIFDΝYGEDGLKGGQPGPDGGGQPGAYTYQFHGDPRATFAQFFGSSDP FGAFFTGGDΝMFSGGQGGΝTΝEIFWΝIGGDDMFAFΝAQAPSRKRQQDPPIEHDLF NSLEENDKGCIKKMKISRMATGSΝGPYKEEKNLRITNKPGWKAGTKITFPQEGDS APΝKTP ADINFIIRDKPHSLFKREGIDLKYTAQISLKQ ALCGALNSNPTLQGSRIQN ΝPΝHEIIKPTTTRRLΝGLGLPNPKEPSRRGDLINSFDIKFPDTLAPSLQΝQLSELLPΝ >17:46:43 |GEΝSCAΝ_predicted_CDS_l 11005_bp atgggcaaagacttctacaagattctgggcctcgagcgcaaggccagcgacgatgagatcaagaaggcctaccgcaaactggc actcaaataccatcccgacaagaacaagagcccacaggcggaggagcgcttcaaggagatcgccgaggcgtacgaggtgctg tcggacaaaaagaagcgcgacatcttcgacaattacggtgaggatggattgaagggcggacagccgggaccagatggcggcg gtcagccgggagcgtacacttaccagttccacggcgatccgagggccacatttgcccagttctttggatcgtcggatccgtttggc gcgttctttaccggcggcgataacatgtttagtggcggtcagggcggcaataccaacgagatcttctggaacattggcggcgacg atatgtttgcctttaatgcccaggcacccagtcgcaagcgccagcaggatccgcccatcgagcatgatctgttcgtgtcgctggag gaagtggacaagggatgcatcaagaagatgaaaatctcacgcatggccaccggaagcaatgggccgtacaaggaggagaag gtgctgaggatcacagtgaagccgggctggaaggccggtaccaagattaccttcccccaagagggtgattcggcgccaaacaa gacgccagctgacatcgtcttcatcattcgcgacaaaccgcattcgctgttcaaacgcgagggaatcgatctaaagtatacagccc agatcagtctgaagcaggccttgtgcggagcactggttagtgtgcccacgctgcagggcagcaggatacaggtgaatccgaacc acgagatcatcaagcccaccacaacgcgccggatcaacggactgggtctgccggtgcccaaggagccatcgaggcgcggcg atctgatcgtctccttcgacattaagtttcccgacacactggcacccagtctgcagaatcagctgtccgagctgctgcccaactag Drosophila Gene Hit rescue sequence: fasciclin I (Fasl) ( M32311) TBLASTN with ORFl : DnaJ homolog (DROJ1) (U34904) Human Homologue TBLASTN with ORFl : DnaJ-like heat shock protein 40 (HLJ1) (U40992.2) Annotated Drosophila genome genomic segment AE003565 Annotated Drosophila genome Complete gene candidate CGI 0578 - DnaJ-1 a chaperone putatively involved in protein folding. Stimulates activity of HSP70 Human homologue of Complete gene candidate 8e-94 1706473 P25685 DNJIJHUMAN DNAJ PROTEIN HOMOLOG 1 (HDJ-1) (HEAT SHOCK PROTEIN 40) (HSP40) Putative function Chaperone involved in protein folding Confirmation by RNAi Almost no GI peak, increased G2/M indicating G2/M arrest Example 51 (Category 4) Line ID 714/11 Category Meiotic defects in testis: cytokinesis defects,abnormal spindles (Ab-01/04) Reversion ? Map Position 66A10-15 Rescue ID 2A4E Rescue Sequence AACCAGAACGAAACTCCAATGCAGTTTCATTTTGTCAGTTTAATCATTAAACA AAGAACTGCGCAACCGATCGCAACTAGCTCGTGGACTCTTGTTCTCCCAATAA TTGGTATGTTTTCCATTTTGCGTTAACATGGAAAATGTGTGAAAAGCTTTTTCC CCCTCCAAAAGAAGCGTACTGAACTAAGCTTTCGGTGGTTAGTAATAGTAGTC GTTATATCTTATTTTTCTTATTTACGTGCAGCTGCAATCATTGGCTGCGTCACTT TGGCGTCAGCTATAAACTGGTGGATCAACTCGGCGGCCTCCAAAAGCTGCGCA TCTGCTCCAGACACTTTAGCCAACGCCAGGAGATGGCCAAAACCCGCATCAA GATGACGCCGCTGCGCAAGTCCTCGTCCTCCAAGGGCATTGTGCTACCCATTA ATGCCGCTGGAGGGTCGGTCATTGCAGGCGCCTTAGCACGAGGAGGAGGTGC A Genomic hit, Accession No. ACO 12390 Associated ORF Genscan ORFl predicted sequences >19:47:45|GENSCANjpredicted_peptide_2|71 l_aa MRSHQANGNLLLAADEALPANQSASNYVNWMAEQPLSPGQSYDIKIADSPSNSS KSITDΝGADVQWFAFEHSQYYQGVQQMFLSALERIDSEFLITLIKRCPYHVDSLVQ LSEVCKMTEDFSLASELLERALLLLESSLHIΝFSLTSGΝCRLDYRRQEΝRSFYIVLF KHAQNLEERACSRTAFEISKLLLSLQPDTDPLAMILPΝQPDQCTGΝMTQLQQAGK IRKRSEKQFPIGTEPRGTDALRFTLQTLASAGRDITWΝIKRLQGSRNTGAAQGNLI DKKTAVQNKITIIAHLKDPΝIDQLFDSSGDGKADLHGSTPDWGCQAMMADAISR YKEGΝPVFYYTWTPYWVSΝELKPGKDVVWLQVPFSALPGDKΝADTKLPΝAGGI EGLIADEEVQVLDALCDAPCVGVSHSCRLLDGΝRRGΝΝELRLFIPGKSQFGVADG CADKQSVMEYHAAKTGHTKFSESEEEKKALTEEEKKAQLALIEEKLKQKRIEREE REKIEALQREKΝRIKSGKDMTEAKRRMEELEMKKIVEQRKREKDEEKAARDRVK AQIEADKAARKAREQKELGΝAEPAPSVSSTTVSSPPAGVKSPPRDYTETRIQGASA ILAAAAPYYQPPAVPQDVQPDRPIGYGAFGVVCGSHISGWHCSAGHYEDGΝEΝFE CLKTFSTSDRIGCEWRWAAATVLAATCISPΝGRCGHYKRVRRPJKTΝITTT >19:47:45|GEΝSCAΝ_predicted_CDS_2|2136_bp atgagatcgcatcaagccgttggcaatctgctgctggcggcagacgaagcgttaccggcggtgcagagcgcgtcggtgtatgtg gtatggatggcggaacagccgctttctccagggcagagttacgacatcaaaattgccgactctccatcggtgtcctccaagtctatc acagataatggagcggacgttcaatggtttgcctttgagcatagccaatactaccagggagtgcagcaaatgttcctttctgctctcg agcgcattgactcggaatttctgatcacacttatcaaacgctgcccctatcatgtcgactccttggttcaactcagcgaagtatgcaa gatgaccgaagacttttccttggcctccgaactgcttgagcgcgcccttctccttctggaatcgtcgctgcacatcaacttcagtttga cgtcgggcaactgccgactggactaccggagacaggaaaaccgatccttctacatcgtgctgttcaagcacgcgcagtacctgg aggaacgagcttgcagccgcaccgccttcgagatctccaaactgctcctgagtcttcagccagacacagatcctcttgccatgatt ctaccaaatcagccggatcaatgtaccggcaatatgacgcagctgcagcaggcgggcaaaatccgtaagcgctcagaaaagca gtttccgatcggtactgaaccgcgcggtactgacgcgttgcgcttcaccctgcagacactggcgtctgccggtcgcgacatcacct ggaatataaagcgtctgcaaggttcccgtgttaccggcgcggcccagggttacctcatcgataagaaaaccgccgtccagtacaa aatcaccatcatcgctcatctgaaagatccgaatatcgaccaactgttcgattcaagcggcgacggaaaagcggatttacacggta gtaccccagactggggctgccaagctatgatggccgacgccatcagtcgctacaaagagggcaacccggtgttttattacacctg gacgccgtactgggtgagtaacgaactgaagccgggcaaagatgtcgtctggttgcaggtgccgttctccgcactgccgggcga taaaaacgccgataccaaactgccgaatgccggtggcatcgaaggcctcatcgccgatgaagaagtccaggtcctcgatgccct ttgtgatgcgccgtgtgttggtgtctcccactcgtgccgactccttgatggcaatcgccgagggaataatgaactgcggctctttatt cccggcaaatcccagtttggagtagctgatggatgtgcagacaagcagagtgttatggagtaccatgccgccaaaaccggtcac accaaattctccgaatcggaggaggaaaagaaggcgctcaccgaggaggagaagaaggcccagctggccctcatcgaggag aagctcaagcagaaacgcatcgaacgcgaggagcgcgagaaaatcgaagccctgcagcgggaaaagaatcgcatcaagtcc ggcaaggacatgaccgaggccaagcggcgcatggaggagttggagatgaagaagatcgttgagcagcgcaagcgcgaaaa ggacgaggagaaggcggcccgcgatcgggtaaaggctcaaattgaggcggacaaggcagcacgcaaggctagagaacaaa aggaattgggcaacgcagagccagctccatccgtgagctccaccacagtttcgtcaccaccggccggtgtgaaatctccgccgc gagactacaccgaaacccgcatccagggcgccagcgcaatcttggccgcagcggctccctactatcaaccgccggctgttccc caggatgttcagccggatcgtcctatcggctatggagcattcggagttgtctgcggttcccacatcagcggctggcattgttctgcg gggcattatgaagatggtaatgaaaatttcgagtgcctcaagacattttcgacttctgaccgcattggctgcgaatggagatgggcg gcagcaactgttcttgccgcaacctgcattagcccgaacggccgttgcgggcattataaacgcgtacgtcgtcgcattaaaacaaa cataacaactacgtga Drosophila Gene Hit rescue sequence and BLASTX with EST: BIP1 (Y14998), BLASTX with genomic sequence matches BIP. Human Homologue BLASTX with BIP1 : alanine: gly oxylate aminotransferase (X53414) ? Drosophila EST GM04749 (AA695904), GM13608 (AA803601) Annotated Drosophila genome genomic segment AE003556 Annotated Drosophila genome Complete gene candidate CG7574 - bipl unknown function CG13681 - unknown Human homologue of Complete gene candidate none Putative function no homologies to indicate functions, Drosophila Bipl interacts with transcriptional activator Bric-a-brac which is required for ovariole formation Confirmation by RNAi Both show reduction in GI and G2/M iondicating fewer cycling cells Example 52 (Category 4) Line ID 763/4 Category Meiotic defects in testis: segregation defects (overcondensation, fewer anaphases) Reversion R Map Position 90F Rescue ID 2F5E-1 Rescue Sequence CGGCAATGTCTGCGCCCCCAATCTGAACTTGCCTCGCCCTCTCCGCCCCTGATC TCATCTCCTCTTCAAACCCCTGCTCCCCTTTTCTGCACACATTAACGTCAGCCT TTAAGTGTGCTTTCTCAGGTGCTGCCCCCTGCGCCCACCATCCCCCGCTCCATG CTCTTTCCATCTTGCGCTCTCTGCGTTCTATCTACATTTTTTTCGAGGTCGCGCG CTGCTTTTTCCGTTGATGTTCGTTCTCGTCAATGTCGC AATATGCGCAAAAGGC AGACAAAAAAAAAATGAGTGGAAAAAGTACATACATACCGGTGATTGATGGG CGGTGGGTGGCGGTGGTGTTAGGNGTGGTTTG Genomic hit, Accession No. AC006495 Associated ORF Genscan ORFl predicted sequences >22:47:02|GENSCAN_predicted_jpeptide_3|283_aa MTERENNVYKAKLAEQAERYDEMVEAMKKVASMDVELTVEERNLLSVAYKNVI GARRASWRIITSIEQKEENKGAEEKLEMIKTYRGQVEKELRDICSDILNVLEKHLIP CATSGESKVFYYKMKGDYHRYLAEFATGSDRKDAAENSLIAYKAASDIAMNDLP PTHPIRLGLALNFSNFYYEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDSTLIM QLLRDNLTLWTSDMQAEEIPIPKLPDRQSKTTLIFSPRSQVNPKILHKNNTIIGRNIC SNFA >22:47:02|GEΝSCAΝ_predicted_CDS_3|852_bp atgactgagcgcgagaacaatgtgtacaaggcaaagctggccgaacaggccgagcgctacgacgaaatggtggaggccatga agaaggtcgcctccatggacgtagagctgaccgtcgaggagcgaaatctgctgtcggtggcgtacaagaatgtgattggagcac gccgtgcctcgtggcgcatcatcacctcgatcgaacagaaggaggagaacaagggggccgaggagaaattggagatgatcaa aacctaccgcggacaggtggagaaggagctgcgcgacatctgctcggatatactgaacgtgctcgagaagcatctcattccatg cgccacatccggcgaaagcaaagtattctactataagatgaagggcgactaccatcgctacctggccgaattcgccaccggctcc gaccgcaaggatgcggcagagaactcgctgattgcctacaaggcggccagcgatattgccatgaacgatctgccaccaacaca ccccatccgtttgggcttggcattgaacttctcggtgttctactatgagattctcaactcgccggaccgcgcttgccgcttggcgaaa gccgctttcgatgatgccattgccgagttggatacactgagcgaagagagctacaaagactcgacactcatcatgcagctgctgc gcgacaacctcacattatggacgtccgatatgcaggcagaagagattccgattccaaaactccccgacagacagtccaaaacca cattgatttttagcccccgaagtcaagtaaacccaaagattctccacaagaacaacaccatcatcggcagagttatctgtagcgtgtt tgcgtga Drosophila Gene Hit rescue sequence: 14-3-3 epsilon isofoπn gene (U84898) TBLASTN with ORFl: 14-3-3 . Human Homologue TBLASTN with ORFl and BLASTX with 14-3-3 : epsilon isoform 14-3-3 protein (U43430.1) Annotated Drosophila genome genomic segment AE003721 Annotated Drosophila genome Complete gene candidate CG8045 complex gene appears to encode 3 things : Transcript: CT24102 unknown Transcript CT24072: transcription factor RNA polymerase II transcription factor , Transcript: CT24092: diacylglycerol- activated/phosholipid dependent protein kinase C inhibitor / 14-3 -3 protein epsilon (suppresspr of ras) Human homologue of Complete gene candidate CT24092: e-119 NP_006752.1| tyrosine 3- monooxygenase/tryptophan 5- monooxygenase activation protein, epsilon polypeptide; 14-3-3 epsilon [Homo sapiens Putative function transcription factor, or 14-3-3 proteins which associate with cdc25 phosphatases Confirmation by RNAi CT24102: wild type profile only, CT24072: Loss of GI peak CT24092: Increase of GI peak Example 53 (Category 4) Line ID 951/8 Category Mitotic defects in brain: (some overcondensation, anaphase bridge, metaphase with swollen chromosome and bipolar spindle) Reversion NR Map Position 73D Rescue ID 2E8S Rescue Sequence GTATAAACAAGATCCCGAGACACCGGTCAGTTGGTGCTACACGCTCTTGGAGA GCGCTGTGTTTGTTCCGTTCAGCGATTAGCGATAGTTTTGTTCGAGCCGGTTGT GTTAACTTGGCTAGCTTCGGGTTTATTGTGACACTTTCCCCAAATCGATCGTTT GCGAAGCGTGCATAGCGGAACATACATACATAGATAACCAGCGTGTCTGGGT GTTCATGAAAAAGAGTGCGTGATATGGGATTCGATATGGCAACACGCTTTATG GATATACTAAAGCTGACCTTTAAGTGAGTTTTCCCAGTCAGTGTCCGCTTCTTG CTCTTGCGGAGCGTTAAACGGTTTTCTGTGTTTTGAGGTCTCGCGTCTTGGTTT TGCAACAGCTTCTGCCCAGCATGCACACATACGTGTGCACTGGGAAAATAGTG TTGCAGAAGTGCTTGATTTATAAATATTACAAAAAATGTGATGAAACACTTTT TATTTTCTTCAAAAAATCAAGAATAAATTAACACTATCCTGCTCTTAAAACAT GGAGATTAATTCAATTTTAATTAAAAAATAATTTTTTTTACAATTTATGATTTA TGAATTTATGCACTCCTTGAAACTATTAAAGACTCAACAGTGA Genomic hit, Accession No. CSC : AGO 15272 Associated ORF Genscan ORFl predicted sequences >23 :03 :05|GENSCAN_predicted_peptide_l |602_aaMGFDMATRFMDILKLTFKPFKTN YTEEKYFNDKLRSSKNIERRYILDVGFRGPTAVTYNPIWVISFKYEQRKLSTAIYSV IKTKSGPVRGVKRNTIWGGSYFSFEKIPFAKPPVGDLRFKAPEAVEPWDQELDCTS PADKPLQTHMFFRKYAGSEDCLYLNVYVKDLQPDKLRPVMVWIYGGGYQVGEA SRGLDVVIVTVAYRLGALGFLSLDDPQLNVPGNAGLKDQIMALRWVQQNIEAFG GDSNNITLFGESAGGASTHFLALSPQTEGLIHKAIVMSGSVLCPWTQPPRNNWAY RLAQKLGYTGDNKDKAIFEFLRSMSGGEIVKATATVLSNDEKHHRILFAFGPVVE PYTTEHTVVAKQPHELMQNSWSHRIPMMFGGTSFEGLLFYPEVSRRPATLDEVGN CKNLLPSDLGLNLDPKLRENYGLQLKKAYFGDEPCNQANMMKFLELCSYREFW HPIYRAALNRVRQSSAPTYLYRFDHDSKLCNAIRIVLCGHQMRGVCHGDDLCYIF HSMLSHQSAPDSPEHKVITGMVDVWTSFAAHGDPNCESIKSLKFAPIENVTNFKC LNIGDQFENMALPELQKIEPNWNSFYAPNKL >23 :03 :05|GENSCAN_predicted_CDS_l 11809_bp atgggattcgatatggcaacacgctttatggatatactaaagctgacctttaagccatttaaaacgaactacactgaagaaaagtattt caatgacaaactcagatcttcgaaaaatattgaaaggcgttatatcttggatgttggctttcgcggacccacagcagtcacgtacaat ccaatctgggtaataagcttcaagtacgagcagcgcaaattgtcaacagcaatatattccgtcataaagacgaaatcaggtcctgtg cggggagtgaagagaaacacaatctggggaggaagctacttcagtttcgagaagatacccttcgcaaagcctccggtgggagat ctgcgcttcaaggccccggaagcagtggagccatgggatcaggaattggattgcacttcgccggcagacaagccccttcagaca cacatgtttttcagaaaatacgcgggctcagaggactgcctctacttaaatgtgtatgtcaaagatctgcagccggataaactgcgtc ccgtgatggtttggatctacggaggaggctatcaagttggcgaagcttctcgaggattggatgtggtcatagtcaccgttgcttatcg actgggtgccttgggcttcctcagcctggatgatccccaactaaacgttcccggaaatgcaggtctcaaggatcaaatcatggccc tgcgatgggtgcaacaaaacatcgaagcattcggcggtgattccaacaatattacactctttggcgaaagtgccggcggagcctc gacccacttccttgcactaagtccccaaactgaaggtcttatccacaaagctatcgttatgtcgggcagtgttttgtgcccctggacg caaccaccgagaaataattgggcttataggctggcccaaaaattgggatacaccggtgacaataaggacaaggcgatctttgagt ttctgcgatcaatgagtggcggggagattgtcaaggccaccgcaacagttctcagcaacgatgaaaagcatcatcggatccttttc gccttcggacctgtcgtagaaccatatactaccgagcacactgtggtcgctaaacaaccgcatgaactgatgcagaatagctgga gtcacaggatacccatgatgtttggaggcacgagcttcgagggattgctattctatccagaggtttcaaggcggccagcaaccctc gatgaggtgggtaactgcaagaatctgctaccgagcgatctcggtcttaacctagatcccaaactgcgtgagaactacggcttgca actgaagaaggcgtatttcggcgacgaaccctgtaaccaggcaaacatgatgaagtttctcgagctatgctcatatcgagagttctg gcaccctatatacagggcagctttgaaccgtgtccggcaatccagcgcacccacgtatctgtatcgattcgatcacgattccaaact gtgcaacgccattaggattgtaclltgcggccatcagatgcgaggtgtttgtcatggtgacgatctgtgctatattttccacagcatgtt gtcgcatcaatccgctcccgattctccggaacacaaggttataaccggaatggtcgacgtttggacgagtttcgcagcccacgga gatcccaactgcgaaagtataaaatcactcaagtttgcacccatcgaaaacgtaaccaactttaagtgtctcaatattggggatcagt ttgaagtcatggcgcttccagaattgcagaaaatcgaacctgtgtggaatagtttctacgccccaaacaaactgtag Drosophila Gene Hit TBLASTN with ORFl : alpha esterase (aE10) gene (U51054) Human Homologue TBLASTN with ORFl and BLASTX with U51054: bile salt- dependent lipase (S 79774) Annotated Drosophila genome genomic segment AE003671 Annotated Drosophila genome Complete gene candidate CGI 131 - alpha esterase 10 Human homologue of Complete gene candidate 4e-48 4557239 ref|NP_000656.1 |pACHE| acetylcholinesterase (YT blood group) precursor >gi|113037|s Putative function alpha esterase Confirmation by RNAi Only wild type profiles observed CATEGORY 5: SMALL IMAGINAL DISCS (BLOCK TO PROLIFERATION) Example 54 (Category 5) Line ID 113/20 Category 2nd chromosome, small imaginal discs Reversion R Map Position 50D/E Rescue ID EcoRl Rescue Sequence 1 CTGAGGCNCTTTGCCAATATGTGTATATTGGGCGGGGNACATGCGTNAATCGG TTAAAGCCGCTACTTACATTCTGTTCTTTGCATCTCCCCCATCCACAGCTATAA AGCAAGATGAGCTACGCCGCTGATGTGCTGAACTCGGCCCATTTGGGAGCTCC ATGGTGGTGGCGACGCCGAGTTGCGTCGTCCATTCGATCCCACGGNCCATGAT TTGGATGCATCCTTCCGCCTTACACGCTTCGCANATCTAAAGGGGCGCGGCTG CAAAGTGCCCGCAAGGAAGTNGCTCCCCCACCT Rescue ID BamHl Rescue Sequence 2 CCACCTGGTACCACAGCGCTCANACGTGTATGTACACGGATTTTCTGCCGCGT GTGTGTAGCGCGGCCCGTGATTGGCTGCAGTCGCGATGGCGGCTAAAACGGG CGAAGTCAGTATTTCTCCCTGTCGACGANGCGAGCAACGTGAACAATGCCCAC TCATTTCAATTGCAAAATGCCAAAAAGTGCGCGCTTTGAATTGGCCATTTGGT TCGTTGCGTTCGTTTGTCTTTTGGTACTTACGTTTGCTTGTGCGATTGTACAAA GATAATTGTAGAGTAACGTTAGCAAATTATATTTATTTTGCGCCTGGTTTTTGC TTTTCCAACGANCGAGATGTCACAACAGGGTTGTATTANCGTGTGCGGCTGAT TCGATATTTGGGATGCCGATTGTCTGAAGCGANGGTTCAACGGGGCTGCCAAC TCCCCCGAAAATCTATCNATGGTATTGTGCGCCAAGGGTAAAATAAATAAAAA TATGTTAAAACCGCGGAATAAATGGGGGAACCGAAGTGGAAACTGTGGTTCA CAGTGCTCTGACTTTCGGGAGCAGTTAATATAGTTGGCATTAATTCAATTAGA GCTCCAAAGTGCTGGTCACAAAGAACGCACAAGAACGGGCCATGAAAAACCT GTTGCGCCAGCAGAACGAAAAGTAAAAATTAGAAGAAACCAT Genomic hit, Accession No. CSC:AC017131 Drosophila Gene Hit rescue sequence: selenophosphate synthetase (ptufl) (U91994) Human Homologue BLASTX with U91994: SELENIDE, WATER DIKTNASE 1 (SELENOPHOSPHATE SYNTHETASE 1) (SELENIUM DONOR PROTEIN 1) (P49903) Drosophila EST LD46437 (AI514756 similar by BLASTN to U91994 selenophosphate synthetase (ptufl) gene) Annotated Drosophila genome genomic segment AE003815 Annotated Drosophila genome Complete gene candidate CG8553 selD selenophosphate synthetase Human homologue of Complete gene candidate 1711372 P49903 SELD_HUMAN SELENIDE,WATER DIKINASE (SELENOPHOSPHATE SYNTHETASE (le-159 ) Putative function selenophosphate synthetase Confirmation by RNAi Only wild type profiles were observed Example 55 (Category 5) Line ID 121/1 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 60B Rescue ID BamHl Rescue Sequence TCCTGTGCACTCATATTGATTTGCCTTGTCAAGTGGCTAAAGAAATATTAAATG TTTGTTATTTCTGTTGCTAGCGCTCCGACAGTCTGGCAGCACTGCTCGCTGTCG ATAGTTCAACTGAGTTGCTGTTTCATCGAACAGAGCTGCCAACTCTATTTTTGT AGCTGGCCAGCCAGGATTGCCAGAGTAAGGCCCTCAAATCAGCTGTTTTGTGT TTTGATTTTATTTTGAAAGTCCTAGTTTAAAATTATGCTTTCTCCGACAGATCA GCACAAATAATACTAATAAAGCTCACAATGCTAAGGTTGTGCCTTCCAACTCG AGCTGGATATGTGCGTAAGTAAGGACTTTACGTCTATAAAACTTGTTATGTAA AGTAAATGTTTGCCTATTGCGCAATTTCTCCAACGAAAAACCCAGAAAACCNA AACCCCCTTNAAANTTTGGAATATNCCCAATGAATGCAGCACCCGTGAAATCC GTAATGCCTTTGTCCAGCTCTCCAAATTGGTAAGTAACTCCAAGATCCAAAGG AGCCTCCTAAACCCTGCCCTTTCCACAGTACCACCCAGATGTTAAGAGCAATG CTGCGTGTCCGGAGCGCACAGCCCGATTTGTTCAGATCTCCGAGGCGTACAAG AACCTGATAAAGCCGGAACGGAAGGAAAAA Genomic hit, Accession No. CSC:AC020499 Drosophila Gene Hit rescue sequence: DnaJ60 gene for dnaJ-like protein (Yl 1900) Annotated Drosophila genome genomic segment AE003463 Annotated Drosophila genome Complete gene candidate CGI 2240 - DnaJ60 CG13570 - spaghetti ser/thr phosphatase Human homologue of Complete gene candidate CGI 2240- 4827026 ref|NP_005138.1|pTIDl| tumorous imaginal discs (Drosophila) homolog >gi|3372677 (AF061749) 7e- 08 CGI 116- 2495728 HYPOTHETICAL PROTEIN KIAA0258(aa) Putative function CGI 2240 : Chaperone involved in protein folding CG13570 : serine/threonine phosphatase Confirmation by RNAi CG12240: Marked reduction in GI and G2/M peaks indicating fewer cycling cells CGI 3570: Marked increase in GI peak Example 56 (Category 5) Line ID 127/2 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 57F Rescue ID EcoRl Rescue Sequence 1 GCCGGTGGGCCCACACTTGTNCGCCCGCGCATCGGCTGTCTGTGGGAGTGCGA NCGAGTCAGATAGTAGATCCGATGCGCTCTCCAGATACTTTTTGAACACTGAA GAAAACGCGCAGTTGTGGGTGAATTCAGCATCATCAGATTGAATCACACACA ATCCTAGTCGCCTCACGCGAAGAGAACTATGTCATGATCAGATATCGGTGTAT GCATTCTATATTATGTACTTCGAAATATGTAATTTATTAAGTTTTCGCTATACT TTTC ATTC AAATTGGC AAAAACC AATTCAAAGGTTTTC AATATTTTCGAAAAG CATTTTAGGCTTTCTATGTAACGTATGTTTTTCAAACAAAATATTAGTTTTTGA AACTTTATTATCGGATAAACAAATGTAAGCCAAATNACAACGTTNTATGATAC TCCCAAAGATCCGCNCTNTTAAAGTGGCCTAAAAATAGCTGACGCATTAANCC ATAGGCGCTTCGCTTCTCAAGATAAAACCTGGCGTGCTCAACTCAAGAAACAA ATATGTGGTTATATACATATATACATATATGGGGCATATAACCGATGTGTGAC GTGACATTGGCTCGTTCTATTCACATACTTAAACACTAAATGCAAACCTATCA AAAACCNACTACACTAAGCGAAAAACGGCAGANATAGTTAAGGAAAGTGGTC CA Rescue ID BamHl Rescue Sequence 2 CTTCTTTTCTCAAAAAACGTCGCTCGNGTCCCNCAATCGTTTTACAAACTTCGC TCGGAACGGACGTGTGCGCGCTCTGAAAGGAAAAAGTGAAAAAGTGTGTGAC AAAGTGCAAATAAGCCACAACGCGCATGTGAGAAATCAAATTTAATTGAGAA GCATCAAAAATTGTATACATATCGAGCGTATCCACATCGCTGTATGTGTGAGT GTGCCAGTGCTAGTGTGGTTTTCCCTTTTCGCCGTGGAAAATATGAAAACTGA ATGAAAAACTGAATCGCAGTCAGCCAGAGCCGAATTGGAAAAGAGTAACTCG CATTGGGGACACGAAGAGGTGTCTCGAAAAAGGTAAAATCTTTTACACAGAA ACGACGCCAGAAAGCGATTAGCGATTTNTGACTATGTGTGAGTGTGTAATTTC GGTCTACGGCTGTGTGTCTGCATTTTATTTAACNTTTTGTTTCCCNGTTNGNTC CACNGTAAAAATAGCTAAAAAAAAAGGGCAAGTACTCTTGGCGCGCTCTCCC TCTCTCTTTGTTGGTCGTGACTGCGACGTCACCGTTCACGTAGAATCGTTTTCA AGTGGCGTTTCTTTCTTTCTTTTTAATGTGCTGCTTCTTGCTTCTGCCTCTTCTTC TTGCCTTTGGCTATCTGCTTTGTTTTGAAATACGTCCATGTTATTCCAGTGTCTG TGCCAAATGTGTGCGANATGATCTCTACTT Genomic hit, Accession No. AC009732 Associated ORF Genscan ORFl predicted sequence >/tmp/aaaaafrla|GENSCAN_predicted_peptide_2|456_aa MQTKGPITDADCIRGMACRALAGLARSDRNRQINSKLPLFASGQLQTLMRDPILQ EKRAEHNIFQKYALELLERNSGKTKPLΝΝPLDPSLSΝMHKAΝNIAQTRIQYΝKQQ LYQLIFEHLESΝGLSQTAQMLQREVGLPLQTPTTRSFHQSPFDYKSLPSGSSSLSRΝ RLRSRMQDVΝAAIMGΝGDLΝRSFGEDSSPAGAGGSΝAGDGVSIPΝFSSLΝTTQTP IKIRRTDRSSVSRSIQKQAMEPGGMSVGLAEDGQLHPKRITLΝTIVTEYLTΝQHSL CΝΝPNTTCPQFDLYEPHKCPDPKPSRLLSSΝYΝLTSRHARTQAGFΝTSRFDRRYN HTHFSPWRSIRSADYEDLEFTCCDLAGKYIINGTQQGDGRNFΝMΝDGNEQFFSΝC HΝFSNDArKAΝRAGDLNITSSFWRTPTSILWSIADDEFKLKLRLPDVTYCEFSQTV QDRLLGTQΝEVY >/tmp/aaaaafrla|GEΝSCAΝ_predicted_CDS_2|1371_bp atgcagaccaaaggacccattacggatgcggactgtatacgtggaatggcctgtagggccttggcgggacttgctcgctccgatc gggtcaggcagatcgtcagcaagcttccactctttgccagcggacaactccagacgctgatgcgggatcccatactccaggaga agcgcgcggaacatgtaatcttccaaaagtacgcattggagttgctagaacgagtgtcgggtaagacgaaaccgctaaataatcc tttggatccatcgctgtccaacatgcacaaggccaatgtaatcgcccagacacgcatccagtataacaagcagcagctgtatcagc ttatcttcgagcacctggaaagcaacggtctctcccagacagcccaaatgctgcaacgggaggtgggtcttccgctacagactcc cactacgcgcagttttcatcaatcacctttcgactacaaaagtcttcccagtggtagtagctcgctgtctagaaatcgtctgcgaagc cgcatgcaagatgtgaacgcagcgataatgggcaatggagacttaaacagaagttttggtgaggactcctcgccggcaggagcc ggtggtagcaatgcgggagatggagtcagcataccaaattttagctcccttaacacaacgcagacgcccataaaaataaggagg acggatagaagttcagttagccgctctatccagaagcaggcaatggagcctggtggcatgtcagttggtcttgccgaagatggtca actgcatcccaagaggatcaccctaaataccatcgtaacggaatacctcaccaaccagcactcgctgtgcaataatccggtgaca acctgcccgcagtttgatttgtacgagccgcacaagtgtccagatccgaagcccagccgattgctaagctcgaactacaacctga ctagtcggcatgctcgaacccaagccggatttaataccagtcgctttgaccgtcgctatgtgcacacgcacttttcaccatggcgta gcattcgatcggcggactacgaggacctagagttcacctgttgcgatttggcgggtaaatacatcattgtgggcacgcagcaggg cgacggacgagtgttcaacatgaacgatggcgtggagcagttcttctccaactgtcacaactttagcgttgatgctattaaggctaat agagccggagacttggtcatcacatctagcttctggcgcacacccaccagcattctatggtctattgcggacgatgagttcaagcta aagttgcgacttcccgatgtcacgtactgtgagttcagtcaaacggtgcaggatcgtttgttgggcacccagaatgaggtatactaa corresponds to CGI 0082 Drosophila EST several including SD04293 (AI532704) Annotated Drosophila genome genomic segment AE003454 Annotated Drosophila genome Complete gene candidate CGI 0082 - novel protein with homology to enhancer Pi uptake Human homologue of Complete gene candidate 1665793 dbj|BAA13393| (D87452) Similar to S.cerevisiae YD9335.03c protein (S54640) [Homo sapiens] (2e-43) Putative function Putative phosphatase or enhancer of Pi uptake protein Confirmation by RNAi Reduced GI and G2/M peaks indicating fewer cycling cells Example 57 (Category 5) Line ID 131/8 Category 2nd chromosome, small imaginal discs Reversion R Map Position 60A Rescue ID BamHl Rescue Sequence 1 C ACGATTGCNGGCCC ATCGAAGTGTGGGTCTATCGAT ACTCGTGGGTAAATAA ACAAGTTCTGAACTGCGATTTCGGGGGTTTGAGGGGTCAATTGTCCCCTGTGT TGGAATGTGTTCCTAAATCTACACAAACACTCCCTAAGCTTATCCTAAACTTAT AAATATTGGTTGCTATTTAAACCCCATTTCACGGTTATCCAGCACGCCCCTGA ACTGTGACCCACATCCCCGATTTTAGTGACTAGTTTTATACTTATCGTGGTTGG CATTTGGTACACTACACTTTCTTATTCACCTAGATCGCCGACTCCGCGCACGGT CGCGCTCCCGTTCCCGCTCCCGATCTCGGCTGCGACTGCGGTCGCGATCCCGTT CCCGGTCGCGGCGACCGGCGCCTCCANATCCGGATCCCTAANCGGCANCNGT CNTGGTGGCAATCNNGGAATGTTCCGGGGNNCCNCTACCNCAGTGNAATCAC TGGTACGTCCCACCGCNAAACTCCGCCCANTGCGGTTGCCGGAACGGGTGGC ANTGCCAATGGGTCGCTGCAGAAGGTACCATCACAGCAATCGCTCACGGANC CCGAAGACTGCCTCTGCCGCCCGGCTGGGCCACTCATACACGCTACACGGTCG GAAATACTACATTGATCACAATGCGCATACCACGCACTGGAATCATCCGTTGG GAACGC Rescue ID EcoRl Rescue Sequence 2 AATTGATTTCCGGACATATAAACAGAATCCAGAACTCATCCGGCAGCAGGCTC AGTCAGGCCAGTAAATCCGAAAAGAGAGTAACCAGCAGGAAAAGAGAATCC ACGTAAATACAGAGAAAATGGCTCTACGCGTCCAATTCGAGAACAACGACGA CATCGGCGTATTCACTAAACTAACCAACACATACTGCCTGGTGGCCATCGGTG GATCCGAGACCTTCTACAGCGCCTTCGAGGCGGAGCTGGGCGACACCATCCCG GTGGTGCATGCGAATGTGGGCGGCTGCCGGATCATCGGCCGCCTCACCGTGGG CAACCGCAACGGCCTGCTGGTGCCCAACTCCACCACCGACGAAGAGCTGCAA CACCTGCGTTACANCCTGCCANAACCCCGGAAANATTTATCGTGTGGAAGAAC GCCTGTCCGCGCTGGGC AACGTTATCGCCTGCAATGATTATGTGGCCCTGGTG CACCCGGATCTGGACAAGGAGACCGAGGAGATCATCGCGGACGTGCTCAAAG TANANGTCTTCCGCCAGACCATTGCCGACAACTCACTGGTGGGCTCTTACGCC GTGCTGAGCAACCAGGGGGGCATGGTGCATCCCAAGACNAGCATTCAGGAAC AGGACAACTGTCGTCCCTGCTGCAGGTTCC Genomic hit, Accession No. CSC.AC020517 Associated ORF Genscan ORFl predicted sequences >22:13:05|GENSCAN_predicted_peptide_4|357_aa MALRNQFENNDDIGNFTKLTNTYCLNAIGGSETFYSAFEAELGDTIPVVHANVGG CRIIGRLTVGNRNGLLVPNSTTDEELQHLRNSLPDAVKIYRVEERLSALGNVIACN DYVALVHPDLDKETEEIIADVLKVEVFRQTIADNSLVGSYAVLSNQGGMVHPKTS IQDQDELSSLLQVPLVAGTVNRGSEVLAAGMVVNDWLSFVGMNTTATEISVIESV FKLNQAQPATVTTKLRAALIEDISRSRVAGGGGGGGGGGSSGGNSSSGPSTSRRTT RNNAAATAADRPKINEADLEGKSPEEVEMLKTMGFCTFDTTKNRKVEGNDVGEV HNILKRKYRQYMNRKGGFNRPLDFVA >22: 13 :05|GENSCAN_predicted_CDS_4] 1074_bp atggctctacgcgtccaattcgagaacaacgacgacatcggcgtcttcactaaactaaccaacacatactgcctggtggccatcgg tggatccgagaccttctacagcgccttcgaggcggagctgggcgacaccatcccggtggtgcatgcgaatgtgggcggctgcc ggatcatcggccgcctcaccgtgggcaaccgcaacggcctgctggtgcccaactccaccaccgacgaggagctgcaacacct gcgtaacagcctgccagacgccgtgaagatttatcgtgtggaggagcgcctgtccgcgctgggcaacgttatcgcctgcaatgat tatgtggccctggtgcacccggatctggacaaggagaccgaggagatcatcgcggacgtgctcaaagtagaggtcttccgccag accattgccgacaactcactggtgggctcttacgccgtgctgagcaaccagggcggcatggtgcatcccaagacgagcattcag gaccaggacgaactgtcgtccctgctgcaggttcccctcgtggccggaacagtgaaccggggcagcgaagtactcgccgccg gcatggtcgtcaacgactggctctccttcgtgggcatgaacaccacggccacagagatctccgtgatcgagagcgtcttcaagctt aaccaggcacagcccgccacagtgacgaccaagctgcgtgcggccctcatcgaggacatatcgcggtcgagggtcgccgga ggaggaggaggaggaggcggcggcggaagcagcggcggcaacagcagctccggaccatcgacgtcgcgaaggacgacg aggaacaatgcggcggccacagctgccgaccggcccaagatcaacgaggcggacctggagggtaaatcgccggaagaggt cgagatgctgaagacaatgggattctgcacgttcgacaccaccaagaacaggaaggtcgagggcaacgatgtcggagaagtgc atgtaatcctcaagcgaaagtaccgccagtacatgaatcgcaagggtggcttcaaccggccgctcgatttcgtggcatag Drosophila Gene Hit rescue sequence and TBLASTN with ORFl : b(2)gcn (EUKARYOTIC TRANSLATION INITIATION FACTOR 6 )((X97641) Human Homologue BLASTX with X97641 : integrin beta 4 binding protein (HUMAN EUKARYOTIC TRANSLATION INITIATION FACTOR 6) (NP_002203.1) Drosophila EST GH08760 (All 09537 similar by BLASTN to X97641 "D.melanogaster b(2)gcn gene." ) Annotated Drosophila genome genomic segment AE003462 Annotated Drosophila genome Complete gene candidate CGI 7611 - bcgn benign gonadal neoplasia homology to Eif6 translation factor Human homologue of Complete gene candidate 6016331 EUKARYOTIC TRANSLATION INITIATION FACTOR 6 (EIF-6)(aa) and 4504771 |ref|NP_002203.1|pITGB4BP| integrin beta 4 binding protein(aa) Putative function eukaryotic translation initiation factor 6 (eif-6)(aa) Confirmation by RNAi Slightly reduced GI and increased G2/M indicating block in G2/M Example 58 (Category 5) Line ID 135/25 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 24A Rescue ID EcoRl Rescue Sequence ATAACATGGGCNCTGGTTTTTAAGTNAAGCTCTANTNATTGGCCCCC ATTCTTA NNCTCTCTCGCTCTCTTCTCGCTCTTTCGCCTGCTCTCTCGCCTGATTATTCTGC TTGGTCGGCTGATGGTTTTTNGTTTTNATCTGGTGTATTTTCTGCGTAGTTTATG ACAAACCGGCTGGTTCTTGTTGTTATTGCCGTATTCTAATATATTCCCCTATTG TTCTTATTTTTGTTGCAGCCTGCACACCTCGGAGGTTCTAGATGATAAGGGGTG TAGCGATGGTGGGGGGCTGTCTTGANGGGCTTCTCGCCTTGAGCTCTTGTTTAT CTTTGGTCATTTGTTATTGTTTAATGCACGGCAATATTATTGGTAAACAAGTTA GCCAACAGCACTAAACGCCAATCGCATTCTTTTCTAAAAACCAAGTCTATTGT CGATCTTGCTAGGGAAATGATGATGACTCAGGTGCAATTGGGATCTTATCTAT GGCTGTCTGGGAATCAAGAAGTGTTCCCGCAGAATTCGTGAANTACTGCCGCT CTCTCCATGGGGCCATTATTTGCACTCGTTTTNCGCGAAATACCATNAATTAGC ATAAAGACACGTCGCCGGCAATCGTGACGTAGGCTATNAATGCCTTCTATGCA TGTGCNAACTCGCGGAAGCATAGCAATTTGAAGGAACAATATTTCANTGCAG GTTTTAATGGGCTAAAAAA Genomic hit, Accession No. CSC:AC014199 Associated ORF Genscan ORFl predicted sequences >20:54:54|GENSCAN_predicted_peρtide_3|117_aa MSASPTARQAITQVMPMITRKNNISDPIQMPEVYSSTPGGTLYSTTPGGTKLIYER AFMKΝLRGSPLSQTPPSΝNPSCLLRGTPRTPFRKCVPVPTELIKQTKSLKIEDQEQF QLDL >20:54:54|GEΝSCAΝ_predicted_CDS_3|354_bp atgtccgcttcacccaccgcccgtcaagccatcacccaggttatgcccatgatcaccaggaaggttgtcatctcggatccgatcca gatgcccgaggtgtactcctcgacgcccggcggaaccctctactccaccactcctggaggcaccaaacttatctacgagcgggc tttcatgaagaatctccgtggctccccattgagccaaactccgccgtccaacgtgcccagttgcttgctgaggggaactccgcgta ctcccttccgcaagtgcgtgcccgtccccacggaactgatcaagcagaccaagtcgctgaagattgaggaccaggaacagttcc aactggatctgtag Drosophila Gene Hit TBLASTN with ORFl : BcDNA.HL08053 mRNA (AF132557 ) Human Homologue TBLASTN with ORFl and BLASTX with AF132557: eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2) (L36056) Annotated Drosophila genome genomic segment AE003579 Annotated Drosophila genome Complete gene candidate CG8846 - phasl translation initiation factor 4E binding protein 2 Human homologue of Complete gene candidate CG8846 - 4758260 ref|NP_004087.1|pEIF4EBP2| eukaryotic translation initiation factor 4E binding protein 2 (4e-16) Putative function EIF4E translation factor binding protein Confirmation by RNAi Slight reduction in GI and G2/M indicating fewer cycling cells Example 59 (Category 5) Line ID 141/12 Category 2nd chromosome, small imaginal discs Reversion R Map Position 21A/B Rescue ID BamHl Rescue Sequence GGCTCTTTTCC AAANAGGC AGTTTCTTGNCCC ATTTCTTGGATTGCTTTGTAGT GAACTNAATCGTTTTGTTGGTTCCTCTGTCGTCCAGTCTTGTGAAAATTTCGTG ATAATAATGCCTGGATAAATANTTAAGCATTTGGAAAACGGGGGAAAAAGGG CTAAGTTGTGTGAAGGAAACAATTGAAGTGACCCTTTGTNTATAAACATTCCA CGACGTGTTTCGAAAACAAACAAAGATATGCGGAAACAAAGTGTTAATAAAA GAGCNAAAAATAGAGAGAGAGTGTCGCGATAAGCGGTTGAGCGAGATAGAG AAAATTGTTGATTAAAATGTGTGTCNAAATAAAACATCAAGCCGCTTGAACGA ACAGTCAGTTAGTTGCTTCTGATAATAACCATGGGAAGCGGCNCGTGTGCTTC GCTCCTCGTTACTTATAAAATATTTAAACGTTTGCATTCTTCNTATTTCCGAAT TTTTGCNCCCCTGAANCAACTTNGTTAAACTGCAAATAGCAATGCAAACAAAC GAATAGAAACTGAAATCGACAACNACATGTGAAATTCACAAATCAAATCGCA ATTGTCATCCCAAAGATATAGAACAAGCTATAGGGAAGATANAGAATGTAAG TGCCAAACTAAAATAAACAAACAAGAATAACATTTCCACAGGTGTTTTGCATT TCAAATGCATATTTCCGTGGCGGNTACAAATCTTTTCAAAACCG Genomic hit, Accession No. CSC:AC017815 Associated ORF Genscan ORFl Predicted sequences >17:48:30|GENSCAN_predicted_peptide_2|554_aa MSNKKMFNRTTSVSPGQLHYYHTDFYYSMPDLHKTRKMHGVKRVLVFCLMIVIL PAILIIMPLHLRKTVFADVIYPMAESDIIEIRAGISSIFCSKHTLRMNSNFNAFQLRNK PEIATNRKHIRLKKSMTLPDDTLEYWGFFLLKGAKVRVKFCSRYDGSRILIIHGHR ELNLCGLTDHNKNKLGANYAKGHEQVQVFFEDNVEITEEKGNQDVLMEHENHG GEDLTEDIPQPQVNIPVKQNNSIQPKLIRKKLKKGTIHHGEHDMHAITDLQGSHHT EHILNHHDHSSNSPAHHHNSTAHHREHSSNITNEETSRNHIRNEDEDPDQNSSKTH YS AESPPHRERLKRHNRVAHRNQKRQDL YDTL YKRSKRENV YDRKTIHGGNAIN FTETDESNSVSSFETGLFQCFNGMILLQEFFRPKNECSNPHIMDTSPNKSSMVVHN VIEDGYYYYIFYSDNDHVQNEIHAIFDIYKPTYQYSNMSESQSCLNTTNCTFNISFL SDEΓVVVEVPTRDGIEHEEDDITNLISTCHPRSEIYAIFPITVLVLILCCSFL >17:48:30|GENSCAN_predicted_CDS_2|1665_bp atgtccaacaaaaagatgttcaacaggactacgtcagtaagtcctggacagttgcattattatcacacggatttctattactcaatgcc gga1fr:gcataaaacccgcaaaatgcacggcgtgaaaagggtgctggttttctgcctgatgattgtgatactgccggccattcttatc attatgccgctgcatttgcgaaagacggtgtttgccgacgtcatctatcccatggcggagtccgatatcattgagattcgggcagga atctcgtcgatct ttgctcgaaacacacactgcgtatgaactccaatttcaacgcttttcaactacgtaataagccggaaattgcgac gaatcgcaagcacattaggctgaagaagtcgatgacattgccggatgatacgcttgaatactggggcttcttcttgctgaaaggtgc caaggtgcgagtgaaattctgctcccgctacgatggatcccgcatcctgatcatccatggtcacagggagcttaatctttgcggtct gaccgatcacaataagaataagttgggcgccaattatgccaaaggtcacgaacaggtgcaggtgttcttcgaagacaatgtggag atcacggaagagaagggcaaccaggatgtgctaatggagcacgagaaccacggcggagaggatttgactgaggatattccaca gccgcaggtgaacatacctgtcaagcaaaacaattctatacagcctaagttaattaggaaaaaactgaaaaagggcacaattcatc atggcgaacatgatatgcatgctataacagatttgcaaggatcacaccatacggaacacatattgaatcaccatgatcacagctcta attctccagcacatcatcacaatagtactgcccatcatcgggagcacagttcgaatatcacaaacgaagaaactagtcgtaatcaca tacgaaatgaagatgaagatccagatcagaattcaagtaagacccattatagtgcggaaagtccgcctcaccgggaacgtctcaa aagacacaatagggtagcccataggaatcagaagagacaggatctttacgatacgctttataaaagatcaaagagggagaatgtc tacgatagaaagacgatccatggaggaaatgctataaattttacggaaacggacgagtcgaattcggtgtccagctttgagacagg actatttcagtgtttcaatggaatgatcctgctgcaggagttcttcaggccaaaaaatgaatgctcaaatccgcacataatggacactt cgcccaacaagagttccatggtggtgcacaacgtcatcgaggatgggtactactattatatattctacagcgacaatgatcacgttc aaaacgagatccacgccatattcgatatttacaagccgacgtatcagtactcaaacatgagcgagtcacaaagctgtctgaatacc acaaattgcacattcaacatcagtttcctttcggatgagattgtggtggtggaggttccaacacgggatggtatcgagcacgagga ggacgatataaccaatctgatctccacctgtcatccgcgcagcgagatatacgccatctttcccattacggtgctggtgctgatccttt gctgctccttcctgtag conesponds to CG9524 Annotated Drosophila genome genomic segment AE003623 Annotated Drosophila genome Complete gene candidate CG9524 - novel His-rich protein Human homologue of Complete gene candidate none Putative function No homologies which indicate function Confirmation by RNAi Reduced GI and G2/M peaks indicating fewer cycling cells Example 60 (Category 5) Line ID 146/2 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 26B Rescue ID EcoRl Rescue Sequence TTTNATCCAAACTGAGANACTNTTGGCCCC AAAACTGAAAACTCGGACTCGGG CGCGTAAGGGAGTCGGTCNTCGGGAGTCGGTCGTCTTTTGTTGATCTTGAGAC TGAAATTCCAATTGTTGATTTATCTCTCGGCTGCTGCGCCGCGGCTGCGCTGCT GCAGCGCAGTCCCACTCCGATTTGACCAGCGACCAAGTTTATAAAACTTTGAG CCAAAATGCAGCGGCGCACAGTTGTTACCAAAACGTTGCACGCGTCGTGGCCC TCATCAAAACAAAAAAAAAAATATAAGCGAAAATGAAAACGAAATTCGGTTA ACGTCAACAGAAGCTGACAAAAGGCAGAAAAGACCGAAACAAGTTGCAGGG CCAGAGTAAGCCAAGTTAAATGCGAAAGAGAAGCAAGAGNCAAGAAGAAAN AATGGGCACTACATACATATATTATAGCCAGCTAATCTGTTGTGCAGTGCGTT TTATCAGCCNNCGAAAAGAAAACGAAAACGAAAAGTCGGTCCAAGTTCGGAC TCAAAATCCAAACAGAAGAGACTCCATNCCATCAGAGACACGCGGATCTCAT CTCGGTAATGTCTCAATAAAAGTAATCTTAACTGCCGCCGGGAATGTTGGAAA AAGTGAAAATTGAAGCGCTTAACGTGTTTCGAAATACGATACATGAGAAGTCC CAAAAAAAAAAA Genomic hit, Accession No. CSC: AGO 19865 Drosophila EST GH19286 (AI388389) Annotated Drosophila genome genomic segment AE003481 Annotated Drosophila genome Complete gene candidate CGI 1353 - novel with weak homology to sugar acetylase? CG7525 - tie receptor protein tyrosine kinase. Human homologue of Complete gene candidate CG7525- 4e-23 4557869 ref|NP_000450.1 |pTEK| TEK tyrosine kinase, endothelial >gi|464868|sp|Q02763|TIE2_ Putative function Sugar acetylase and receptor tyrosine kinase Confirmation by RNAi Both gave a reduction in GI and increase in G2/M peaks indicating arrest in G2/M Example 61 (Category 5) Line ID 155/13 Category 2nd chromosome, small imaginal discs Reversion R Map Position 21B Rescue ID BamHl Rescue Sequence 1 GNTTTAGTCCNCTTTTGANAGGGNCTTGGNGNCTTAAANAANNAAAAAAGGG GNCCCGGCNCCCAGCAAANAGNNTAAAACTTGAATGGTTTAATTCGAAAATC TTTTAGAAATGTCGCCTAATACCTTATCGGTATAGAGTTCACCTCGTCTCCTAA TCCATATTTTAAGATATCAATATCTATTAACAATTTTTATCGTATGATTAGAAA TTCGCATTGTTTTATTATTTCGACCTTTGGGCTTTACATCGACAGCTACTCTCTA TCCAGACAGGAGACTGGGAGAGAGAGCACGATGCTGTCTGAAAGCATGAATG ATGGATGCTGTGCCTATGTGCGATATGCACGTTGCCTGAGCTAAAACGAAACG AGATTATTAATCTATCCGCAAGATTCAGATGCTGATTCCACATGAGTGAGCGA GTCCGTGAGTGGATATTGCTCTCTCCGAAATGCATGCATGAGTGAGCAGGGGG GCTTCAATCGCNCTNTCGATNTGCGACAGNGACATNTTTTTATCTTCGACNAT GCNCTCNCTCCCTCCCACAGAAATCTTGCGCTNGNTCTCCGANNTNGGGNTNG ANGGCNCTCTTCTCTNTCCTTAAATTGGGANTTNNCTTTTTTCNAANAAGGGN NAGA Rescue ID EcoRl Rescue Sequence 2 AATCNTTTTNTCCATTNGGCGNCTTNCTCAAAACATATTCACATTTGGNCCCAA CGGCGTANGACTTNATCTCACGATTGTTTGGTTTCCTACTCTCCCGCGCTCCCT CTCTTCTGAGTCTCTTTCTGGCTGATTCGCATTCGATTTTAGCCGCTGCCATCG CCGTTGTTTTGCCTACCTATGTGTGTGTGTGAGGAGTGTGTCTTGTATTTCAGT CCGCAATGCGCTCCGCTC ATTATTTGTTTGANCGCCGCGGTGTAAAGTTGTAA AAAGTCCAAGTGCTCGTGGAAACTCGATGCAAGACGGGGAAAACGAAACGCG ATAAATCGTGAGAAAAGAGAGTGCGCTAAAGGAAGAGGGAGTGATAATCAN ACGAAATGGAATAATGTNTTTGCAGAGGCNACAACAACAATGCAAATAGTTG TCATTGAGGCGCAATGAATGATAATTAGTGCTTANTTGAAATCATAATCNTGA AGAAAGCGTAAAGCTCGATTNTGGC AATNTATTCTTGATTACCANTGAGTCTG TGATATTGCCGTGTGTNCCGAAAATGGANGTTATNAAACCCATGGACTTCAGC ACCTTCTCCGCGTTCTGCGAACATCTTAACAAATCTCCACAAAATTGCAGCAA CAACTGCANCGACGGTACCGCCAACTATAANCAATGGAAAANGCATTATTTG GAGGTAANAGCNAAAAATACCAATNTTTCCAATGCGAAATTGCNAGCNTGG Genomic hit, Accession No. AC004274 Annotated Drosophila genome genomic segment AE003590 Annotated Drosophila genome Complete gene candidate CGI 3693 - novel Human homologue of Complete gene candidate 6e-05 4507659 translocated promoter region (to activated MET oncogene) >gi|1730009|sp|P12270|TPR_ HUMAN POOR MATCH Putative function No homologies to indicate function Confirmation by RNAi Only wild type profiles observed Example 62 (Category 5) Line ID 162/24 Category 2nd chromosome, small imaginal discs Reversion R Map Position 55C Rescue ID EcoRl Rescue Sequence 1 TTTTNTTTCANGGNTCTTTGCNC ATAAAANACACGNGCCCTCNTGTCC ATTC AC ATTTTACTTGGAGTCGGTAACGTTGAGTTCCGCGTCCGTGCGTTCTGCCTTCCA ATACAAAGTCTGGTGTGAATCTACCAAGCATTCCAGTGNGAAAATCAACTCAC ATTGCTCGGTGATCCNTGCGGCGGTATNATCGCACCCGGAATTGCATAAGTTG CGGNGAGCGGAAAGAGAGTGCACGGATTTNCNGTTATCNAAGGGCCGGCANC NGTGGGGCGGCGACGGNAGAGCACGCAGAANAANAATANANTGNNGTGGCG AATTNAAAAATANNATNAAAGAAAATTCGGGCCGCTAATTTTTCTTCAAATTT GTGTGCGGTCGGCGAAAAACAACGTGTTTTTCNATGGTTGATAATACACACGG ACGGNNCACTCGCGCTCACCCACATAGTCACNAAAGTCGGCGACGTCGACGA CCCNCACNCTCACATANGGACNTTTAATCCCGTNCATNCGTGTAGCGTNCNTA TTTAACCNTNTCTGTCCATCGGAACGCNCGCNTTCTCGCCTTCNTTCTNCTTTA CTTTAATTTCCTATTTNNAAGGGGNAGNCCNATCTTTTTNCCTNTCNNTGCCNT TTAANNTCATCCACANCCTCNCTTTNTCNTTCCTCCNCCTTNTNTTCTTTTCNTC TTNCTTNTGNCCTTGCCTCGTTCTTTCTCTTCNTCTCCTTNCCCTTCTCCTCCTTT TTTCTCCTTCCCCCC Rescue ID BamHl Rescue Sequence 2 AAGNCNCCTTGGCCGNNTTNAACGGNAANTAANCCGGGNCCNCGGGNCNCGA TAATCAGGTCNANCCTTGTGCCTACCACCACCAAATTGAAAAAGAGCNAAGA TTCTCTAAGGCAAAAAACTCCCCAATCTGTGGAATTTCCGGAAGCGAGAGCAC ATTCAAAGCTACCAGTTATCAGCGAGCAGCATGTCTAAGCTCAGGAACCTGTT GCCCACAATCTTTGGCGGGAAGGAGGCACAGAATCCGACACCCGTCGAGGGA CGCCTGGAATAGGACGCAGCTCCCGTGGACGACAACGAACCNGATTACTACT ACTGCGGAGCCATGGCGCTGCCCTCCACCGCTGGCACGCCCACAGCCTCCTCG GATCTGACCGAATCCGTGCTGCGCGAGCTCAGCGACCCAAACTACAATTCAAT GGATGTGGTGCTTTCNNCCTNTTTTCCGGGCACTCTCAGTAACGTCCAGACAA ACAACACCATGAACGTTCACNGCGCCCAGCAACAGGTGGTCATGAACTTCTCG AATGCCAATAATCTGCACTTCGGCTCCGTCTTCAACTTCAACCAAAACTTGAG CGCCTGCNGCTCNCGAANGGGTTTCACCNGTTCGCANAAGAATCGGTCGCCTC TCCANACNGT Genomic hit, Accession No. CSC:AC012981 Associated ORF Genscan ORFs: ORF2 predicted sequences >18:26:17|GENSCAN_predicted_peptide_7|1320_aa MEETNNATTIEQQPIALINGQEQNANEQQPSSPTSNATPTSTTSGGTGNATPAFSY DDLFPALPANTSAQSQSGASGSTLARNTSSQKTHINHVPCKERKSTESEKFGEGES KRICQQITKETGAQIEIASRQVTVPREHFRVILGKGGQRLREIERVTATRTΝIPSQSD ESEFITIAGTKEGIAQAEQEIRQLSAEQYKKSSDRITVPKVYHPFIVGPYSEΝLΝKLQ EETGARTΝVPPQQVQKDEIVISGEKDAVAAAKAKVEAIYKDMEKKCSTVSVEVAK PKHRYVIGPKGSTIAEILQLTGVSVEMPPΝDSPSETITLRGPQVALGΝALTVVYQK SΝSVKSVEIΝAAHWIHKYVFGRKGAΝMKQLEEDCPΝVΝVΝCLEDKIKLEGDPEΝ NDRANAYLSEIIKΝYΕEΝFTFENMTNΝPSNYKHIIGKAGAΝNΝRLKDELKNΝRΝIE EREGQΝΝIRIEGPKEGVRQAQLELQEKIDKLEΝEKSKDVIIDRRLHRSIIGAKGEKI REVKDRYRQNTITIPTPQEΝTDINKLRGPKEDNDKCHKDLLKLNKEIQESSHIIENPI FKQFHKFNIGKGGAΝIKKIRDETQTKIDLPAEGDTΝENINITGKKEΝNLEAKERIQK IQΝELSDINTEENQIPPKNYΝSIIGTGGKLISSIMEECGGNSIKFPΝSDSKSDKNTIRG PKDDVEKAKVQLLELAΝERQLASFTAEVRAKQQHHKFLIGKΝGASIRKIRDATGA RIIFPSΝEDTDKEVITIIGKEESVKKAREQLEAIIKECDEVTEGEVSVDPKHHKHFVA KRGFILHRISEECGGVMISFPRVGΓΝSDKVTIKGAKDCIEAARQRIEEIVADLEAQTT IEVVIPQRHHRTIMGARGFKVQQVTFEFDVQIKFPDRDATEPVEGLTΝGGSGEΝG GEΝEGQEGEQEVEKEAEQEPVRQCDVIRITGRIEKCEAAKQALLDLIPIEEELSVPF DLHRTIIGPRGAΝVRQFMSKHDVHVELPPSELKSDVIKVCGTPARVAEAREALVK MIEDYEADRADRELRSFVLQVDVDTEFHSKLIGRHGAVIΝKLRADHDVIISLPKRD EPΝDRIISITGYQAΝAEAARDAILEIVGDPETLHREVIEIDKRIHPHLIGQRRRTIRKII EDΝKVΝIKFSADDDΝPΝSIFISGKIEDVEΝVKELLFGMAEDYERDYLDΝVAIAPPTI GAFLTGFWIRCRRCQRERIRHQRRTVGEAKAGQKPDCAQHSVAGGLPALRCWRG SGGLHAYHLRVGPQKLSASGRVSRSPAVAAILQVGVRRGSELEMDQELEQKLELE LELDYRAMSGRAAAVVRTSL >18:26:17|GEΝSCAΝ_predicted_CDS_7|3963_bp atggaggaaactaacaacgcaactaccatcgagcagcagcccatcgctctcattaatggccaagagcaggtggccaacgagca gcaaccatcctcgccaacttcagtggccacgcccactagtaccactagcggcggaactggcaatgccacacccgcctttagctac gacgacctgtttccggccctgccggccaacacttcggctcaatcgcaatccggagcttccggttcgactctagctcgtgtgacgag ttcccaaaaaactcatattgtgcatgttccctgcaaggagcgcaagtccacggagtcggagaagtttggcgaaggcgagtcgaag cgtatttgccagcagatcaccaaggagaccggagcccagatcgagattgccagtcggcaggtgaccgttcctcgggagcacttc cgcgtcatcctcggcaagggtggccaacggctgcgcgaaatcgagcgtgttactgcgacgcgcatcaacatccccagccagag cgatgagagcgagtttatcacgattgccggaaccaaggagggtattgcccaggccgagcaggagatccgtcagctgtcagccg agcagtacaagaagtcatcggaccgcatcacggtgcccaaagtttaccatcccttcatcgtgggcccctacagcgagaacctaaa taagctgcaggaggagaccggcgctaggatcaacgtgccgccgcagcaggttcagaaggacgagatcgtcatctcgggcgag aaggacgcggtcgcagcggcaaaggccaaggtggaggccatttacaaggatatggaaaagaagtgctctaccgtcagtgtgga ggtagctaagcccaagcaccgatatgtcattggtccgaagggctccaccatcgccgagattctgcagttgaccggtgtgtctgtag agatgcctcccaatgactccccctcggagacgatcactttgcgtgggccgcaagtggctttgggaaatgccctaaccgttgtctac caaaagtccaactcggtcaagtctgtggagatcaatgcggcacattggatccacaagtatgtgttcggtcgcaagggggccaaca tgaagcagctggaggaggactgccccaacgtgaacgtgaattgcctggaagacaagatcaagctggagggagatcccgagaa cgttgacagggctgtagcctacttgtccgaaatcatcaaaaactacgaggagaacttcacattcgaggtgatgacggttaatccttc gtactacaagcacatcatcggtaaggctggagccaacgtaaatcgcctgaaggatgaactgaaggttaacattaacatcgaagag cgcgagggccagaacaacatccgtatcgagggtcccaaggagggagtacggcaggcgcagcttgaattacaagaaaaaatcg acaaactggaaaacgaaaaatcgaaggatgtgatcatcgaccgccgtctccatcgttctattatcggagctaagggcgagaagatt cgcgaggtgaaggaccgctaccgccaggttacaatcacgatacctacgccccaggagaataccgatattgtgaagctgcgcgg acccaaggaggatgtggacaagtgtcacaaggatctgcttaagctggtcaaggagattcaggaatcgtcgcacattatcgaggtg cccatctttaagcagttccacaagttcgttattggcaagggcggcgctaacatcaaaaagatccgcgatgagacccagactaaaat tgatctgcctgccgagggtgacaccaacgaagtgatcgtaatcaccggcaagaaggagaacgtgctcgaggcgaaggaacgta tccaaaagattcaaaacgagctttccgacattgtcaccgaggaggtgcaaatcccgcccaagtactacaactcaatcatcggcact ggcggcaaactcatctcctcgatcatggaggaatgcggtggtgtttctatcaagttccccaacagcgactccaagagcgataaggt cactattcgcggtcccaaggacgatgtggagaaggctaaggttcagctattggagctggccaacgaacggcagctggcttccttt accgccgaggtgcgcgccaagcagcaacaccacaagttcctgatcggcaagaatggcgcttctatccgtaagattcgcgatgcc actggtgcccgcattatcttcccttcaaacgaggacactgacaaggaagtgatcaccatcattggcaaggaagaaagcgtaaaga aggcccgtgagcagctggaggcgatcatcaaggagtgcgacgaagtaaccgaaggtgaggtttctgtcgatcccaagcaccac aagcacttcgtggccaagcgtggcttcatcctgcaccgcatttcggaggagtgcggcggcgtgatgatctccttcccccgtgtcgg catcaactccgataaggtgacgatcaagggtgccaaggactgcattgaagcggcccgccagcgcatcgaggagatcgtcgccg atctggaagcgcagaccaccatcgaggtggtgattccacagcgtcatcatcgcaccatcatgggcgcacgtggatttaaggttca acaagtcacctttgagttcgatgtgcagatcaagttccctgatcgtgatgccaccgaacccgtcgagggtctgaccaacggaggc agcggagagaatggaggcgagaatgaaggccaggagggagagcaggaagtagagaaggaagccgaacaggagccggttc gtcagtgcgatgttatccgaatcacgggcagaattgagaagtgcgaggccgccaaacaggctctgcttgatcttatccccatcgag gaggagttgtcggtgcctttcgacctccatcgtaccatcatcggaccgcgcggtgccaatgtgcgtcagtttatgtccaagcacgat gtgcacgtagagctgccacctagtgagcttaagtcggatgtgatcaaggtctgcggtacgcccgctcgcgtcgccgaggcccgc gaagcgctggtgaaaatgattgaggattacgaggctgatagggccgatcgtgagctgcgctcctttgttctccaggtggacgtaga tacggaattccattcgaagctcattggtcgtcatggcgctgtgattaacaagctgcgtgccgatcacgacgtcatcatttcgctgcct aagcgggatgaacccaatgaccgcatcatctctatcaccggctaccaggccaatgcggaggcagcccgcgatgccatcctaga gattgttggcgaccccgagacacttcatcgcgaggttatcgagatcgataaacgcatccacccccacctcattggccaacgccga cgcaccattcgcaagatcatcgaggataataaggtgaacatcaagttctcagctgatgatgacaaccccaattcgatcttcatcagt ggcaagatagaggacgttgagaacgtcaaggagttgctcttcggcatggctgaggactacgagcgtgactacttggataacgtg gcgatagcgccgccaacgattggtgccttcctaactgggttctggatccgatgccgcaggtgccagcgagaacggattcgtcatc aaagacgcaccgtgggagaagcaaaagcaggccaaaaacctgactgcgcccaacactcagtcgcaggaggacttcccgcact tcgctgctggcggggctccggtggcctccacgcctatcacctccgtgtggggccccaaaaactaagtgcatcgggccgagtgtc ccgatcgccagcagtagcagcaatactacaagtcggggtgcgccggggatcggagctggagatggaccaggagctggagca gaagctggaactggaacttgaattggattatcgggcaatgagcggcagagcagcggcagtcgtgcggacatctctttag Drosophila Gene Hit BLASTN with rescue sequence 1: dodeca-satellite protein 1 (DDP- 1) (AJ238847). TBLASTN with ORF2. -dodeca-satellite protein 1 (DDP-1) (AJ238847). Drosophila EST GH20785 (AI389573), LP07358 (AI294065) Annotated Drosophila genome genomic segment AE003799 Annotated Drosophila genome Complete gene candidate CG5170 - Dpi dodecasattelite DNA binding protein CG5576 - Bg5 involved in cytoskeleton organization and biogenesis which is putatively a componentof the plasma membrane Human homologue of Complete gene candidate CG5170- 4885409 refjNP_005327.1 |pHDLBP| high density lipoprotein binding protein >gi|2498434|sp|Q00341 |HB CG5576- 2e-07 4506539 ref|NP_003795.1|pRIP| UNKNOWN >gi|3426027 (U50062) RIP protein kinase [Homo sapiens] Putative function CG5170 : DNA binding protein (homology with Scp 160p, a new yeast protein associated with the nuclear membrane and the endoplasmic reticulum, is necessary for maintenance of exact ploidy) CG5576: death domain containing protein, possibly involved in signal transduction Confirmation by RNAi CG5170: Reduced GI and G2/M peaks indicating fewer cycling cells and more polyploidy CG5576: Loss of GI peak Example 63 (Category 5) Line ID 40/2 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 39B Rescue ID BamHl Rescue Sequence 1 TTTTTGCCTCCGCTTTTTAATTAAAAAAATGTNTGTTTNGCCCTGGAGCTCTCG GTCTGTTAGCGAGCGTTGCCACCTTTCTGCGAGCTGTTGCTGCACACTGCCACT TTACGAACACAGCTCTGATAGCGGGACAAAATACGTCAAGGCAGCGACGGTG GGTTACTAGTGAATTTGGAACGGTGGTCTTAAGACGTACTGGTCTTTTATATTT TCATTATTTTTTAAATTGTCGCTCATTTACCAATAAACCTTTTTACTTTTTCCTG ATAGTCCGAAGTCAGATCAAATAGGAAGTTTCACAAAAAATTTTCATCCAGAG AAAATACGCCGACGCTATTCGAGTTTTTTGTATTCGTTAACCGGGAAAGAATA GTTCGAATTCGTTCGCACTTTATCGATAGTAGATTGCTATTATGGAGCCCACTA GTAAATTAATTAAATTCCAGACTGATAAAAGCGATCAACTTTTGTTAATGGGT TTAANTCTATAATAATNCTTAGTCCAAATTGTNTCAAAGTAGTCGATAATTTAT AATAACAGTTTTAGATGACCTCTAGGAAATAACTAATTACCCACATNCTTCAA GAAAGTGTTTNCAATTTGTNCTATAATTAAATAACAGTTGTATTAATTATGTTG TNATTGTNACTCATAATACAAATTAAACAATATAAACACACATAAATAAGAG AATTGGAATATTTTGTCTCAGATTAGATTTNCCAC Rescue ID EcoRl Rescue Sequence 2 AACGGGGGGCTTCCGCGNCNCCAAAACGCAATNTACCGTTCATGCTGTGAAG CGAAAAAGAGTGGTAGCGCCTACCNTGGCATATGTAGTTAAATCCGTGAAAT AAGTGAATAAGAATATATGTATGTACTTAATTCGAAAACCTTTTCGCCGTCAG CACAACGGGTGAACGAGAGAGCGGAAGTGGAGTTTTTTGTGGCGGGTCGTCT CGCTCGCACCGCAAANGTCGTCCGTGGCTGCGTGTATGGGTGTGTGGAAAAA GCGTCGAGGTGAATGTGGATTTCTAACCACACCAGCATTGCAAAGACATTGAT TGATATTTAAAGCTGCAGCAGCGAACAAAGCAAATCCTAATTTCGGCAAAGTT TAAGAATAACGAGTGACTGGGGCGCGCGCAATAAGATAAAATTGAAGGTTAT CTGTGTGCGTGTGAGTGACCGTNTACCAGTGTGTGTGTGCGANCGTCCATTGT AAACAAAAAACAAGTGTTGTGAGCGGAGAGAAGAAAGGGAAAGAGAGAAAG AGCGAACAGACTGGCGAGAGAAAAAAGAGATGCCACAAANAAAGCAGCGCA CAAAGGAAAGCTGAAAATTTCANTAAATCTGCAAAAGTGAAGAAAACCACAA GAACCCGCAGTCNTGTTAAATAAAACCCAGANTCCAAGAAACNTTAAAAGAA GCAGTGCAAACAAACTGGTGCTNTGAATGCGGTTTATTTTGAAAAAAAATGCA ATTCGGTCCGATGGAA Genomic hit, Accession No. CSC:AC014744 Drosophila EST several including LD46342 (AI544109 BLASTN similar to mRNA L07550) Annotated Drosophila genome genomic segment AE003669 Annotated Drosophila genome Complete gene candidate CG8678 - novel with ankyrin homology Human homologue of Complete gene candidate CG8678 -gi7661580 B69CEC399B56F35C ]ref|NP_056425.1 ]DKFZP434J 154 protein [Homo sapiens] (2.20E-85) Putative function Novel protein with ankyrin domains, unknown function Confirmation by RNAi Reduced GI and G2/M indicating fewer cycling cells Example 64 (Category 5) Line ID 55/12 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 49C Rescue ID BamHl Rescue Sequence TCTCATGNTC AGGGGGCCTTTACN ATGTC AAAGAGC AAATTGTCC AC AGGGC A GCAACCGCAAGTGAGAGACGGGTGGAAAACTGGGCGGCATGACCATGAATGA AAGCCGCGACCGGCAAACGTGGCCCGCCCACAAAGCGAGCATTTTCACATTTT AACTGTCTGGACATTTTGTAAGTTACACCAAGGCAATGATACCAGTAAAAAAG AAGAAACAATCATTTTTGAATAGATTAATCACCTGATTAATGTTGGTTGTATGT TGATTGTAGGTGTTTTAATATACAATGTCTCTATTACTGCTTTCCTTTATTCAAA AGCCATGTGTAAGTGTAAGTTCTCGATTTCGGCTAGATTTTGAAGTTCTGCCAT TATCAATTAAAAGTCCAGTTCCTCTATAAATTGGTAATAAAATAGCTCTTTACA GCCAAGTATATGTGCAATTTTGTAAGATTAAANGTCCAAATGTTGTGAACCTT TCCTGGCCCTGAATTTTAAAAAACCATTAAATTGGTCCCATTTGACATTAAATG TTCTATGTACATTAATATGACTTTTTGTGGATGGTTTTATAAACAAGCATTACT ATATTCTAAAAATCAAGGATAAAGGACNAGCTTTACAGGAGGTAACATTCCTA TTGTACGGCTTTATTTTCTTATACCCATAAGAGCATACCACTAGGATCCGTCGA CCTGCAGATCTCTAAAAACTTGCCTTTGCTGGCGTTTTCCATAA Genomic hit, Accession No. AC007085 Associated ORF Genscan ORFl predicted sequences >21:54:l l|GENSCAN_predicted peptide_3|108_aa MGLVTAAFKLKRKDIQDRYQHDINRICHTRSTAHTAYAHFAEHLLRRSPRQRFVN GKGAALNLILLNSAARQFSGSTGAYKLGNRVGKNEGEQQEYKLQDRTTHFCGN >21 :54: 11 |GENSCAN_predicted_CDS_3|327_bp atggggctggtaaccgccgccttcaagctgaagcgcaaggatatccaggacagatatcagcatgatattaaccgcatctgccaca cacgtagcacggcacacacggcgtatgctcattttgcggagcatctgttgcgacgaagtccacgtcaacggtttgtcaacggcaa aggtgctgcgcttgtgctcatcctcctcgtttctgcggctcgacaattttctggctcgacaggtgcctacaaactgggtaatagagttg gaaaagtagaaggggaacagcaggaatacaaactacaagacagaacaacacatttttgtggcaattaa Corresponds to CG8732 Annotated Drosophila genome genomic segment AE003836 Annotated Drosophila genome Complete gene candidate CG8732 - l(2)44Dea homology to fatty-acid- Coenzyme A ligase, long- chain previously described spindle/chromosome abnormalities in neuroblast squashes Human homologue of Complete gene candidate le-171 4758330 ref|NP_004448.1 |pFACL31 fatty-acid-Coenzyme A ligase, long-chain 3 >gi|4165018|dbj|BAA371 and LCFD_HUMAN LONG- CHAIN-FATTY-ACID--COA LIGASE 4 le-157 Putative function Fatty acid CoA ligase Confirmation by RNAi Only wild type profiles observed Example 65 (Category 5) Line ID 6/7 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 28E Rescue ID BamHl Rescue Sequence 1 TATNAATAATCATAGGGCTCTTGCTCTTACGTGTAAGGCCTGCCCCTCTNCC A GTCTATATACAAAGAAAAACACACACACACTGGCACACTGGTGTTCGCATATG CCAAAGCCGAGTTAATTTCACTTTGTTTAATCTATCGTTTGGTGTTTTTGCATTT TTTAACCGCGCAAACGGTATTTGCGCGTTTTGCGCCTCTTACTTTGCGATTTAT TGCACCGCTTGGCTGTGTTTTGCAATTTCTATCTTGATTTTCATTGGTATTCACG CGTAATGTAATTCTTAGCAGCGTGACCGCGCCGATAACGATAAAAAATACCAC GGGACCAAAAATAAATACCATATGATACCACTTCAGGGAAAAGAAATCCTAT TTAATACCACTCACTTTAAAAATAAGTTTTTAAAAATATATATNTTTATTTAAA AAAAGGTGTATTTATAATCAAATACTCGGTACTTNTTAATTACTCCAAGAANA ATTAATTTGAAAAAAAGGGGTTCCATTATAAAATATATATTAACCGCTTACAC ATAATCCCCAAACAAAACAGCGATTGGGATTTAAAAGGTTCTAAGTCCATCAT TATAAAAGATCATTTCCGAAAAACAAAAGAAATAGATTCAAAATTAGGCGAC ATCAGCCCGCTGATAANGATCATAAAAATACAGAAGCTNATTCAGCGAATCA GAAANTCCTACTCGCCACTATCCGAAAACNTNGAAAAAAAATGG Rescue ID EcoRl Rescue Sequence 2 TGAAAGGTAGCAACAACGTTTCCTTGGAAAAAGCTGTAAATAGTAAACAAAA TTGTCAAGTTAACGAGCCAAAGTTATTAAATAAGGTTCGAGTACGTTGGCATC GGCTGCCCAGGCAGCAAANAAAAACAAAGACGCAGTTCAAGATCAGCTGGAC ACTTAGAAGANTTTAAGAATTGAAGCACATTNNAAAGAAGANAAACAAGAAC CCCACCAAAAACCCGCGTGCGTTTGTATGTGTGTGTGCCATCAAATTTCCCGC ACTGGGTGAATGTGCNTGCGTGTGTTNTGTGTCATTTAATTTTCCTACCAATAA TCGCCTTCCAAGAAGTGAATACCAGCCGATCCACCGCTAAATCGAAAAAAGTT TNACTCTGGGTTAANTCACTGTTTACGGCTTTTGTGCTATAATTACCTTTCCCG TAAGCNGTGGGAANCTAAAANCCAAAACNTNAGAATCCGAATTCCG Genomic hit, Accession No. CSC:AC017934 Associated ORF Genscan partial ORFl predicted sequences >22:35 :21 )GENSCAN_predicted_peptide_4| 128_aa MGTNSGATAGINNKPNGGATGAGVLVGGGVGGANSSIGGVLSNSLGGGGSGGLS ISGLNAGGQNANVGGMGNVGGDDGGNGMVGGGVNNQQATTPQYTIPGILHFIQ HEWSRFELERSQWDVDRAELQ >22:35 :21 |GENSCAN_predicted_CDS_4|384_bp atgggcaccaattcgggagccaccgctggcataaacaacaagccggttggcggtgcaacaggagccggcgtccttgtaggcg gcggtgtgggcggtgccaattcctcgatcggcggtgtcctgtcgaacagcctgggcggtggcggcagcggcggtctgagcatc agcggcctcaacgctggtggacagaacgccaatgtgggcggaatgggcaacgttggcggcgacgacggcggaaacgggatg gtgggcggcggtgtaaataaccagcaggccacaacgccccaatacacaataccgggcatcttgcacttcatccagcacgagtgg tcgcgcttcgagctggagcgatcacagtgggacgtggacagggccgaattgcag Human Homologue TBLASTN with ORFl : very weak homology with striatin, calmodulin-binding protein (STRN) (NM_003162.1) Drosophila EST several including LD42534 (AI516610), LD03224 Annotated Drosophila genome genomic segment AE003619 Annotated Drosophila genome Complete gene candidate CG7392 - novel WD40 family member Human homologue of Complete gene candidate CG7392- SG2N HUMAN CELL-CYCLE NUCLEAR AUTO ANTIGEN SG2NA (S/G2 ... 622 e- 178 A cell- cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells Putative function WD40 protein a novel nuclear protein mainly expressed in S and G2 phase cells that was characterized using autoantibodies from a cancer patient Confirmation by RNAi Reduction of Glpeak , more polyploidy Line ID 103/1 Category 2nd chromosome, small imaginal discs Reversion R Map Position 57B Rescue ID BamHl Rescue Sequence 1 GATTTCAAAATTAGGCGACATCAGCCCGCTGATAAAGAATCATAAAAAATACT GAGGCTTATTTTAGCGAGTCAGAGACTCCTACTCGCCAACTATCGAAAACATA GNGAAGATATAGTCGCCAACCGATCTGCCTTCTATAGTGTTGCTTATTGTTGTC CCCTAATCAAATTAATAAAAATCTGCATTAGGCTGCTTCGCCGGCCAGCAACA AATGTTTTACACCTACTGTACTTTTCGCAGAACAGAGATCCAAATGCAGGATC GTTTCCATGACTGTACATTTATTCGGATTAGACATTAAATTACACCCTACAGCT ATACATACTAACAGTGAACACGGCAAATGCTTAGCTAGCATTGGGCCACTTTC GTTGACTGCGAATAAAAATGATTGGCCGATGCCTTTAGCAGATTCCTTTTGAT CGAATTACTCGGATGGCTTGTGTGTCCACCTCTTACAAGAACTCCTCGCACCA ATCGTTGAGACAGTTGTAGCAATCGGATGCTTGGTTGGAGCTGGCGTGGCACA CCTTCTTCATCCAGTCCTTGGACAGNTTCTTGGNCCTTTTCAGNANCAGGATCT GGTCCCAAACGGNGGAAGGCCTAAAACGAATGGNAATTGATCGGTAGCCCTT GACTGGCATTGGTAATTTGCGCACATGGGNGTCATCGGATTTACACACGCACC ATATCGAATCAGCGTCCTTAAGCGTCAACCGAGGGTTTCCCCAATTCCGGCCA GTTCCGTCACCGACTTGGTTGCCATTGG Rescue ID EcoRl Rescue Sequence 2 ATCAAAGCGNCTGGGCCCGTGCATCGCCNCAGCGTTCGTCTTAATTAATTAGT GATTGCAAGCGGGTGCAATTATGCACAAAATTACGGACTAATACAACTGCCC GCTTCGCGCTCTCTCCATCTCCCTTCCAAATAGTCGTTTGCTCTTCGCACACAA AAGTGTAAACCCTGTGAAAGGTAGCAACAACGTTTCCTTGGAAAAAGCTGTA AATAGTAAACAAAATTGTCAAGTTAACGAGCCAAAGTTATTAAATAAGGTTCG AGTACGTTGGCATCGGCTGCCCAGGCAGCAAAGAAAAACAAAGACGCAGTTC AAGATTCAGCTGGACACTTAGAAGAGTTTAAGAATTGAAGCACATAAAAAAG AAGAGAAACAAGAACCCCACCAAAAACCCCGCCGTGCGTTTGTATGTGTGTG TGCCATTCAAATTTCCCTGCACTGGGTGAGTGTGCGTGCGTGTGTGTGTGTGTC AGTTTAATTTTCCTACCAATAATCGCCTTTCCAAGACGTGATTACCAGCCGATC CACCGCTTAAAATTGATAAACGTTTTAACTCTTGCGTTACATCAGCTGTTTTAC GGCTTTTTGTGCTATAAGTTACGCTTTTCCCGTAAGCCGTTGGCAACACTAGAA CGCAAAAGAGCATAAAGAATCGCGAGTACCGTANAGAGGAAGAGAGGAAGA GAGAGAGATAGAGAGTGTGAGCGTGTGAGTGAGCGGGGAATGTGGGGGCGGT TCCGGTGCGAAAAAACGTAGTAGTAGTACATNNAGAGAGTGCGAACGAGAGG GAGGCAGCCAGCGAGTGTCCTGCGACTGCTCCCCCCTTTACCCTCGTCGCTTTT CTATTCGGAAAATTCAATGACCTCATTTGTTTCATGTGCCGAACTTTGCTTTTC TTTCCCAACCTAAAAACGCAAAAAAAAAAAACNCCAAACAGGATATACGTNG GAACANTGANCAAACNANTTCGANAAAACCAACAACNANGGACCGTGCCCTG GGGCNCCTGAAAGGCAAACAGCTGGCNNCAAATCCGGAAAAGGATCNGGAA NAACAGGATCNGCGGGCNCAAGGATCNCCGGAACAGGCAAAGGAAACNCCC GGCNCACNGCACAAGCCNCTGAAAAGCAACNTGAACCAATGGGCACCANTTC CGGGANCCACCGCTGGCATTAAA Genomic hit, Accession No. CSC:AC017934 rest of results as for line 6/7 Example 66 (Category 5) Line ID 65/24 Category 2nd chromosome, small imaginal discs Reversion. NR Map Position 48A Rescue ID BamHl Rescue Sequence TACGATTTTTGC ANTGCNCC ATTTCGTGGCACCCGATTTGTATATATATTTTTT ATATAACCCACGGATTGCCAACTTTCATTGCCCTTTCACACTCTTATTCGCCAT TTATGAACTCTTCTTTGACGATTGGAACGGTTCTTTTTCGCTATTTTCGACTGC ACCCGCGCTCTTTTCGCTTCGCTCTCCTCCCTCTCTACACACCGCTCTTTATCCT TAATTGCTTTTTCTATTTAGCGGAATTGATCGTTCTCAACTTGGTCGCCATTGC AGCTCCACAGGCGAAAAAATCGGTGGAAATGCCAATACAGGTGCACGGCGAG TGCCGATAAGCTGGAAAATCGGGAAAACGCACGCCTACACATTCATTGCCAG CATCGGCTTTGCCTTTTCGCTGTCGAGATTAGCATATTTCCACTTTTGGTTCGC GCACAACACTANCTAAATTATTGNTTATTTTTTTCCCCAACTGTGAGGTGAAAC TGTGAAACAAAACCACTGTGGGCGGGTCAGTGTGACCCTCTCGCGGTGGGTG AAAATCCTAGTGAGCTTCGTTGTTAGGGCTGTATGACACGAAAGCAAGTTGAA AAGAAACTTTTTTAAAATTATATTGGTTAATTGAGCAGAACTAAAACTATATN AAAATATTTAAGAATNCAGATTAGTGATGTATTTAATATAATAATAGTAAGAT GTTC Rescue ID EcoRl Rescue Sequence 2 CTTNTTTGATAGANATAGGCTTCTTTTAAAAAAAAANAAGCAGCANCAGGGG CCCNGAAGTGCGTGNNTGTGAACGCTGATTGCTTGCAAGTGTGTTCGTGTGTG TGTGATTGTGTGCTCCGANCAAGTGAAATCAATAATATTTGCAGCCACAAGCA ATTAATAAAAACTGCAATAATGTCAAAAAATCTAATTGAGGCAACAAATTAN CAAAGCCATNAAAGCAGGCTGCACTGCGAGAAAATTGTGCCTTTCCACAGAT CTTCTGCTGCAAAGCNAAAGAANGTAAGCAAGTCGGCCANTTTATTNCATTCT TCTCATCTCTCTTCTTCGCGAATTGGCGCNTANCACTTACAATAATTNATATNA CTTCTTAAATTTCAAANTCCCTTTCNTGAACGGANCTTTTAACGGAAAACAAA GCGGGTAAACTAACTTAACTAAACTAATTANAANTGTANGTATAAATGAACC GAACTCGCTTTAGATATNATGCGTTTCACTAACANATTANAACAAACTTTGAA GCTGTANTGTCAGGTTGTTATTNCGTTCACCANATGTAGACTGNCCGNNAATT TNACCTTTCCCATANTCTGTTCTTAANTGTNTTGTTTTTTCCCAATNNTTTGATC ATNCNTTGGTNAATNANCTNAACGGCCCAAAGTNAATGAATTCCANTCACGTC CACTGGCTCTGGTTCNATANTTAATNGGCTGTTTCTTACTTCCCTTAACCCTAA CATCTNTTAATCACCTGTGCCATNTGTTTGTGTGTGTGTGAACGAATGAGAAA AAAAA Annotated Drosophila genome genomic segment AE003825 Annotated Drosophila genome Complete gene candidate CG9005 - novel putative cell adhesion Human homologue of Complete gene candidate CG9005- Ensembl predicted gene ENSP00000006008 Gene:ENSG00000005238 Clone:AC004472 Contig:AC004472.00001 6.00E-38 (KIAA1539 protein AB040972) and AK022837 Homo sapiens cDNA FLJ12775 4e-33 Putative function Putative cell adhesion protein Confirmation by RNAi Reduced G2/M peak Example 67 (Category 5) Line ID 74/3 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 47A Rescue ID EcoRl Rescue Sequence GC AC AGAATGGCNCCTTCACGAC AAAAGATCTNCNAATTAGGATGATGC AGA AGGAGGACACGCTTTTCATTATCTGGTTGCCACCTAATTTAAGTTCCACATCAA GGGAAGAAGGAAATACGTTCCAACGGACGTCAAATTTACTAACTACACTACTT GAAAAGCCTGTCTATAAAAACACGATAACGTTTTTGCTAATCTCAAGACAATG TTAAATATAATTGGAGAAAGTATTGAATATGAATATCACAAAAATTGTTTAGG GTCTCTACGTGGTAAATAGTATTTGGCATAGACAGTGAGATGTGAGTCGTACG TACTAATTAATAAAGTTGTTCAARAGAACCTCATATACTGTAAGTGACAACGA ACGAAGCTGACAACTCTGCTTGCACATATTTGGCGGAGTTCGAAAATATCATC GCATTGGTATTGTTTTTGTNTCCACCNTGGGGCGAGATTTTGTTGTTGCTTTAC TTTGCTTGTTTTTTCNCCACAAANCGAACCATAATGTTCGAAATGGTAAAATTA CCGTGCCAACAAGCTCTCTCTCTCCCCACTCCGAAACTCTCTCATCTCTCCTTG CAATTGTTTAAGGTGTGCAAGGAAATGAAAAATGTCCCGGCTGTGTTNCCATG CATTCCCCTTCAAAGCCAATTATNTTTGTGCCTCTCCAACNTTTTTGATCGGNN TGATTTTTTTGGCTCCCCNTANTCCCCCCCCCTTTCNCCCATTCCGGGTTANAT TATTNTNCCAATTTTCCTATTTTACGGTCCCNGTTCCCTGGAAATANTTCCTNC AATCNCCGCTCCATNTCNCCATNTTTGACAGATTTTC Annotated Drosophila genome genomic segment AE003829 Annotated Drosophila genome Complete gene candidate CGI 2052 lola -a specific RNA polymerase II transcription factor involved in axon guidance Human homologue of Complete gene candidate le-09 3789797 (AF059569) actin binding protein MAYNEN [Homo sapiens] Putative function lola-like specific RNA polymerase II transcription factor Confirmation by RNAi Almost no GI peak and increase in G2/M peak indicating arrest in G2/M Example 68 (Category 5) Line ID 79/7 Category 2nd chromosome, small imaginal discs Reversion R Map Position 55B Rescue ID BamHl Rescue Sequence 1 GTCTCATGC ACCCTGGCCCTNAGCTGC ATAAGTGTAAGTGTGTGNCTGTGTGC GAGTGTGGGTAGGCGGCGGCAACTATCTCGCTTGCTCTTGCGTCCGGGGTTAT CGGTAGCTTCTTCTAGGCTGAGTGCATTTCGTTGAATCGTGGATGTTGAAAGTT GTCTAATTTCCGAACTATTGATTTTTCCCCTTCCCCGTCAAGAAACTGCATTGT TGCTTCTTGAAGACCAGTTTTGGTAACATCAGGAGAATGGAAAGGAGCGAGT GAGTCGGTGAGTAAGTGAGTGAGCGATGCGAGCGAC AAAATC AACAACAAC A ACAACAACGGTCAAAACGAGTTCCAACGAAAGTTGCAACACTCTCAACAATT TGAGCAGCTCCGTTTGTTGTTATTGCATTACTCAATCGGGAAGACTCTACACTC GACGGAATAGTGTGCTCGTCTGAAATTTATCNATTTCCATTCCTTCCTTTGTTT TTGGGCCAAACAATGGCNTCGGCAANCGTTCGTGGAAAACCGCAGGAACCAC CAAAATGCCTGGCGTCACATTAACCGAGCCGCCTTTGTTTATGCAAATATTATT GTAATATTTGGTNAAAATTAAGTCGCGCTTCNCGTTACTTTTTATTTCATATAC ACGCAGCAGCAGCACGCATACAGTCACGTCACGCACACATACAATCGCCGTN CACATACACTTGTCTTTTTNCCACACACTTTCCTAATCAT Rescue ID EcoRl Rescue Sequence 2 NGGNGTCTCATGCACCCTGGCCCTNAGCTGCATAAGTGTAAGTGTGTGNCTGT GTGCGAGTGTGGGTAGGCGGCGGCAACTATCTCGCTTGCTCTTGCGTCCGGGG TTATCGGTAGCTTCTTCTAGGCTGAGTGCATTTCGTTGAATCGTGGATGTTGAA AGTTGTCTAATTTCCGAACTATTGATTTTTCCCCTTCCCCGTCAAGAAACTGCA TTGTTGCTTCTTGAAGACCAGTTTTGGTAACATCAGGAGAATGGAAAGGAGCG AGTGAGTCGGTGAGTAAGTGAGTGAGCGATGCGAGCGACAAAATCAACAACA ACAACAACAACGGTTCAAAACGAGTTCCAACGAAAGTTGCAACACTCTCAAC AATTTGAGCAGCTCCGTTTGTTGTTATTGCATTACTCAATCGGGAAGAACTCTA C ACTCGACGGAATAGTGTGCTCGTCTGAAATTTATCNATTTCCATTCCTTCCTT TGTTTTTGGGCCAAACAATGGCNTCGGCAANCGTTCGTGGAAAACCGCAGGA ACCACCAAAATGCCTGGCGTCACATTAACCGAGCCGCCTTTGTTTATGCAAAT ATTATTGTAATATTTGGTNAAAATTAAGTCGCGCTTCNCGTTACTTTTTATTTC ATATACACGCAGCAGCACGCATACAGTCACGTCACGCACACATACAATCGCC GTNCACATACACTTGTCTTTTTNCCACACACTTTCCTAATCATNNTA Genomic hit, Accession No. AC004296 Associated ORF Genscan: ORF2 predicted sequences >15:31:31|GENSCAN _predicted_peptide_3|109_aa MVTSFRHLRDEKSFTDVTLACEGQTCKAHKMVLSACSPYFKALLEENPSKHPIIIL KDNSNIHLQAILEFMNAGENNNSQEQLPAFLKTADRLKNKGLAETPSSIKREG >15:31 :31 |GEΝSCAΝ_predicted_CDS_3|330_bp atggtgacctcgttccgtcacctgcgcgacgagaagagcttcacagatgtaacactcgcctgcgagggccaaacctgcaaagcc cacaaaatggtgctttccgcttgcagtccctactttaaagcgctactggaggagaacccatcgaagcatccgatcattatcctgaaa gatgtctcctacattcacctacaggctatactggagttcatgtacgccggtgaggtgaacgtgtcccaggaacaattgccagcattt cttaagaccgccgatcgcctcaaagtgaaaggcctcgcagagacacccagttcgataaagcgggaaggttga Drosophila Gene Hit TBLASTN with ORF2: several zinc finger proteins including Broad-Complex mRNA for BRcore-Z2 protein ( X54665) Human Homologue TBLASTN with ORF2: kelch (Drosophild)-like 2 (Mayven actin binding protein) (KLHL2) (AF059569) Annotated Drosophila genome genomic segment AE003800 Annotated Drosophila genome Complete gene candidate CG5738- lolal, lola-like putative kelch-like putative specific RNA polymerase II transcription factor known to affect disc morphology or could be CGI 0914 - novel unknown Human homologue of Complete gene candidate CG5738- 9e-09 3789797 (AF059569) actin binding protein MAYVEN [Homo sapiens] CGI 0914- predicted gene ENSP00000051207 Gene:ENSG00000047313 Clone: AC068261 Contig:AC068261.00019 4.00E-49 (potental cell division GTP binding protein 1: ENST00000051207 Putative function CG5738: lola like specific RNA polymersae II transcription factor, CG10914: Possible GTP binding protein Confirmation by RNAi Both show marked reduction in GI to G2/M ratio Example 69 (Category 5) Line ID 80/2, 81/8 Category 2nd chromosome, small imaginal discs Reversion R Map Position 57D/E Rescue ID BamHl Rescue Sequence 1 C ANTTTC AGAGGCC ATAGNCCTTC AC AAAATTCNCC ATCTCTGCCCGGC ATCC GTGCTTGAAAATGGTGCCAATGCGTCGTGGAGAATCTGCTGCACTCGATGGTC TGCAAAATTGCACATTTATTAGATTTAATAAATTTTTCAACTGTCCGCGANCAC GTTTGCTCGTGTTGAATTTCGAGTACAAAATTAGTGCGACTGTTGGATTGCATT GAAATGCCAAAAATCGGTGTGACCATTTCGAAGTCCCCACAGGCTCATGACTT TCGCGGTTC ACC AAATCC AAATAACGC AAGCTGGTC ACGCTGTC AAAC ATCGG TGACGGAATGGTGACGACACAAACAATTTGCTTAAAAACTTTCTTGCGGCCGT AAAAATGCGCAAGCAGCCTGGCAGCGCAACGCACGTACACGTAATTGGAACA AATGTTTGCTGAACCACAACCGCCCACTAAATGTTANCCGCCAAGTCTTTTCC CCCGCCGCCGCCGTCNTCNTCNTCNCCGGATTATTTGGTTTACAATTTGCTTAC ACAAGTGCAATCGTCGATAGCGCTTCATTTTGGAGTAACAAGTAATATTTTGC GCCGTACTGCTGTTCGCCGTATCAGACAGAAGGTTGGTATCAGTTCGACGCAG CTTGTGACGGTATTGCATACGCGGCGAAACGCCCACGTGAAAACGGATCGCA GTTCTCGAAAACTCNGGATAAAAA Rescue ID EcoRl Rescue Sequence 2 TGGGGTCTCANGCCCCGACGGCCATATTTTAACACAAGATTCNNCANCTCTGC AGGGCATCCGTGCTTGAAAATGGTGCCAATGCGTCGTGGAGAATCTGCTGCAC TCGATGGTCTGCAAAATTGCACATTTATTAGATTTAATAAATTTTTCAACTGTC CGCGAGCACGTTTGCTCGGTGTTGAATTTCGAGTACAAAATTAGTGCGACTGT TGGATTGCATTGAAATGCCAAAAATCGGTGTGACCATTTCGAAGTCCCCACAG GCTCATGACTTTCGCGGTTCACCAAATCCAAATAACGCAAGCTGGTCACGCTG TCAAACATCGGTGACGGAATGGTGACGACACAAACAATTTGCTTAAAAACTTT CTTGCGGCCGTAAAAATGCGCAAGCAGCCTGGCAGCGCAACGCACGTACACG TAATTGGAAC AAATGTTTGCTGAACCAC AACCGCCC ACTAAATGTTAGCGCCA ACTNCTTTTCCCCGCCGCCGCCGGTCGTCNTCNTCCCGGATTATTTTGTTTACA ATTTGCTTACACAAGTGCAATCGTCGATAGCGCTTCATTTTGGAGTAACAAGT AGTATTTTGCGCCGTACTGCTGTTCGCCGTATCANACAGAAGGTTGGTATCAG TTCGACGCAGCTTGTGACGGTATGCATACGCGGGGAAACGCCACGTGAAAAC GGATCGCAGTNCTCGAAACTCNGGATAAAAGAAAAAGTAGGCTGAATG Genomic hit, Accession No. AC007175 Associated ORF Genscan: ORF2 predicted sequences >16:09:09|GENSCAN_ρredicted_peptide_3|2497_aa MNEGNSAGGGHEGLSPAPPAVPDRVTPHSTEISVAPANSTSTTVRAAGSVGAALP ATRHHQHIATQVKGIASSSSKQQKQLASAQLPVPLSPLPQQQQQTAEATAAAAAP AHSNNSNSSSTIEASNLPPQAKRQRLDDNEDRTSAASINGPAESSNINSSLLPASNA SSSEVGGLSSTALQDLΝALKKRILQQKLQILRΝLKERHLEΝVSENFYLQΝGGSMM DYPAWRKKTPTPQFISYSΝAΝRIDQLIHEDKPSTSAAAAAAQΝQKYTTQQTDSNE SSLNSGIGTGATKGAPLDGΝISΝSTVKTΝTQSQVPSKIGSFTESTPAATESΝSSTTVP GTATSGAATSTSATSAEASGΝVLAVEAEIKIPAVGATPVAISTKLPAAVVQLTQQG GTPLLPCΝTSAGSTALRRPQGQΝΝASSGSAAASGGGGSLTPTPLYTGΝGPAALGG SGGLTPGTPTSGSLLSPALGGGSGTPΝSAAQEFSFKAKQEVYVMQRISELQREGL WTERRLPKLQEPSRPKAHWDYLLEEMVWLAADFAQERKWKKΝAAKKCAKMV QKYFQDKATAAQRAEKAQELQLKRVASFIAREVKSFWSΝVEKLVEYKHQTKIEE KRKQALDQHLSFIVDQTEKFSQQLVEGMΝKSVADTPSLΝSSRLTSPKRESDDDFR PESGSEDDEETIAKAEEDAADVKEEVTALAKESEMDFDDFLΝDLPPGYLEΝRDKL MKEEQSSAIKTETPDDSDDSEFEAKEASDDDEΝTISKQEEAEQEIDHKKEIDELEA DΝDLSVEQLLAKYKSEQPPSPKRRKLAPRDPELDSDDDSTAVDSTEESEDAATED EEDLSTVKTDTDMEEQDEQEDGLKSLMADADATSGAAGSGSTAGASGΝKDDML ΝDAAALAESLQPKGΝTLSSTΝVVTPVPFLLKHSLREYQHIGLDWLVTMΝERKLΝ GILADEMGLGKTIQTIALLAHLACAKGΝWGPHLIVVPSSVMLΝWEMEFKKWCPG FKILTYYGSQKERKLKRVGWTKPΝAFHVCITSYKLVVQDQQSFRRKKWKYLILD EAQΝIKΝFKSQRWQLLLΝFSTERRLLLTGTPLQΝDLMELWSLMHFLMPYVFSSHR EFKEWFSΝPMTGMIEGΝMEYΝETLITRLHKVIRPFLLRRLKKEVEKQMPKKYEHN ITCRLSΝRQRYLYEDFMSRAKTRETLQTGΝLLSVLΝVLMQLRKVCΝHPΝMFEARP TISPFQMDGITFHTPRLVCDIMEYDPFTQIΝLETLΝLLLLHLEQTMTAYVSHKSRLL APPRKLIEDIDTAPLPAPRCPΝGKYRFHIRVRSAELAQRIKLΝAVKVGASPAMRLE GSKIMPMRΝLLPSGRVLKRVSASΓΝPVΝMALKPVVΓΝSVVTTTSSSTTASSPTGAL SVLSΝSKLLGARSQΓΝAPTPAKVAKTMQDGKPFFYLTPATΝSGAAGARLTLTSKT TASASTTTSRTTVTASTTSGQQLIRDPIVKDLATHVKSTVQKQSIAΝGKTEPEEETE AEDPYKVQELIQMRKEQRLAALKRMAMΓΝRRRTDATPIYGEDCREAIQRCMQAT RSLKRSTWQTRGYAΝCCTAMAHRΝGWSLΝHLLKSFEERCADLKPVFAΝFVIYVP SVCAPRIRRYVQΝLSSTHWQHEQRIEΝIVDQALRPKLALLHPΠSEMTTKFPDPRLI QYDCGKLQTMDRLLRQLKVΝGHRVLIFTQMTKMLDVLEAFLΝYHGHIYLRLDGS TRVEQRQILMERFΝGDKRIFCFILSTRSGGVGΓΝLTGADTVIFYDSDWΝPTMDAQA QDRCHRIGQTRDVHIYRLVSERTIEVΝILKKAΝQKRMLSDMAIEGGΝFTTTYFKSS TIKDLFTMEQSEQDESSQEKSEΝKDRIVATTTLSDTPSTVVETEKQSLRAFEHALA AAEDEQDVQATKTAKAEVAADLAEFDEΝIPIATEDPΝAEGGPQVELSKADLEMQ ΝLVKQLSPIERYAMRFVEETGAAWTAEQLRAAEAELEAQKREWEAΝRLAAMHK EEELLKQETEAEEMLTYSRKDSSΝQVΝTKTDSΝSΝKRRLVREΝRRΝSAQKLSRSV SSHSTGSΝΝKΝSKSATTRGΝSQΝSLΝQTVPVGSGISRVΝRTGAGVSSSSRGKSΝST KSTGKGTDAAPQVRRQTRLHSLGAVΝMASARTPPTRKTTRTALAASAAASTLED ASLIVEERPKRQSAΝIAMSKMMKTPFKQΝVPSΝISIKTTPPKRGRRDSVAAAATRS KLLERRATIAAPLKHMDDESDQDEEEQEEQESEEDTEGEEAΝATVDDDEEGEEEL ASLDEETIQTGSQTΝDEEDDDEEEVGEEGMVDIDTEDSEADVKSSSTYGTAADGK PEEAESLDGWDAHDQVQDTTMTSSTYYΝVSEESDTDEHHDSKAEAKEPPQΝSDK SDESEAVGHTPRTRSRGTVKTΝLWTLDVSPVAΝALΝKSSAΝRSLKKAPRTESTPK ESQSEPRRKITQPKLPKKEETΝΝKSΝSΝIGTLHRWISKSPRVMLRSTPVTAASASSS AAVSGVSGGΝASSSGTAR >16:09:09|GEΝSCAΝ_predicted_CDS_3|7494_bp atgaatgaaggtaattcagcaggaggggggcatgaagggctcagcccggcccctcctgctgtgccagaccgcgtaactccaca ttcaacggaaatttcagttgcccccgccaattctacaagcacaacagtacgagcagcaggatcagtaggagcagccttgccggcc acccgccatcaccaacatatagcgacccaagtgaagggaatcgccagcagcagcagcaaacaacagaagcaactggccagtg cgcagctgcctgtgccgctgtcgcccttgccgcaacaacaacagcaaacggcagaggcaacggcagcagcagcagcacccg cccactccaacgtatccgtttcctccagcacaatagaagcctctgttttgccgccgcaggccaagcgtcagcgtttggacgacaac gaggacaggacgagtgccgccagcattgttggaccagccgagagcagcaacattgtaagctccctgctaccagcgtcggtggc ctccagcagcgaggtcggcgggctttcttctacggccctgcaggacttgaatgccctcaagaagcgcatactccagcagaaattg cagatcttgcgtaatcttaaagaaaggcatcttgaaaatgtgtccgaatacttttacctacaaaacggcggcagtatgatggactacc ccgcgtggcgcaagaagacaccaaccccgcagttcatcagctacagcaatgcgaatcgtatagatcagctgatacacgaagata agccaagcacatcagcagcagcagctgcggcacagaatcagaaatataccacccaacagacagactctgtggagtcctcacta gtcagtggcatcggtactggagcgacaaaaggagcgccattggatggcaatatcagcaatagtactgtgaaaacgaatacgcaa tctcaagttccaagcaagattggcagcttcacagaatcaacgcccgcagcaacagaaagcaactcaagtaccacagttccagga acagctacaagtggcgccgcaaccagcacatcagctacttcggccgaggctagtggtaatgtcctggcagtggaagcagaaatc aaaatcccagctgttggagccacaccagtggccatttccaccaagcttcccgctgccgtcgtccagctaacgcaacaaggtggca cccctttattgccctgcaatacatccgccgggtccacggcgcttcgtcgtccccaaggtcagaacaatgcctcaagcggatccgc cgcggcatctggaggcggaggaagcctcacacccacaccgctctacactggcaatggcccggccgctctgggcggtagcgga ggactcacgcctggcactccaacttctggcagtctgctcagccctgccttgggcggtggctccggaacgcccaacagtgcggcg caggagttctcttttaaggccaagcaagaggtgtatgtgatgcagcgtatatcggaactacagagagagggattatggactgagc ggcgcctgcccaagctgcaggagcccagccgccccaaggcgcattgggactatcttctcgaggagatggtctggctggcggca gattttgcacaggaacgcaagtggaagaaaaacgcggccaagaagtgtgccaagatggtgcagaagtatttccaggacaaggc caccgctgcccagcgggcggaaaaggcccaagagctgcagctaaagcgtgtcgcttcctttattgcacgcgaggtgaagagctt ttggtcgaatgttgagaagctggtcgagtacaagcaccaaactaagatcgaggaaaaacgcaagcaggctttagaccaacacct cagctttattgtagaccagacagaaaagttctcacagcaattggtagagggaatgaacaagagtgtggcggatacgcccagtctta attctagccgtctaacatcgccgaaacgggagtccgatgatgactttcgccctgagtctggttcagaagatgatgaggagactatc gccaaggccgaagaagatgcagccgatgtgaaagaggaggtgacggcgctagctaaggaatctgaaatggactttgatgacttc cttaatgatctaccacctggctatctggaaaatcgtgataagcttatgaaagaggagcagagctcggcgataaagaccgaaacgc ctgatgacagcgatgatagtgagttcgaggcgaaggaagccagcgacgatgacgaaaataccatcagcaagcaggaagaagc cgagcaggagatagaccacaaaaaggagatcgatgaactggaggcagacaatgatctctcagtggagcagttgttggcgaaat acaagtctgaacaacctcctagtcccaagcgacgaaagttagcgccgcgtgatcctgagctggactctgatgatgattcgacggc agttgattccaccgaagaaagcgaagatgcggccaccgaggatgaagaagatctctctactgttaaaactgatacggatatggag gaacaggatgaacaggaggacggtcttaagagtctaatggcggacgctgatgcaacaagtggtgctgctggcagcggaagcac ggctggggcaagcggcaacaaggatgatatgctgaacgacgctgccgccctggccgagagcctccagcccaagggtaatacc ttgtcctcaaccaatgtggttactcctgtgcccttcctgctaaagcactccttgcgtgagtaccagcacatcgggctcgattggctggt cacaatgaatgagcgcaagttaaacggcatcttggccgacgagatgggtctgggcaagaccatccagaccattgcgctattggc ccaccttgcctgcgcaaagggcaactggggacctcatctcattgtggtgccttcgtctgtgatgctcaattgggaaatggagttcaa gaagtggtgccccggctttaaaatactcacctactacggctcccagaaggagcgcaagctaaaacgcgtaggttggaccaagcc aaatgcgttccatgtgtgtatcacgtcctacaagctggtggtgcaagatcaacaaagcttccgccgcaaaaagtggaagtatctcat cctggatgaagcgcagaacattaagaactttaagtcccagcgctggcagttgctacttaacttttccacagagaggcgtctgttatta actggaaccccactacagaacgatctgatggagctgtggtccctgatgcacttccttatgccatatgtgttctcatcgcaccgcgagt ttaaggaatggttctcgaacccaatgactggcatgattgagggcaacatggagtacaacgagactttaattactcgtctgcacaagg tgattcgtccgttcctacttcgacgcctcaaaaaggaggtggaaaaacagatgcccaagaagtacgagcatgttataacgtgtcgt ctgtcgaatcgccagcgctatttatatgaggacttcatgagccgcgccaaaactcgtgagactctgcaaacgggaaacttgttgag cgtgataaatgtactgatgcagttgcgaaaagtgtgcaatcatccgaacatgtttgaagcgcgtcctacgatctcgccatttcaaatg gacggaattacattccacactccgcgactcgtctgcgatataatggaatatgatccgttcacgcaaataaatctagagacgttaaac ctcttgctgttgcatttggagcaaactatgaccgcctacgtctcgcacaaatcccgcctgctcgccccgcctcgcaagctgatcgag gatatcgatacggctccattgccagctccccgttgtccaaatggcaaataccgctttcatatccgagttcgtagcgctgaactggcg cagcgcatcaaattgaatgctgtgaaggtaggagcaagtccagccatgcggttggagggttcaaagattatgccaatgcgcaattt gctaccaagtggaagagtgctgaaaagggtcagtgcttcgatcaaccctgtgaatatggctttgaaaccagtggtgatcaatagtgt ggtgacaacaacatcatcatcgaccacagcatcttctcctactggagctttaagcgtgctgagcaactccaagttgctgggtgcac gttcacaaattaatgctccaacgcccgctaaagtagcgaaaacgatgcaagacggaaaaccatttttctacctcacaccggcgac gaattcaggagcagcaggagcgcgtcttaccctgacaagcaaaaccacagcctcggcgtccacgacgacctccagaacaaca gttacagcatcaactacttctggtcagcaactaataagggatcccattgtcaaagatttggccactcatgtaaaaagcacagtacaa aagcaaagcattgccaatgggaagacggagcccgaggaagaaactgaagcagaggatccctacaaagtacaggagctgattc agatgcgcaaggagcagcgattggcagcgcttaaacgtatggcaatgataaatcgtcgccgaacggatgccactcccatatacg gcgaagattgtcgcgaggctatacagcgctgcatgcaggcgacccgatccctaaagcgatcaacctggcagacgcgtggatac gccaactgctgcactgccatggcgcatcggaacggttggtccctaaaccacttgctgaagagcttcgaggaaaggtgcgctgatc taaagccagtgtttgccaactttgtgatctacgttccttctgtttgtgcgccccggatccgtcgttatgtacaaaatctctcatcgacgc actggcagcacgaacaaaggattgaaaacattgtggatcaggccctgcggcctaagctggcgttgctgcatccaatcatttcgga aatgaccactaagttcccagatccgcgtctcatccaatacgactgtggcaagttgcagaccatggatcgtttgctacgccagctaaa ggttaacgggcatcgtgtactgatattcactcagatgaccaagatgttggatgttttggaagcttttctcaactaccacggtcatatttat ctgcgtttagatggctctactcgggtggaacagcggcagatcctgatggagcggtttaatggagataaacgaatcttctgcttcatc ctctccacgcggtctggtggagtgggcatcaatttgacgggtgccgatactgtgatcttttacgactccgactggaaccccacaatg gatgcgcaggcccaagatcgttgccatcgtattggtcaaacgcgagatgtacatatctaccgtcttgtctccgaaagaaccataga ggttaacattcttaagaaggcaaaccaaaagcgaatgctgagcgacatggccatcgagggtggcaactttacaactacgtacttta agagttccaccataaaggatctctttacaatggagcagagcgagcaggacgagtcgagccaagagaagtcggaaaacaaggat agaattgttgctacaacaacgctttcagatacgccttcgacggttgtggagacggagaagcagtcactgcgtgcatttgagcacgc gttggctgccgccgaggacgagcaggatgtgcaggccacgaaaacggctaaagccgaagtggcagctgatctggccgagttc gacgagaacattcctattgcaacagaagatccaaatgcggaaggaggtcctcaagtggaactcagcaaggccgatctggagatg cagaacttggttaaacagctctcaccgatagagcgatatgccatgcgctttgtggaagaaactggagcagcatggacggcggaa caattgcgagccgcggaagcggagctggaggcccagaaacgcgagtgggaggccaatcgcttggcggccatgcacaagga ggaggagctgttgaagcaagaaacggaagcggaggagatgcttacctacagtcgcaaggattcgagtaatcaggttaataccaa aacagattccaattccaataagcgacgactggtgagggaaaatcgcagaaactcagctcagaagctgagcaggagtgttagcag ccatagcaccggtagcaacaacaagaacagtaaatcggcaacgacccgtggaaatagccagaacagcctcaatcagactgtac cagtggggtcaggaataagcagggtgaatagaacgggggcgggggtcagtagcagtagccgaggcaaaagtaacagcacga agtcaacggggaagggaacagacgccgcaccgcaagttcggcggcagacccgtctccactctctgggcgcagtcaatatggc cagcgcccgaacaccgcccactagaaagacaacacgtacagctctggctgcatctgcagctgcatctactttagaggatgcctctt tgatcgtcgaggagcgtcccaaaagacagtcggccaacatagctatgagcaagatgatgaagacgcccttcaaacagaatgttc catccaacatcagtataaagacaactcctcctaaaagggggcgaagagacagtgttgcagctgccgccacacgcagtaaactgc tggaaagaagagctacaattgctgctcctttaaaacatatggatgatgaaagtgaccaggatgaagaggagcaggaagagcagg agtctgaagaagataccgagggcgaggaagcaaatgccacagtagacgacgacgaggagggggaggaggagttggcgtca cttgacgaagagaccatacaaaccggatcgcaaacaaatgatgaagaagacgatgacgaggaagaagttggtgaagagggaa tggttgatattgatactgaagattcagaggcagatgtcaaatccagctccacctatggtacagcggcagatggtaagcccgaagaa gccgaaagcttggatggctgggatgcacacgaccaggtgcaggacaccacaatgactagctccacctactacaatgtcagcga ggaatcagacacggatgagcatcacgatagcaaggcggaggctaaagagccgccgcaaaattccgataagagcgacgagag cgaggctgttggacacacaccacgtacaaggtcgcgcggcacagtaaagatcaatctgtggaccctggacgtgagtcccgtagc aaacgcattgaataaaagcagcgccaataggagcctcaaaaaagcaccaaggactgagtccacgccaaaggagtctcagagc gagccaaggcgaaagattactcagccaaagctgccgaagaaagaagaaactaacaacaaatctaacagcaatatcggcacctta caccgctggatatcgaagtccccccgagtaatgcttcgatccacacctgttacggcagcgagcgctagctcatcagcagcagtca gtggtgtttcgggaggaaatgcctcctcgagcggaacagccaggtga Drosophila Gene Hit TBLASTN with ORF2: brahma protein (M85049) and imitation- SWI protein (ISWI) (L27127) and chromodomain-helicase-DNA- binding (CHD-1) Human Homologue BLASTX with EST TBLASTN with ORF2: Snf2-related CBP activator protein (SRCAP) (AF143946) and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) (NM_003072.1) Drosophila EST several including SD07794 (AI534784), LD34465 (AA990657) Annotated Drosophila genome genomic segment AE003453 Annotated Drosophila genome Complete gene candidate CG9696 - domino an enzyme involved in DNA repair homology to snf2 family helicases Human homologue of Complete gene candidate CG9696- gi4557447 416409C913D6A935 |ref|NP_001261.1| chromodomain helicase DNA binding protein 1 [Homo sapiens] (1.90E-85 Putative function snf2 helicase family member protein that contains a chromodomain, which occurs in proteins that are implicated in chromatin compaction, and an SNF2/SWI2-like helicase domain, which occurs in proteins that are believed to activate transcription by counteracting the repressive effects of chromatin structure Confirmation by RNAi Loss of GI, peak,increae in G2M indicating arrest in G2/M Example 70 (Category 5) Line ID 99/31 Category 2nd chromosome, small imaginal discs Reversion NR Map Position 53E Rescue ID EcoRl Rescue Sequence 1 AAGGCCCGACC AGAAACGAAATTTTCGGCGCGTNTTTTAAAATGCGCGGTAA ATTCACTTTGATTTTTGTTTTTCTCTCTCGTTCTTCACACACACAGTTAGTTAGA TTGTGTGTTCGCCTGGCTTTGCCTTTTAATTTTTTATTTACCTGCATCCGATTCG GTATTTGAAACAGCCGTTGAGTCTCCTTTGGCTTTTTTATCAGCGACGTCATCA GTGGCGGCAGAAGCAGAAGCGTCGACAGCGGCGGGGGATTCGGCTGCATCTT TGGAGCCCCTTTCCGGCTGTGCCCCCACGGCTTTCGCCACCCCCGCAGTAACC GATGCATTTTCCACATCGCTTACCTTATCGGCGGCATTTTCTTTGGCTGCCGTT TCTGCCGCTTTGTTAGCATCCTTTTCGTGCGGCGANGGCATGGAAAGATACAA ATCAGAATTGGATTACACTTGCTAATTTTTTGGCGGNCAATACAATGGTTCGG TGCGCCTATTCTTTTTTAATCGAATCGCAATTGAGTGTNAATTAAGTCTCCGCA ATGCAATTTGTGTATCTGTCTCCTCCCCGANCGAACAACGATNGAAAAAGGAA CCAGAAATAAAANAGGNAATGAAAAAACACATTGCAATCTATAAGGCCACAC ACACACATATCATCCCGTCTACCANTCCATCGGATTCGANCCACANAANCCAT NTTTATACCNCAACGAACGNGGAAAAAACNATATCNGNAATTACCCCCCGAA AATTGTTGCCNCTTTTACCCAAATATTTACAACCNCCGTTCATTCACTCCTGGA ACATTCCNGGCTTTCCCAATTTTCNCCTTTACTACAATTTCAATGGTTTCTTTTT CCTCAC Rescue ID BamHl Rescue Sequence 2 CCTNAAATGTNGCGCTGGGNCCTAAANCGTCNCTCCTTGTGTCTCTCTTGTTTA CCGCGCTATGCTGATGTTGGCATGTGGTTCGATCCCCCTCCGTGTCGATGTTTA CAAAACCATNATTAGAGTTTGATGATTGAGTTCTCTTAACTTTCCTTCCTCCTT CCTTCCTTGGCTTTTGTTCATGCTAAATCCTTTAAATGGGGTTCTGCGTAGTTT AATGCCGAGGTACAGCAAAACTTCAATATTCATGTTCCCTTGCGCTCCCAAAC GAAATTAGCATTGGACGTCCCAAGGTTGAAGACATTTNATTATTTTAACATCT TTTTNATTTTATTACATTTGAACTCTTACAAGTAATAATAATTACAATTAATAT TATAGCTGCAGCGGACAAAAAGGAGAAATCCCCCTCGCCGGTAATAAAGAAT CCAACAATAAGGATGCTNAAAANGAAGAAAACCCNAAAAAGGAGAAGAAAA ATCGGAANAAGGNGATGAGCCNGAAGATGAGGNNGATGAGAAAGCTAGCGA TGAAGAGAGCGAGAAGAAGAAANCGANATGAGATGCAGAGGACAGATAAAG GATGCCACNGATGAATCCAAGCCAAAATCGGGAGCCGATAAGCCCAAGAAAC TGAGCCCAAGGCCAAGAATGGCAAGGTGGNT Genomic hit, Accession No. CSC:AC020063 Associated ORF Genscan ORFl predicted sequences >16:48:25|GENSCAN_predicted__peptide_l|722_aa MPSPHEKDANKAAETAAKENAADKVSDVENASVTAGVAKAVGAQPERGSKDA AESPAAVDASASAATDDVADKKAKGDSTAVSNTESDAAAADKKEKSPSPVIKKS NNKDAKKEDNSEKDEENSEDGDEPEDEADEKASDEESEKKKPKLDAEDKIKDAT DESKPKSGADKPKKPEPKAKNGKVAKEEDDDEEDEDDEDAEDDDGDENDGLDK NNEVAEDDENVVALAEIDRINENΓNKTRVDGLQTLHAICFGAQGKNNVVKKNLRS FAGFEFAKDSAEYNKKLEAIKKNDNKGLRSICEILTLDRKGSKNETVLRVLKFLM EPDESLCLEQGDEEEEEDAEDEDLDEDEEDPPSEEDKKRKSGKSSGGAGRGSARN STGRPRI^TAGKKMSAYVDFSSSDDSEQKNANPKRRRNDDSESGSDYNPSANSD SDGGRGGGAGAAGRKNPSRGGRGRPARKSRRRNSDSEEEEESENSDADSDNPKR KRGSNGKRGRPAAPASAGRRGRGRGAASRKRKDSDSEDEENSEDEEEEDNSDFA SDQSENCKFΝLISSIWCFIKYMPIFQEERPKKSKKPITPAKΝSKAΝΝKSKPAGKADS RSKKSKKESSEEDDDNDDKDESDEDEPLTKKGKQAFPTDEQIRGNNKEILDKAΝL EEITMKTNCKQNNAKYPDFDLTDKKDFIKATNKADGNQDLDGSPELIPRGRTTNT IWLICCCΝΝQIFGET >16:48:25|GEΝSCAΝ_predicted_CDS_l|2169_bp atgccatcgccgcacgaaaaggatgctaacaaagcggcagaaacggcagccaaagaaaatgccgccgataaggtaagcgatg tggaaaatgcatcggttactgcgggggtggcgaaagccgtgggggcacagccggaaaggggctccaaagatgcagccgaatc ccccgccgctgtcgacgcctctgcctctgccgccactgatgacgtcgctgataaaaaagccaaaggagactcaacggctgtttca aataccgaatcggatgcagctgcagcggacaaaaaggagaaatccccctcgccggtaataaagaagtccaacaataaggatgc taaaaaggaggacaactccgaaaaggacgaggagaactcggaagacggcgatgagccagaagatgaggctgatgagaaagc tagcgatgaagagagcgagaagaagaaaccgaaattagatgcagaggacaagataaaggatgccactgatgagtccaagcca aaatcgggagccgataagcccaagaaacctgagcccaaggccaagaatggcaaggtggctaaggaggaggacgacgacga agaggacgaggatgatgaggatgccgaagatgacgatggagacgagaacgatggcctggacaagaacaacgaggtggccg aggatgatgagaatgtcgtcgctctcgccgagattgatcgcattaatgagaatatcaacaagactcgtgtagatggtctgcaaacat tgcatgcaatctgctttggcgcccaaggcaagaacaatgtggtcaagaagaacttgcgatcctttgccggtttcgagtttgccaagg attcagcggagtacaacaaaaagctggaggccatcaaaaaggtggataataagggcctgcgcagcatctgcgagatccttaccc tcgatcgcaagggcagcaagaacgagactgtccttcgagtgctcaaattcctaatggaaccggacgagtcgctttgcttggagca gggtgatgaggaggaggaggaagatgccgaggacgaggatctggatgaagatgaggaggacccgcccagtgaagaggaca agaagcgcaagagcggaaagtctagcggcggcgctggcagaggctctgcacgcaattccaccggacgtccaaggcgcgcga cggcaggaaagaaaatgtccgcctatgtagatttctccagctctgacgatagcgagcagaaagttgcagttcccaaaaggagacg aaatgatgactccgagtcgggctcagattacaatccttctgccaattccgactctgacggtggtcgtggtggtggtgctggtgcagc aggtcgcaaagtcccaagccgcggtggacgcggtcgtcctgcgcgcaaaagtcgcagaagaaactctgattccgaggaagaa gaggaatcggaagtttccgatgccgatagtgatgtcccaaaacgtaaacgtggttccgtgggtaaacgtggacgaccggcagct cctgcgtcagctggacgaaggggtagaggacgaggtgcagcttcccgcaagcgtaaagattcagatagcgaagatgaggagg tatccgaggatgaagaggaggaggatgtctccgattttgccagcgatcaaagcgaagtatgtaaatttaatttaatatcgagcatttg gtgttttatcaagtatatgccaatttttcaggaggaacgtcccaaaaagagcaagaagcccattacgcctgcgaaaaatagcaaag ctaacaacaagtcaaaaccagctggaaaggccgatagtcgatcgaaaaaatcaaagaaggaatcgtccgaggaagatgatgat gtcgatgacaaagatgaatccgacgaggatgagccactaaccaaaaagggcaaacaggcattcccaacggatgaacaaatacg cggatatgtcaaagagattctggataaagccaatcttgaggagattacgatgaaaaccgtgtgcaaacaagtttatgcaaaatatcc agactttgacctaacagacaagaaagacttcatcaaggcgacagtgaaagcggacggagttcaggatttggatggtagtcccga actgatcccgcgtggccgaacaacggttacaatatggttgatctgctgttgcaacaatcagatatttggggagacgtaa Human Homologue TBLASTN with ORFl : poor homology with DEK gene (D6S231E) (NM_003472.1) Drosophila EST several including LD33301 (AA979048) Annotated Drosophila genome genomic segment AE003805 Annotated Drosophila genome Complete gene candidate CG5935 - EG:EG0003.6 - novel with weak homology to DEK oncogene CG8648 - EG.EG0003.3 - novel XPG/ flap endonuclease-like, DNA repair? Human homologue of Complete gene candidate CG5935- le-174503249 ref|NP_003463.1|pD6S231E| DEK gene >gi|544150|sp|P35659|DEK_H UMAN DEK PROTEIN >gi)284375| CG8648- 4758356 |ref|NP_004102.1 |pFENl | flap structure-specific endonuclease 1; MATURATION FACTOR 1 (MF1); DNase IV; RAD2_HUMAN(aa) Putative function CG5935: function unknown but putative DNA-binding protein predicted to be involved in chromosomal organisation. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA CG8648: Novel XPG/ flap endonuclease-like, DNA repair protein Confirmation by RNAi Both show slight reduction of GI peak REFERENCES Deak, P., Omar, M.M., Saunders, R.D.C., Pal, M., Komonyi, O., Szidonya, J., Maroy, P., Zhang, Y., Ashburner, M., Benos, P., Savakis, C, Siden-Kiamos, I., Louis, C, Bolshakov, V.N., Kafatos, F.C., Madueno, E., Modolell, J., Glover, D.M. (1997) Conelating physical and cytogenetic maps in chromosomal region 86E-87F of Drosophila melanogaster. Genetics 147:1697-1722. Torok, T., Tick, G., Alvarado, M., Kiss, I. (1993) P-lacW insertional mutagenesis on the second chromosome of Drosophila melanogaster: isolation of lethals with different overgrowth phenotypes. Genetics 135(l):71-80 Saunders, R.D.C., Glover, D.M., Ashburner, M., Siden-Kiamos, I., Louis, C, Monastirioti, M., Savakis, C, Kafatos, F.C.(1989) PCR amplification of DNA microdissected from a single polytene chromosome band: a comparison with conventional microcloning. Nucleic Acids Res. 17:9027-9037 Lefevre, G. (1976) A photographic representation and interpretation of the polytene chromosomes of Drosophila melanogaster salivary glands. In: The Genetics and Biology of Drosophila, Eds Ashburner,M. and Novitski,E. Academic Press. Jowett, T. (1986) Preparation of nucleic acids. In "Drosophila: A Practical Approach." Ed Roberts,D.B. IRL Press Oxford. Pinotta, N. (1986) Cloning Drosophila genes. In: . In "Drosophila: A Practical Approach." Ed Roberts,D.B. IRL Press Oxford. Altschul, S.F. and Lipman, D. J. (1990) Protein database searches for multiple alignments. Proc. Νatl. Acad. Sci. USA 87: 5509-5513 Burge, C. and Karlin, S. (1997) Prediction of complete gene structures in human genomic DNA. J. Mol. Biol. 268, 78-94. Each of the applications and patents mentioned above, and each document cited or referenced in each of the foregoing applications and patents, including during the prosecution of each of the foregoing applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the foregoing applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific prefened embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Claims: CLAIMS 1. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 70 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 70, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 70 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 2. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 14 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 14, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 14 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 3. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 15 to 19 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 15 to 19, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 15 to 19 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 4. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 20 to 30 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 20 to 30, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 20 to 30 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 5. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 31 to 53 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 31 to 53, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 31 to 53 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 6. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in 54 to 70 or the complement thereof. (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in 54 to 70, or a fragment thereof. (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 54 to 70 or a fragment thereof. (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c). 7. A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of Claims 1 to 6. 8. A polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 70 or in any of Examples 1 to 14, Examples 15 to 19, Examples 20 to 30, Examples 31 to 53 and Examples 54 to 70, or a homologue, variant, derivative or fragment thereof, 9. A polynucleotide encoding a polypeptide according to Claim 8. 10. A vector comprising a polynucleotide according to any of Claims 1 to 7 and 9. 11. An expression vector comprising a polynucleotide according to any of Claims 1 to 7 and 9 operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell. 12. An antibody capable of binding a polypeptide according to Claim 8. 13. A method for detecting the presence or absence of a polynucleotide according to any of Claims 1 to 7 and 9 in a biological sample which comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe according to Claim 9 under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample. 14. A method for detecting a polypeptide according to Claim 8 present in a biological sample which comprises: (a) providing an antibody according to Claim 12; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed. 15. A polynucleotide according to according to any of Claims 1 to 7 and 9 for use in therapy. 16. A polypeptide according to Claim 8 for use in therapy. 17. An antibody according to Claim 12 for use in therapy. 18. A method of treating a tumour or a patient suffering from a proliferative disease comprising administering to a patient in need of treatment an effective amount of a polynucleotide according to any of Claims 1 to 7 and 9. 19. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polypeptide according to Claim 8. 20. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of an antibody according to Claim 12 to a patient. 21. Use of a polypeptide according to Claim 8 in a method of identifying a substance capable of affecting the function of the conesponding gene. 22. Use of a polypeptide according to Claim 8 in an assay for identifying a substance capable of inhibiting the cell division cycle. 23. Use as claimed in Claim 22, in which the substance is capable of inhibiting mitosis and/or meiosis. 24. A method for identifying a substance capable of binding to a polypeptide according to Claim 8, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide. 25. A method for identifying a substance capable of modulating the function of a polypeptide according to Claim 8 or a polypeptide encoded by a polynucleotide according to any of Claims 1 to 7 and 9, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated. 26. A substance identified by a method or assay according to any of Claims 21 to 25. 27. Use of a substance according to Claim 26 in a method of inhibiting the function of a polypeptide. 28. Use of a substance according to Claim 26 in a method of regulating a cell division cycle function.

Inventors: DEAK PETER, GLOVER DAVID MOORE, MIDGLEY CAROL, DEAK, PETER, GLOVER, DAVID, MOORE, MIDGLEY, CAROL
Applicants: CYCLACEL LTD, DEAK PETER, GLOVER DAVID MOORE, MIDGLEY CAROL, CYCLACEL LIMITED, DEAK, PETER, GLOVER, DAVID, MOORE, MIDGLEY, CAROL
Application year: 2001
Main classification: C07K14
IPC codes: C07K14, C12N15